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Abstract 
In a mouse model of amelogenesis imperfecta (Al), an amelogenin p.Y64H 
mutation was reported to cause the abnormal retention of amelogenin in the 
ameloblast secretory pathway. This was hypothesised to be due to enhanced 
pathological aggregation of mutant amelogenin. The aim of this thesis was to 
develop purification methodologies to deliver large amounts of wild-type (WT) and 
mutant recombinant amelogenins (r-amelogenins) and develop microplate based 
binding assays to study protein-protein interactions of these recombinants to 
elucidate the effect of the mutation on aggregation. His-tagged r-amelogenin was 
extracted from Escherichia coli (E. Coli) with 3% acetic acid. This extract was 
subject to nickel affinity chromatography (targeting the His-tag); the 'gold standard' 
technique for purifying recombinant proteins from bacterial contaminants. The His­
tag was then removed but cleavage was only -50% efficient. Cleaved r-amelogenin 
unexpectedly still bound the nickel column (presumably due to the presence of di 
and tri histidine motifs in the amelogenin sequence) which precluded its isolation 
from uncleaved contaminant. Size exclusion chromatography was also trialled and 
also found to be ineffective. Finally, preparative SOS PAGE was found to produce 
cleaved r-amelogenin at single band purity on analytical SOS PAGE. After 
optimising the purification regime, simple and cost-effective microplate binding 
assays were developed initially using amelogenin rich porcine enamel matrix 
derivative (EMO) as a surrogate. Initially the aim was to immobilise EMO on the 
plate and then measure the binding of FITC-labelled EMO by simple end point 
fluorescence measurements. An alternative method trialled UV spectrophotometry 
to monitor the loss of EMO from free solution in real time as it bound EMO 
immobilised to the well surfaces. This latter method provided an adaptable, simple 
and cost-effective means of monitoring amelogenin binding and aggregation. It 
provided pilot data suggesting that p.Y64H mutant r-amelogenin was clearly more 
aggregative than WT r-amelogenin. 
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Chapter 1   Introduction 
1.1 Dental enamel 
Enamel is the hardest mineralised tissue in vertebrate biology and is evolutionarily 
conserved between species (Sire et al., 2007). It can form the outer layer of teeth in 
sarcopterygians (tetrapods and lobe finned bony fishes) and has been associated with 
the dermal bones and scales of fossilised lobe finned fish (Qu et al., 2015). It protects 
teeth from physical and chemical stresses encountered during feeding. Such a vital 
function would explain the high degree of conservation amongst the proteins involved 
in generating enamel (amelogenesis). Enamel’s hardness and strength originates from 
its highly structured organisation of hydroxyapatite crystallites. The formation of 
enamel per se occurs in four discrete stages. In humans, amelogenesis begins in 
utero for deciduous teeth and at 0-1 years for permanent teeth (Nanci and Ten Cate, 
2013). Developing enamel consists initially of a protein matrix secreted by the enamel 
forming ameloblasts which partially mineralises on secretion. Later, the protein matrix 
is degraded and the partially mineralised tissue undergoes secondary mineralisation. 
This process is described in detail later in the Introduction. 
 
1.1.1 Structure and function of mature enamel 
Teeth are an essential component of the digestive system; their primary function is 
food mastication, which breaks food into small particles accessible to digestive 
enzymes. Teeth are also important in speech, aesthetic appearance (in humans), self -
defence or predation in some species. Mastication, which consists of tearing and 
crushing food, requires extremely resistant teeth, of an appropriate shape and 
hardness. To carry out millions of masticatory cycles over a life time (in humans), a 
robust structure is necessary as each cycle generates forces between 28 and > 1200 
N (Ferrario et al., 2004, He et al., 2013).  
Enamel is the external covering of teeth (Figure 1A). It comprises over 90% inorganic 
mineral by weight (De Menezes Oliveira et al., 2010), its mineral phase being 
essentially hydroxyapatite crystals (Deakins and Burt, 1944). Such a highly 
mineralised structure protects the dentine from physical and chemical stress which 
would otherwise cause demineralisation and pain due to the damaging effects of acid 
drinks and foods, and bacterial colonisation (Chun et al., 2014). 
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A study of human maxillary second molars reported enamel hardness values between 
3 and 6 GPa and a Young elasticity modulus ranging from 70-115 GPa (Cuy et al., 
2002). At the microscopic scale, enamel is a highly ordered structure where thousands 
of elongated hydroxyapatite crystallites are organised into bundles called prisms (or 
rods) interspersed with similar crystallites which comprise the interprismatic enamel 
(He and Swain, 2008) (Figure 1B). Prism organisation varies amongst species and 
tooth type and gives rise to histological banding features in enamel known as Hunter-
Schreger bands. In rodent incisors, prisms are inclined relative to each other at about 
60° generating an extreme decussating pattern. This arrangement confers mechanical 
strength, hardness and an ability to resist crack propagation and wear (Bajaj and 
Arola, 2009, Yahyazadehfar et al., 2013). This capacity to deflect crack stress 
propagation also protects the dentine enamel junction (DEJ) and the bulk of the tooth 
which is composed of dentine (Palmer et al., 2008). This creates a compound 
structure able to withstand mastication forces (He and Swain, 2008). In terms of 
evolution, the decussating structure of the enamel (as well as the thickness) have 
been linked to species selections and adaptation to hard-object diets (Dumont, 1995, 
Teaford and Ungar, 2000, Lambert et al., 2004).  
Enamel per se is, however, brittle, with a fracture toughness measured at 0.6 -1.5 MPa 
(Park et al., 2008). It would be susceptible to cracking if it was not supported by the 
dentine, which is tougher and softer, and absorbs applied masticatory stresses (Chun 
et al., 2014). Studies carried out in primates suggested that this is further facilitated by 
the scalloped structure of the dentine-enamel junction, which resists delamination 
(Shimizu and Macho, 2007). 
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Figure 1 Schematic showing enamel on a simplified tooth. (A) Enamel is the 
outer mineral layer of teeth. Its colour is transfull/opaque. It protects the 
tissues of the inner layers. (B) Tissue architecture of rodent enamel relative 
to mineral crystals: enamel structure is highly ordered, organised into 
decussating prisms and interprismatic enamel, which makes it one of the 
toughest tissues in the organism and confers its mechanical properties. 
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1.1.2 Development of enamel: cellular and extra-cellular events 
This Section provides a brief over view of amelogenesis as part of tooth formation and 
as applicable to human deciduous teeth, permanent teeth and also to tooth 
development in other species. A distinctive characteristic of tooth development in rats 
and mice is that their incisors continuously grow. In these cases, the enamel forms 
continuously but amelogenesis occurs via a similar route (further description is 
provided in Section 1.3.4.1.1 pp. 66 - 67).  
1.1.2.1 Embryonic origins of enamel tissue 
Human tooth formation is initiated after 37 days of development in utero, as the oral 
epithelium thickens at the internal surface of the upper and lower jaws. It forms 
primary epithelium bands that grow into the underlying mesenchyme comprising 
neural crest cells, forming the dental lamina. Tooth formation originates from this 
structure and advances through three stages: bud, cap, and bell stage (Figure 2). It is 
at the cap stage (8 weeks development in utero, deciduous teeth) that the enamel 
organ can be distinguished (Figure 2C). Its peripheral inner epithelial layer 
differentiates during the bell stage into ameloblasts, which are responsible for enamel 
formation. 
During the bell stage, the inner enamel epithelium (IEE) directly faces the dental 
papilla and these two structures will form the enamel and dentine respectively. 
Amelogenesis can be described as a four-step process: (1) first, during a pre-secretory 
stage, the IEE cells differentiate into ameloblasts. (2) Second, during the secretory 
stage, the ameloblasts acquire secretory functions and secrete proteins forming the 
enamel matrix. The secretory stage is followed by (3) a transition stage, during which 
the secretion of enamel proteins stops and the ameloblasts undergo morphological 
changes reflecting a change of function. (4) Finally, the enamel matrix achieves full 
mineralisation throughout the maturation stage. All these steps are illustrated in Figure 
3 and are discussed in detail below. 
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Figure 3 (A) Enamel develops incrementally with secretion of matrix proteins, 
associated with changes of cell morphology and function. Upon 
differentiation of epithelial cells, presecrectory ameloblasts are formed. 
They eventually start to incrementally secrete enamel matrix proteins 
(EMPs), into the forming enamel matrix. (B) During the secretory stage, 
EMPs are secreted via the amelobasts Tomes’ processes. As matrix 
proteins are secreted, long, thin mineral crystals are deposited. The matrix 
at this stage is 33% mineral /33% protein and 33% water. (C)Tomes’ 
processes resorb during the transition/maturation stage where the enamel 
has reached its full thickness. (D) At the maturation stage, the ameloblasts 
have changed in morphology (now half height, no Tomes’ process), cells 
are more resorptive than secretory. Crucially, cells now pump large 
amounts of mineral ions into the matrix so pre-existing thin crystals grow 
in width and thickness to occlude >90% of the tissue. The panel A is 
adapted with permission from Hu et al. (2007), Cells Tissues Organs 
2007;186:78–85. S.G.Karger AG, Basel1 (itself adapted from Uchida et al. 
(1991))2. The histology analyses of mouse incisors in panels B, C, D are 
reproduced from Barron et al. (2010), Human Molecular Genetics 2010;19 
(7):1230-47 by permission of Oxford University Press3. 
1 HU, J. C., CHUN, Y. H., AL HAZZAZZI, T. & SIMMER, J. P. 2007. Enamel formation and amelogenesis 
imperfecta. Cells Tissues Organs, 186, 78-85. 
2 UCHIDA, T., TANABE, T., FUKAE, M. & SHIMIZU, M. 1991a. Immunocytochemical and 
immunochemical detection of a 32kDa nonamelogenin and related proteins in porcine tooth germs. 
Archives of Histology and Cytology, 54, 527-538. 
3 BARRON, M. J., BROOKES, S. J., KIRKHAM, J., SHORE, R. C., HUNT, C., MIRONOV, A., 
KINGSWELL, N. J., MAYCOCK, J., SHUTTLEWORTH, C. A. & DIXON, M. J. 2010. A mutation in 
the mouse Amelx tri-tyrosyl domain results in impaired secretion of amelogenin and phenocopies 
human X-linked amelogenesis imperfecta. Human Molecular Genetics, 19, 1230-47. 
A 
B C D 
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1.1.2.2 Presecretory stage: Inner enamel epithelium cells differentiate 
into ameloblasts 
At the onset of amelogenesis, the cuboidal cells of the IEE are separated from the 
underlying mesemchymal dental papilla cells by a basement membrane. The cells 
engage in reciprocal intercellular signalling across the basement membrane which 
triggers the differentiation of IEE cells into presecretory ameloblasts and the dental 
papilla cells into odontoblasts which are responsible for dentine formation. Just before 
the first layer of dentine forms, differentiating IEE cells secrete proteins possibly 
involved in the epithelial-mesenchymal signalling (Thesleff, 2003), which drives the 
terminal differentiation of odontoblasts. 
Initially low columnar cells, with a large central nuclei and underdeveloped secretory 
apparatus, and resting on the basement membrane (Figure 4A), the differentiating IEE 
cells undergo morphological and functional changes (Smith and Nanci, 2003). As 
odontoblasts begin to secrete a predentine matrix, IEE cells become taller and 
columnar. Their nuclei migrate proximally (towards the side bordering the stratum 
intermedium) while their Golgi and the rest of their secretory apparatus migrate 
towards the distal end: the IEE become ameloblasts, organised as a monolayer, 
separated from the odontoblasts by a basement membrane (Figure 4B).The 
ameloblasts become secretory, sending projections through the basement membrane, 
which is degraded (Figure 4C) (Reith, 1967). 
Figure 4 IEE cells differentiate into ameloblasts following reciprocal induction 
(highlighted by two yellow arrows) with odontoblasts (and their 
mesenchymal precursors). 
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1.1.2.3 Secretory stage: ameloblasts acquire secretory function in 
contact with pre-existing dentine, then secrete enamel matrix 
The newly differentiated ameloblasts initially secrete low levels of proteins. However, 
following initiation of dentinogenesis the ameloblasts become highly active secretory 
cells and develop the so-called Tomes’ processes which appears to direct the 
secretion of enamel proteins towards formation of discrete prismatic and interprismatic 
enamel (Nanci and Warshawsky, 1984, Warshawsky et al., 1987) 
The secretory ameloblasts are tall columnar cells attached to each other by junctional 
complexes, forming a monolayer. They show typical characteristics of specialised 
secretory cells including an expansive Golgi and rough endoplasmic reticulum (ER) 
and membrane- bound secretory granules packed with EMPs (Reith, 1961, Reith, 
1970, Sasaki et al., 1984). Responsible for the synthesis of EMPs, ameloblasts are 
adapted to manage the large amount of proteins transiting through the rough ER and 
the Golgi apparatus (Warshawsky, 1968). The secretory vesicles migrate to the 
Tomes’ process, where they are released and added to the extracellular enamel matrix 
already secreted (Kallenbach, 1973). By incrementally secreting EMPs, the 
ameloblasts migrate away from the dentine surface (Figure 5A). This incremental 
apposition of matrix proteins leads to the deposition of the full thickness of enamel.  
The enamel matrix is highly proteinaceous during the secretory stage: it comprises 
mainly amelogenin, ameloblastin, and enamelin; amelogenin is the major protein, 90% 
(Termine et al., 1980), and catalytic amounts of matrix metalloproteinase 20 (MMP-20) 
are present, which is responsible for extracellular processing of the EMPs (detailed 
later in Section 1.2.3.1, pp. 30 -32). Enamelin is expressed and released into the 
matrix from the early secretory stage to the early maturation stage. A study in mouse 
molars showed that its expression finishes before that of amelogenin (Hu et al., 2001). 
After their secretion, the nascent amelogenin, ameloblastin and enamelin molecules 
are soon processed by MMP-20 so that the bulk of the tissue is comprised of a range 
of enamel protein-derived polypeptides (Smith et al., 1989, Fukae and Tanabe, 1998, 
Uchida et al., 1998) which may also have architectural function (Bartlett, 2013). 
Almost simultaneously with protein secretion, thin plate-like enamel apatite crystals 
elongate in length (c-axis growth) measuring at least 100 µm (Nylen et al., 1963) and 
possibly spanning the full thickness of the enamel (Daculsi et al., 1984, Margolis et al., 
2006). Their growth is restricted to the c-axis as the EMPs likely act as a constraint to 
crystal growth in thickness and width (Robinson et al., 1998). 
In effect, the crystal architecture is lightly “sketched in” during the secretion stage 
(Figure 5B) but how these crystals are nucleated is not fully established. Initially, 
calcium and phosphate ions are present in the earliest enamel secreted (Deakins and 
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Burt, 1944, Robinson et al., 1974, Takano et al., 1986). Mineral is nucleated in the 
extracellular environment to form an ordered crystal array (Fincham et al., 1999). The 
crystals appear thicker at the dentine-enamel junction and thinner at the secretory 
front . The mechanisms for this have not been fully elucidated, the hypotheses drawn 
to date are detailed in Section 1.2.3.1.2 (pp. 33 – 35). 
Figure 5 Secretory stage of amelogenesis (A) Secretory ameloblasts are long 
columnar cells, specialised in EMPs secretion. Enamel matrix forms 
incrementally. (B) enamel crystallites are ‘sketched in’ during the secretory 
stage. 
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1.1.2.4 Transition and maturation stages: reduction of secretory activity 
and secondary mineralisation 
The transition stage starts just before enamel has reached its full thickness. The 
ameloblasts retract their Tomes’ process and stop secreting secretory stage proteins 
such as amelogenin and ameloblastin, enamelin and MMP-20 (Bartlett, 2013, Smith et 
al., 2017b). They begin to decrease in height and start secreting a final layer of 
aprismatic enamel matrix before finally secreting a new basement membrane onto the 
surface of the enamel (Figure 6A). The basement membrane is present throughout the 
maturation stage, where maturation-stage-specific secretory calcium-binding 
phosphoproteins (SCPP) are found.  
These SCPPs include amelotin and odontogenic ameloblast associated (ODAM) 
protein. Amelotin was identified in 2005 by differential display polymerase chain 
reaction analysis of mouse ameloblasts. Its encoding gene AMTN is conserved 
between species located close to the genes encoding other members of the SCPP 
family such as ENAM and AMBN on chromosomes 5 in mouse or 4 in humans 
(Iwasaki et al., 2005). Both mRNA expression pattern and protein localisation analyses 
showed that its expression is specific to maturation stage ameloblasts (Somogyi-
Ganss et al., 2012). The predicted translation product has an elevated content of 
proline, leucine, glutamine and threonine (52%) which may drive hydrophobic 
interactions promoting amelotin aggregation (Iwasaki et al., 2005, Somogyi-Ganss et 
al., 2012). Amelotin has been found in the outer enamel layer during the transition 
towards maturation stage, and at the basement membrane-like structure of maturation 
stage ameloblasts (Moffatt et al., 2006b, Somogyi-Ganss et al., 2012), where it 
interacts with ODAM and secretory calcium-binding phosphoprotein proline-glutamine 
rich 1 (Holcroft and Ganss, 2011, Fouillen et al., 2017). Its aggregative nature 
suggests that amelotin may mediate the attachment of ameloblasts to the mineralising 
enamel during the maturation stage (Moffatt et al., 2014, Smith et al., 2017b). It was 
also shown to promote hydroxyapatite mineralisation (Abbarin et al., 2015). 
ODAM, also known as APin, is another protein secreted by ameloblasts specifically 
during the maturation stage. Although it is overexpressed in some epithelial tumours 
(Kestler et al., 2008), its amelogenesis-specific expression is physiological and it was 
identified and characterised by secretome analysis of the rat enamel organ (Moffatt et 
al., 2006a, Moffatt et al., 2008). ODAM is highly conserved in mammals and has a rich 
content of proline and glutamine (28%) and hydrophobic residues (30%). During the 
maturation stage it co-localises with amelotin at the basement membrane (Park et al., 
2007, Moffatt et al., 2008) and a yeast two-hybrid (Y2H) assay showed that they may 
interact (Holcroft and Ganss, 2011), possibly contributing to ameloblast adhesion to 
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the mineralising enamel matrix. Other proteins involved in cell adhesion, predominant 
during maturation stage include integrin β6 (ITGB6), at the distal membrane of 
ameloblasts (Wang et al., 2014a) 
At the onset of the maturation stage, the enamel matrix has reached its full thickness. 
The ameloblasts decrease further in height until they are only half the height of 
secretory stage ameloblasts. Their apical membranes oscillate between ruffle and 
smooth states (Figure 6B) (Josephsen and Fejerskov, 1977, Reith and Boyde, 1981). 
They begin to secrete kallikrein-related peptidase 4 (KLK4), a serine protease which 
further degrades the spectrum of proteins and peptides generated during the secretory 
stage processing (Hu et al., 2002). Ruffle-ended ameloblasts secrete bicarbonate ions 
and are responsible for pumping calcium into the enamel matrix whereas smooth-
ended ameloblasts allow for calcium intercellular transit towards the enamel matrix. 
The bicarbonate ions are assumed to buffer the decrease in pH in the matrix caused 
by the release of protons as the hydroxyapatite crystals grow in width and thickness 
(Smith, 1998). 
The maturation stage is further characterised by an increase in mineral content and 
the concomitant loss of the protein degradation products generated by KLK4 
proteolysis activity as they are endocytosed by ruffle-ended ameloblasts (Bartlett and 
Simmer, 2014, Pham et al., 2017). WD repeat-containing protein 72 (WDR72), whose 
predicted structure suggests a role in vesicle formation, may be involved in EMPs 
degradation products removal (Katsura et al., 2014). Fluid (enamel fluid) replaces the 
degraded enamel proteins. This fluid is kept supersaturated with respect to 
hydroxyapatite as the ameloblasts pump mineral ions into the enamel which drives the 
growth in thickness and width of the enamel crystals until the enamel becomes fully 
mineralised. Maturation stage ameloblasts also express solute carrier family 24 
member 4 (SLC24A4), which is a sodium/potassium/calcium exchanger, playing an 
important role during maturation stage by transporting Ca2+ ions into the enamel matrix 
(Wang et al., 2014b). 
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Figure 6 Transition and maturation stages. (A) ameloblasts reduce their 
secretory activity and start secreting KLK4 which is responsible for protein 
degradation. (B) during the maturation stage, ameloblasts maximally 
secrete KLK4 and oscillate between smooth-ended and rough-ended 
morphologies as they pump mineral ions into the matrix and resorb matrix 
protein degradation products. The enamel becomes fully mineralised. 
The above description (Section 1.1.2 pp. 4 - 12) provides a brief overview of all stages 
of amelogenesis. However, the main focus of this thesis concerns the EMPs 
predominant at the secretory stage and the next Section describes these proteins in 
more detail. 
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1.2 Secretory stage enamel matrix proteins 
The previous Section (1.1.2) provided a brief overview of amelogenesis. This Section 
details the state of knowledge about the synthesis, structure, assembly and function of 
the EMPs at the secretory stage, especially amelogenin, which is the main focus of 
this thesis.  
During the secretory stage, enamel is ~30% protein by weight, comprising mainly 
proteins secreted by ameloblasts (Fukae and Shimizu, 1974). The major structural 
matrix proteins characterised to date are amelogenin, ameloblastin and enamelin. 
which can be found in the secretory enamel matrix as various isoforms (further 
information is described in the next Section). Proteinase MMP-20 is also found in the 
matrix during the secretory stage. Structural matrix proteins are secreted by 
ameloblasts on the preformed dentine (Hu et al., 2007) where they self-assemble to 
form a matrix that supports crystal formation.  
1.2.1 Amelogenin, the major enamel matrix protein 
Amelogenin is the major enamel protein, accounting for over 80-90% of total proteins 
in the secretory stage matrix (Eastoe, 1965, Termine et al., 1980).To date, neither the 
structure nor the precise function of amelogenin is fully understood. It is essential for 
amelogenesis as knock-out (KO) mice display a chalky white, disorganised hypoplastic 
enamel. Scanning electron microscopy (SEM), light microscopy and other analyses 
including sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS PAGE) 
and western blotting, carried out on these KO mice, suggested that amelogenin is 
necessary for the generation of enamel of the correct thickness and prismatic 
structure, but not for the formation of mineral crystals (Gibson et al., 2001). Various 
mutations in the amelogenin gene have been reported in cases of human AI; this is 
detailed in the Section 1.3.3 (Figure 12 p. 58). In the enamel matrix, amelogenin exists 
as a heterogeneous mixture. The factors explaining its diversity are detailed in a 
review by Brookes et al. (1995); they include gene sexual dimorphism, alternative 
splicing, and proteolytic processing in the extracellular matrix (Brookes et al., 1995). 
1.2.1.1 Sexual dimorphism 
Amelogenin is encoded by AMELX, located on chromosome X, and by AMELY on 
chromosome Y in human, pig and cow species (Note: AMELX in capital letters is the 
nomenclature for the human gene, specifically). In mouse and rat, the amelogenin 
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locus is found only on the X chromosome (Lau et al., 1989, Gibson et al., 1992, Veis, 
2003, Ikawa et al., 2005). In humans, the amino acid sequence of proteins AMELX 
and AMELY share 88% similarity by Clustal Omega sequence alignment (by aligning 
the entries Q99218-1 and Q99217-1) (The UniProt Consortium, 2017). At the gene 
level, the 5’ and 3’ UTR regions appear to be much less conserved. At the gene level, 
the exon and intron structures do not differ significantly, however the 5’ upstream 
regions share only 80% similarity, possibly causing a difference of transcriptional 
activity between AMELX and AMELY genes . This may explain why AMELX transcripts 
are 10-fold more abundant than AMELY transcripts in male tooth buds (Fincham et al., 
1991a, Salido et al., 1992). In this thesis, amelogenin will refer to the proteins encoded 
by AMELX only. 
1.2.1.2 Transcription variants of amelogenin (alternative splicing) 
Alternative splicing is another factor explaining the diversity of amelogenins. Early 
studies include Northern hybridisation experiments, which discerned two species of 
mRNA derived from a single amelogenin gene in bovine ameloblasts (Shimokawa et 
al., 1987). Alternative amelogenin spliced products were also found in mouse (Lau et 
al., 1992), pig (Yamakoshi et al., 1994) and human species (Salido et al., 1992). In 
most species studied, the gene structure comprises seven exons. The primary 
transcripts obtained are subjected to alternative splicing, and several mRNA isoforms 
(shown in Figure 7) have been identified, with many being confirmed at the protein 
level. In most eutherian mammals, the major mRNA transcript for amelogenin 
comprises exons 1, 2, 3, 5, 6, 7 (Salido et al., 1992) which encodes for a protein of 
173-197 amino acids (excluding a N-terminal signal peptide) depending on species.
Note: Throughout this thesis, that major splicing isoform of amelogenin (see Figure
7b), minus its N-terminal signal peptide, are refered to as either the “full-length”,
“nascent” or “parent” amelogenin when it is unprocessed.
Exons 1, 2, 3, 5, 6, 7 correspond to the ancestral gene of amelogenin, they are
present in mammals including monotremes (platypus) and non-mammalian species
such as frogs and lizards (Sire et al., 2012). They are highly conserved, even though
the length of the longest exon, exon 6, varies between species.
Exon 1 contains the 5’ untranslated region of the mature mRNA, a region which
expands into the 5’ end of the exon 2. Downstream, exon 2 comprises the initiation
codon followed by the sequence encoding the signal peptide and the first two amino
acids of the secreted protein. Exons 3 and 5 encode short amino acid sequences (16-
17 amino acids each). Exon 4 is spliced out in most variants (Figure 7, ‘b’-‘k’) which
include the dominant isoform (‘b’). In some of these splicing variants, exons 3 and 5
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have also been spliced out (Figure 7, isoforms ‘c, d, f, i’). Exon 6 encodes a proline-
rich, hydrophobic sequence comprising 137 (porcine) to 161 (bovine) amino acids. 
This difference in size is linked to the number of repeats of a proline-glutamine motif 
(Brookes et al., 1995). As exon 6 is a large exon, many internal splicing sites have 
been identified at the transcript level, favouring alternative splicing (see isoforms ‘e’-‘i’ 
in Figure 7) (Veis, 2003). Removal of the 5’ section of exon 6 generates an 
alternatively spliced mRNA encoding the 59-amino acid leucine-rich amelogenin 
peptide (LRAP), which was found in the developing enamel matrix of various 
mammalian species including mouse, rat and cow (Fincham et al., 1981, Fincham et 
al., 1982, Fincham et al., 1983, Gibson et al., 1991, Lau et al., 1992, Bonass et al., 
1994). LRAP is rather acidic, with a pI = 4.1. It comprises the N- and C-terminal 
charged regions of the full-length amelogenin. Although its precise function in enamel 
development is still unknown, in vitro studies have been carried out to determine its 
structure, assembly (Tarasevich et al., 2015) and function, supporting its role in 
controlling enamel crystal growth (Shaw et al., 2004, Le Norcy et al., 2011).  
The rarely used exon 4, encodes a short sequence of 14 - 17 amino acids depending 
on species. The amelogenin protein isoforms containing exon 4 (Figure 7a) are only 
found in the matrix in minor amounts (Yamakoshi et al., 1994). As highlighted by 
Brookes et al (1995), exon 4 is not well conserved: unlike the translated products of 
other exons, porcine and human (cDNA) exon-4-peptides share only two amino acids 
homology (Brookes et al., 1995). Present only in mammalian genes, exon 4 was 
predicted in silico to appear in ancestral therians (220 Ma) and be functional from 
artiodactyl order (104 Ma) onwards (Sire et al., 2012). 
Additional exons exist, found in amelogenin genes of eutherian mammals. Sire et al 
(2012) hypothesise that these are a possible evolutionary trait. Exon 4b is a copy of 
exon 4, found downstream of Exon 7. It is present in the amelogenin gene of rodents 
that diverged from squirrels. Not detected in transcripts, it is assumed to be spliced out 
(Bartlett et al., 2006a). In rodents, a further 2 exons have been identified downstream 
of exon 7. Exons 8 and 9 were identified in mRNA splicing variants in mouse and rat 
(Li et al., 1998, Papagerakis et al., 2005, Bartlett et al., 2006a) and at the protein level 
represent the largest amelogenin gene products secreted during rodent amelogenesis. 
Exon 8 results from a duplication of exon 5, translocated downstream of exon 7. 
Although the nucleotide sequences are 91% identical, the resulting amino acid 
sequence is only 50% conserved (Bartlett et al., 2006a). Transcripts comprising exon 
8 also comprised exon 9. Exon 9 was predicted in silico to appear in the gene of 
ancesteral placental mammals (176 Ma) as a downstream sequence, but was 
activated later (50 Ma) in rodents (Sire et al., 2012) as exons 4b and 8 (Bartlett et al., 
2006a) appeared.  
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Figure 7 Alternative splicing variants of amelogenin in mammals. The isoforms 
‘b’ (Dominant splice product) and ‘e’ (LRAP), in boxes, are the most 
abundant splicing isoforms identified in enamel matrix (Gibson et al., 
2011). Rodent genes include an additional three exons downstream of E7: 
E4b, E8 and E9. In the rodent transcripts identified, E4b is spliced out; E8 
and E9 were found, always together (k) but never with E7 (j). 
a 
b 
c 
d 
e 
f 
g 
h 
i 
j 
k 
LRAP 
Dominant splice product / Major isoform 
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1.2.1.3 Properties of amelogenin protein  
The secreted amelogenin product (excluding the N-terminal signal peptide) of the 
major mRNA transcript is conserved between mammalian species (Brookes et al., 
1995). The full-length amelogenin protein is largely hydrophobic, its isoelectric point is 
in the range of neutrality, e.g. murine amelogenin has a pI of 6.6 (Simmer et al., 1994, 
Tan et al., 1998) . Its hydrophobicity is a reflection of the high abundance of proline 
and leucine in amelogenin (Eastoe, 1965, Fang et al., 2011).  
1.2.1.3.1 Primary structure 
The primary amino acid sequence of mouse amelogenin (the major isoform secreted) 
has been known since the 1980s, when it was determined by cDNA sequencing 
(Snead et al., 1985) and by Edman sequencing of translated proteins (Takagi et al., 
1984). Major native amelogenin molecules have predicted molecular weights ranging 
between 16-21 kDa on secretion depending on the animal species but on SDS PAGE 
their electrophoretic mobility is decreased, which leads to overestimation of the 
molecular weights. Hence, the full-length amelogenin (major isoform) is often referred 
to as the “25 kDa” amelogenin in the literature. Such shift in electrophoretic mobility 
has been linked to amelogenin’s high proline content (Termine et al., 1980), after the 
presence of proline was previously shown to affect the mobility of other proteins (de 
Jong et al., 1978). A more useful nomenclature has found favour in the literature in 
recent years. The amelogenin in question is identified with a letter to denote species 
and a number corresponding to the number of amino acids present in the protein. For 
example P173 and M180 denote the secreted unprocessed amelogenin translated 
from the dominant amelogenin mRNA transcripts (see Figure 7b) in pig and mouse 
respectively. 
The most abundant newly secreted amelogenin (excluding exon 4) is predicted to be 
hydrophobic overall with a hydrophilic C-terminal fragment, based on a Hopp & Woods 
hydrophilicity plot of recombinant rM1791 (Fincham et al., 1994). It is divided into three 
domains, of which the N-terminal and C-terminal are highly conserved between 
species (Brookes et al., 1994, Brookes et al., 1995, Margolis et al., 2006). The first 45 
amino acids comprise a rather hydrophobic domain,though still containing charged 
residues. Remarkably, this domain also has a relatively high tyrosine content (6 
tyrosine residues), hence its name ‘tyrosine-rich amelogenin peptide” (TRAP). It 
comprises a run of 13 amino acids that contain 3 tyrosine residues that has been 
1 rM179 corresponds to the recombinant M180 expressed by E. coli, which has lost 
Met1 due to E. coli endogeneous methionine aminopeptidases (Simmer et al., 
1994). 
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shown to have functional importance: this so-called amelogenin trityrosyl motif peptide 
(ATMP), was reported to recognise and bind N-acetylglucosamine (Ravindranath et 
al., 1999, Ravindranath et al., 2000). The importance of the ATMP sequence is 
discussed in greater details in Section 1.2.2.2.1 pp.21 - 22 . The central domain of 
amelogenin is particularly hydrophobic, being made up of XXP repeats (wherein X is 
often glutamine). The number of XXP repeats differs between species, reflecting the 
variability in length of exon 6 in the mature transcript (Fang et al., 2011, Margolis et al., 
2006). The C-terminal domain comprises the last 11-15 amino acids and is highly 
hydrophilic, with a pI of 4.65. Studies using the LRAP variant showed that this 
“telopeptide” has the capacity to bind to hydroxyapatite crystals (Shaw et al., 2004, 
Shaw et al., 2008), which researchers suggested could be associated with the control 
of crystal growth, and also “a potential candidate for promoting crystal nucleation” 
(Tarasevich et al., 2007). The latter assumption appears however contradictory with a 
previous mouse KO study, which reported that amelogenin is not necessary to the 
formation of mineral crystals (Gibson et al., 2001). A further report suggested that the 
telopeptide may also drive the ordered supramolecular assembly of amelogenin 
nanospheres within the enamel matrix (Fang et al., 2011).  
To date, one site of amelogenin post-translational phosphorylation has been identified 
at serine 16 (Ser16) (Fincham and Moradian-Oldak, 1993) . The role of phosphorylation 
in amelogenesis has therefore been a subject of interest. Phosphorylation of Ser16 per 
se has been studied in vitro using the 20 kDa porcine amelogenin processing product 
(P148), the major degradation product found in enamel matrix (Yamakoshi et al., 
1994) and full-length amelogenin (P173). In comparison with their respective non-
phosphorylated counterparts produced in E. coli using recombinant DNA technology, 
the native phosphorylated P148 and P173 amelogenins are capable of regulating 
mineral formation and stabilizing amorphous calcium apatite for longer periods of 
times (>1 day) (Kwak et al., 2009, Kwak et al., 2011). Fourier transform infrared 
spectroscopy (FTIR) measurements comparing phosphorylated LRAP with non-
phosphorylated LRAP showed that phosphorylation affects the secondary structure of 
this splicing isoform, and strongly suggested that it is a determinant factor involved in 
the interactions of LRAP with hydroxyapatite and/or amorphous calcium apatite 
(Yamazaki et al., 2017). Using a quartz crystal microbalance (QCM), researchers 
found that phosphorylation of amelogenin (native porcine P173) affected amelogenin 
conformation and binding to hydroxyapatite surfaces (Connelly et al., 2016). The only 
in vivo studies considered to date have consisted of testing the effect of experimentally 
induced single point mutations of Ser16 to alanine leading to a significantly affected 
enamel, as presented by Dr. H.C. Maroglis’s group in Enamel IX International 
symposium (Kirkham et al., 2017), abstract no. 74. However, one major criticism of 
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this approach is whether the affected phenotype is caused by the loss of the 
phosphate group or whether it is due to the presence of alanine, a non-polar amino 
acid that may cause a gain of toxicity independent from the loss of the phosphate 
group. 
Apart from the phosphorylation on Ser16, no other post-translational modifications are 
known. Studies investigating potential glycosylation showed that amelogenin is not a 
glycoprotein. Fincham et al (1991), using immunological procedures, found that 
amelogenin is not glycosylated (Fincham et al., 1991b). 
1.2.1.3.2 Secondary structure 
Structural studies using circular dichroism (CD), FTIR and nuclear magnetic 
resonance (NMR) identified secondary structure motifs such as beta sheet, beta 
strand or alpha helices in bovine amelogenin (Renugopalakrishnan et al., 1986, 
Renugopalakrishnan et al., 1989, Delak et al., 2009). These motifs were found locally 
without forming further any ordered structured domain. Most studies agree that 
amelogenin is an unstructured or intrinsically disordered protein (IDP) (Delak et al., 
2009, Lakshminarayanan et al., 2009, Ruan and Moradian-Oldak, 2015).  
Amelogenin has a high proline content, which is a disorder-promoting residue (Theillet 
et al., 2013) and also possibly responsible for polyproline II (PPII) motifs, which make 
extended and flexible structures. Lacking stabilising hydrogen bonds, the PPII motif is 
most likely to be an open and flexible structure (Williamson, 1994, Tompa, 2002). 
Reviewed by Adzhubei et al, (2013), PPII regions are most common in IDPs. 
Favouring low affinity interactions, and simultaneously allowing a high specificity of 
recognition, these motifs are favourable to protein assembly and have been implicated 
in protein recognition, signal transduction, or protein complex assembly. PPII motifs 
have also been found in proteins involved in conformational diseases such as Prion 
PrPC proteins, α-synuclein, tau protein, Alzheimer extracellular amyloid β peptide 
fragment (Adzhubei et al., 2013).  
In amelogenin in particular, PPII structures were identified by CD in recombinant 
rP172 and in rP148 (identical to the native P173 and P148 respectively but missing the 
N-terminal methionine and the phosphate group on Ser16; rP148 was engineered with 
an extra methionine in position 149). Increasing the protein concentration from 5 μM 
to >62.5 μM was reported to favour formation of β-sheet structures 
(Lakshminarayanan et al., 2007, Delak et al., 2009). Within the temperature range 5-
45°C, β-sheet tended to form “at the expense of PPII structure” (Lakshminarayanan et 
al., 2009). Therefore, under physiological conditions it is possible that both β-sheet 
and PPII structures might contribute towards amelogenin assembly and aggregation 
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properties (though it is unclear what impact the lack of N-terminal methionine and the 
phosphate group on Ser16 would have on these data).  
1.2.1.3.3 Tertiary structure 
Efforts have been carried out to solve the crystallographic structure of amelogenin. 
Crystallographic data reported in 2005 showing a birefringent microribbon structure 
(Du et al., 2005), was later found to be due to the presence of a cellulose contaminant, 
as highlighted in the erratum by Du et al (2005)The difficulty in crystallising 
amelogenin may be due to its high proline content since proline-rich regions and/or 
PPII structures make it difficult to crystallise certain proteins (Williamson, 1994). To 
date, no amelogenin tertiary structure derived from crystallography has been reported. 
Due to the lack of any X-ray crystallographic structure or any other template, in silico 
prediction using homology modelling has not been achieved.  
1.2.1.3.4 Quaternary structure: amelogenin self-assembly 
The formation of quaternary structures of amelogenin is a highly complex 
phenomenon due to amelogenin self-assembly and aggregation properties, which are 
of fundamental importance in amelogenesis. This has therefore attracted a great deal 
of interest and is discussed in greater details in Section 1.2.2 below. 
1.2.2 Amelogenin self-assembly 
1.2.2.1 Amelogenin propensity to aggregate 
The PPII motif, in combination with the hydrophobic domains of amelogenin, appears 
to favour hierarchical self-assembly of amelogenin as suggested by variable 
temperature CD and isothermal titration calorimetry (ITC) studies (Lakshminarayanan 
et al., 2007, Lakshminarayanan et al., 2009). PPII is found in protein regions available 
for recognition and binding (Adzhubei et al., 2013). Early reports suggested that PPII 
motifs are responsible for the temperature-dependent but reversible propensity for 
amelogenin to aggregate (Nikiforuk and Simmons, 1965, Mechanic et al., 1967). This 
characteristic behaviour of amelogenin has been further characterised by high-
resolution size exclusion chromatography (HR-SEC), dynamic light scattering (DLS), 
atomic force microscopy (AFM) and transmission electron microscopy (TEM) (Fincham 
et al., 1994, Moradian-Oldak et al., 1994). The size of the amelogenin aggregates 
increases with temperature in the range 5 - 37°C (Moradian-Oldak et al., 1998).The 
formation of these aggregates has been linked to the low solubility of amelogenin, 
shown by quantitative analyses using recombinant mouse amelogenin rM179. The r-
amelogenin is only sparingly soluble at physiological pH and temperature (Simmer et 
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al., 1994, Tan et al., 1998), as physiological pH is around amelogenin’s predicted 
isoelectric point of 6.8. Amelogenin solubility was also found to decrease with higher 
ionic strength of the solution (Tan et al., 1998). 
1.2.2.2 Amelogenin hierarchical assembly 
Despite being aggregative, amelogenin self-assembles in an ordered fashion, to form 
hierarchical structures (Fang et al., 2011), which are presumed to be necessary to 
guide the formation of enamel crystals. This Section addresses: i) the domains 
involved in amelogenin self-assembly (Section 1.2.2.2.1) , ii) evidence of the first level 
of supramolecular structures which form in the ameloblasts (Section 1.2.2.2.2) and iii) 
the assembly into larger structures found in the extracellular matrix (Section 1.2.2.2.3). 
1.2.2.2.1 Domains involved in amelogenin recognition and self-assembly 
Amelogenin self-assembly was characterised by Y2H assay conducted by Paine and 
Snead (1997). The authors confirmed that amelogenin (M180) is capable of binding to 
itself with a greater affinity than that seen for protein p53 binding to SV40 large T-
antigen. p53 and SV40 large T-antigen were used as positive controls as they are 
well-known binding partners, yielding 150 β-galactosidase (Miller) units in the Y2H 
assay (Li and Fields, 1993). Two domains were found to be necessary for amelogenin 
self-assembly: the N terminal 42-residues (Met1-Met42) A domain and the 16-residue 
(Ser157 – Lys173) C-terminal B domain (Paine and Snead, 1997). Deletion experiments 
in vitro and in vivo confirmed the importance of the A and B domains in the formation 
of supramolecular assemblies (Paine et al., 2000). The N-terminal 42 residues, which 
comprise the majority of the TRAP domain as described in Section 1.2.1.3.1 p. 17 (and 
part of the hydrophobic core of amelogenin) specifically drives the formation of 
supramolecular amelogenin assemblies (so-called nanospheres). The C-terminal 16 
residues (hydrophilic) were reported to be essential in maintaining the integrity and 
stability of these nanospheres (Paine and Snead, 1997, Moradian-Oldak et al., 2000) 
by preventing clustering of hydrophobic cores of amelogenins. Later, another Y2H 
assay testing different truncated mouse r-amelogenins indicated that Pro169 plays a 
pivotal role in driving self-assembly, but point mutations Pro169 →Thr or Pro169 →Lys 
surprisingly did not affect significantly affect the self-assembly (Paine et al., 2003b). In 
vitro, a study comparing the aggregates formed by recombinants rM166 and rM179 
suggested that the C-terminal telopeptide was essential to form stable and 
monodisperse aggregates (Moradian-Oldak et al., 1994) The r-amelogenins rM166 
and native P161 lacking the conserved C-terminal telopeptide, had a larger size 
distribution and a reduced affinity for hydroxyapatite (Moradian-Oldak et al., 2002). 
They formed larger aggregates than their full-length precursors, as measured by DLS 
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and small-angle X-ray scattering (SAXS) (Moradian-Oldak et al., 2002, Aichmayer et 
al., 2005). Native P148, which also lacks the C-terminal telopeptide as well as the 
Pro162 (corrresponding to the mouse amelogenin Pro169) was also capable of forming 
nanospheres, though of a smaller size (Moradian-Oldak et al., 2002). DLS data and 
fluorescence studies using recombinant porcine amelogenins found that rP1482 
formed similar oligomers, even though smaller, as rP172 (Bromley et al., 2011). This 
clearly questions the importance of the C-terminal telopeptide and the Pro169 (in mice, 
or Pro162 in pig) in amelogenin supramolecular assembly. 
While both A and B domains are present in the full-length amelogenin (major splicing 
isoform) sequence, alternatively spliced variants such as LRAP lack these domains. 
Paine and Snead (1997) showed that LRAP does not self-assemble (Paine and 
Snead, 1997). LRAP lacks the sequence Tyr34-Met42, i.e. the ATMP domain; their 
finding suggests that the ATMP is a necessary, though not sufficient, driver of 
amelogenin self-assembly. The importance of the ATMP motif in amelogenin self-
assembly has been supported by Wald et al (2017), who focused on the evolutionarily 
conserved “Y/F-X-X-Y/L/F-X-Y/F” motifs (including the amino acids sequence 
YPSYGY), present in amelogenin and ameloblastin. Interestingly such motifs are short 
linear sequences rich in hydrophobic residues and are well-known drivers of IDP 
assembly (Mészáros et al., 2007). Comparing the WT (YPSYGY) and mutant 
(GPSGGG) recombinant human amelogenins and using HR-SEC, TEM and surface 
plasmon resonance (SPR), Wald et al showed that the integrity of the YPSYGY motif 
is necessary for amelogenin self-assembly, and possibly amelogenin-ameloblastin 
recognition (Wald et al., 2017). This latter observation supports previous works by 
Ravindranath et al, discussed in further details later (Section 1.2.5.2, pp. 45 - 49) 
1.2.2.2.2 Intracellular assembly of amelogenin in vivo 
Cross-linking studies in rat enamel organs showed that amelogenin begins to self-
assemble within the ameloblast secretory pathway. Diagonal SDS PAGE analysis 
followed by western blotting with anti-amelogenin antibodies showed the presence of 
dimers, tetramers, pentamers and hexamers of full-length M180 amelogenin. Through 
cross-linking, hexamers appeared to be the biggest unit forming intracellularly 
(Brookes et al., 2006) prior to further assembly steps in the extracellular matrix. These 
levels of assembly are detailed below, in Section 1.2.2.2.3. 
2 For clarification, recombinant rP148 used by Bromley et al. (2011) differs from the 
native P148 since it lacks Met1 and Ser16 phosphorylation, and carries and extra 
methionine at position 149. 
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1.2.2.2.3 Extracellular assembly of amelogenin observed in vivo 
Having demonstrated that amelogenin assembly begins in the intracellular secretory 
pathway (Brookes et al., 2006), Brookes et al. (2006) hypothesised that the hexamers 
undergo further assembly within the newly secreted matrix. The first stages of 
hexamer assembly may lead to the formation of transient aggregates, which may 
constitute the stippled material observed near the Tomes’ processes in developing 
enamel (Fincham et al., 1994). The transient aggregates further assemble into 
spherical structures, ‘nanospheres’, each comprising approximately 100 amelogenin 
units (Moradian-Oldak et al., 2002). Freeze-etching and AFM of developing enamel in 
rat incisors showed the presence of 30-50 nm diameter nanospheres (Robinson et al., 
1981). TEM of mouse, bovine and hamster developing enamel also showed spherical 
electron-lucent structures of 20-50 nm diameter with uranyl acetate staining; these 
nanospheres appear themselves to be organised as arrays of beads surrounding the 
forming enamel crystallites (Fincham et al., 1995). Fincham et al (1995) assumed that 
the nanospheres observed in the TEM were made up of amelogenin aggregates. They 
appeared electron-luscent because the hydrophobic nature of amelogenin may 
prevent them from binding to the heavy metal contrasting agent used to stain the TEM 
sections by increasing the electron absorption of specific structures comprising the 
section linking their observations to previous experiments where purified porcine 
amelogenins showed negative heavy metal staining when contrasted with ammonium 
molybdate. 
In addition to the in vivo studies described above, a plethora of vitro studies has been 
carried out to characterise amelogenin assembly. The literature reviewed below ( in 
Section 1.2.2.2.4) used r-amelogenin rM179 (Simmer et al., 1994), an analogue of 
major mouse amelogenin M180, lacking phosphorylation in Ser16 and the N-terminal 
Met. Amelogenin assembly studies discussed below also used porcine 25 kDa full-
length amelogenin, P173, which can be obtained from pig developing teeth obtained 
as a by-product of the meat industry (Aoba et al., 1987a, Limeback, 1987). 
- 24 -
1.2.2.2.4 Characterisation of amelogenin self-assembly in vitro 
The solution properties of r-amelogenin, i.e, its propensity to self-assemble and 
aggregate were thoroughly investigated in vitro using rM179. The techniques 
employed include DLS, HR-SEC, TEM and AFM. While the assembly of amelogenins 
in macromolecular structures is hierarchical, in vitro studies reported various assembly 
modes: nanospheres, micelles, or microribbons, as discussed below and illustrated in 
Figure 8.  
 Nanospheres
The self-assembly of amelogenins into nanospheres (briefly mentioned previously in 
the Section 1.2.2.2.1) has been supported since the 1990s using rM179 (Fincham et 
al., 1994, Moradian-Oldak et al., 1998). “Spherical aggregate structures” of 12-18 nm 
diameter were observed using TEM on parlodion-covered carbon-coated copper grid, 
while 15-20 nm diameter spheres were shown by AFM on mica surface (Fincham et 
al., 1994, Wen et al., 2001), which is consistent with the nanosphere structures 
observed in vivo, described above in Section 1.2.2.2.3. DLS studies at pH 7-8 in Tris-
HCl showed that their molecular weights ranged between 2000 - 3800 kDa, which 
suggests that they are made up of 100-200 amelogenin monomers {Moradian‐Oldak, 
1994 #142}. A cryoelectron microscopy study of rM179 At pH 8 in Phosphate-buffered 
saline (PBS) supported the formation of 15-20 nm diameter nanospheres at room 
temperature within 10 minutes of incubation (Fang et al., 2011). A combination of DLS 
and SAXS studies suggested that these nanospheres comprise a dense hydrophobic 
core (detected by SAXS), surrounded by a looser shell of protein that was 
hypothesised to be comprised of the C-terminal hydrophilic telopeptide (Aichmayer et 
al., 2005).  
The formation of the nanospheres was shown to be pH, temperature and 
concentration-dependent. Initial DLS studies at room temperature (25-29°C) indicated 
that the size and distribution of aggregates varies with pH (Moradian-Oldak et al., 
1994, Moradian-Oldak et al., 1998). At pH values below 6, aggregates were relatively 
small (hydrodynamic radii 4-7 nm in Tris-HCl, or 3.9 - 4.5 nm in sodium acetate at pH 
4.4) whereas at pH 7.4, the hydrodynamic radius of the aggregates was increased to 
19.2 nm. This might be expected as pH values below 6 would induce a greater charge 
on rM179, making it more soluble and less prone to aggregation. The increased size of 
the aggregates at physiological pH is linked to their decreased solubility. At pH values 
≥ 7.8, which is significantly above the pI of rM179, the solubility of amelogenin 
increased, and the size of the aggregates decreased to 15-16 nm hydrodynamic radii 
(Tan et al., 1998, Moradian-Oldak et al., 1998). 
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DLS studies also showed that nanosphere assembly is sensitive to environmental 
temperature: Below 25°C, the nanosphere hydrodynamic radius was 15-18 nm, 
whereas at 37-40°C, it increased to 60-70 nm (Moradian-Oldak et al., 1998). 
Moradian-Oldak et al (1998a) observed that variation of pH between values 4.4 and 8 
affected the size of amelogenin aggregates significantly more at 37°C than at 25°C. 
While the size of the aggregates reached a maximum radius of 25 nm at pH=7.4 and a 
temperature of 25°C; this increased to 35 nm at pH=7.4, and then to 58 nm at pH=8, at 
37°C.  
The hydrodynamic radius of amelogenin aggregates also increases with ionic strength. 
For example at pH 7.4, increasing the ionic strength from 0.05 M to 0.16 M increased 
nanosphere hydrodynamic radius from 19.2 nm to 28.8 nm (Moradian-Oldak et al., 
1994). The physiological ionic strength of enamel fluid is 0.164 mM (Aoba and 
Moreno, 1987), suggesting that physiological temperature and ionic strength favours 
amelogenin aggregation and the assembly of larger nanospheres.  
In light of the effect of temperature on amelogenin interactions we may question the 
relevance of amelogenin in vitro aggregation/binding experiments when these are 
carried out at non-physiological temperatures. A typical example is the mechanism of 
amelogenin hierarchical assembly into nanospheres, proposed by Fang et al (2011) 
from data obtained at 25°C. In their report, the authors hypothesised that 1) 
amelogenins form dimers via their C-terminal extremities, 2) six dimers associate side-
by-side to form dodecamers and 3) dodecamers associate to form nanospheres (Fang 
et al., 2011). Fang et al’s hypotheses contrasts with previous knowledge on 
amelogenin assembly in that the ATMP motif is necessary in amelogenin self-
assembly in first place (discussed in the Section 1.2.2.2.1, p. 22), and the C-terminal 
hydrophilic peptide DKTKREEVD is not sufficient to trigger amelogenin-amelogenin 
interaction. For instance, LRAP does not self-assemble as indicated by Y2H studies 
(Paine and Snead, 1997). 
 
 Micelles 
Other modes of amelogenin assembly have been proposed. In 2007, Fukae et al 
(2007) speculated that amelogenins associate as micelles, using porcine 25 kDa 
amelogenin and its proteolytic processing products (Fukae et al., 2007). Their 
hypothesis was based on the Kyte and Doolittle amphiphilicity index and Robson 
secondary structure prediction. They claimed that the N-terminal amino acids (Met1 to 
Trp45) form the hydrophobic core of the micelles while the 13 kDa (Leu46 to Ser148) 
domain acts as a rod-like structure that connects the micellar core to the hydrophilic C-
terminal segment comprising Lys166- Asp173, which is exposed at the surface of the 
micelle facing the aqueous environment. Fukae et al (2007) add that the highly 
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charged C-terminal segments form α-helices and can interact with each other by 
intermolecular ionic interactions that mediate amelogenin-amelogenin interactions, and 
furthermore, inter-micelle assembly and aggregation. There is, however, a lack of 
evidence supporting this micelle model and there is a caveat to consider. Given that 
amelogenin is reportedly an IDP and that no tertiary structure has been found to date 
(see Section 1.2.1.3.3, p. 20), it is difficult to reconcile the in silico predicted structural 
features Fukae et al. (2007) describe with the experimental data obtained by others. 
 Ribbons
Other groups reported that amelogenin supramolecular structures are ribbon-like with 
amelogenin monomers either assembling directly into so-called nanoribbons or 
amelogenin nanospheres assembling into so-called microribbons. A first X-ray 
structure was published in 2005. The authors of that report claimed that the 
birefringent microribbons visible by synchrotron X-ray diffraction (XRD) and SEM were 
supramolecular assemblies of amelogenin nanospheres (Du et al., 2005). The report 
was later retracted (2005), following Beniash et al’s observation that the fibrillar 
structure observed was actually that of contaminanting cellulose fibres. Moradian-
Oldak et al (2006) later maintained that amelogenin supramolecular assembly results 
in the formation of microribbons using FTIR and Raman microspectroscopy, and 
proposed that amelogenin nanospheres assemble into collinear arrays which 
correspond to microribbons. They reported that these features had not yet been 
verified in vivo (Moradian‐Oldak et al., 2006). One criticism of this study is that 
polyethylene glycol, which is a protein precipitant (Ingham, 1984) was used to drive 
the amelogenin to form ribbons. It is unclear how relevant these experimental 
conditions are to the situation in vivo. A recent paper by Carneiro et al (2016) claimed 
that human amelogenin rH174 self-assembles into nanoribbons in vitro. Using AFM 
and TEM; they proposed that an N-terminal segment (Gly8 - Thr21) drives amelogenin 
self-assembly into nanoribbons through β-sheet interactions (Carneiro et al., 2016). 
However these are in silico predictions, and the formation of nanoribbons in vitro was 
observed at acidic pH (4.5-5.5 or 6.5), which again raises questions around the 
relevance of their findings to the situation in vivo. 
- 27 -
To summarise, most reports agree that amelogenin assembly is an ordered 
hierarchical process, though different modes of assembly have been reported 
(summarised below in Figure 8). The most plausible model of assembly to date is 
nanospheres of 20-50 nm diameter, which could be the spherical structures observed 
in developing mouse enamel (Fincham et al., 1995). Further in vivo investigations are 
needed to confirm the precise identity of these structures e.g. are they pure 
amelogenin or are other enamel proteins involved? 
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1.2.3 Matrix biochemistry and processing of amelogenin 
Understanding the process of amelogenin self-assembly (discussed in the previous 
Section) and its interactions with other proteins and mineral within the matrix is a 
critical step in determining the role of amelogenin in amelogenesis. Amelogenin is a 
major and essential component of developing enamel matrix, suggested to control the 
growth of enamel crystals (Wallwork et al., 2001). As mentioned in the Section 1.1.2.3 
(pp. 8 - 9), the enamel crystallites sketched in during the secretory stage of 
amelogenesis appear thicker at the dentine-enamel junction (older enamel) and 
thinner at the secretion front (newer enamel). This correlates with a progressive 
proteolytic processing of amelogenin within the enamel matrix, with full-length 
amelogenin present in the newer enamel, where crystals are thinner, and its 
processing products present in the older enamel, where the crystals are thicker and 
wider (Daculsi and Kerebel, 1978, Robinson et al., 1998). Once the enamel matrix has 
reached its full thickess maturation begins; the amelogenins and processing products 
are degraded and removed, then the enamel becomes fully mineralised. 
This Section addresses i) The proteolytic processing of amelogenin throughout 
secretory stage and its possible role in the reduction in amelogenin- mineral binding 
(Section 1.2.3.1). Then it addresses ii) the full degradation of amelogenins during 
transition and maturation stages (Section 1.2.3.2). 
1.2.3.1 Amelogenin processing throughout secretory stage 
The full-length “25 kDa” amelogenin is restricted to the outer layer of the forming 
enamel and is rapidly processed after being secreted (Fukae et al., 1980, Uchida et 
al., 1991b). This processing is sequential and results in the formation of different 
processing products with various physico-chemical properties. The properties of the 
major processing products of amelogenin are described in the Section 1.2.3.1.1 below 
and how these are involved in the control of enamel crystallites growth is addressed in 
the Section 1.2.3.1.2. 
1.2.3.1.1 Protelolytic processing during secretion 
Proteolytic processing has been extensively studied in pig developing enamel. Once 
secreted into the secretory-stage enamel matrix, the full-length amelogenin (P173), 
whose apparent mobility on analytical SDS PAGE is 25 kDa, is rapidly degraded into 
smaller fragments (Fincham et al., 1991b). In pig secretory enamel, these include a 23 
kDa, 20 kDa, 13 kDa, 11 kDa, 7 and 5 kDa fragments (Yamakoshi et al., 1994) (Figure 
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9), most of which were shown to be the result of cleavage by MMP-20 that is co-
secreted during the secretory stage (Ryu et al., 1999, Nagano et al., 2009).  
The newly secreted 25 kDa amelogenin (P173) has a high degree of polarity, with a 
major hydrophobic portion and an extremely hydrophilic C-terminal portion (the last 12 
amino acids comprising the C-terminal telopeptide), Figure 9. It is quickly degraded by 
MMP-20 and as a result the intact full-length secreted product is restricted to the newly 
secreted enamel matrix at the surface of the developing enamel (Uchida et al., 1991b). 
The first MMP-20 processing step removes the hydrophilic C-terminal telopeptide, 
producing a 23 kDa amelogenin (P161). P161 is also present transiently (Yamakoshi 
et al., 1994) and is further processed resulting in the loss of its C-terminal comprising 
Met149-Trp161. The resulting processing product is P148 (commonly referred to as the 
20 kDa amelogenin from SDS PAGE analysis). P148 is relatively stable in the enamel 
matrix, and therefore accumulates, so that it appears clearly as the major band on 
SDS PAGE analyses of secretory stage pig enamel (Shimizu M, 1983, Yamakoshi et 
al., 1994, Brookes et al., 1995, Maycock et al., 2002). It was argued that P148 might 
be derived from either the 23 kDa fragment or directly from the parent amelogenin. 
Both P161 and P148 fragments self-assemble in vitro to form nanospheres; the P161 
fragment appears to form more heterogeneous nanospheres on AFM while the P148 
fragment formed smaller nanospheres with hydrodynamic radii of 10-14 nm (Moradian-
Oldak, 2001). 
Further processing of 20 kDa amelogenin was shown in vivo to generate 5 and 13 kDa 
fragments (Tanabe, 1984, Aoba et al., 1987b, Fincham and Moradian-Oldak, 1993). 
The 5 kDa fragment is the TRAP domain, comprising the first 45 amino acids. It is 
relatively insoluble and is highly conserved between species (Fincham et al., 1983, 
Fincham et al., 1989). It is also the ‘A-domain’ involved in protein-protein interactions 
identified by Y2H experiments (Paine and Snead, 1997). The loss of TRAP disrupts 
amelogenin self-assembly, and the resulting 13 kDa fragment, comprising Leu46- 
Ser148 (P46-148), does not self-assemble and is completely soluble in the enamel fluid 
(Brookes et al., 1995). However, there appears to be conflicting reports as to whether 
these lower molecular fragments are generated by the cleavage of P148 by MMP-20 
(Nagano et al., 2009, Kwak et al., 2016): while Nagano et al (2009) supported that the 
TRAP and P46-148 result from the cleavage of P148 by MMP-20, Kwak et al (2016) 
argued that P46-148 would be generated by the cleavage of P173 by MMP-20 instead, 
supporting that MMP-20 does not cleave P148. Otherwise, a minor alternative 
processing route was reported to generate an 11 kDa fragment, spanning Ala63 - 
Ser148 (Aoba et al., 1987b). 
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1.2.3.1.2 Effect of amelogenin processing on mineral binding and role of 
amelogenin in enamel matrix mineralisation 
The protein matrix of developing enamel supports and potentially directs the 
elongation of thin plate-like enamel crystals that grow in length (c-axis growth) (Nylen 
et al., 1963) as they pursue the retreating ameloblasts. By AFM, amelogenin 
nanospheres appeared to be organised in linear arrays, aligned with the side faces of 
the enamel crystals (Fincham et al., 1995, Fincham et al., 1999). In effect, the crystal 
architecture is lightly “sketched in” during the secretion stage but how these crystals 
are nucleated is not fully established. Initially, calcium and phosphate ions are present 
in the earliest secreted enamel (Deakins and Burt, 1944, Takano et al., 1986, 
Robinson et al., 1974). Crystals nucleate in the extracellular environment to form an 
ordered crystal array (Fincham et al., 1999), possibly in the initial form of octacalcium 
phosphate which later changes phase to form hydroxyapatite, which are the basic unit 
of the prisms observed in mature enamel. As nucleation of hydroxyapatite is not 
thermodymically favourable, it requires a “catalyst” to proceed. This catalyst may take 
the form of a proteinaceous template which promotes heterogeneous nucleation by 
matrix-mineral electrostatic interactions (Kirkham et al., 2002) but it is unclear which 
protein(s) are involved. They could originate either from the dentine or the DEJ, or 
from EMPs themselves. Both protein-mineral and protein-protein interactions mediate 
enamel crystallites and prism formation.  
Aoba et al. (1987a) hypothesised that processing and degradation of amelogenins 
favours crystallite growth in width and thickness– suggesting that full-length 
amelogenin constrains enamel crystal growth to c-axis only. This hypothesis was 
based on the smaller crystal thickness observed in the outer layer being concomitant 
with the location of full-length 25 kDa amelogenin essentially in that region. Its rapid 
degradation in the deeper layers (Uchida et al., 1991b) was related to reduced protein-
to-mineral adsorption which relieved inhibition of crystal growth and allowed the 
crystals present in the deeper enamel to grow in width and thickness (Aoba et al., 
1987a).  
However, this theory can be challenged. It must be noted that crystals in the deeper 
enamel are simply older and have been exposed to the mineralising environment for 
longer and have had more time to grow. That they appear thicker at the dentine-
enamel junction and thinner at the secretion front can be explained on this basis alone 
in the absence of any crystal growth inhibition associated with mineral bound full-
length amelogenin. 
A major challenge to the hypothesis proposed by Aoba et al. (1987a) was highlighted 
in S.J. Brookes’s thesis (1995, pp. 172-175) citing observations and TEM 
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measurements of enamel crystallites’ thickness and width reported by Daculsi and 
Kerebel in 1978 (shown below in Figure 10). These measurements do indeed indicate 
that crystallite thickness and width increase with depth; however, the rate of increase 
in width and thickness is faster in the “outer” 50 µm, (within the first 50 µm depth, from 
the Tomes’ processes, the width and thickness increase by 160% and 220% 
respectively), which is where the supposedly inhibitory full-length amelogenin is found. 
In contrast at 200-500 µm depth from the Tomes’ processes, where amelogenin 
degradation products dominate, the crystal width and thickness have only increased 
by 5.7 and 52.4% in thickness and width respectively (Daculsi and Kerebel, 1978). 
However, it must be rembered that the youngest crystals will be imperfect and exhibit 
more growth sites than older crystals so may be growing faster despite the presence 
of supposedly inhibitory full length amelogenin at this point. It may be that full-length 
amelogenin is actually damping very active growth near the surface and although the 
rate of growth is higher, it is less than it would be in the absence of the full length 
amelogenin.  
Figure 10 Growth of crystal width and thickness with enamel depth, as 
measured by Daculsi and Kerebel, 1978. Note the rate of growth is highest 
near the surface where the supposedly inhibitory full-length amelogenin is 
localised. 
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Amelogenin processing products have different biochemical properties to the full-
length amelogenin and may therefore have distinct and specific roles in enamel 
formation. For instance, studies suggested that (25kDa) P173 guides ordered 
hydroxyapatite crystal formation unlike (20kDa) P148, although both are involved in 
amorphous calcium phosphate stabilisation (Kwak et al., 2014). The consequences of 
amelogenin degradation may be more complex than merely generating space for 
crystallite growth in width and thickness (which Aoba et al (1987) appeared to suggest, 
as described above).  
However, in keeping with previous reports (Aoba et al., 1987a) other studies reported 
that amelogenin affinity for apatite surfaces is reduced on proteolytic processing. The 
C-terminal domain, which is charged, has strong affinity for hydroxyapatite crystals 
(Shaw et al., 2004) and its loss (processing of the full-length 25 kDa amelogenin) 
results in reduced affinity for apatite surface (Moradian-Oldak et al., 2002).The 23 kDa 
and 20 kDa amelogenins, present in higher ratio in the enamel matrix (with the 20 kDa 
amelogenin more stable), have different physico-chemical properties, per se, than the 
parent protein (more hydrophobic, illustrated in Figure 9). Such species form different 
supra-molecular assemblies in vitro to generate nanospheres with different sizes and 
polydispersity which may alter the structure and biochemical nature of the matrix 
(Moradian-Oldak, 2001). However, in vivo, the processing fragments are already 
assembled in nanospheres even as they are generated by MMP-20 processing so it is 
unlikely that monomeric forms of P161 and P148 are available in the matrix and the 
relevance of these in vitro findings is questionable.  
In addition to proteolytic processing (detailed above in Sections 1.2.3.1.1-2), 
amelogenin dephosphorylation might affect structure and function of amelogenin. 
Dephosphorylation may certainly have a functional role since phosphatases are 
present in the developing enamel matrix (Brookes et al., 1998). Phosphorylation per se 
can affect the secondary structure in LRAP in terms of its ability to stabilise the mineral 
phase (Yamazaki et al., 2017). As for P148, De-phosphorylation (or the lack of 
phosphorylation in rP147) affects the abilty of P148 to control crystal growth in vitro 
(Kwak et al., 2009). 
 
1.2.3.2 Amelogenin degradation during maturation stage 
As mentioned in the Section 1.1.2.4 (pp. 11-12), the increase in mineral content during 
the maturation stage is concomitant with the loss of the proteins in the matrix. The 
EMPs are degraded by the serine protease KLK4. KLK4 degrades the spectrum of 
proteins and peptides generated during the secretory stage processing (Hu et al., 
2000, Ryu et al., 2002). KLK4 proteolysis generates small peptides that can be easily 
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removed from the matrix. These peptides are endocytosed by ruffle ended 
ameloblasts (Bartlett and Simmer, 2014, Pham et al., 2017). Fluid (enamel fluid) 
replaces the degraded enamel proteins. This fluid is kept supersaturated with respect 
to hydroxyapatite as the ameloblasts pump mineral ions into the enamel which drives 
the concomitant growth in thickness and width of the enamel crystals until the enamel 
becomes fully mineralised.  
Using cervical enamel from incisor germs from human fetus (6-8 months old) and from 
erupted “temporary” teeth, Daculsi and Kerebel (1978) analysed the growth of the 
enamel crystallites in width and thickness using high resolution TEM. They showed 
that the crystallites grow mostly in width during the first stage of enamel development, 
and that until the end of foetal development the width has nearly stabilised to its 
average value in mature (erupted?) enamel. By then and until complete maturation, 
the crystallites grow only in thickness (Daculsi and Kerebel, 1978) as illustrated in 
Figure 10. 
As enamel hydroxyapatite crystals grow during the maturation stage, the pH drops 
since the formation of calcium hydroxyapatite unit releases protons, as shown in 
equation (1) (Simmer and Fincham, 1995). 
(1) 10 Ca2++ 6 HPO42- + 2 H2O ⇋ Ca10(PO4)6(OH)2 + 8H+ 
To buffer the increase of acidity, ruffle-ended ameloblasts secrete bicarbonate ions 
towards the matrix. The pH of the enamel matrix oscillates between 6.1 and 7.4, as 
ameloblasts shift between ruffle-ended, which is when they secrete bicarbonate ions to 
neutralise the protons released, and smooth-ended. This possibly buffers the 
variations of pH caused by hydroxyapatite formation.  
DLS studies showed that amelogenin nanospheres were extremely sensitive to 
changes of pH (addressed in Section 1.2.2.2.4, pp. 24-25 ), which may have a 
functional importance during amelogenesis. While the size of the aggregates were 35 
nm at pH=7.4 they increased to 58 nm at pH=8, that is, an increase of 66% over 0.6 
pH units (Moradian-Oldak et al., 1998). During the maturation stage, the drop and 
variations of pH may help break up the amelogenin nanospheres and thereby, 
facilitate amelogenin degradation and removal.   
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1.2.4 Other structural proteins of the developing enamel matrix : 
ameloblastin and enamelin 
Ameloblasts secrete three major EMPs during the secretory stage (enamelin, 
amelogenin and ameloblastin) and two during the maturation stage (amelotin and 
ODAM, detailed earlier in Section 1.1.2.4, pp. 10 - 11). Evolutionary analyses indicated 
that the five genes encoding these proteins are related; all are derived from the 
enamelin encoding gene ENAM (Sire et al., 2007), which highlighted their importance 
in amelogenesis, and the potential necessity of a coordinated action of their 
expression products. This Section focuses on ameloblastin and enamelin, which are 
structural proteins specific to the secretory stage. Like amelogenin, they have a 
relatively high content of proline and glutamine (Smith et al., 2009). Their properties 
and hypothesised functions are addressed below. 
1.2.4.1 Ameloblastin 
Ameloblastin is the second most abundant protein in the developing enamel matrix 
after amelogenin and is another essential component in enamel formation as ambn-/- 
(null) or overexpression mouse models exhibited odontogenic tumours or AI 
phenotypes respectively (Paine et al., 2003a, Fukumoto et al., 2004). Mutations in 
ameloblastin gene AMBN drove some cases of AI in man, as detailed later in Section 
1.3.2.2 (p. 53 - 54). 
The ameloblastin gene, in rats, comprises an open reading frame predicted to encode 
a protein of 422 amino acids, with a molecular weight of 45 kDa. The protein encoded 
has a high content of proline, glycine, leucine and alanine and a predicted pI of 5.54 
(Černý et al., 1996, Krebsbach et al., 1996). Ameloblastin is first expressed during 
amelogenesis as the IEE differentiates into ameloblasts, through the secretory stage 
and also during early maturation and its expression is much reduced at the end of 
maturation stage (Lee et al., 1996). The ameloblastin gene is alternatively spliced (Lee 
et al., 2003); and two major alternatively spliced transcripts have been reported in 
human, mouse, rat and pig (MacDougall et al., 2000).  
As a secreted protein, ameloblastin was detected by immunohistochemistry transiting 
the ER, Golgi apparatus and secretory granules within ameloblasts prior to secretion 
(Uchida et al., 1997). Within the secretory pathway, the newly synthesised 
ameloblastin undergoes post-translational modifications, O-glycosylation and 
phosphorylation, which increase its apparent molecular weight on secretion (Uchida et 
al., 1997). Newly secreted ameloblastin is found mostly at the surface of the 
ameloblast Tomes’ process during the secretory stage (Krebsbach et al., 1996). Once 
secreted, ameloblastin undergoes processing and degradation, with in vitro studies 
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suggesting that MMP-20 is the protease responsible (Iwata et al., 2007). Sequential 
extraction studies showed that some of the degradation products interact with enamel 
mineral and need to be desorbed from enamel crystal surfaces with phosphate buffer 
in order to be extracted from the tissue (Brookes et al., 2001). Initial cleavages of 
newly secreted ameloblastin generate a number of N-terminal polypeptides, some of 
which are found in the prism sheath. The remaining C-terminal polypeptides are 
quickly degraded and lost after secretion (Uchida et al., 1997). Although ameloblastin 
has a different spatial distribution within the extracellular matrix than amelogenin (i.e. 
N-terminal fragments accumulate at prism peripheries) they both share the same
secretory pathway in the ameloblasts and are co-secreted (Nanci et al., 1998, Zalzal et 
al., 2008) 
Although the precise function of ameloblastin is not clear, it is assumed to be involved 
in the control of crystal growth and in ameloblast attachment to the extracellular matrix. 
The major ameloblastin isoform carries in its sequence the amino acid motifs DGEA 
and VTKG; sequences found in adhesion molecules (Yamada and Kleinman, 1992). 
Studies using Ambn-/- (null) mouse models highlighted the importance of ameloblastin 
during ameloblast differentiation and maintaining of the ameloblast monolayer as the 
absence of ameloblastin resulted in detachment of ameloblasts from the matrix, loss of 
cell polarity and uncontrolled proliferation. The Ambn-/- (null) mouse models developed 
odontogenic tumours and dysplastic mineralised material was formed at the dentine 
surface (Fukumoto et al., 2004). A later study found that this so-called null mouse 
model actually expressed a truncated from of ameloblastin, Ambn-5,6/-5,6 which lacks 
exons 5 and 6 (Wazen et al., 2009). This highlighted the importance of exons 5 and 6 
as functional domains essential in ameloblast adhesion, control of ameloblast polarity 
and proliferation as described above (Fukumoto et al., 2004).  
In common with other EMPs, ameloblastin has been a topic of interest in tissue 
regeneration research due to its cell signalling and growth factor-like properties 
(Zeichner‐David et al., 2006, Lu et al., 2013). It was shown to promote the 
proliferation of mesenchymal stem cells and osteoclast and their differentiation 
(Tamburstuen et al., 2010) and showed poential in preventing and healing bone 
fracture (Lu et al., 2016).  
1.2.4.2 Enamelin 
Enamelin accounts for 3-5% of EMPs . Its importance in amelogenesis was shown by 
enamelin-null mouse models where the enamel matrix failed to mineralise, leading to 
the lack of enamel in erupted teeth, enamelin-null mice did not display any enamel. 
The loss of enamelin results in the most severe of enamel phenotypes, suggesting 
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enamelin has a primordial role in enamel matrix mineralisation (Hu et al., 2008, Smith 
et al., 2009). 
Immunofluorescence studies showed that enamelin is mostly located at the secretion 
front and at the dentine-enamel junction (Brookes et al., 2017b). Enamelin is 
expressed and secreted before amelogenin at the early secretory stage, though 
amelogenin and enamelin co-localise later at the “secretory face of the ameloblasts” 
(Gallon et al., 2013). Full-length enamelin has been identified as a 186 kDa protein 
that is glycosylated and phosphorylated (Hu et al., 1997). It is also degraded 
throughout the secretory stage of amelogenesis, and its processing products were 
shown to have a high affinity for mineral and crystal surfaces (Brookes et al., 2002). 
This explains why it has been suggested to influence crystal growth and enamel 
mineralisation. The major processing (32 kDa) product, which makes up 1% of the 
developing enamel matrix, is spread throughout the enamel layer (Uchida et al., 
1991b). How can such a small amount be sufficient to cover the enamel surface?  
In vitro studies suggested that enamelin and amelogenin act cooperatively in the 
control of crystal growth: CD and DLS analyses in PBS at pH 6.5 found direct 
interaction between recombinant rP1481 and 32 kDa enamelin (Fan et al., 2011) and 
the addition of enamelin into an amelogenin gel-like matrix increased the stabilisation 
of an amorphous calcium phosphate transient phase (Iijima et al., 2010).  
It is clear that the enamel matrix structural proteins have the potential to work 
cooperatively, within the matrix, to deliver an ordered mineralisation process. Their 
secretion by the ameloblasts also appears to be coordinated; e.g. amelogenin and 
ameloblastin were shown to be co-transported (Zalzal et al., 2008, Mazumder et al., 
2014). The secretion process of EMPs is addressed in greater details below. 
  
                                               
1 The recombinant rP148 differs from the native P148 since it lacks Met1 and Ser16 
phosphorylation, and carries and extra methionine at position 149. 
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1.2.5 Amelogenin transit through the ameloblast ER for secretion 
Amelogenin is trafficked intracellularly towards the ameloblast Tomes’ processes for 
secretion into the extracellular matrix (Simmelink, 1982, Nanci et al., 1985). Its 
propensity to aggregate requires a tight monitoring within the ameloblast ER, which is 
the organelle responsible for overseeing protein folding and the assembly of subunits 
that comprise multimeric proteins. As a secreted protein, amelogenin is synthesised by 
ribosomes associated with the rough ER and simultaneously translocated into the ER 
lumen where, like all proteins, presumably adopts an energetically favourable 
conformational state assisted by the ER folding machinery (chaperone proteins that 
interact with the client protein to prevent pathological aggregation in order to direct 
protein folding towards the correct functional end point). It then transits through the 
Golgi and by vesicular transport reaches the Tomes’ process, where it is released into 
the extracellular matrix. Ameloblasts are cells specialised in secretion and are adapted 
to manage large amounts of EMPs destined for secretion. The volume of these 
secretory organelles is maximal during the secretory stage to maintain ameloblast ER 
proteostasis (Warshawsky, 1968, Tsuchiya et al., 2008). This Section (i) describes the 
secretory pathway in general (Section 1.2.5.1) and (ii) focuses on intracellular transit of 
amelogenin during secretion (Section 1.2.5.2). 
1.2.5.1 Ameloblasts: cells specialised in protein secretion require an 
efficient ER trafficking machinery 
The ER handles secretory proteins or transmembrane proteins, starting from their 
synthesis to their transfer to the Golgi apparatus. The ER handles both protein 
synthesis and folding so that that proteins achieve their functional 3-dimensional 
conformation. This is important as the ER environment is crowded, with concentrations 
of proteins reaching 300-400 g/L (Ellis and Hartl, 1999) and up to 30% of WT proteins 
destined for secretion can spontaneously mis-fold (Schubert et al., 2000). Misfolded 
proteins may result in in loss of biological activity inactive, or be cytotoxic, or may 
induce pathological intracellular protein aggregation. 
As discussed in more detail in Section 1.3.4.2 (pp. 75 - 77), a first-line mechanism to 
relieve potentially pathological situations in the ER employs folding machinery 
comprised of so-called chaperone proteins which interact with client proteins transiting 
the ER and directing their folding towards the correct conformational endpoint whilst 
preventing abnormal aggregation. In addition, the ER is able to direct misfolded or 
aggregated proteins towards degradation which helps restore ER proteostasis. When 
neither of these factors is sufficient to restore proteostasis, the ER becomes 
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“stressed”. ER stress triggers numerous signalling cascades which comprise the so-
called unfolded protein response (UPR) which triggers a number of downstream 
actions designed to relieve the stress or ultimately commit the cell to apoptosis. 
 ER folding machinery
The ER folding machinery comprises a variety of protein chaperones, co-chaperones 
and folding enzymes (foldases) that assist protein folding during synthesis to prevent 
protein aggregation (Dobson, 2003). This process is called ER-assisted folding 
(ERAF) and a list of its components is detailed in Table 1. The chaperones recognise 
the hydrophobic portions exposed at the surface of immature, misfolded or 
aggregation-prone proteins and then assist their folding (Braakman and Hebert, 2013). 
One of the most abundant and well-known chaperones, binding protein (BiP)/GRP78, 
which belongs to the heat shock protein 70 (HSP70) family, actively promotes folding 
through conformational changes driven by ATPase activity, resulting in ATP hydrolysis 
(Hartl, 1996). It is noteworthy that the chaperone “Binding immunoglobulin protein” 
(BiP) has been shown to interact with amelogenin in vitro (Fukuda et al., 2013) 
indicating that amelogenin is likely to be chaperoned during its transit through the ER. 
Associated co-chaperones include proteins from HSP40 and GrpE families, which 
modulate the ATPase activity of BiP (Yoshida, 2007). Other chaperones include 
GRP94 (HSP90 family) which has ATPase activity, and the chaperones calnexin and 
calreticulin. The latter two are lectins that bind transiently to N-linked glycosylated 
proteins and act together to help folding of the target proteins in what is called the 
calnexin-calreticulin cycle (Ou et al., 1993, Helenius and Aebi, 2001). ER folding 
enzymes, which change the energy landscape and increase the rate of protein folding, 
include protein disulfide isomerases (such as GRP58/ERp57), which catalyse 
oxidoreduction reactions (involving disulfide bonds), and peptidylprolyl isomerases 
(including FKBP family), which catalyse the conversion cis-trans of peptide bonds 
involving proline (Lang et al., 1987, Harding et al., 1989). A remarkable feature is that 
peptide bonds involving proline adopt either cis or trans configuration unlike regular 
peptide bonds (without proline), which spontaneously adopt the trans configuration. 
With proline peptide bonds, cis-trans isomerisation reactions are needed to reach the 
protein’s native state. This requires a high activation energy (~20 kcal/mol) (Andreotti, 
2003) which curbs the kinetics of protein folding. To overcome that limiting step, 
peptidylprolyl isomerases in the ER catalyse the cis-trans isomerization reaction, 
preserving the rate of protein folding and transit (Andreotti, 2003). Their role is 
presumably all the more important when the proteins destined for secretion, such as 
amelogenin, have an high proline content. 
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 ER associated degradation
Once properly folded, the protein is ready for use or secretion out of the cell. However, 
in some cases, the protein can evade the ERAF pathway, due to a mutation for 
example, and misfold. The misfolded protein is detected and then processed for 
destruction, via ER-assisted degradation (ERAD). The misfolded protein is 
translocated towards the cytosol, through specific molecular recognition / interaction 
mechanisms, where it is ubiquitinated and degraded in proteosomes (Yoshida, 2007). 
ERAD thus helps to reduce the load of misfolded proteins; the ERAD components 
involved are listed in Table 1. When ERAD or ERAF are not sufficient to restore 
homeostasis, a third mechanism involving signalling cascades is activated as a last 
resort: the UPR. 
 The unfolded protein response (UPR)
The UPR consists of intracellular signalling cascades that control the expression of 
numerous genes in the cell. Misfolded proteins in the ER lumen activate trans-ER 
membrane molecular sensors. In higher eukaryotes such as mammals, the UPR 
comprises three signalling cascades, each of which is initiated upon the activation of 
an associated sensor protein: protein kinase RNA-like ER kinase (PERK), inositol-
requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6). In the 
resting state, the three sensors are kept inactive through their interaction with the ER 
chaperone BiP. However, BiP preferentially binds misfolded proteins, so in the 
presence of misfolded proteins, BiP tends to disassociate from the sensor proteins and 
the sensor proteins become activated (Bertolotti et al., 2000, Shen et al., 2002) 
triggering downstream signalling cascades. The UPR aids cells to manage large 
secretory loads by increasing ER volume (via synthesis of membrane lipids), ERAF 
and ERAD machinery (Travers et al., 2000).  
Figure 11 summarises the transit of secreted proteins such as amelogenin through the 
ER. The ER quality control machinery is listed in Table 1. 
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Figure 11 Diagram illustrating the transit of secreted proteins (e.g. amelogenin) 
through the ER for secretion. The ER handles synthesis and folding of 
proteins destined to secretion (or transmembrane proteins, not addressed 
here). Following translocation1, the proteins fold (1) to adopt the correct 
conformation, which may require the ER folding machinery (which includes 
chaperones, co-chaperones and folding enzymes). When the folding 
machinery fails (‘(2) No folding’), the proteins may be targeted for 
degradation (case ‘(2.1)’) to alleviate the load of misfolded proteins in the 
ER to limit ER stress. In the case where the ER folding and ER-degradation 
do not suffice to alleviate ER stress, transmembrane sensors (PERK, IRE1α 
and ATF6) are activated (case ‘(2.2)), triggering signalling cascades which 
impact on gene expression. This is the so-called UPR which attempts in 
first instance to increase the folding capacity of ER or alleviate the load of 
misfolded proteins to reduce ER stress. If the ER fails to return to 
proteostasis then the UPR triggers apoptosis. The balance between the 
UPR acting in pro-survival mode and pro-apoptotic mode is detailed later in 
Section 1.3.4.2. 
1 Co-translational translocation is the mechanism used to target proteins into the ER in 
eukaryotes. 
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1.2.5.2 Protein-protein interactions associated with amelogenin as it 
transits the ameloblast secretory pathway 
To ensure amelogenin’s proper transit through the ER and the rest of the secretory 
pathway, amelogenin needs to adopt a conformation that allows correct assembly and 
interactions with itself and with other proteins (or put another way, needs to avoid 
accessing energetically stable conformations that may favour aggregation or other 
pathological outcomes). This Section focuses on the protein-protein interactions 
involved during intracellular transit of amelogenin. It addresses: (i) potential binding 
partners (Section 1.2.5.2.1 below) and (ii) the domain(s) of amelogenin possibly 
involved in protein-protein interactions (Section 1.2.5.2.2 below). 
1.2.5.2.1 Importance of binding partners 
Various studies have identified multiple potential binding partners for amelogenin. 
These include amelogenin itself (self-assembly, detailed previously in Section 1.2.2.2, 
p. 21), cellular components (such as those involved in the ER-quality control 
machinery), or specific EMPs. 
 Amelogenin self-assembly
As detailed previously (Section 1.2.2), amelogenin has a well-known propensity to self-
assemble, with an in vivo study (discussed in Section 1.2.2.2.2, p. 22) demonstrating 
the formation of dimers, tetramers, pentamers and hexamers in the ameloblast 
intracellular secretory pathway (Brookes et al., 2006). However, this is predated by 
multiple studies reporting the aggregative nature of amelogenin, which has been 
documented since the 1960s (Nikiforuk and Simmons, 1965, Mechanic et al., 1967). 
 Binding of amelogenin with elements from the ER-folding
machinery
Potential binding partners for amelogenin (other than amelogenin itself) including 
protein components of ameloblasts and the enamel matrix have been investigated. 
A proteomics study using affinity chromatography and immunofluorescence 
microscopy in an SaOS-2 osteoblastic cell line found that HSP70 family proteins 
(especially BiP/Grp78) and other proteins of the ER folding machinery such as 
calreticulin, protein disulphide isomerase precursor and tapasin-ERp57 bound 
amelogenin (Fukuda et al., 2013). Fukuda et al. (2013)’s work was in fact focused on 
the mechanisms by which amelogenin (in the form of Emdogain) stimulated 
periodontal regeneration rather anything relating to amelogenin secretion by 
ameloblasts per se. They were actually studying the uptake of Emdogain by 
osteoblastic cells and identified amelogenin binding partners in the course of this work. 
Nevertheless, their work provides data that may be relevant to amelogenin secretion 
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by ameloblasts. Within the same study, other cellular amelogenin-binding proteins 
identified included cytoskeleton proteins such as actin, vimentin, tubulin. Another 
group used the Y2H assay, screening a 17-day mouse embryo pretransformed with a 
Y2H expression library, to identify EMP binding partners. They identified fetuin-A, 
biglycan and CDC63 as binding partners for amelogenin and also for ameloblastin or 
enamelin (Wang et al., 2005).  
 Other EMPs destined for secretion
As mentioned above, the EMPs (amelogenin, ameloblastin, enamelin) were found to 
have mutual (potential) binding partners such as CDC63, fetuin-A or biglycan (Wang et 
al., 2005). Whether this is of importance in amelogenesis remains to be clarified. 
Nonetheless, it is well known that their expression and secretion need to be 
coordinated and their actions cooperative for amelogenesis (See Section 1.2.4 pp. 37-
39). An association between amelogenin and ameloblastin has been put forward, as 
both are expressed and secreted at the same time, and share the same secretory 
pathway within the ameloblasts. They were found co-localised in secretory vesicles 
(Nanci et al., 1998, Zalzal et al., 2008). They were reported to interact via the 
amelogenin ATMP domain by enzyme-linked immunosorbent assay (ELISA), 
dosimetry and Scatchard analyses (Ravindranath et al., 2004). Immunofluorescence, 
CD and fluorescence spectroscopy studies also found that both proteins interact with 
the interaction being between the N-terminus of amelogenin (TRAP) and the 
ameloblastin domain encoded by exon 5 (Mazumder et al., 2014, Su et al., 2016). 
Currently, while amelogenin-ameloblastin interactions have been suggested in vitro, 
no in vivo evidence has been published to date. 
In contrast, Y2H assays indicated that amelogenin and ameloblastin do not interact 
(Paine et al., 1998, Bartlett et al., 2006b) .The Y2H system is a popular method to 
study protein-protein interactions in living yeast cells and has been useful to define the 
domains involved in amelogenin-amelogenin interaction (see appendix E). It verifies 
the interaction between two recombinant proteins in a living yeast cells, which 
activates the expression of a reporter gene should they interact (Fields and Song, 
1989). The system is considered an in vivo assay (Brückner et al., 2009) but both 
recombinant proteins involved are fused to Gal4 binding or activating domain which 
may alter the folding, function or the binding behaviour of the two potential binding 
partners. In addition to this, protein interaction detected using the Y2H system take 
place in the yeast nucleus. This is a very different environment to the mammalian 
rough ER and will be missing ancillary chaperones or part of the folding control 
machinery, usually resident in the mammalian rough ER. Furthermore, proteins in the 
Y2H system will not undergo post-translational modification such as phosphorylation. 
These caveats must be considered when interpreting Y2H system data.  
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1.2.5.2.2 Importance of the amelogenin tri-tyrosyl motif peptide (ATMP) in 
mediating amelogenin-protein interactions 
The integrity of amelogenin (in terms of its primary sequence) is necessary to allow its 
folding (or lack thereof), interaction with ancillary chaperones and ultimately its safe 
transit through the ameloblast secretory pathway. As amelogenin self-assembly has 
been the most studied protein-protein interaction involving amelogenin, the binding 
domains responsible for its self-assembly are the best understood.  
As detailed previously in Section 1.2.2 amelogenin self-assembly binding domains 
were identified in N- (A-domain) and C- (B-domain) terminals by Y2H experiments 
(Paine and Snead, 1997). Within the A domain, the sequence of amino acids Tyr34-
Met42 , that is: YPSYGYEPM (ATMP domain) was shown to be crucial in driving 
amelogenin-amelogenin interactions. This domain has also been the focus of reports 
by Ravindranath et al (1999) who carried out extensive work suggesting that the 
domain interacted with sugars, glycoproteins, cytokeratins, and also possibly 
ameloblastin. 
These authors reported that the ATMP domain potentially binds glycoproteins by using 
hemagglutination and hemagglutination inhibition (hemagglut.) tests with sugar, and 
dosimetry with [14C] N-acetyl-D-glucosamine (GlcNAc). This first report indicated that 
the amelogenin ATMP domain can bind to GlcNAc (Ravindranath et al., 1999). Then, 
based on the sequence similarities that they observed between the amelogenin ATMP 
sequence and wheat germ agglutinin, Ravindranath et al (2000) tested whether 
amelogenin could bind to GlcNAc-mimicking peptides whose sequence is present in 
cytokeratins. They found that ATMP was capable of binding to the GlcNAc-mimicking 
peptide “SFGSGFGGGY” (Ravindranath et al., 2000), a sequence known to be 
present in cytokeratin 14 (Shikhman et al., 1994). 
In a following report, a dosimetric binding assay verified the affinity of cytokeratin 14 
for rM179 and for the ATMP sequence and in the same report the authors investigated 
and corroborated its relevance in vivo. Looking at mouse incisors by confocal 
microscopy, they reported that amelogenin and cytokeratin 14 co-assemble “in the 
perinuclear region of ameloblasts” at day 0 post-natal, then between day 1 and day 3-
5, the complex as observed to migrate towards the ameloblast’s apical region and then 
disassemble. Dissociation of cytokeratin 14 from amelogenin was observed in the 
Tomes’ processes by autoradiography with [3H]ATMP and [3H]GlcNAc-mimicking 
peptide (Ravindranath et al., 2001) which led them to hypothesise that cytokeratin 14 
may act as a chaperone for amelogenin during its intracellular transport. In 2003, the 
same group also identified cytokeratin 5 as a binding partner for amelogenin 
(Ravindranath et al., 2003). Cytokeratin 5 is a protein that is post translationally 
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modified with GlcNAc and can pair with cytokeratin 14 to form the intermediate 
filaments of basal epithelial cells including ameloblasts (Kasper et al., 1989) The role 
of ATMP binding to cytokeratin 5 was confirmed by ELISA, western blotting and 
confical laser scanning microscopy on post-natal ameloblasts (Ravindranath et al., 
2003). Ravindranath et al. (2003) observed a cytokeratin 5-amelogenin complex 
migrating towards the periphery of the ameloblasts. Towards the secretory ends of the 
ameloblasts, confocal microscopy showed amelogenin, cytokeratin 14 and cytokeratin 
5 co-localised at day 5 of postnatal growth of enamel. At day 9, the complex appeared 
dissociated as cytokeratin 14 was no longer found co-localised with either cytokeratin 
5 or amelogenin. Cytokeratin 5 may be found either co-localised or dissociated from 
amelogenin. Remarkably, Ravindranath et al. (2003) raised a question/issue regarding 
the function of the ATMP domain by suggesting that it may be involved in GlcNAc 
binding, rather than amelogenin self-assembly, previously reported by Paine and 
Snead (1997). They opposed the hypothesis of Paine and Snead that the ATMP 
domain drives amelogenin self-assembly. This raises two questions: (1) Does the 
ATMP domain drive amelogenin self-assembly or is it the binding site for cytokeratin 
which appeared to partner amelogenin during its journey through the secretory 
pathway? And (2) Are these two functions mutually exclusive? 
To complicate matters, Ravindranath et al. (2004) reported that recombinant 
ameloblastin bound to amelogenin and peptides corresponding to the ATMP 
sequence, despite the fact that their recombinant ameloblastin did not contain GlcNAc 
or the amino acid sequence that mimics GlcNAc (Ravindranath et al., 2004). This 
contrasts with the Y2H studies previously described that were unable to demonstrate 
any interaction between ameloblastin and amelogenin (Paine et al., 1998). However, 
as already stated, certain caveats need to be considered when interpreting Y2H data. 
Ravindranath et al (2004) explained the apparent paradox – how can recombinant 
ameloblastin bind the ATMP sequence when it contains neither GlcNAc nor the 
GlcNAc mimicking amino acid motif - by hypothesising that the GlcNAc mimicking 
motif may actually be formed by the relevant amino acids, lying far apart in the primary 
sequence, coming into the correct juxtaposition to form the GlcNAc mimicking motif 
once the ameloblastin molecule has folded. Paine et al (1998) may have failed to 
identify ameloblastin-amelogenin interactions in the Y2H system due to the specific 
conformation leading to the correct juxtaposition of amino acids to form the GlcNAc 
mimicking motif being disturbed by fusion of the ameloblastin sequence with Gal4 
binding or activating domain on which the Y2H assay depends. Another problem with 
Y2H system is that there are glycosylated proteins produced by the yeast which may 
compete with ameloblastin by binding to the amelogenin ATMP. 
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While a number of studies appeared to suggest that the ATMP domain may mediate 
amelogenin-protein interactions, convincing in vivo evidence is lacking. On the basis 
that ATMP may drive protein recognition, it is likely to have an essential role in 
amelogenesis, and it would be of worth to determine how conserved this domain is 
between species. Wald et al (2017) identified the ATMP domain as a conserved ‘Y/F-
X-X-Y/L/F-X-Y/F’ motif. This study, using HR-SEC, TEM and SPR and site-directed 
mutagenesis, showed the importance of the integrity of the ATMP domain in mediating 
amelogenin self-assembly and ameloblastin recognition (Wald et al., 2017). Indeed, 
mutations in the ATMP domain (for example p.P70T) are associated with AI in humans 
(Collier et al., 1997) and as discussed later, the p.Y64H mutation in mice appears to 
cause pathological intracellular aggregation of amelogenin in ameloblasts suggesting 
altered amelogenin-amelogenin binding characteristic (Barron et al., 2010, Brookes et 
al., 2014).  
The assembly and cooperation between EMPs is clearly a requirement for enamel 
biomineralisation. This cooperation starts within the ER in the ameloblasts, and proper 
protein-protein interactions are necessary for transit throughout the secretory pathway 
of the ameloblasts. Failure of the ER secretory pathway has been shown to the 
underlying mechanism of enamel pathology in the mouse model carrying the p.Y64H 
amelogenin mutation.  
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1.3 Enamel pathologies and therapies to date 
Enamel is an acellular tissue, as ameloblasts are lost upon tooth eruption; it cannot 
cannot undergo cell mediated self regeneration or repair (Moradian-Oldak, 2009, 
Jayasudha et al., 2014). This is problematic in a variety of conditions including 
treatment of caries lesions, accidental, environmental or hereditary defects as enamel 
damage cannot be reversed. These require either recurrent fillings, veneers or tooth 
replacement with dental implants (Jayasudha et al., 2014). Regeneration studies using 
peptides have been a recent subject of interest. Self-assembling anionic peptide P11-4 
was engineered and shown to promote repair of enamel under simulated intra-oral 
conditions (Kirkham et al., 2007) and proved to be a safe and effective treatment of 
early caries lesions in clinical trials (Brunton et al., 2013). Another study used repeated 
applications of amelogenin-derived peptides, resulting in the formation of aprismatic 
enamel-like tissue, however these results were only reported, so far, in vitro 
(Mukherjee et al., 2018).  
Enamel developmental defects can result from environmental perturbations (physical 
shocks or chemical stresses) as described above, or be hereditary. Research has also 
increasingly focused on the role that genetics might play in the aetiology driving 
enamel conditions linked to ‘environmental’ factors such as caries, molar incisor 
hypomineralisation (MIH) or fluorosis (Kirkham et al., 2017).  
1.3.1 Enamel pathologies and developmental defects 
Dental caries, MIH and fluorosis are relatively common oral diseases usually linked to 
environmental factors. Growing evidence suggest that genetic factors and heredity 
may play a significant role in the development of the diseases . 
Fluorosis is caused by exposure to excessive fluoride during tooth development. The 
enamel is hypomineralised and secretory-stage EMPs are abnormally retained in the 
maturation stage enamel, where they could hinder secondary mineralisation, as 
reviewed by Brookes et al (2017a) (Brookes et al., 2017a). 
Dental caries is caused by acids arising from bacterial metabolism that dissolve tooth 
minerals. Affecting enamel initially but progressing into the dentine, or directly affecting 
dentine in the case of root caries, caries can lead to severe inflammation, tooth loss, 
infection or abscess if left untreated (Bagramian et al., 2009). Affecting 2.3 billion 
people (permanent teeth) and 560 million children (deciduous teeth) worldwide, it is 
the most prevalent noncommunicable disease worldwide (WHO, 2017). The cariogenic 
potential of bacterial biofilms present on teeth is sensitive to environmental influences; 
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mainly the availability and frequency of fermentable carbohydrate entering the oral 
cavity. However, it is increasingly clear that there is a genetic predisposition to caries. 
For example, specific genetic polymorphisms in amelogenin increased caries risk 
(Kang et al., 2011).  
MIH is a condition characterised by hypomineralised enamel on the molar and incisor 
teeth, which causes tooth sensitivity to cold, warmth, and mechanical stimulation such 
as toothbrushing (Weerheijm et al., 2001). Its prevalence varies worldwide, from 2.4% 
in Bulgaria to 40.2% in Brazil (Vieira and Kup, 2016). MIH shows different degrees of 
severity from minor discoloration in the milder cases to enamel fracture in the most 
severe cases. Since the late 1970s, MIH has been regarded as an idiopathic disease 
(Koch et al., 1987). Its aetiology has been a topic of continuing interest. Although the 
underlying mechanisms are not entirely clear, research to date supports a combination 
of environmental and genetic factors. Environmental factors include exposure to 
bisphenols and dioxin, illnesses, and malnutrition and health problems during prenatal, 
perinatal and neonatal periods; however, reviewers have questioned the robustness of 
evidence for these factors (Crombie et al., 2009, Alaluusua, 2010). Genetic 
susceptibility was supported by a genome-wide association study (Kühnisch et al., 
2014) and a twin study (Teixeira et al., 2018). Variants of genes involved directly in 
enamel development such as AMBN, TUFT1 and TFIP11 were associated with MIH, 
(Jeremias et al., 2013). 
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1.3.2 AI: major inherited pathologies of enamel 
AI refers to the major group of inherited enamel pathologies that affect both deciduous 
and permanent dentitions. This implies that AI is non-syndromic, affecting only the 
teeth, whereas it can be both syndromic and non-syndromic. It is characterised by an 
altered appearance (hypomineralisation, missing enamel, enamel discolouration and 
roughness) and sensitivity of the teeth which affects the patients’ quality of life. AI-
related issues also include difficulties with oral hygiene maintenance and loss of self-
esteem (Hu et al., 2007, Coffield et al., 2005). No preventative cure for AI exists to 
date and its prevalence ranges between 1:14000 in the U.S, to 1:700 in Northern 
Sweden (Crawford et al., 2007). Different AI classifications have been proposed but 
the usual criteria for classification include the clinical phenotype, the mode of 
inheritance, the genetic molecular basis (Aldred et al., 2003). 
1.3.2.1 Phenotype and classification 
Clinical diagnosis of AI has been largely based on clinical appearance, radiographic 
assessment and by interrogating the family history (Crawford et al., 2007) though more 
recently genetic diagnostics have been called for, e.g. targeted 21-gene panel test for 
AI introduced by the NHS in 2016 (McDowall et al., 2018). Previously however, AI has 
been classified according to the clinical phenotype exhibited by the patient.  
Hypoplastic AI is a defect in the ‘quantity’ of enamel present, characterised by 
abnormally thin enamel, which in extreme cases may be absent altogether. It is usually 
attributed to defective enamel matrix formation during the secretory stage which in turn 
undermines elongation of the crystals so although the resulting enamel is mineralised, 
it is extremely thin (Gadhia et al., 2012). The secretory stage may be affected either by 
mutations in genes encoding structural EMPs such as enamelin, ameloblastin or 
amelogenin; or it can be affected by genes encoding master controllers of 
amelogenesis such as DLX3 or FAM20A as reviewed by Smith et al (2017b) (Smith et 
al., 2017b).  
Hypomineralisation is another type of AI, thought to be caused by the enamel matrix 
reaching normal thickness but failing to mineralise due to a defective maturation stage. 
The resulting enamel is soft, weak and discoloured. Hypomineralised AI can be 
divided into two categories: Hypomaturation, which is thought to result from a failure to 
remove the EMPs; mutations in human and mice KOs of genes encoding enamel 
matrix proteases MMP-20 and KLK4 were associated with hypomature phenotype 
(Caterina et al., 2002, Wright et al., 2009, Simmer et al., 2009, Yamakoshi et al., 2011, 
Hu et al., 2016, Núñez et al., 2016). The second hypomineralisation category is 
hypocalcified AI, which is where the mineralisation has failed, and is characterised by 
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a soft enamel (Hu et al., 2007). In both types of hypomineralised AI, enamel may be 
lost post eruption (Smith et al., 2017b). 
1.3.2.2 Genes known to underlie AI 
Usually, AI is considered as non-syndromic inherited enamel defects. Actually, AI is a 
spectrum of inheritied enamel pathologies ranging from the non-syndromic, where 
enamel only is affected, to syndromic cases, where non-dental tissues may be 
affected. AI is a heterogeneous group of conditions with at least 18 genes involved 
identified (Smith et al., 2017b). The patterns of inheritance vary with examples typical 
of autosomal dominant, autosomal recessive (Wright et al., 2015) and X-linked 
(Lagerstrom et al., 1991) inheritance patterns.  
Smith et al. (2017b) provided a comprehensive review of AI and associated mutations 
(Smith et al., 2017b). Genes associated with AI include for example those encoding 
EMPs, for instance AMELX (Lagerstrom et al., 1991), ENAM (Rajpar et al., 2001, 
Mardh et al., 2002) or AMBN (Poulter et al., 2014). Mutations in genes encoding 
enamel matrix proteases such as MMP20 and KLK4 were shown to cause AI (Kim et 
al., 2005, Hart et al., 2004). Genes involved in AI also encode proteins involved in cell-
cell and cell-matrix adhesion such as amelotin (Smith et al., 2016), and FAM83H (Kim 
et al., 2008);  proteins involved in transport such as WDR72 (El-Sayed et al., 2009) 
and SLC24A4 (Parry et al., 2013); proteins involved in pH sensing, e.g.GPR68 (Parry 
et al., 2016) and genes tentatively associated with hydroxyapatite nucleation, e.g. 
C4orf26 (Parry et al., 2012). Other genes expressed in ameloblasts, such as ACPT, 
were shown to be associated with AI upon mutation, yet the role of the encoded 
proteins in amelogenesis is unclear (Smith et al., 2017b). The mutations associated 
with AI cited in this Section are listed below in Table 2. There have been various point 
mutations, deletions or insertions - possibly causing frame shifts identified to date. 
Even silent mutations that affect the DNA but not the amino acid sequence of an 
encoded protein have been shown to be associated with AI, for instance the inclusion 
of exon 4 in the mature transcript (for the major amelogenin isoform) lead to 
hypoplastic and hypomineralised enamel (Cho et al., 2014). 
For some genes, specific mutations lead to syndromic conditions while other mutations 
in the same gene lead to enamel defects only, which blurs the boundaries between the 
non-syndromic and syndromic enamel defects. Genes involved in AI, such as ACPT, 
FAM20A and DLX3 are expressed in ameloblasts and in other tissues. In the case of 
autosomal recessive mutation of FAM20A, hypoplastic AI can be spotted as an early 
symptom of enamel renal syndrome (Jaureguiberry et al., 2012, Wang et al., 2013, de 
la Dure-Molla et al., 2014) and thereby provide a means of early diagnosis since renal 
problems only manifest later in life.  
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1.3.3 X-linked AI: Amelogenin mutations and AI 
Given that the focus of this thesis is around amelogenin and in particular the p.Y64H 
amelogenin mutation a detailed account of AI linked to amelogenin mutation is 
provided below.  
1.3.3.1 X-linked AI: Amelogenin mutations and AI 
The gene encoding amelogenin AMELX is located on the short arm of the X 
chromosome in the region p22.1-p22.3 (Lau et al., 1989). X-linked AI accounts for 5% 
of all AI cases. The phenotypes involve various degrees of hypoplasia and/or 
hypomaturation (Hart et al., 2002, Wright et al., 2003). Within a single family, affected 
heterozygous females showed a milder phenotype than males or homozygous 
females. In heterozygous females, the phenotype is characterised by alternatinging 
stripes of affected and normal enamel. This is caused by “Lyonisation” which is the 
process by which one of the two X chromosomes present in every female cell is 
randomly deactivated. This leads to the differentiation of cohorts of ameloblasts that 
are either expressing a copy of the defective amelogenin gene or an unaffected WT 
copy (Berkman and Singer, 1971). 
To date, over 16 mutations causing X-linked human AI have been reported. The 
known amelogenin mutations are detailed in Figure 12. Three single point mutations 
were found in the sequence encoding the signal peptide resulting in a lack of 
amelogenin secretion and hypoplastic AI. Eight mutations were found in the N-terminal 
and central domains. One deletion causes truncation of the amelogenin gene to 18 
amino acid codons (Lagerstrom et al., 1991, Lagerstrom-Fermer et al., 1993) and the 
resulting phenotype comprised hypomineralised enamel with various levels of 
hypoplasia. In another case, a mutation affected amelogenin mRNA splicing so that 
the major amelogenin mRNA transcript included exon 4 (exon 4 is normally spliced 
out). This mutation was associated with enamel hypomaturation and to a lesser extent 
enamel hypoplasia in affected patients and hypomineralised AI in a transgenic mouse 
model (Cho et al., 2014). 
Although genotyping has been an important tool in understanding the causes of AI, 
there is a need to better understand genotype-phenotype links. Clinical studies 
currently consist of recruiting AI patients, evaluating their medical, dental and family 
histories, and establishing their clincial enamel phenotype following examination by 
principal investigators (Hart et al., 2002). To date, the understanding of underlying 
mechanisms is poor (Wright et al., 2015) apart from genotype-phenotype correlations. 
Mutations in the signal peptide and toward the C terminus (green and blue portions in 
Figure 12B) are associated with hypoplastic AI while mutations in N-terminal and 
- 57 -
central domains (yellow portion in Figure 12B) cause hypomaturation AI with variable 
hypoplasia (Hart et al., 2002, Smith et al., 2017b, Kim et al., 2017) studies focusing on 
the aetiological mechanism involved (e.g. the impact of a mutation on protein folding 
and assembly, protein to mineral binding, intra- and extra-cellular transit and matrix 
function) have been carried out (described overleaf in Section 1.3.3.2). They were 
intended to provide not only a better understanding of the normal function of the 
protein in question but also open the possibility of developing therapeutic interventions 
to overcome the deleterious effect of the mutation during enamel development. 
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1.3.3.2 Characterisation of the effects of amelogenin mutations in vitro: 
Effect of point mutation p.P70T  
Investigations are currently focusing on the effect of amelogenin mutations on protein 
assembly, protein-to-mineral binding, mineral nucleation, protein binding, and intra- 
and (mostly) extra-cellular processing in X-linked AI. Two point mutations causing AI in 
humans have been investigated by multiple in vitro studies: p.T51I (Lench and Winter, 
1995) and p.P70T (Collier et al., 1997). P.T51 and p.P70T are both located in the 
conserved N-terminal portion of amelogenin, part of the ‘A’ domain which reportedly 
drives amelogenin self-assembly (Paine and Snead, 1997). The following Section 
focuses on the p.P70T mutation, which affects a part of the ATMP domain (the 
importance of this domain is detailed in the Section 1.2.2.2.1 p. 22 and 1.2.5.2.2 pp. 
47 - 49); it is also the mutation for which in vivo studies have been carried out (mice 
carrying the pY64H mutation). In vitro, p.P70T mutation has been the focus of multiple 
studies aiming to understand the underlying mechanisms of AI. The techniques 
employed include Y2H, SPR, DLS, NMR, Hemaglut., western blotting or ELISA. The r-
amelogenin-amelogenin interactions and supramolecular assembly were significantly 
affected (Moradian-Oldak et al., 2000, Paine et al., 2002, Lakshminarayanan et al., 
2010). However, there does seem to be some confusion in the literature regarding the 
precise location of the p.P70T mutation and this is rectified below (Section 1.3.3.2.1). 
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1.3.3.2.1 Clarification of amelogenin mutation nomenclature with respect to the 
p.P70T mutation
The p.P70T mutation was originally described as a p.P41T mutation by Collier et al 
1997.The authors described the mutation relative to the amino acid sequences of 
rodent, pig and cow amelogenin. However, the human sequence is lacking Met29 so 
the actual mutation in the human sequence is more accurately described as p.P40T. 
P40 is highlighted in yellow in the sequence below corresponding the major 
amelogenin isoform lacking the signal sequence and exon 4 secreted form: 
1                                     40                            70 
MPLPPHPGHPGYINFSYEVLTPLKWYQSIRPPYPSYGYEPMGGWLHHQIIPVLSQQHPPTHTLQPHHHIP 
VVPAQQPVIPQQPMMPVPGQHSMTPIQHHQPNLPPPAQQPYQPQPVQPQPHQPMQPQPPVHPMQPLPPQP 
PLPPMFPMQPLPPMLPDLTLEAWPSTDKTKREEVD 
This nomenclature is confusing because the canonical form listed in the Uniprot data 
base , Q99217-1, includes the signal peptide but still lacks exon 4 
(The UniProt Consortium, 2017). It is based on the sequence derived from mRNA 
formed by the dominant splice product (Figure 7b, p.16), except that the exon 1 is not 
translated since it is part of the 5’-untranslated region. Using this canonical sequence 
the p.P40T mutation becomes the p.P56T mutation as shown below, with the signal 
peptide highlighted in green: 
1                                                     56            70 
MGTWILFACLLGAAFAMPLPPHPGHPGYINFSYEVLTPLKWYQSIRPPYPSYGYEPMGGWLHHQIIPVLS 
QQHPPTHTLQPHHHIPVVPAQQPVIPQQPMMPVPGQHSMTPIQHHQPNLPPPAQQPYQPQPVQPQPHQPM 
QPQPPVHPMQPLPPQPPLPPMFPMQPLPPMLPDLTLEAWPSTDKTKREEVD 
The problem with this canonical sequence is that it provides no means of describing 
any mutation present in exon 4.To get round this problem some authors describe 
mutations relative the amelogenin sequence derived from the collinear splicing of all 7 
exons that generates a mRNA transcript that includes exon 4. Using this sequence the 
p.P40T mutation becomes the p.P70T mutation as shown below with exon 4 
highlighted in blue: 
1                                                                   70 
MGTWILFACLLGAAFAMPLPPHPGHPGYINFSYENSHSQAINVDRTALVLTPLKWYQSIRPPYPSYGYEP 
MGGWLHHQIIPVLSQQHPPTHTLQPHHHIPVVPAQQPVIPQQPMMPVPGQHSMTPIQHHQPNLPPPAQQP 
YQPQPVQPQPHQPMQPQPPVHPMQPLPPQPPLPPMFPMQPLPPMLPDLTLEAWPSTDKTKREEVD 
This nomenclature has been used several times in the literature to describe this 
mutation as p.P70T, e.g. (Gibson et al., 2007, Zhu et al., 2011) and is the one used in 
Figure 12A (p. 58), which lists the amelogenin mutations causing AI in human.  
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The difference of nomenclatures has led to some confusion in the literature. For 
example Buchko and Shaw (2015) published a report using NMR to study the effects 
of the p.P70T mutation. They used site-directed mutagenesis against recombinant 
mouse amelogenin to convert Pro71 (analogous to human Pro70) to Thr71. However, 
they based the amino acid numbering on the sequence corresponding to the major 
amelogenin isoform lacking the signal sequence and exon 4 which resulted in the 
wrong proline residue (highlighted in red) being substituted as shown below:  
1                                     40                            70 
MPLPPHPGHPGYINFSYEVLTPLKWYQSIRPPYPSYGYEPMGGWLHHQIIPVLSQQHPPTHTLQPHHHIP 
VVPAQQPVIPQQPMMPVPGQHSMTPIQHHQPNLPPPAQQPYQPQPVQPQPHQPMQPQPPVHPMQPLPPQP 
PLPPMFPMQPLPPMLPDLTLEAWPSTDKTKREEVD 
The authors reported that their “p.P71T” mutation caused amelogenin self-association 
to occur at lower protein concentrations. However, this has no bearing on the aetiology 
of the true p.P70T mutation in humans since the actual mutation investigated was 
p.P100T as shown below:
1                                                                   70 
MGTWILFACLLGAAFAMPLPPHPGHPGYINFSYENSHSQAINVDRTALVLTPLKWYQSIRPPYPSYGYEP 
100 
MGGWLHHQIIPVLSQQHPPTHTLQPHHHIPVVPAQQPVIPQQPMMPVPGQHSMTPIQHHQPNLPPPAQQP 
YQPQPVQPQPHQPMQPQPPVHPMQPLPPQPPLPPMFPMQPLPPMLPDLTLEAWPSTDKTKREEVD 
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1.3.3.2.2 Amelogenin p.P70T mutation impairs amelogenin self-assembly and 
mineral binding 
P.P70T mutation has been widely studied in vitro using recombinant proteins. It was 
reported to affect the secondary structure of amelogenin (Lakshminarayanan et al., 
2010). A Y2H assay also showed that this point mutation affected amelogenin self-
assembly by reducing the strength of amelogenin-amelogenin binding by 25% (Paine 
et al., 2002); a consistent finding with SPR data obtained with r-amelogenins (Paine et 
al., 2002). 
Multiple studies analysed the effect of the p.P70T mutation on the formation of 
supramolecular amelogenin assemblies: NMR studies carried out in a buffer of 2% 
deuterated acetic acid (C2H3COO2H), 7% deuterated water (2H2O) and 91% water 
(H2O), at pH 3.0, found that amelogenin carrying the mutation self-assembled at lower 
concentration and ionic strength than the WT amelogenin (Buchko et al., 2013) 
suggesting an increased propensity to self-assemble. However, the data should be 
interpreted carefully since the NMR buffer did not correspond to physiological 
conditions. DLS and AFM studies using recombinant mouse (M180) or human (H174) 
amelogenins carrying a polyhistidine tag (His-tag) reported that amelogenin formed 
larger and more heterogeneous aggregates while carrying the p.P70T mutation 
(Moradian-Oldak et al., 2000, Zhu et al., 2011). Zhu et al (2011) also found that the 
p.P70T mutation increased the affinity of amelogenin for apatite and that it delays and 
constrains apatite crystal growth (Zhu et al., 2011). 
1.3.3.2.3 Amelogenin p.P70T mutation impairs interaction with other proteins 
As detailed previously in Section 1.2.5.2.2 (pp. 47 - 49), the ATMP domain may be 
critical in mediating amelogenin interaction with other proteins. Hemagglut. studies 
showed that the p.P70T mutation precluded ATMP binding to GlcNAc, GlcNAc-
mimicking peptides, cytokeratins 5 and 14 or ameloblastin (Ravindranath et al., 1999, 
Ravindranath et al., 2000, Ravindranath et al., 2001, Ravindranath et al., 2003, 
Ravindranath et al., 2004). Substrate competition assay, pull-down assays and SPR 
studies showed that the p.P70T mutation also precluded the interaction between 
amelogenin and MMP-20 (Tanimoto et al., 2008) , which may significantly hinder the 
cleavage of amelogenin by MMP-20 as previously reported (Li et al., 2001).  
Together, the studies cited above showed the consequence of the p.P70T mutation on 
amelogenin binding behaviour in vitro. Apart from Y2H studies, most of these studies 
used recombinant (His-tagged) amelogenins, they were carried out under conditions 
that did not reflect the environment in vivo. To validate these findings and elucidate the 
pathogenesis of AI, in vivo evidence is needed.  
- 64 -
1.3.4 Pathogenic mechanisms driving AI 
A plethora of in vitro studies has been carried out ( described in Section 1.3.3.2, 
above) to understand mechanisms underlying AI but their relevance to the situation in 
vivo is never clear. As illustrated in Figure 13 below, combinations of in vitro, in cellulo 
and in vivo studies would be better suited for characterising the role of mutations (for 
example, single point mutations in amelogenin) on the pathogenic mechanisms driving 
AI. The molecular mechanisms involved in amelogenesis and its pathologies are a 
current priority in enamel research (Kirkham et al., 2017) as understanding these 
mechanisms would provide a breakthrough in understanding genotype-phenotype 
correlations and help develop diagnostic tools, therapeutic interventions as well as 
informing on better ongoing restorative patient care. 
In vitro studies and in silico prediction tools do not necessarily require ethical approval 
and are cost-effective compared with preclinical and clinical studies. They can provide 
information on protein structure and function and as such are important for gaining the 
rational understanding required to identify therapeutic targets and develop drugs 
against these targets. However, in vitro and in silico studies alone are unable to 
elucidate with complete confidence the details of EMPs’ functions and the effect of 
mutations on these proteins in vivo. Never the less, in vitro and in silico studies remain 
useful adjuncts to in cellulo and in vivo studies using animal models and are often 
used at the start of a research project to develop hypotheses and inform on 
downstream research strategies employing in cellulo and in vivo model systems. 
Compared to in vitro studies, in cellulo studies provide a broader picture of the 
biological and chemical mechanisms involved. They can be carried out in parallel with 
in vitro experiments to guide the design of in vitro experiments and to validate the 
results from the latter. Naturally, at some point the research pipeline must include in 
vivo studies focusing on the whole tissue, organ or the entire organism. Animal models 
are necessary for the initial characterisation of a pathological phenotype at all stages 
of amelogesis as human-derived material is limited to clinical observations of teeth in 
situ or analysis of exfoliated teeth. Animal models are also a means to validate in vitro 
or in cellulo data at the later stages of research and of course any pharmacological 
interventions developed must be trialled in a suitable enamel model prior to human 
trials. To study amelogenesis and AI, mice have been the most useful model as they 
have the particularity of having continuously growing incisors (Smith et al., 2017b). A 
good example of the above strategy is the detailed phenotypic analysis of mice 
phenocopying human AI together with in cellulo and in vitro experiments allowed the 
underlying aetiological mechanism to be identified; in this case the p.Y64H mutation in 
amelogenin was shown to lead to pathological ER stress in the ameloblasts and 
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ameloblast apoptosis. Moreover, elucidation of the aetiological mechanism involved 
allowed for a therapeutic intervention to be applied which effectively rescued the 
phenotype in affected heterozygous female mice (Brookes et al., 2014). This is 
discussed in more detail in the following pages. 
 
 
Figure 13 Combination of approaches to consider to study the effect(s) of a 
single point mutation on amelogenin assembly and function(s) and 
trafficking.  
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1.3.4.1 In vivo studies: the use of mouse models to study amelogenesis 
and AI 
Phenotyping of teeth from AI patients is potentially confounded by post-eruptive 
changes (e.g. mechanical damage and demineralisation) that might occur during the 
time the enamel has spent in the mouth. In extreme cases, there may be no enamel 
left that can be analysed as a prelude to developing testable hypotheses as to the 
aetiological factors driving that particular case of AI. Obtaining unerupted genotyped 
human embryonic teeth would be almost impossible and certainly ethically 
questionable and precludes the direct study of human amelogenesis. However, where 
enamel survives on exfoliated human AI teeth (especially if the tooth is unerupted e.g. 
an impacted 3rd molar) enamel composition and ultrastructure can provide a record of 
sorts as to what went wrong during amelogenesis, allowing hypotheses to be 
developed and subsequently tested using in vitro, in cellulo or in vivo animal models. 
Rodents, whose incisor enamel forms continuously, have proved to be an invaluable 
animal model in AI research as all stages of development are present on a single 
incisor as detailed below (Section 1.3.4.1.1). 
1.3.4.1.1 Rodent incisors as models for studying amelogenesis and aetiologies 
driving AI 
Rodent incisors have evolved to grow continuously in response to attrition at the biting 
edge of the tooth caused by gnawing on hard foods (Hu et al., 2014). In addition, 
rodents actively wear the incisal edges to keep them chisel-sharp during thegosis; a 
behavioural process which is distinct from mastication related to feeding (Byrd, 1997). 
Continuous tooth formation and growth originates from the labial cervical loop located 
at the apical end of the incisor. It comprises permanent reservoirs of stellate reticulum 
cells, providing a stem cell niche. These cells generate so-called “transit-amplifying 
cells”, whose progeny ultimately differentiate into ameloblasts. (Harada et al., 1999).  
Tooth development occurs in the apical-to-distal (or root to biting edge) direction, with 
the ‘newest’ dental tissue forming towards the apical end, and the most mature tissues 
at the distal end (illustrated in Figure 14). Thus, all steps of amelogenesis can be 
visualised simultaneously on a single incisor and at any time. This is not feasible in 
other models where teeth are not continuously growing (e.g. pig). In such cases, 
developing teeth have to be dissected from the jaws of several animals at different 
developmental stages to capture all stages of amelogenesis. 
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1.3.4.1.2 Use of mouse models in studying amelogenesis and AI – current state 
of the art 
The advantage of using mouse models in preclinical studies is that mice are relatively 
easy to modify genetically and various mutations can be introduced to investigate 
correlations between genotype and phenotype, understand protein function and the 
aetiological mechanisms driving AI. Mouse and human developing enamel proteomes 
are highly conserved and the cellular and extracellular event occurring during 
amelogenesis are very similar. The enamel produced in both species is essentially 
identical at the biochemical level though the structural organisation of rodent incisors is 
somewhat unique in that the prisms adopt a more obvious decussating arrangement. 
Mouse ‘null’ models or KO models are those where the expression of a specific gene 
has been abolished. Although the KO models cannot explain fully the exact details 
around phenomena such as protein-protein interactions and cellular (or extra-cellular) 
processing, they can show that the protein in question has a specific role to play in 
amelogenesis overall or more usefully in a specific facet of amelogenesis. 
Various murine KO models have been engineered that lack the expression of genes 
involved in amelogenesis and the resulting enamel (developing or mature) 
characterised. The KO models studied to date include KOs of amelogenin (Gibson et 
al., 2001), ameloblastin (Fukumoto et al., 2004), enamelin (Hu et al., 2008, Smith et 
al., 2009), MMP-20 and KLK4 (Caterina et al., 2002, Wright et al., 2009, Simmer et al., 
2009, Yamakoshi et al., 2011, Hu et al., 2016, Núñez et al., 2016), amelotin (Núñez et 
al., 2016), FAM83H (Wang et al., 2016), WDR72 (Katsura et al., 2014), SLC24A4 
(Stephan et al., 2012), GPR68 (Parry et al., 2016), FAM20A (Vogel et al., 2012) and 
DLX3 (Morasso et al., 1999). 
The relevance of KO mouse models in reflecting human AI has been discussed by 
Wright et al, (2009). Mice KOs models might be expected to accurately model human 
cases of AI where the human mutation effectively abrogates expression of the protein 
in question (e.g. a mutation that destroys a promoter region). However, rather than 
knocking out a protein completely, numerous cases of human AI involve more subtle 
changes to the protein in question e.g. deletion of part of a protein, amino acid 
substitutions, affected splicing recognition sites resulting in faulty splicing and the 
introduction of premature stop codons resulting the expression of a truncated protein. 
These mutations may cause a different AI phenotype to that obtained when the protein 
in question is simply knocked out. This is because a KO model is based on loss of 
function due to complete absence of protein whereas an abnormal protein that is 
expressed may provide a ‘gain of toxicity’ meaning that although the protein is present 
it may actually be frankly toxic in addition to any loss of function the mutation may 
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have caused. In short, mouse KO models can only tell us so much; to understand the 
aetiology specific cases of human AI there is a need for mice models carrying 
mutations that replicate the specific mutations that cause human AI.  
1.3.4.1.3 Mouse model carrying the p.Y64H mutation 
As briefly eluded to above, a recent mouse model was described that carried the 
substitution of Tyr64 into a histidine (p.Y64H) mutation in amelogenin. The mice 
phenocopied human X-linked AI (Barron et al., 2010) and although the p.Y64H 
mutation has not been identified in any cases of human AI to date, it lies very close to 
the p.P70T mutation known to be associated with human AI (Collier et al., 1997) with 
both mutations lying in the previously discussed ATMP domain. The mice exhibited 
severe defects of enamel bio-mineralisation, loss of ameloblast phenotype and 
disruption of the ordered ameloblast monolayer due to premature apoptosis of affected 
ameloblasts. Affected ameloblasts failed to secrete amelogenin into the extracellular 
matrix, instead, amelogenin accumulated intracellularly, disrupting the secretory 
organelles, rough ER and Golgi apparatus (Barron et al., 2010). The observed 
abnormal retention of p.Y64H mutant amelogenin (along with ameloblastin and 
potentially other matrix proteins) led to the identification of ER stress as a possible 
factor driving AI in this model. The ameloblasts eventually succumbed to apoptosis 
due to the ER stress activating the so-called UPR, which had tipped towards pro-
apoptotic mode (the UPR is mentioned in Section 1.2.5.1, p.42 and UPR fate is 
discussed in greater details in Section 1.3.4.2, pp. 75 - 79). A concomitant increase of 
UPR markers was shown in the ameloblasts expressing mutant amelogenin (Brookes 
et al., 2014). The same group demonstrated that 4-phenylbutyrate, a histone 
deacetylase inhibitor and so-called chemical chaperone, could rescue the phenotype 
in heterozygous female mice, as ameloblast cell viability was maintained (apoptosis 
was dramatically decreased) and the mineralisation of the enamel was restored 
(Brookes et al., 2014).  
The precise molecular mechanisms leading to abnormal retention in the secretory 
pathway, ER stress and UPR-triggered apoptosis and pharmacological rescue of the 
phenotype in these mice remain to be unravelled. The UPR in theory attempts to 
relieve the ER stress in the first instance, but upon prolonged ER stress, such as the 
abnormal retention of p.Y64H mutant amelogenin, the UPR triggers ameloblast 
apoptosis which here would disrupt the ameloblast monolayer and compromise 
amelogenesis. The hypothesis, as it applies to female mice heterozygous for the 
mutation, in which only ~50% of the ameloblasts are affected (due to random 
inactivation of the X chromosome – Section 1.3.3.1 p. 56) is illustrated in Figure 15 
(pp. 72 - 73). This figure also shows the hypothesised means by which intervention 
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with 4-phenylbutyrate rescues the phenotype; the drug inhibits apoptosis so the 
ameloblast monolyayer is maintained and even though half the ameloblasts 
expressing the p.Y64H mutant fail to secrete protein, the remainder expressing the WT 
amelogenin gene are able to complete amelogenesis as normal. The next Section 
(1.3.4.2, pp. 74 - 79) describes the UPR signalling cascades in more detail, and 
addresses the molecular basis of how the UPR switches from pro-survival to pro-
apoptotic mode. 
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1.3.4.2 ER stress, the UPR and proteopathic diseases  
As detailed previously (Section 1.2.5.1), proteins destined for secretion fold in the ER 
and attain their correct functional 3-dimensional conformation. This is important since 
misfolded proteins may be trapped in a conformation that could be inactive and/or 
promote pathological intracellular aggregation which may be more toxic to the cell than 
the simple loss of function of the protein. When neither ERAD or ERAF (described in 
Section 1.2.5.1) comprising the first-line defence mechanism against misfolded 
proteins is sufficient to alleviate ER stress, the UPR sensors PERK, IRE1α and ATF6 
are triggered (detailed in Section 1.3.4.2.1). The UPR is activated and supports the 
cell as it attempts to handle its secretory burden by triggering the expression of 
downstream pro-survival genes. However, the UPR is not only triggered when mutated 
proteins are being trafficked. WT proteins can also misfold and in specialised secretory 
cells, where the secretory traffic is heavy even under normal conditions, e.g. insulin 
producing pancreatic cells (Lipson et al., 2006) and WT secretory ameloblasts (Wu 
and Kaufman, 2006, Tsuchiya et al., 2008), the UPR is activated as a normal 
physiological response to a particularly heavy period of secretory activity. 
During the initial response, the UPR attempts to alleviate ER stress caused by 
misfolded proteins by increasing the ER folding or degradation capacity of the cell, 
reducing the rate of global gene expression to reduce the number of client proteins 
entering the ER and by increasing the actual amount of ER in the cell (Lin et al., 2007). 
As mutated proteins may show greater propensity to misfold and aggregate, this may 
cause abnormally lasting ER stress which cannot be alleviated. In such cases the UPR 
switches from a pro-survival mode to pro-apoptotic mode (Ron and Walter, 2007, 
Hetz, 2012). This switch underpins the so-called proteopathies or conformational 
diseases; including some cancers, neurodegenerative diseases (Lindholm et al., 
2006), diabetes (Scheuner and Kaufman, 2008) and cystic fibrosis (Younger et al., 
2006) and now, AI (Brookes et al., 2014).  
The following Section (i) describes the three UPR pathways in more detail (Section 
1.3.4.2.1), (ii) addresses the balance between pro-survival and pro-apoptotic 
outcomes of the UPR (1.3.4.2.2) and (iii) addresses the consideration of UPR in 
dental pathologies (Section 1.3.4.2.3) 
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1.3.4.2.1 Activation of the UPR and signalling cascades and UPR fates 
The UPR comprises three signalling cascades (Figure 16) which are initiated upon the 
activation of a sensor protein: PERK, IRE1α and ATF6. At rest the three sensors are 
maintained in their inactive state by the bound ER chaperone BiP. BiP preferentially 
binds to misfolded proteins, so when misfolded proteins are in excess, BiP unbinds 
from the sensor, which then becomes activated (Bertolotti et al., 2000, Shen et al., 
2002) triggering downstream signalling cascades. 
 ATF6 pathway (Figure 16A)
ATF6 is a transmembrane protein (Haze et al., 1999) that is inactive when bound to 
BiP under quiescent conditions. It is activated upon release of BiP, after which ATF6 is 
transported to the Golgi by vesicles (Shen et al., 2002) where it is cleaved by 
proteases SP1 and SP2 (Ye et al., 2000). Its cytosolic domain (pATF6 N), which 
contains a basic leucine zipper, reaches the nucleus where it binds directly and 
specifically to DNA target sequences (Yoshida et al., 1998, Yoshida et al., 2000). 
which results in the transcription of chaperones BiP, GRP94, ERp57, calreticulin and 
components involved in the ERAD pathway (Adachi et al., 2008). 
 IRE1 pathway (Figure 16B)
IRE1 was the first known UPR sensor (initially identified in yeast) and is also the most 
highly conserved (Cox et al., 1993). The IRE1 pathway is activated on release of 
bound BiP under conditions of ER stress but can also be independently activated by 
direct binding of unfolded proteins to IRE1 (Credle et al., 2005, Gardner and Walter, 
2011). Activation of IRE1 starts with IRE1 autophosphorylation and oligomerisation 
(Shamu and Walter, 1996, Bertolotti et al., 2000, Ron and Walter, 2007). This 
activates the RNase domain of IRE1α (Hetz and Glimcher, 2009), which is in the 
cytosolic portion of IRE1 and catalyses in the unconventional splicing of X-box binding 
protein 1 (XBP1) mRNA. This splicing, produces a mRNA that will be further translated 
into the spliced isoform XBP1 (pXBP1s) (Gonzalez et al., 1999, Uemura et al., 2009). 
pXBP1s is itself a transcription factor (Yoshida et al., 2001) that upregulates genes 
involved in ERAD, chaperone synthesis, and expression of components necessary for 
lipid biosynthesis (necessary for increasing ER membrane biogenesis). In addition, 
activated IRE1α independently triggers activation of the transcription factors JNK or 
TRAF/JNK which lead to cell death (Yoshida, 2007) or cell rescue (Ogata et al., 2006) 
depending on the precise flux and nature of the UPR signalling occurring. 
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 PERK pathway (Figure 16C)
The PERK pathway also involves the release of bound BiP (Bertolotti et al., 2000), 
with resulting dimerisation and transphosphorylation (Liu et al., 2000). Once activated, 
PERK phosphorylates and represses eIF2α, a translation initiation factor, which 
causes an overall reduction in protein translation, in an attempt to alleviate the ER 
stress (Scheuner et al., 2001). When eIF2 is repressed, ATF4 is preferentially 
translated and regulates expression of proteins involved in metabolism and oxidative 
stress resistance, protein folding, and autophagy (Wek et al., 2006). ATF4 also 
activates transcription of C/EBP homologous protein (CHOP, also named GADD153) 
which contributes to cascades leading towards cell death (Wek et al., 2006, Brewer, 
2014). Other than eIF2 repression cascade, PERK induces NrF2 (Cullinan et al., 
2003), a transcription factor that promotes the synthesis of cytoprotective components 
(Kensler et al., 2007). 
A more detailed analysis of the 3 signalling arms is beyond the scope of this review. 
Suffice to say that the precise scope and nature of the signalling involved, especially 
with regard to cross talk between the 3 arms, is still under investigation. The essential 
point is that integration of the signals emerging from the 3 arms dictates whether the 
UPR remains in pro-survival mode or switches to pro-apoptotic mode; i.e. the “match 
point” decision.  
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1.3.4.2.2 UPR fates: “Match-point” decisions 
The UPR is an adaptive mechanism that attempts to alleviate ER stress but it can be 
thought of as a double-edged sword as it switches to pro-apoptotic mode upon 
prolonged stress. The duration and intensity of stress that trigger the pro-apoptotic 
mode depend on the specific context of cellular stress. The cross-talk and integrated 
signals originating from the three sensor-led arms of the UPR (Illustrated in Figure 17) 
is a key element determining the UPR fate (Tabas and Ron, 2011, Chen and 
Brandizzi, 2013). 
Figure 17 Cross-talk of the integrated signals driven by the 3 arms of the UPR.1 
PERK and IRE1α pathways are known to be either pro-survival or pro-death, and their 
prolonged activation reportedly converge towards an apoptotic endpoint (Hetz and 
Glimcher, 2009, Tabas and Ron, 2011). Current studies focus on signal integration 
(Hetz and Glimcher, 2009, Brewer, 2014). How the components are regulated, and 
how crosstalk and kinetics are synchronised, is still a matter of debate though fine-
tuning of IRE1 and prolonged PERK signalling are known to play an central role 
(reviewed by Hetz and Glimcher, 2009).  
1 Figure 17 is reproduced from Brookes et al. (2017) under the terms of the Creative 
Commons license CC BY (https://creativecommons.org/licenses/by/4.0/). 
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The molecular mechanisms driving UPR fate (pro-survival or pro-apoptotic modes) are 
currently topic of interest, as increasing numbers of publications report UPR as a 
pivotal driver of many human diseases (Wang and Kaufman, 2016). 
1.3.4.3 Amelogenin p.Y64H mutation: consequences of single amino acid 
change on amelogenin binding behaviour and intracellular 
trafficking 
The precise molecular mechanisms leading to abnormal retention of p.Y64H 
amelogenin, in the secretory of pathway of mouse ameloblasts, remains to be 
unravelled. For that, two questions are to consider: 
(1) At the amino acid level, how can a single substitution of a tyrosine into a histidine 
possibly alter amelogenin biochemical properties? The properties of both amino acids 
will be detailed in Section 1.3.4.3.1, to propose avenues for consideration. 
(2) When p.Y64H amelogenin was co-transfected with WT ameloblastin in COS-7 
cells, the apoptosis was increased (Brookes et al., 2014). Are there any other factors 
than solely amelogenin aggregation to consider, to explain its abnormal retention in 
the ER? Section 1.3.4.3.2 proposes avenues for consideration. 
1.3.4.3.1 Tyrosine and Histidine chemical properties 
At the local (amino acid) level, how can the substitution of Tyr64 into a histidine cause 
such change of amelogenin binding behaviour? At this stage of research, it would be 
difficult to predict the effect of a single amino acid substitution on amelogenin structure 
and function, as amelogenin tertiary structure has not been elucidated (see Section 
1.2.1.3.3, p. 20). This Section reminds briefly the biochemical properties of both amino 
acids (shown in Figure 18 overleaf).  
 Tyrosine (Figure 18A)
Tyrosine is a hydrophobic amino acid. With its aromatic ring, it mediates stacking 
interactions with other aromatic amino acids. In proteins, it is preferentially buried in 
protein hydrophobic cores and tyrosine can be substituted by another aromatic amino 
acid (Betts and Russell, 2003). It comprises a reactive hydroxyl group that confers its 
polarity and allows hydrogen bonding (Baker and Hubbard, 1984). It allows interaction 
with non-carbon atoms and provides with a site for phosphorylation, important in the 
cellular signal transduction (Hunter, 2014).  
 Histidine (Figure 18B)
Histidine comprises an imidazole ring. It is ionisable and can carry a positive charge. 
The imidazole ring’s tertiary amine comprises a lone pair of electrons that make it a 
nucleophile and hydrogen bond acceptor and confers its basic properties, while its 
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secondary amine is an electrophile. This confers histidine/imidazole its chemical 
versatility and adds complexity to the type of interactions it can engage into: It can be 
involved in π – π stacking, however there is a charge involved; It can also form (cation 
– π) interactions, which can be attractive or repulsive depending on histidine
protonation state (Liao et al., 2013); (hydrogen – π) bonds and can coordinate with 
metals (Liao et al., 2013). With its ability to accept or donate protons, histidine is often 
found in enzyme catalytic triads as a nucleophile activator (Betts and Russell, 2003). It 
can also coordinate with metal cations, hence its presence in metalloproteins (Strange 
et al., 1987). With a pKa close to 7, it is present as both protonated (charged) and 
unprotonated (uncharged) at physiological pH; therefore in proteins, it is not clear 
whether it will be exposed to the surface or buried in the hydrophobic core. Due to 
these complex and unique properties, histidine cannot easily substitute to any other 
amino acid.  
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Figure 18 Tyrosine and Histidine: structures and chemical properties. 
 
So, the properties of tyrosine and histidine differ in that:  
- Tyrosine is more likely buried in hydrophobic core and can be involved in π - π 
stacking interactions. Such properties are not that obvious for histidine since histidine 
can be protonated.  
- It is not always clear when histidine will be buried in the hydrophobic core or be 
exposed at the surface. It may thereby be hypothesised that the single substitution 
p.Y64H could expose to the solution a domain of amelogenin which possibly should be 
buried. 
Another point to consider is the location of the point mutation. It occurs in the ATMP 
domain, which, as Wald et al (2017) suggested, might be critical in driving amelogenin 
binding behaviour (see Section 1.2.2.2.1, p.22, for detailed explanation). 
- 82 -
These hypotheses cannot be yet confirmed, as the amelogenin 3-dimensional 
structure has not been solved (Section 1.2.1.3.3, p.20). Instead, it is more realistic to 
consider studying amelogenin binding behaviour, and how this is affected by the 
p.Y64H mutation. This is indeed among the aims of this thesis.
Amelogenin binding behaviour is assumingly affected by the p.Y64H mutation, but to 
which extent, and how this causes its abnormal retention in the ER and subsequent 
UPR remains to study. The mutation may not only affect amelogenin self-assembly, 
but also affect amelogenin interaction with other proteins during its intracellular transit, 
as explained below in Section 1.3.4.3.2. 
1.3.4.3.2 Co-transfection of p.Y46H mutant amelogenin with WT ameloblastin in 
COS-7 cells increased apoptosis  
In cellulo, ER stress was observed in cells co-transfected with p.Y64H amelogenin and 
WT ameloblastin, but not with amelogenin p.Y64H alone (Brookes et al., 2014). The 
ameloblastin may be overexpressed in this case compared with its expression in 
ameloblasts in vivo, which may have increased further the protein load in the ER. It 
provides a hint to consider, though, that the p.Y64H mutation in amelogenin may 
cause ER stress by affecting amelogenin binding beviour with itself and/or with other 
proteins. Amelogenin self-assembles and may interact with other proteins including ER 
components and ameloblastin, as reviewed in Section 1.2.5.2.1 (pp. 45 – 47). The 
p.Y64H mutation impairing amelogenin binding behaviour may thereby impair the 
balance of protein-protein interactions necessary for amelogenin trafficking and 
secretion. The situation is illustrated below in Figure 19 below.  
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Figure 19 Amelogenin p.Y64H mutation affects amelogenin binding behaviour 
and therefore may perturb the balance of protein-protein interactions 
involving amelogenin: hypothesis. 
 
Bearing in mind that p.Y64H mutation may affect the balance of amelogenin 
interactions with itself or other potential binding partners during its intracellular transit, 
the first step should be to analyse how p.Y64H mutation affects amelogenin self-
assembly. To this end, large amounts of WT and p.Y64H mutant r-amelogenins were 
needed. The next Section reviews the challenges met with production and purification 
of amelogenins (native and recombinants). 
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1.3.5 Need for relevant expression and purification system for 
future amelogenin protein-binding assays 
To gain better insight of molecular mechanisms driving AI and to identify therapeutic 
targets, in vitro studies are a necessary initial step prior to in cellulo and in vivo 
studies. This thesis focuses on the possible pathogenesis mechanism(s) of p.Y64H-
associated AI in a mouse model which phenocopies human AI. In vitro functional 
studies designed to characterise intracellular amelogenin-amelogenin interactions 
would first require a reliable and plentiful source of purified wild type and p.Y64H 
amelogenins. Purifying native proteins from developing enamel is challenging when 
using teeth from large animals, such as the pig but the amounts of secretory stage 
enamel protein obtained from existing mice models expressing p.Y64H amelogenin 
would simply be too small to be of any use in protein binding studies. The cost of 
genetically modifying a large animal such as a pig to express p.Y64H amelogenin and 
the associated animal husbandry costs would be prohibitive. In addition, since p.Y64H 
amelogenin is not secreted and does not accumulate in the enamel matrix, the only 
biological source of p.Y64H amelogenin would be from the affected ameloblast 
monolayer which would still only return minuscule amounts of amelogenin.  
The only viable source of mutated amelogenin (or for that matter WT rodent 
amelogenin) is therefore via recombinant technology. 
Recombinant proteins are widely used as therapeutic agents and as tools to study 
structure-function relationships, protein interactions with other molecules and as 
antigens for antibody production. E. coli based expression systems are the most 
widely used methodology for producing r-amelogenin even though post translational 
phosphorylation of Ser16 will be absent. Baculo virus (Taylor et al., 2006, Xu et al., 
2006) and Leishmania (Yadegari et al., 2015) expression systems, having the potential 
to carry out post translational phosphorylation, have been used to produce r-
amelogenin but as yet do not appear to have been widely adopted, perhaps due to 
uncertainty as to whether the amelogenin was phosphorylated or low yield. In contrast, 
a yeast-based expression system has been reported to generate correctly 
phosphorylated r-amelogenin (Cheng et al., 2012) but again has not been widely used. 
Efforts have been made previously to purify r-amelogenin. One of the most frequently 
used purification methods, published for rM179 starts with cell lysis under denaturing 
conditions (6 M guanidine hydrochloride), centrifugation, precipitation with ammonium 
sulphate, and preparative C4 reverse phase column chromatography in 0.1% trifluoric 
acid/acetonitrile (Simmer et al., 1994). This method has been widely used for in vitro 
studies e.g. characterising amelogenin assembly into nanospheres (Moradian-Oldak et 
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al., 1994) but does not provide amelogenin at single band purity. Moradian-Oldak et al 
(1994) noted recombinant mouse amelogenins were co-chromatographed with 
contaminating E. coli proteins. Nickel-nitrilotriacetic acid (Ni-NTA) metal-affinity 
chromatography was also used to purify His-tagged r-amelogenins for functional 
studies (Moradian-Oldak et al., 2000).  
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1.3.6 Protein-protein interactions and existing analytical techniques 
As detailed in Section 1.2, the developing enamel matrix is comprised of several gene 
products whose function appears to be associated with protein-protein interactions – 
the presence of amelogenin nanospheres is the prime example of this.  Understanding 
these protein interactions is key to understanding normal amelogenesis as well as the 
aetiology of AIs driven by perturbed protein interactions. One aim of this thesis was to 
develop a simple method for studying protein interactions that also provided a high 
throughput with a view to developing a screening tool that might be used in the future 
to assess the impact of drugs on pathological enamel protein-protein interactions. The 
method ought to mimic the in vivo environment as necessary to properly characterise 
protein-protein interactions. 
1.3.6.1 Mathematical description of protein-protein interactions  
Protein recognition and binding is driven by hydrophobic bonding (Young et al., 1994), 
van der Waals forces (Roth et al., 1996), electrostatic bonds (Sheinerman et al., 
2000), hydrogen bonds (Jiang and Lai, 2002) or covalent bonds. Whether these 
interactions can occur depends on the conformations and the accessible surface area 
of the proteins involved (Jones and Thornton, 1996). These ‘intrinsic’ factors 
themselves also depend on the environment in which the protein-protein interactions 
occur such as pH, ionic strength, nature of the solvent, temperature or redox 
conditions. 
Protein-protein interactions are kinetic phenomena that can be described 
mathematically. The protein binding partners associate at a rate ka and dissociate at a 
rate kd as illustrated below in Figure 20. The ratio (ka/kd) corresponds to the binding 
affinity KA, and the inverse measure is the dissociation constant KD (= kd/ka). These 
parameters can be measured experimentally and provide a tool to compare the 
binding behaviours of mouse WT and mutant p.Y64H r-amelogenins. 
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Figure 20 Protein-protein interactions as an equilibrium. In the case of a first 
order reaction (simplified) the two binding partners associate at rate ka and 
dissociate at rate kd. The affinity or dissociation constants can be 
measured at equilibrium, where ka.[A].[B] = kd. [AB]. 
To obtain kinetics parameters that are as reliable as possible, the experimental 
conditions should be set up so as to reflect in vivo environment as accurately as 
possible. There exists a plethora of protein-protein interaction studies in vivo/in cellulo 
and in vitro. The most popular methods are addressed below in Sections 1.3.6.2 – 
1.3.6.4 (with further detail on their principles, pros and cons, provided in Appendix E), 
where the principles of the techniques are described in more detail).  
1.3.6.2 Protein-protein interaction assays in cellulo or in vivo 
To date, various in vivo or in cellulo protein-protein interaction studies have been 
carried out; Y2H assay (Fields and Song, 1989) protein fragment complementation 
assay (PCA) (Johnsson and Varshavsky, 1994, Hu et al., 2002, Galarneau et al., 
2002), fluorescence/bioluminescence resonance energy transfer (FRET/BRET) 
(Stryer, 1978, Xu et al., 1999) and cross-linking (Wong, 1991). Other techniques 
including immunofluorescence microscopy, which previously identified amelogenin 
binding partners (see Section 1.2.5.2, pp. 45 - 46) are not detailed here. 
The Y2H assay is commonly used, allowing high-throughput screening for protein-
protein interactions, and has contributed to the creation of maps of interaction 
networks (Ito et al., 2001). It has been used to characterise binding partners and 
domains for amelogenin (Paine and Snead, 1997). The protein-protein interactions 
associated with the Y2H system occur in the yeast nucleus, which may not reflect the 
natural environment in which the protein-protein interactions actually occur (Piehler, 
2005). The PCA assays, whose principle is similar to that of Y2H, in that the two 
proteins of interest, the bait and prey, are each attached to two separate fragments of 
a reporter protein that are brought together only when the two proteins of interest 
interact and then able to generate reported signal. The interaction between the ‘bait’ 
and ‘prey’ proteins can occur anywhere in the cell (Johnsson and Varshavsky, 1994). 
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Other techniques, FRET and BRET, where fluorophores or bioluminescent labels are 
attached to the proteins of interest, allow direct and real-time detection of protein-
protein interactions in cells. The signal is generated actually by the close proximity of 
the proteins of interest.  
While these techniques provide in vivo data and identify protein-protein interactions in 
real-time, they can be technically demanding and involve protein-labelling or protein 
fusion, which per se may affect the actual interactions of interest.  
Chemical cross-linking studies allow the direct study of protein-protein interactions 
without any tag or label. It has been used to analyse amelogenin self-assembly in the 
enamel matrix (Brookes et al., 2000) and in the ameloblast (Brookes et al., 2006). 
Crosslinking captures protein-protein-interactions and freezes them in time allowing for 
crosslinked complexes to be identified but precludes the generation of kinetic data. To 
date, label-free techniques that characterise the kinetic parameters of protein-protein 
binding are mostly available in vitro. They are addressed in the next Section. 
1.3.6.3 Protein-protein interaction assays in vitro 
A plethora of in vitro methods exist to characterise protein-protein interactions. Among 
popular methods, SPR, ITC, or QCM allow direct measurements in real-time of protein 
binding, generating kinetics parameters such as kd, ka , or affinity/dissociation 
constants KA, KD. 
SPR allows the detection of real-time kinetics of protein binding with a versatile assay 
format. QCM (Marx, 2003) can analyse protein adsorption and antibody-antigen 
recognition with similar sensitivity as SPR (Köβlinger et al., 1995) and both methods 
have been used in parallel in protein-protein interaction reports (Köβlinger et al., 
1995). With both SPR and QCM one binding partner is immobilised while the other 
binding partner is solubilised and binds the immobilised partner from solution. This is a 
difficulty to consider while studying the binding behaviour of amelogenin which exhibits 
poor solubility and aggregates at physiological pH and temperature (Tan et al., 1998). 
Unlike SPR or QCM, ITC avoids immobilisation of either binding partner on a surface 
as interactions are studied in solution (Brown, 2009). In studying amelogenin binding 
behaviour, ITC indicated that amelogenin self-assembly, using rP172, is driven by 
hydrophobic interactions and the formation of a hydrophobic core with water removal 
(Lakshminarayanan et al., 2009). 
AFM and DLS have been widely used to study amelogenin interactions and 
assemblies (see Sections 1.2.2.2.4 p. 24 and 1.3.3.2.2, p. 63). AFM can be used to 
visualise the structure of protein complexes (e.g. to visualise selective adsorption of 
amelogenin nanospheres onto specific faces of enamel crystals (Wallwork et al., 2001) 
and to directly measure the forces involved in the protein-protein interactions (e.g. 
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interactions between amelogenin and cell surface receptors (Kirkham et al., 2006) and 
also to analyse protein folding (Fisher et al., 1999, Yang et al., 2003). DLS can provide 
high-throughput data, and possibly quantitative analyses of reaction stoichiometry 
including equilibrium dissociation constants of protein-protein interactions occurring in 
solution (Hanlon et al., 2010). It has been used to characterise amelogenin self-
assembly, as reviewed in Section 1.2.2.2.4 (pp. 24 - 25). 
While most of these techniques can generate binding data such as association or 
dissociation constants or binding strength; they require large amounts of proteins and 
specialised and costly equipment. As discussed in the next section, microplate-based 
binding assays in contrast require no specialised equipment, are simple to carry out 
and are low cost.  
In order to compare protein-protein binding behaviours of r-amelogenin WT and 
p.Y64H mutant, pilot tests were carried out to determine optimum working conditions.
They used EMD as surrogate protein model since EMD is available in large quantities,
unlike mouse WT and mutant p.Y64H r-amelogenins.
1.3.6.4 Use of  microplate-based solid-phase protein-binding assays to 
study the effect of the p.Y64H mutation on amelogenin self-
interactions 
In this thesis, microplate binding assays were chosen because they are cost-effective, 
flexible and easily carried out in house with standard laboratory equipment which 
facilitates method development.  
A high-throughput solid-phase microplate protein binding assay, derived from ELISA 
methodology, was developed, allowing the characterisation of the interactions between 
two different proteins, one of which was non-covalently immobilised on the microwells 
of a microplate, while the other was soluble in solution and able to bind the 
immobilised protein (Biesiadecki and Jin, 2011). After washing steps, Biesiadecki and 
Jin (2011) measured the amount of soluble protein bound to its immobilised partner by 
probing with a specific antibody to the soluble binding partner in conjunction with a 
chromogenic detection step – as used in standard ELISA assays. This method proved 
to be cost and labour- effective, providing for flexible conditions and allowing the study 
of both protein association and disassociation kinetics. However, the aim in this thesis 
was to characterise the interaction between two identical proteins – the interaction 
between r-amelogenin molecules. In this case an antibody detection system would be 
of no use since the antibody would not be able to distinguish between the immobilised 
r-amelogenin and r-amelogenin bound to the immobilised r-amelogenin.
To get round this problem it was initially decided to measure directly the amount of
fluorescently-labelled free amelogenin bound to non-labelled immobilised amelogenin.
Aims and Objectives 
This thesis aims at obtaining purified WT and mutant p.Y64H r-amelogenins for in vitro 
binding assays with the aim of investigating whether the p.Y64H point mutation has an 
effect on amelogenin binding behaviour. Such studies would test the hypothesis that the 
p.Y64H point mutation causes amelogenesis imperfecta via ER stress triggered by
inappropriate aggregation in the secretory pathway.
Aim 1: Production and purification of r-amelogenins 
As addressed in Section 1.3.5, the purification of r-amelogenin has often proved 
challenging using classic chromatographic methods, as amelogenin co-eluted with  
contaminating host cell proteins (even when His-tagged recombinants were subjected to 
nickel column chromatography; the gold standard method for purifying recombinant 
proteins). Contaminating proteins could be problematic for use in downstream in vitro 
studies due to the unpredictable way in which they might modify r-amelogenin interactions. 
Recently, an extraction method based on amelogenin preferential solubility in acetic acid 
allowed a significant enrichment of r-amelogenin from E. coli which could be potentially 
useful in purifying r-amelogenin from bacterial host proteins.  
Specifically the objectives were to: 
1) Optimise the acetic acid extraction method to enrich mouse r-amelogenins in large
quantities.
2) Evaluate the use of the acetic acid extraction method as an initial clean-up step for
His-tagged r-amelogenins and optimise a range secondary purification
technologies:  nickel column chromatography based purification, size exclusion
chromatography and preparative SDS PAGE.
The importance of obtaining r-amelogenins at maximum purity (e.g. single band on 
analytical SDS PAGE with silver staining) is that it avoids any interference due to 
contaminants in functional studies. This is a major consideration for studying the effect of 
the p.Y64H single point mutation. 
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Aim 2: Studying the effect of the p.Y64H mutation 
As addressed in Section 1.3.4, the p.Y64H mutation in mouse amelogenin was associated 
with abnormal retention of amelogenin in the ameloblast secretory pathway, causing ER 
stress and subsequent pro-apoptotic UPR. Further understanding of the underlying 
mechanisms is required to identify therapeutic targets. A first route of investigation to 
consider is the effect of the p.Y64H mutation on amelogenin self-assembly and binding 
behaviour.  
Amelogenin protein-protein interactions have been investigated in multiple studies, as 
described in Sections 1.2.2.2 and 1.3.3.2. With the methods available to analyse protein-
protein interactions (see Section 1.3.6), binding assays remain technically challenging due 
to WT amelogenin’s intrinsic propensity to aggregate. 
This thesis aims at developing a cost-effective and simple method for studying protein-
protein interactions with a view to compare the binding behaviours of WT and p.Y64H 
mutant r-amelogenins in vitro and develop a screening tool for future drug design 
methodologies.  
Specifically the objectives were to: 
1) Develop a simple, high throughput and cost-effective microplate-based binding
assay, which is flexible enough to use solute conditions similar to those in vivo in
order to confidently compare with the binding behaviours of WT and mutant
p.Y64H r-amelogenins.
2) Attempt to address the question related to AI research, which is whether the
p.Y64H mutation affects amelogenin binding behaviour.
The importance of such methodologies is to define working in vitro conditions that reflect 
physiological environment so as to analyse, as accurately as possible, the effect of 
amelogenin p.Y64H mutation. 
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Chapter 2 Materials and Methods 
2.1 Production and purification of r-amelogenins 
2.1.1 General methods 
2.1.1.1 Expression of recombinant WT and mutant p.Y64H amelogenin in 
E. coli
Recombinant His-tagged amelogenins either WT (WT+His) or carrying the p.Y64H 
mutation (Mut+His), were expressed by E. coli Rosetta DE3 competent cells previously 
transfected with vector pET28/Amelx-WT+His or Amelx-MutY64H+His. The plasmid 
production and transfection were performed by a commercial company (Novagen, 
Merck Chemicals Ltd) (Barron et al., 2010, Gabe et al., 2017). Vector pET28 carried 
the T7 promoter, WT His-tagged amelogenin gene (Amelx-WT+His) or mutant His-
tagged amelogenin gene (Amelx-Mut+His), and chloramphenicol and kanamycin 
antibiotic resistance genes to allow for the selective growth of transfected cells. The 
predicted amino acid sequences of the r-amelogenins are shown below in Table 3 (the 
His-tag cleavage site is underlined and the actual peptide bond cleaved is indicated by 
a “#” character). 
Table 3  Primary sequences or r-amelogenins WT+His and Mut+His. The cleavage 
site is underlined and indicated by a “#” character. The position of p.Y64H 
point mutation is indicated in red.  
r-amelogenin Primary sequence 
WT+His 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSL
EVLFQ#GPGSMPLPPHPGSPGYINLSYEVLTPLKWYQS
MIRQPYPSYGYEPMGGWLHHQIIPVLSQQHPPSHTLQP
HHHLPVVPAQQPVAPQQPMMPVPGHHSMTPTQHHQP
NIPPSAQQPFQQPFQPQAIPPQSHQPMQPQSPLHPMQ
PLAPQPPLPPLFSMQPLSPILPELPLEAWPATDKTKREE
VD 
Mut+His 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSL
EVLFQ#GPGSMPLPPHPGSPGYINLSYEVLTPLKWYQS
MIRQPHPSYGYEPMGGWLHHQIIPVLSQQHPPSHTLQP
HHHLPVVPAQQPVAPQQPMMPVPGHHSMTPTQHHQP
NIPPSAQQPFQQPFQPQAIPPQSHQPMQPQSPLHPMQ
PLAPQPPLPPLFSMQPLSPILPELPLEAWPATDKTKREE
VD 
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The E. coli cells were stored on beads at -80 °C until required. Their growth was 
initiated on the first day of culture by spreading cells on selective medium agar plates 
and incubating them overnight at 37 °C under conditions of 5% CO2. The agar medium 
was made up of 20 g/L LB Lennox Broth (alfa Aesar H26760, Johnson Matthey Co., 
Heysham, UK) in distilled water mixed with 12 g/L Technical Agar No. 3 (Thermo 
Fisher Scientific Oxoid Ltd, Basingstoke, UK). The mixture was autoclaved at 121 °C 
for 15-20 minutes, before the addition of kanamycin A (LKT Laboratories, St. Paul, 
MN) at the concentration of 61.2 μM to favour the growth of transfected cells carrying 
the genes that provide resistance to this antibiotic. 
The resulting colonies were picked under sterile conditions and used to inoculate 8 mL 
selective liquid growth medium. The liquid growth medium was comprised of 20 g/L 
LB/Broth (alfa Aesar H26760, Johnson Matthey Co., Heysham, UK) in distilled water 
and had been sterilised by autoclaving at 121°C for 15-20 minutes. Before each 
inoculation, the medium was brought to 37 °C and kanamycin A (LKT Laboratories, St. 
Paul, MN) and chloramphenicol (Sigma-Aldrich, St Louis, MO) were added at 
concentrations of 61.2 μM and 76.4 μM respectively. The inoculated tubes were 
incubated at 37°C (ISF-1-W Kuhner AG, Basel, Switzerland) with shaking at 200 rpm. 
The next day the bacterial culture was diluted 100 times in fresh liquid growth medium 
and bacterial growth monitored by spectrophotometry at a wavelength of 600 nm 
(OD600nm) using a Jenway 6305 spectrophotometer (Bibby Scientific Limited, Stone, 
UK) until the optical density reached a value comprised between 0.6 and 1.2 AU.  
After the OD600nm reached a value between 0.6 and 1.2 AU, isopropyl 1-thio-β-D 
galactopyranoside (IPTG) (Generon Ltd, Maidenhead, UK) was added to the medium 
at a concentration of 1 mM to induce the expression of r-amelogenin. Following the 
addition of IPTG, the culture flasks were left overnight on the shaking incubator at 
37 °C. The following day the mixture was centrifuged at 15,008 g for 10 minutes at 4°C 
(Avanti J26-XP, Beckman Coulter). Supernatants were discarded and cellular pellets 
were retained and stored at -20 °C; due to their physical aspect, the cellular pellets 
harvested after E. coli culture and expression of r-amelogenin will be referred to as 
“paste” in the thesis. To monitor the expression of r-amelogenin in the E. coli, a 100 μL 
aliquot was taken from the bacterial growth flask before induction with IPTG and kept 
at -20°C. After addition of IPTG to the remaining culture and subsequent overnight 
incubation, a 100 μL aliquot was taken. The protein contents of E.coli in both pre- and 
post-induction aliquots were analysed by analytical SDS PAGE and western blot. The 
methods for analytical SDS PAGE and western blotting are described below in Section 
2.1.1.4 (pp 100 - 103). The preparation and loading of samples for analytical SDS 
PAGE and western blot analyses is detailed in the supplementary data (CD). 
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2.1.1.2 Optimisation of 3% acetic acid amelogenin extraction procedure 
The first step in isolating r-amelogenin from the bacterial paste (obtained from the 
cultures described above) from the plethora of contaminating bacterial proteins 
involved extraction in 3% acetic acid. This method, based on the apparent preferential 
solubility of amelogenin at acidic pH, was first published using non-His-tagged human 
r-amelogenin (Svensson Bonde and Bulow, 2012). Svensson Bonde and Bulow (2012)
washed the E. coli cells in 150 mM NaCl and resuspended them in 0.5 – 5% acetic 
acid. The cell suspension was heated to 60-80°C in a water bath for 20 minutes and 
then subjected to centrifugation at 20,000 g for 20 minutes. The authors reported that 
higher concentrations of acetic acid gave optimum results and that at 3% acetic acid, 
within ‘weight of E. coli to volume of acetic acid’ ratios of 0.035 – 0.35 g of E. coli paste 
per mL of acetic acid, the higher volume of acetic acid provided a higher yield but they 
did not elaborate further in terms of the optimum volume of acid to use for a given 
mass of cells (Svensson Bonde and Bulow, 2012).  
Based on this data, WT+His and Mut+His mouse r-amelogenins were extracted from E. 
coli in 3 % acetic acid. However, due to the presence of the His-tag (absent in the 
original work reported by Svensson Bonde and Bulow (2012)) and the fact that mouse 
and human amelogenins are not 100 % conserved, the volume of 3 % acetic acid used 
to extract r-amelogenin from a given weight of E. coli cells and the cell lysis conditions 
for mixing and heating were optimised for this study. 
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2.1.1.2.1 Determining the volume of 3 % acetic acid to E. coli to give optimum 
extraction efficiency 
To identify the ratio of E. coli to volume of acetic acid required to give the optimum 
yield of r-amelogenin in a single extraction step without over dilution, the extraction of 
mouse r-amelogenin in 3 % acetic acid was tested in ranges of 0.0033 - 0.33 g/mL of  
E. coli paste (obtained as described in Section 2.1.1.1 pp. 92 - 93) in acetic acid. 
Cells expressing WT+His r-amelogenin were washed to remove extracellular proteins by 
resuspension in 150 mM NaCl at 0.033 g/mL E. coli paste in NaCl solution and 
centrifuged at 3220 g for 20 minutes at room temperature. After centrifugation, the 
supernatant was discarded and the pelleted cells were resuspended in 3 % acetic acid 
at either 0.33, 0.17, 0.033 or 0.0033 g/mL by manual mixing and then heated at 75°C 
for 20 minutes in a water bath and centrifuged at 3220 g for 15 minutes. The protein 
content in the supernatant was analysed by SDS PAGE (see Section 2.1.1.4, pp. 100 - 
102). The preparation of the samples for analytical SDS PAGE is detailed in the 
supplementary data (CD). 
2.1.1.2.2 Optimisation of the mixing regimen and extraction temperature on the 
yield of r-amelogenin extracted from E. coli 
Svensson Bonde and Bulow (2012) extracted r-amelogenin by subjecting the cells 
(resuspended in acetic acid) to either sonication (8x10 seconds), followed by heat 
treatment or simply by a 20-minute heat treatment at 60-80 °C in a water bath. They 
obtained r-amelogenin at a greater purity by using direct heat treatment rather than 
sonication. However, it was not clear what form of sonication was used; was it 
relatively mild using a sonic water bath or more extreme using an ultrasonic probe 
designed specifically for tissue homogenisation? 
For E. coli expressing Mut+His, resuspending the cells in acetic acid manually was 
inefficient, being both time and effort-consuming. The extraction regimen was 
therefore optimised in an attempt to make it quicker and easier and to improve the 
yield. An ultrasonic probe was trialled as an alternative technique that simultaneously 
resuspended the cell pellet and ruptured the cells.  
The optimisation of the mixing regimen including use of an ultrasonic probe is 
illustrated in Figure 21A p.92. After resuspension in 150 mM NaCl, the E. coli cells 
expressing Mut+His were pelleted by centrifugation 3220 g for 20 minutes. The pellets 
were crudely resuspended by hand in 3 % acetic acid at 0.033 g/mL cells in acetic 
acid. The mixture was sonicated for 30 - 60 seconds, using an ultrasonic liquid 
processor (Ultrasonix processor XL sonicator, Misonix) operated at maximum 
permissible power (power setting 4 (arbitrary units)) followed by heating at 75°C in a 
water bath for 20 minutes. The mixture was then allowed to cool to room temperature, 
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followed by centrifugation at 3220 g for 20 minutes. The protein content of the mixture 
was analysed by SDS PAGE with Coomassie Blue staining (see Section 2.1.1.4, pp. 
100 - 102). The preparation of the samples for analytical SDS PAGE is detailed in the 
supplementary data (CD).  
To investigate the efficacy of the heating step on yield, the extraction procedure was 
also carried out at room temperature (as illustrated in Figure 21B below). The contents 
of the supernatant and pellet fractions were analysed by analytical SDS PAGE with 
Coomassie Blue staining (see Section 2.1.1.4, pp. 100 - 102). The preparation of the 
samples for analytical SDS PAGE is detailed in the supplementary data (CD). Gel 
densitometry was used to compare the extraction yield with and without heating. 
Figure 12  Panel (A) summarises optimisation of the mixing regimen used during 
the acetic acid extraction of r-amelogenin. The effect of ultrasonication and 
manual mixing on the resulting acetic acid extract were investigated by 
comparing the protein contents of the final supernatant and pellet by 
analytical SDS PAGE. Panel (B) describes the procedure carried out to 
investigate the effect of the heat treatment on the extraction yield. The 
effect of heating treatment was analysed by comparing the contents of final 
supernatants and pellet by analytical SDS PAGE. 
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2.1.1.2.3 Large scale acetic acid extraction of r-amelogenin using the optimised 
extraction methodology 
Following the optimisation described above, it was decided that an extraction regimen 
that included ultrasonication and heating to 75°C gave the best results (see Section 
3.1.1.2.2 pp. 140 - 141). The finalised extraction procedure of r-amelogenin in 3 % 
acetic acid was scaled up and is summarised in Figure 22. The cells harvested after 
induction of protein expression were washed in 150 mM NaCl, at a ratio of 0.033 g/mL 
E. coli paste in NaCl solution, then centrifuged 3220 g for 20 minutes. The supernatant 
was discarded and the cells were resuspended to 0.033 g/mL wet weight cells in 3 % 
acetic acid, then sonicated until the mixture appeared homogeneous and heated for 
20-25 minutes at 75°C in a water bath. After removal from the water bath, the lysate 
was left to cool to room temperature and was then centrifuged again as above. The 
supernatant was frozen at -80°C, lyophilised and desalted (see Section 2.1.1.3, p. 99 
for desalting procedure). The desalted extracts were subjected to mass spectrometry 
analyses (see Section 2.1.1.5, p. 104, for mass spectrometry analyses). 
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Figure 2 2 Flow-diagram of the optimised extraction procedure. (1) E. coli were 
washed in 150 mM NaCl and (2) resuspended in 3 % acetic acid at 0.033 g 
cell paste per mL acetic acid. The suspension was (3) mixed by 
ultrasonication, and (4) heated at 75°C for 20 minutes. (5) The fraction of 
proteins solubilised was isolated in supernatant by centrifugation at 3220 g 
for 20 minutes and (6) was lyophilised. 
- 99 - 
 
2.1.1.3 Desalting procedure 
Samples containing r-amelogenins were desalted against degassed 125 mM formic 
acid by size exclusion chromatography (SEC). The larger r-amelogenin molecules are 
excluded from the size exclusion beads and washed through the column quickly in the 
mobile phase. Smaller molecules (ions, salts, etc.) enter the beads and their passage 
through the column is retarded, meaning they elute after the protein. Degassed formic 
acid at 125 mM was prepared by dissolving formic acid (cat. no. 33015, Sigma-Aldrich, 
St Louis, MO) to 125 mM in ultrapure water1 and then degassing. It was used as the 
mobile phase because it provides the hypothetical ionic strength to reduce undesirable 
interactions between the sample proteins and the gel filtration medium. The pKa formic 
acid is 3.75 (Riddick et al., 1986), so the pH of 125 mM formic acid is low enough 
(2.34) to solubilise r-amelogenin (Tan et al., 1998) without causing long term damage 
to the column medium. In addition, formic acid is volatile and can be easily removed 
from the desalted protein by lyophilisation.  
The lyophilised samples containing amelogenin (either r-amelogenin or EMD 
components- see later, detailed in Section 2.2.1 p. 120) were dissolved in a minimum 
volume of degassed 125 mM formic acid. Any precipitate/insoluble contaminants were 
removed by filtering the mixture through a 0.45 µm filter. Then, the solution was loaded 
onto the HiPrep 26/10 column (GE Healthcare, Buckinghamshire, UK) previously 
equilibrated with degassed 125 mM formic acid. The elution was carried out at room 
temperature and a flow rate of 3.5 mL/minute using an AKTA FPLC chromatography 
system (GE Healthcare, Buckinghamshire, UK). The column eluate was monitored at 
280 nm and the desalted protein, eluting in the first peak, was frozen at -80 °C, after 
which the volatile formic acid was removed by lyophilisation. 
Some procedures required desalting of r-amelogenin that had been previously 
lyophilised from 0.1 M Na2CO3 (see Sections 2.1.2.3.2 p. 118 -119 and 2.2.1.1 p. 120). 
Because of the presence of Na2CO3 in the lyophillisate, the addition of 125 mM formic 
acid failed to acidify the solution sufficiently to dissolve the r-amelogenin without 
massively over-diluting the sample. Instead, increasing volumes of 100 % formic acid 
were added to the mixture until it appeared clear. It was then subjected to filtration and 
subsequently desalted as described above. 
  
                                               
1 In the thesis, ultrapure water (18.2 MΩ.cm) was supplied by Purelab Option-Q 
system (ELGA LabWater, Buckinghamshire, UK). 
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2.1.1.4 SDS PAGE analyses and western blotting  
SDS PAGE analyses were based on the method of Laemmli, 1970 (Laemmli, 1970) 
except that the resolving gel also contained 20 % (v/v) glycerol, to increase its density 
so that the stacking gel could be cast directly on top of the resolving gel without having 
to wait for it to polymerise. Proteins were resolved  “using a 12 % resolving gel at pH 
8.8 and a 4 % stacking gel at pH 6.8” (Gabe et al., 2017). Gels were of 1.0 mm 
thickness, cast using a Mini-PROTEAN III electrophoresis system with 15 sample 
wells (Bio-Rad Laboratories Ltd., Hertfordshire, UK). The composition of the gels and 
buffers is detailed in Table 42. The reagents for SDS PAGE were supplied by National
Diagnostics (National Diagnostic, Nottingham, UK). Gels were polymerised using 
ammonium persulphate solution (stock 10%) and N,N,N’,N’-
tetramethylethylenediamine (TEMED) (Sigma-Aldrich, St Louis, MO) immediately prior 
to casting. After the gels were cast and polymerised, samples containing the proteins 
to be separated were loaded in to the sample wells. The preparation of samples to 
load on SDS PAGE was carried out in one of two ways depending upon whether the 
samples were in solution or lyophilisates: 
- Protein in solution was prepared by mixing with concentrated 4 times (4X) Laemmli
non-reducing sample buffer (composition detailed in Table 4) at a ratio of 3:1 (v:v) 
sample volume: sample buffer. The mixture was heated for 1.5 minutes at 90-100°C, 
cooled to room temperature and then loaded on the gel. 
- Lyophilised samples were resuspended at their original concentration in concentrated
1 time (1X) Laemmli non-reducing buffer (composition detailed in Table 4). The 
mixture was heated for 1.5 minutes at 90-100°C, cooled to room temperature and then 
loaded on the gel.  
The sample preparation for each case is specified in the supplementary data (CD). 
Loading for each gel was optimised in each case (further details about the volumes 
loaded are provided in the supplementary data (CD)). Electrophoresis was carried out 
at a constant 200 V until the bromophenol blue tracker dye had reached the bottom of 
the gel. After electrophoresis, the proteins were detected using Coomassie Blue 
(Expedeon Ltd., Cambridgeshire, UK) or a silver staining (kit # 24612, ThermoFischer 
Scientific, Leicestershire, UK) or by UV illumination in ultrapure water where 
fluorescence detection was required.  
For molecular weight analysis and characterisation of the bands observed on 
analytical SDS PAGE, molecular weight markers were ran on the analytical SDS 
PAGE in separate lanes. The markers used were either “Precision Plus Protein All 
2 The composition of the gels and buffers, detailed in Table 4, was the same for 
analytical and preparative SDS PAGE (the latter, detailed later in Section 2.1.2.3) 
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Blue Standards” (cat no. 161-0373, Bio-Rad Laboratories Ltd., Hertfordshire, UK) or 
“Prestained SDS PAGE Standards, Broad Range” (cat no. 161-0318, Bio-Rad 
Laboratories Ltd., Hertfordshire, UK). 
 
Western Blotting 
To confirm the presence and identity of r-amelogenin in the extracts, the proteins were 
electroblotted onto 0.2 µm nitrocellulose membranes for western blotting analysis (Bio-
Rad Laboratories Ltd., Hertfordshire, UK) during which the membranes were probed 
with antibodies specific for amelogenin. The proteins resolved on the gels were 
transferred onto the membrane by electroblotting for 1 hour at 60 V using the 
‘sandwich’ procedure (Towbin et al., 1979). The membrane was placed in blocking 
buffer for at least 1 hour at room temperature or overnight at 4°C in order to block non-
specific binding of antibodies to the membrane. The blocking buffer was comprised of 
5 % (m/v) non-fat dry milk in Tris buffered saline (TBS). After blocking, the membrane 
was washed 2 x 7 minutes in TBS containing 0.05 % Tween 20 (TTBS). Then the 
membrane was incubated for 1 - 2 hours with affinity purified rabbit IgGs raised 
against a peptide corresponding to the amelogenin hydrophilic C-terminal (telopeptide) 
(custom made by Eurogentec, Southampton, UK) diluted in blocking buffer or TTBS 
(see Supplementary data (CD) for details on dilutions and buffers, as these are 
specific of the western blot analysis). It was then washed 2 x 7 minutes in TTBS before 
incubation with goat anti-rabbit secondary antibodies conjugated to peroxidase 
(Sigma-Aldrich, St Louis, MO) diluted in blocking buffer or TTBS (see Supplementary 
data (CD) for details on dilutions and buffers, as these are specific of the western blot 
analysis). This was followed by 5 x 7 minute washes with TTBS, and the cross 
reactivity was visualised by developing the blot with metal-enhanced 3,3'-
diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Dorsetshire, UK ) according to 
the manufacturer’s instructions. The membrane was rinsed with distilled water as soon 
as bands appeared; development took between a few seconds to 7 minutes (the 
duration is specified for each analysis in the supplementary data (CD)). Then, the 
membrane was dried overnight between weighted paper towels. 
The reagents used in western blotting are listed in Table 5. Since all western blotting 
procedures carried out in this work used the same antibodies (rabbit anti-telopeptide 
IgGs and goat-anti-rabbit IgG peroxidase conjugates), whose specificity for r-
amelogenin was confirmed by controls, western blotting in this thesis will be referred to 
as ‘anti-amelogenin western-blotting’. 
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2.1.1.5 Mass spectrometry analyses  
After desalting and lyophilisation, samples (obtained after acetic acid extraction, see 
Figure 22 p. 98 or after preparative SDS PAGE, see Figure 26 p.117) were 
characterised by mass spectrometry, a technique that separates molecules based on 
their charge-to-mass ratio and allows for the accurate determination of molecular mass 
of each species present. An accurate mass determination helps confirm the identity of  
proteins present in the samples as well as their degree of purity.  
Electron spray mass spectroscopy (TOF MS ES+) was performed by the mass 
spectrometry facility (Astbury Centre for Structural Molecular Biology, Astbury Building, 
Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK). 
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2.1.2 Strategies for secondary purification to obtain purified r-
amelogenin for binding studies 
Following the process optimisations carried out as described above, the extraction 
procedure of r-amelogenins in 3% acetic acid was scaled up as summarised in Figure 
22 p. 98. As shown in the Results chapter (Sections 3.1.1.2.1-2, pp. 138 - 141) this 
process resulted in a significant enrichment of r-amelogenin. However, acid-soluble 
contaminating bacterial proteins were still visible between 10 – 75kDa on SDS PAGE 
with Coomassie Blue staining. Therefore, it was deemed necessary to carry out 
secondary purification to isolate r-amelogenin at single band purity on SDS PAGE for 
future use in binding assays. A panel of standard protein purification techniques were 
tested and eventually optimised (Sections 2.1.2.1, 2.1.2.2, 2.1.2.3). The range of 
purification strategies explored is summarised below in Figure 23. 
 
 
Figure 2 3 Secondary purification of r-amelogenin from 3% acetic acid extracts. 
Summary of the strategy developed to determine the optimum method 
providing with r-amelogenin at a suitable purity for future binding studies. 
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2.1.2.1 Purification of r-amelogenin using nickel column chromatography 
His-tag affinity chromatography using nickel affinity chromatography column (referred 
to as “nickel column” chromatography) is a purification method commonly used to 
isolate a protein of interest from a whole protein mixture (Hochuli et al., 1988). 
Recombinant proteins (including those described earlier in this thesis) are frequently 
initially engineered to carry six consecutive histidine residues present in an N-terminal 
tag (see Table 3 p. 92) which have a high affinity for nickel. In theory, when a mixture 
of proteins is pumped through the nickel column in loading buffer, proteins without the 
His-tag are not retained and pass through the column, leaving the His-tagged protein 
of interest bound to the column. After the non-His-tagged contaminants have washed 
through the column, the His-tagged protein can then be eluted from the column by 
increasing the concentration of imidazole in the buffer, as imidazole has a high affinity 
for nickel and competitively displaces the His-tagged recombinant protein. Once the 
protein is collected and the elution buffer salts removed, the recombinant protein can 
either be used directly in functionality studies, or undergo further steps of preparation 
that include removal of the His-tag with the aim of obtaining a recombinant protein as 
close as possible to the native form. The His-tag can be removed enzymatically by a 
protease and the cleavage mixture is subject to a second round of nickel column 
chromatography to isolate the His-tag-free recombinant protein which, now unable to 
bind, washes straight through the column whilst uncleaved recombinant protein and 
the cleaved His-tag are retained.   
Nickel column chromatography was used in this thesis to attempt to purify His-tagged 
r-amelogenins before and after cleavage of the His-tag as summarised above. This
preparation process included desalting and buffer exchange steps. The equipment 
used is listed in Table 6 below. The procedure is summarised below in Figure 24, with 
specific methodological details provided in the Sections 2.1.2.1.1 – 2.1.2.1.3 below..  
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Table 6  List of reagents used in nickel column chromatography purification. All 
buffer solutions were made with ultrapure water and degassed. 
Nickel column 
chromatography 
(Both rounds) 
Sections 2.1.2.1.1 
and 2.1.2.1.3 
Chromatography equipment 
• Ni-NTA column: HisTrap FF 5mL(GE healthcare bioscience, 
Buckinghamshire, UK) used in conjunction with AKTA FPLC 
system (GE healthcare bioscience, Buckinghamshire, UK) 
Nickel column chromatography buffer 
Loading buffer: 4 M urea, 50 mM Tris, 400 mM NaCl,  
20 mM imidazole, HCl, to pH = 7.6 
Elution buffer: Loading buffer plus imidazole (60 - 200 mM) 
His-tag cleavage 
Section 2.1.2.1.2 
• Recombinant type 14 3C protease from human rhinovirus  
HRV 3C (Merck Millipore, Darmstadt, Germany) 
• Buffer: 50 mM Tris, HCl to pH = 8 
Buffer exchange 
Included in Section 
2.1.2.1.2 
Chromatography equipment 
• HiPrep 26/10 column (GE healthcare bioscience, 
Buckinghamshire, UK) 
Buffer 
• 4 M urea, 50 mM Tris, 400 mM NaCl, 20 mM imidazole,  
HCl to pH = 7.6 
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Figure 2 4 Overview summary of purification of r-amelogenin using two rounds of 
nickel column chromatography. The details of steps (1), (2) and (3) are 
described respectively in the following Sections (2.1.2.1.1, 2.1.2.1.2, 
2.1.2.1.3). 
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2.1.2.1.1 Step 1: First round of nickel column purification of His-tagged r-
amelogenins extracted in acetic acid 
Following the method used by Gabe et al (2017), desalted and lyophilised crude 
extracts of r-amelogenin WT “were dissolved in a minimum volume of nickel column 
binding buffer (20 mM imidazole, 4 M urea, 50 mM Tris-HCl, 400 mM NaCl, pH = 7.6), 
loaded on to a nickel column up to a maximum protein load of 40 mg and eluted at a 
flow rate of 4 mL/minute. Unbound proteins (column flow through) were collected. 
Bound r-amelogenin was eluted by increasing the imidazole concentration to 200 mM”. 
“Fractions were analysed by analytical SDS PAGE and anti-amelogenin western 
blotting” (Gabe et al., 2017). SDS PAGE procedure is described in Section 2.1.1.4 (pp. 
100 - 103). Details for sample preparation, loading and blotting conditions are provided 
in the supplementary data (CD). The fractions comprising r-amelogenin were desalted 
by SEC against 125 mM formic acid, as described in Section 2.1.1.3 (p. 99) and 
lyophilised.  
2.1.2.1.2 Step 2: His-tag cleavage 
Similar to what was done by Gabe et al (2017) the lyophilised r-amelogenin obtained 
from the first round of nickel column purification (see previous Section), “was dissolved 
at 2 mg/mL in 50 mM Tris-HCl, pH = 8 […]. The His-tag was removed enzymatically by 
adding recombinant restriction grade protease HRV3C (Merck Millipore, Watford, UK) 
at a ratio of 3 μL enzyme solution per mg recombinant protein”. The cleavage was 
performed over 24 hours at 4°C and the protein contents of the solutions were 
analysed by analytical SDS PAGE (see Section 2.1.1.4 , pp. 100 - 102, for the 
procedure). The sample preparation and loading is described in the supplementary 
data (CD). “The resulting cleavage reaction mixture comprising cleaved r-amelogenin, 
any uncleaved r-amelogenin, free His-tag and other contaminants was finally buffer-
exchanged into nickel column binding buffer by SEC (HiPrep 26/10 column, GE 
Healthcare) ready for a second round of nickel column chromatography” (Gabe et al., 
2017). 
2.1.2.1.3 Step 3: Second round of nickel column purification to remove 
uncleaved r-amelogenins, free His-tag, and cleavage enzyme 
Similar to what was done by Gabe et al (2017), “a second round of nickel column 
chromatography was employed to remove cleaved His-tag and other contaminants 
present in the cleavage reaction mixture including any uncleaved recombinant. 
Cleavage products in binding buffer were loaded on to the nickel column” as described 
in Section 2.1.2.1.1. “Unbound proteins (expected to contain the cleaved r-
amelogenin) were collected in the column flow through. Bound proteins (expected to 
- 110 -
contain any uncleaved r-amelogenin, His-tag, and His-tagged HRV3C) were eluted 
using a stepped imidazole gradient” (Gabe et al., 2017). The imidazole concentrations 
were 60 and 200 mM. Fractions were analysed by analytical SDS PAGE (see Section 
2.1.1.4, pp. 100 - 102 and Supplementary data (CD)). 
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2.1.2.2 Purification of r-amelogenin using size exclusion chromatography  
Size exclusion chromatography (SEC) allows for separation of proteins within a 
mixture according to their apparent molecular weights. The protein sample is dissolved 
in a buffer (mobile phase1) which is pumped through a column matrix of porous micro 
beads. Larger molecules are excluded from the column matrix and quickly pass 
through the column carried along in the mobile phase and are eluted first. Lower 
molecular weight components with a smaller hydrodynamic radius can diffuse from the 
mobile phase into the beads and thus their progress through the column is slower and 
depends on their rate of diffusion in and out of the beads (Grubisic et al., 1967). 
Therefore, lower molecular weight protein elutes later.  
SEC was explored as a possible purification strategy when seeking to isolate r-
amelogenins in the current study. The effect of operational variables such as matrix 
pore size and column length were investigated on the resolution of separation. The 
reagents and equipment used are listed in Table 7 below; the development of a size-
exclusion-based purification method is summarised below in Figure 25.  
Table 7  Equipment used in SEC2: column models and matrices. 
 
Column characteristics Matrix 
Bio-gel P-30 
(35 cm) 
Section 2.1.2.2.1  
Column XK 16/40  
(GE Healthcare bioscience. 
Buckinghamshire, UK) 
Bio-gel P-30, 
cat. no. 1504154 
(Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK) 
Bio-gel P-10 
(35 cm) 
Section 2.1.2.2.2 
Column XK 16/40  
(GE Healthcare bioscience. 
Buckinghamshire, UK) 
Bio-gel P-10, 
cat. no. 1504144 
(Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK) 
Bio-gel P-10 
(95 cm) 
Section 2.1.2.2.3 
Column XK 16/100 
(GE Healthcare bioscience. 
Buckinghamshire, UK) 
Bio-gel P-10, 
cat. no. 1504144 
(Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK) 
 
                                               
1 The mobile phase employed in this thesis was degassed 125 mM formic acid, 
prepared as described in Section 2.1.1.3 (p .95). 
 
2 The size exclusion chromatography used the equipment AKTA FPLC system (GE 
healthcare bioscience, Buckinghamshire, UK). 
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Figure 2 5 Purification of r-amelogenin using SEC: optimisation of column length 
and pore size. Once lyophilised, the acetic acid extract containing r-
amelogenin was directly subjected to SEC. For a column length of 35 cm, 
two matrices with different pore sizes were tested:  Bio-gel P-30 matrix 
(detailed in Section 2.1.2.2.1) and Bio-gel P-10 matrix (detailed in Section 
2.1.2.2.2). The second column length tested was 95 cm, using Bio-gel P-10 
matrix (detailed in Section 2.1.2.2.3). Small aliquots from the fractions 
collected were taken for SDS PAGE analyses. 
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2.1.2.2.1 Size exclusion chromatography using Bio-gel P-30 matrix, 35 cm bed 
height 
SEC was carried out on the AKTA FPLC system using 40 x 1.6 cm GE healthcare XK 
column (GE healthcare bioscience). The column was packed with a polyacrylamide 
matrix Bio-Gel P-30 (fractionation range of 2.5 - 40 kDa) (Bio-Rad, cat no 150-4154) 
according to the manufacturer’s instructions to a bed height of 35 cm. The sample was 
prepared by dissolving 15 mg of acetic acid extract of r-amelogenin WT (prepared as 
in Figure 22 p. 98, lyophilised, not desalted) in degassed 125 mM formic acid to 10 
mg/mL and 1.44 mL of the sample were loaded and injected onto the column that had 
been previously equilibrated with degassed 125 mM formic acid. The separation was 
carried out at room temperature using a mobile phase comprised of degassed 125 mM 
formic acid at a flow-rate of 0.25 mL/minute. The elution was carried out using 1.5 
column volumes of degassed 125 mM formic acid and 7 fractions were collected 
manually as indicated on the chromatograph (Figure 46, p. 163). The protein contents 
of the fractions 1-7 were analysed by analytical SDS PAGE (see Section 2.1.1.4, pp. 
100 - 102 and Supplementary data (CD)). 
2.1.2.2.2 Size exclusion chromatography using Bio-gel P-10 matrix, 35 cm bed 
height 
Bio-gel is supplied with a range of pore sizes. Altering the pore size changes the 
exclusion limit of a column, which in turn changes the fractionation range of the 
column. Bio-gel P-10 has small pores and a fractionation range of 1.5 - 20 kDa. It was 
thought that this might therefore provide a better fractionation of r-amelogenin than 
Bio-gel P-30 (fractionation range 2.5 – 40 kDa). The matrix was packed according to 
the manufacturer’s instructions (Bio-Rad, Ltd. Hertfordshire, UK) into a 40 cm long 
column (XK 16/40) to a bed height of 35 cm. Eleven milligrams of acetic acid extract of 
r-amelogenin WT (prepared as in Figure 22 p. 98, lyophilised, not desalted) were 
resuspended in 1.1 mL of degassed 125 mM formic acid and clarified by centrifugation 
at 20,800 g at 20°C for 10 minutes. The supernatant was collected and 1 mL was 
loaded and injected on to the column that had been previously equilibrated with 
degassed 125 mM formic acid. The separation was carried out at room temperature 
with a flow-rate of 0.35 mL/minute. The elution was carried out using 1.5 column 
volumes of degassed 125 mM formic acid and 10 fractions of 1 mL were collected. 
The protein contents of the fractions 1, 2, 3, 4, 10 were analysed by analytical SDS 
PAGE (see Section 2.1.1.4, pp. 100 - 102 and Supplementary data (CD)).  
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2.1.2.2.3 Size exclusion chromatography using Bio-gel P-10 matrix, 95 cm bed 
height 
An attempt to further improve the resolving power of Bio-gel P-10 matrix was carried 
out by increasing the bed height to 95 cm. The matrix Bio-Gel P-10 was packed 
according to the manufacturer’s instructions into a 100-cm-long column (XK 16/100) to 
a bed height of 95 cm. The sample was prepared by dissolving 11 mg of acetic acid 
extract of r-amelogenin WT (prepared as in Figure 22 p. 98, lyophilised, not desalted) 
in degassed 125 mM formic acid to 10 mg/mL. The mixture was then centrifuged at 
20,800 g at 20°C for 10 minutes. The supernatant was collected and 1 mL was loaded 
and injected on to the column that had been previously equilibrated with 125 mM 
formic acid. The separation was carried out at room temperature with a flow-rate of 
0.40 mL/minute. The elution was carried out using 1.5 column volumes of degassed 
125 mM formic acid and 10 fractions of 1 mL were collected. The protein contents of 
the fractions 1-10 were analysed by analytical SDS PAGE (see Section 2.1.1.4, pp. 
100 - 102 and Supplementary data (CD)). 
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2.1.2.3 Purification of r-amelogenins using preparative SDS PAGE 
An alternative purification strategy used preparative SDS PAGE to isolate r-
amelogenin based upon apparent molecular weight. This was trialled with the aim of: 
(1) Isolating His-tagged r-amelogenin from acetic acid extracts prior to cleavage and 
nickel column chromatography (Section 2.1.2.3.1, summarised in Figure 26 p. 117), 
and 
(2) Isolating cleaved r-amelogenin following His-tag cleavage without the need to use 
nickel column chromatography (Section 2.1.2.3.2, summarised in Figure 27 p. 119).  
The reagents for the gels and buffer used in preparative SDS PAGE were the same as 
those used for analytical SDS PAGE (Section 2.1.1.4, pp. 100 - 102, the reagents are 
listed in Table 4 p. 102). 
Analytical SDS PAGE was capable of resolving r-amelogenin from bacterial 
contaminants and in theory could be scaled up to for preparative use. The Model 491 
Prep Cell (Bio-Rad Laboratories Ltd., Hertfordshire, UK) was trialled here to assess 
the potential of preparative SDS PAGE in purifying r-amelogenin. Briefly, the sample 
was electrophoresed down a cylindrical gel that has the capacity to resolve tens of mg 
of protein (compared to tens of µg in the case of analytical SDS PAGE). Rather than 
stopping the electrophoresis and staining the gel as it is the case in analytical SDS 
PAGE to visualise the resolved protein bands, in preparative SDS PAGE, separated 
proteins were deliberately electrophoresed off the bottom of the separating gel into an 
elution chamber from where they were continually removed by a flow of buffer to a 
fraction collector. 
2.1.2.3.1 Isolation of His-tagged r-amelogenin from crude acetic acid extracts by 
preparative SDS PAGE 
After desalting and lyophilisation, acetic acid extracts (containing WT+His r-amelogenin) 
were solubilised in 1X non-reducing SDS PAGE sample buffer (see Section 2.1.1.4, 
p.100) at a concentration of 1 mg/mL. Ten millilitres of the starting solution were 
subjected to preparative SDS PAGE. Preparative electrophoresis was carried out 
using a Model 491 Prep Cell (Bio-Rad Laboratories Ltd., Hertfordshire, UK). As carried 
out by Gabe et al (2017), a 12 % resolving gel (composition detailed in Table 4, p. 
102) “was cast in the 28 mm internal diameter gel tube to a height of 9.5 cm with a 2-
cm 4% stacking gel” (composition detailed in Table 4, p. 102). “The gel was run at a 
constant 12 W power at room temperature using the circulating cooling pump as 
recommended by the manufacturer. Immediately after the tracker dye began to run out 
of the gel, 2.5 mL fractions were collected at a flow rate of 0.8 mL/minute” (Gabe et al., 
2017). Every third fraction collected was subjected to analytical SDS PAGE with 
Coomassie Blue staining to identify approximately which of the fractions contained 
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WT+His r-amelogenin (further details provided in Section 2.1.1.4, pp. 100 - 102 and 
Supplementary data (CD) for analytical SDS PAGE). Once the range of fractions 
containing the WT+His r-amelogenin had been identified, all fractions in that range were 
subjected to analytical SDS PAGE with silver staining and anti-amelogenin western 
blotting to accurately determine whether the fractions contained WT+His r-amelogenin 
at single band purity on silver staining. The fractions comprising WT+His r-amelogenin 
at single band purity were pooled together, lyophilised, desalted then lyophilised again. 
The final amount of purified WT+His r-amelogenin obtained by preparative SDS PAGE 
was weighed to obtain the yield and further characterised by mass spectrometry (See 
Section 2.1.1.5 p. 104). The purification process is summarised in Figure 26 below. 
The plan was to subject the lyophilisate to His-tag cleavage and then nickel column 
chromatography to obtain a purified ‘cleaved’ r-amelogenin (Dashed box in Figure 26).  
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Figure 2 6 Purification strategy of WT+His r-amelogenin from acetic acid extracts 
using preparative SDS PAGE. The acetic acid extract was desalted, 
lyophilised and resuspended into SDS PAGE sample buffer 1X and heated, 
to solubilise the proteins. The mixture was loaded on to the preparative 
SDS PAGE gel to separate its components according to their apparent 
molecular weights. From the fractions collected, small aliquots were taken 
and their content was analysed by analytical SDS PAGE with Coomassie 
blue staining, silver staining and western blotting to identify the fractions 
containing r-amelogenin at single band purity. These fractions were pooled 
together, desalted, lyophilised and subjected to mass spectrometric 
analysis.  
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The purification of the sample achieved with preparative SDS PAGE (shown later in  
Section 3.1.2.3.1) was such that nickel column chromatography was not actually 
needed anymore to isolate the cleaved r-amelogenin. Instead, Preparative SDS PAGE 
was tested to isolate the cleaved r-amelogenin directly after His-tag cleavage of r-
amelogenin in acetic acid extract. This second method is described in Section 
2.1.2.3.2 below. 
 
2.1.2.3.2 Isolation of cleaved r-amelogenin by preparative SDS PAGE 
This Section describes the attempt to isolate cleaved (His-tag-free) r-amelogenin by 
preparative SDS PAGE after His-tag cleavage of the His-tagged r-amelogenin without 
any involvement of nickel column chromatography. The process carried out is 
summarised in Figure 27. 
The crude acetic acid extract containing WT+His r-amelogenin was desalted against 
125 mM formic acid and lyophilised. The lyophilisate was then dissolved in 0.1 M 
Na2CO3 , pH = 9 at 2 mg/mL and incubated with HRV3C protease (Merck Millipore, 
Watford, UK) for 48 hours, at 2.5 µL enzyme stock solution per mg protein. The 
mixture was then lyophilised and desalted against 125 mM formic acid (Section 
2.1.1.3, p. 99), then lyophilised again. The lyophilisate was dissolved in 1X non-
reducing SDS PAGE sample buffer (as described in Section 2.1.1.4, pp. 100 - 102) at 
2 mg/mL and 5mL were subjected to preparative SDS PAGE as described in Section 
2.1.2.3.1, p. 115. Every third fraction collected was subjected to analytical SDS PAGE 
with Coomassie Blue staining to identify approximately which of the fractions 
contained the cleaved r-amelogenin (further details provided in Section 2.1.1.4, pp. 
100 - 102, and in the supplementary data (CD) for analytical SDS PAGE). Once the 
range of fractions containing the cleaved r-amelogenin had been identified, all 
fractions in that range were subjected to analytical SDS PAGE with silver staining 
(further details provided in the supplementary data (CD)). Fractions containing cleaved 
r-amelogenin at single band purity on silver staining were pooled together, desalted 
and lyophilised. The final amount of the purified cleaved r-amelogenin was estimated 
by spectrophotometry at 280 nm. 
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Figure 2 7 One-step purification of His-tag free ‘cleaved’ r-amelogenin from acetic 
acid extract using preparative SDS PAGE. The methodology carried out 
was the same as that described in Section 2.1.2.3.1 (see Figure 26 p. 117), 
except that an additional step of His-tag cleavage (with subsequent 
lyophilisation, desalting and lyophilisation) was added. The fractions 
obtained from preparative SDS PAGE purification were analysed by 
analytical SDS PAGE. 
 
.  
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2.2 Development of protein-binding assays  
Two binding assays were developed in order to study amelogenin-amelogenin binding 
and ultimately to investigate the effect, if any, of the p.Y64H mutation. 
 
2.2.1 Method 1: Fluorescence-based binding assay  
The basic strategy for method 1 involved immobilising amelogenin (bait protein) to 
microplate well surfaces to which was added fluorescein isothiocyanate (FITC)-
labelled amelogenin (the free ligand in solution). After incubation, wells were washed 
and any amelogenin-amelogenin binding was determined by measuring the 
fluorescence remaining bound to the wells. To conserve r-amelogenin, the 20 kDa 
amelogenin, abundant in enamel matrix derivative (EMD – the non-commercial form of 
Emdogain) (Maycock et al., 2002) was purified by preparative SDS PAGE to be used 
as a surrogate for initial method development. 
The EMD was kindly provided by Dr. Petter Lyngstadaas, University of Oslo, NO. The 
FITC was cat no.F7250 (Sigma-Aldrich, St Louis, MO) 
The methods presented below detail  
(i) FITC labelling of EMD  
(ii) purification of FITC labelled 20 kDa amelogenin from EMD and  
(iii) studies using FITC-20 kDa amelogenin in a microplate based binding assays 
 
2.2.1.1 FITC labelling of EMD 
The method employed to label EMD with FITC was adapted from the FITC 
manufacturer’s instruction (F7250 - Product Information Sheet, Sigma-Aldrich, St 
Louis, MO). EMD was dissolved at 5.5 mg/mL in a solution of 0.1 M Na2CO3 at pH = 9. 
The mixture was left stirring at 4°C overnight. FITC was dissolved to 10 mg/mL in 
dimethyl sulphoxide (DMSO) and FITC solution added slowly by 10 μL increments to 
the EMD solution at 4°C with stirring to give a final concentration of 58.33 μg FITC per 
mg EMD. The labelling mixture was then stirred overnight at 4°C. The next day, the 
mixture was frozen to -80°C and lyophilised. 
 
2.2.1.2 Purification of the 20 kDa amelogenin from FITC-labelled EMD 
using Preparative SDS PAGE  
The lyophilised labelling mixture (prepared as described above, Section 2.2.1.1) was 
desalted against 125 mM formic acid (see Section 2.1.1.3, p .99) and lyophilised 
again. The lyophilisate was dissolved in 1X non-reducing SDS PAGE sample buffer 
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(as described in Section 2.1.1.4, pp. 100 - 102) at a concentration of 8 mg/mL. 
Approximately 0.8 mL of the starting solution were subjected to preparative SDS 
PAGE. Preparative electrophoresis was carried out as described in Section 2.1.2.3.1 
(p. 115). Fractions containing the labelled 20 kDa amelogenin were pooled together, 
desalted against 125 mM formic acid (see Section 2.1.1.3, p .99) and lyophilised for 
binding assays (detailed in Section 2.2.1.3 overleaf). The 20 kDa amelogenin was 
identified based on its migration on analytical SDS PAGE and by the fact that it is the 
most abundant species present in EMD (Maycock et al., 2002). The purification 
process is summarised in Figure 28. 
 
 
Figure 2 8 Diagram summarising the preparation and purification of FITC-labelled 
EMD proteins for fluorescence binding assays. 
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2.2.1.3 Measuring amelogenin binding between free FITC-labelled 
amelogenin and immobilised amelogenin as binding partners  
To test the effect of the p.Y64H mutation on amelogenin binding behaviour, a 
microplate-based binding assay was developed, involving the immobilisation of 
unlabelled amelogenin on the microplate well surfaces to which FITC-labelled 
amelogenin was allowed to bind. The degree of binding could then be determined (and 
compared) by measuring the amount of retained fluorescence. This method was 
adapted from a “FITC-anti-FITC system” previously published (Harmer and Samuel, 
1989). As explained earlier (p. 120), the 20 kDa amelogenin from EMD (obtained as 
described in Section 2.2.1.2) was used as a surrogate. 
First, it was necessary to ensure that the unlabelled 20 kDa amelogenin from EMD 
(bait protein) saturated the polystyrene microwell surfaces to prevent false positives 
caused by FITC-labelled 20 kDa amelogenin (free ligand) binding to any exposed 
polystyrene (incompletely covered wells). In addition, it was also necessary to verify 
whether the binding affinity of the 20kDa amelogenin bait protein for the well surfaces 
was sufficiently large to resist the various washing and handling steps involved in 
carrying out the assay. For convenience, FITC-labelled 20 kDa amelogenin (purified 
from EMD using preparative SDS PAGE as described in Section 2.2.1.2, p. 121) was 
used as a surrogate unlabelled bait protein to investigate the binding kinetics of 
amelogenin to the microwell surfaces; this could be easily measured using the 
fluorescence microplate reader.  Note: for clarification, the actual binding assays were 
to be carried out later, using non-labelled r-amelogenin bound to the wells as the 
immobilised bait protein with FITC-labelled r-amelogenin being used as the free ligand 
in solution.  
In the optimisation experiments, FITC-labelled 20 kDa amelogenin, acting as surrogate 
bait protein, was dissolved at 20 μg/mL in binding buffer (see below) and serially 
diluted to concentrations of 1, 2, 5, 7.5, 10 and 20 μg/mL. Three different binding 
buffers were tested for efficacy of coating: 0.1 M Na2CO3 at pH=9, PBS at pH=7.4 and 
TBS at pH=7.2. The incubation of the plates was carried out overnight at either room 
temperature or 4°C. 
One hundred microlitres of unlabelled 20 kDa amelogenin in binding solution were 
added per microwell in triplicate and left to incubate overnight with the microplates 
sealed with parafilm. The microplates used were black 96‐well microfluor 2 plate (cat. 
No. 7205, ThermoFisher Scientific, Loughborough, UK). After overnight incubation, the 
fluorescence signal was measured using an excitation wavelength of 490 nm and an 
emission wavelength of 525 nm. The microwells were then washed. Washing 
consisted of emptying the microwell content by discarding binding solution and tap-
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drying, followed by addition of 120 μL of washing buffer (either PBS + 0.05 % 
Tween20, or TB S+ 0.05 % Tween20) which was subsequently discarded and the 
plates tap-dried. After washing the microwells, 150 μL of blocking solution were added 
per microwell and left to incubate for 1 hour at room temperature and sealed. The 
blocking solution was made up of 1 % bovine serum albumin (BSA) in washing buffer 
(blocking serves no purpose in this experiment but was included as it would later 
feature in the actual binding assays; to prevent false positives caused by FITC- 
labelled ligands binding to the well surfaces directly rather than the immobilised bait 
proteins).      
After blocking, the microwells were washed 3 times as described above and pure 
water was added prior to fluorescence detection (490 nm/525 nm). The fluorescence 
associated with bound 20 kDa amelogenin was then measured. The process is 
summarised in Figure 29.  
 
Figure 2 9 Design of experiment to determine whether amelogenins can adsorb to, 
and coat the surfaces of the microwell for later use in a fluorescence 
binding assay. FITC-labelled 20 kDa amelogenin at 1, 2, 5, 7.5, 10 and 20 
μg/mL were adsorbed onto the microwell surface to determine the lowest 
concentration required to saturate the microwell surface. Saturating the 
microwell surface with bait protein was essential in order to reduce false 
positives in the later binding experiments if protein ligands free in solution 
were able to adsorb directly to the exposed microwell surface rather than 
to the immobilised bait proteins.
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2.2.2 Method 2: Determining the kinetics of protein-microwell 
binding by monitoring the disappearance of amelogenin from 
solution  
The second method to characterise amelogenin binding events in microwell plates 
involved simply incubating unlabelled EMD proteins (comprising manly amelogenin) in 
UV transparent microwells. The decrease in UV absorbance was monitored (illustrated 
in Figure 30) as proteins initially adsorbed to the microwell surfaces (protein-
polystyrene binding) and free proteins bound to the immobilised proteins (protein-
protein binding). Protein concentration in solution is frequently measured 
spectrophotometrically at 280 nm, which is the absorbance maximum of the aromatic 
side chains of tryptophan and tyrosine (Layne, 1957). However, these amino acids are 
not particularly common in amelogenin so in order to increase sensitivity, absorbance 
was measured at 220 nm, which is within the wavelength range at which peptide 
bonds maximally absorb UV (Goldfarb et al., 1951) and is within the transparency 
range of the UV transparent microplates used. 
The microplates employed were polystyrene NUNC 96-well UV transparent microplate 
8404 (Thermofischer Scientific, Loughborough, UK). Absorbance was monitored at 
220 nm over time after adding unlabelled EMD protein and recorded using a Varioskan 
Flash microplate reader - SkanIt software (Thermoscientific, UK). 
The methods presented in this Section detail the development of the microplate 
binding assay with regards to: 
(i) The effect of the initial EMD concentration on the EMD-polystyrene
binding equilibrium (Section 2.2.2.1),
(ii) Optimisation of the methodology to investigate the kinetics of EMD
protein-protein interactions (Section 2.2.2.2),
(iii) The effect of EMD proteins adsorbed to the bottom of the microwell and
attenuating the UV before it passes through the free proteins still in
solution potentially confounding the absorbance readings (Section 2.2.2.3)
(iv) Attempts to block EMD adsorption to the bottom of the microwells to
circumvent the issue of UV attenuation by EMD adsorbing to the bottom of
the micro wells (Section 2.2.2.4).
(v) A use of the assay to study p.Y64H mutant and WT r-amelogenin
interactions (Section 2.2.2.5).
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2.2.2.1 Effect of the initial EMD concentration on binding equilibrium: 
determination of an EMD concentration required to saturate the 
microwells surfaces.  
The minimum concentration of EMD proteins required to saturate the polystyrene 
surface of the microwells was optimised by measurement of loss of protein from 
solution using spectrophotometry in the UV at 220 nm.  
At room temperature, EMD was dissolved in 1 % acetic acid to 48,308 µg/mL to 
prepare a stock solution. The stock was then diluted 1:290 with PBS to give a final 
EMD concentration of 166 μg/mL. This solution was then further diluted with PBS 
(containing 1 % acetic acid at 290:1) to give solutions containing EMD at 166, 99.6, 
66.4 and 33.2 μg/mL. Immediately after preparing the EMD solutions, aliquots were 
taken for SDS PAGE analyses. Then, 200 μL of each solution were added into empty 
polystyrene UV-transparent microwells (n=6 replicates) and left to incubate for 24 
hours in the microplate reader1. Absorbance measurements at 220 nm were recorded 
every hour during the incubation period. The averages of the 6 replicates were plotted 
using Excel software, after subtracting the blank values and the standard deviations 
calculated. At the end of the incubation, 15 µL aliquots were taken from each of the 
replicates, pooled, frozen to -80°C and lyophilised. The lyophilisates were re-dissolved 
to their original volume in 90 µL non-reducing sample buffer for analytical SDS PAGE 
(see Section 2.1.1.4, pp. 100 - 102 and Supplementary data (CD))  
2.2.2.2 Optimisation of the methodology to analyse the kinetics of 
protein-protein interactions  
In the Section above (2.2.2.1), the conditions required to saturate the surface of the 
microwells with EMD were identified. The next stage in developing the binding assay 
was to determine the effects of adding a fresh solution of EMD to the already saturated 
microwell surface to investigate whether subsequent protein – protein interactions 
occurring between immobilised EMD (bait protein) and the freshly added EMD free in 
solution could be followed by monitoring the disappearance of free EMD from solution 
by UV absorbance spectroscopy. Figure 31 below shows a hypothetical result 
illustrating the principle of the method. Any decrease of absorbance (protein 
concentration in solution), during the second incubation period would be assumed to 
reflect protein-protein binding rather than the loss of protein due to a combination of 
1 Note: The absorbance measurements started 10 minutes after the EMD solution was 
prepared. As 10 minutes represent 0.7% of the 24-hour incubation period, these 
10 minutes were considered as negligible and the starting time of absorbance 
measurement was considered to be the starting time of experiment. 
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protein-surface + protein-protein interactions occurring during the first incubation 
period during which the microwell surface becomes saturated. 
Figure 3 1 Hypothetical signal pattern obtained while monitoring initial EMD-
polystyrene interactions that saturate the microwell surface and 
subsequent EMD-EMD interactions occurring after the addition of fresh 
protein solution. The absorbance decrease in this second incubation 
period is assumed to be due to depletion of the solution due to the freshly 
added EMD interacting with the EMD already immobilised to the 
polystyrene surface during the initial saturation step. 
The procedure is described below and summarised in Figure 32 (p. 129). 
EMD was accurately dissolved in 1 % acetic to 42,735 µg/mL to provide a stock 
solution. The stock was then diluted 1:284 with PBS (pre-warmed to 37°C) to give a 
final EMD concentration of 150 μg/mL. Immediately after preparing the solutions, 
aliquots were taken for SDS PAGE analyses. A blank solution comprising of 1 % 
acetic acid diluted with PBS (pre-warmed to 37°C) at a ratio 1:284 was also prepared. 
Then, 200 µL of each solution were added into empty polystyrene UV-transparent 
microwells (n=6 replicates), and subjected to an initial incubation period of 24 hours at 
37°C during which time the well surfaces became saturated with EMD protein (“Phase 
1”). The microplate was covered with cling film to prevent evaporation and the process 
was monitored by recording absorbance measurements at 30-minute intervals 
throughout the incubation period. The average absorbance of the 6 replicates were 
plotted with after the subtracting the blank at each time point and standard deviations 
calculated. At the end of the incubation period, 15 µL aliquots were taken from the 
solutions in each microwell replicate, pooled, frozen to -80°C and lyophilised. The 
lyophilisates were redissolved to their original volume (90µL) in non-reducing sample 
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buffer (see Section 2.1.1.4, p.100) for analytical SDS PAGE. Further details regarding 
the SDS PAGE analyses are provided in Section 2.1.1.4 (p. 100 - 102) and in the 
supplementary data (CD)).  
The microplates were then inverted and tapped forcefully to remove the residual 
solutions from the microwells.  
Aliquots of a fresh solution of the EMD (at concentration 150 µg/mL as described for 
phase 1 above) were taken for analytical SDS PAGE and a second incubation period 
was then immediately initiated (“Phase 2”) by adding 200 µL of the fresh EMD solution 
to the recently emptied microwells (the resulting protein interactions are referred to as 
“EMD- EMD” i.e. free EMD was presumed to be interacting with EMD already 
immobilised to the surface). Two-hundred microliters of the fresh EMD solution were 
also added into microwells previously incubated with blank solutions as a control (this 
condition is referred to as “EMD-Polystyrene” i.e. free EMD is just interacting with the 
polystyrene surface and is essentially a repeat of phase 1 but it is concomitant with 
phase 2). The microplate was covered with cling film to prevent evaporation and the 
second incubation lasted 24 hours at 37°C. UV absorbance at 220 nm was again 
recorded every 30 minutes throughout. The average absorbance readings of the 6 
replicates were plotted, readings for the blanks subtracted and standard deviations 
calculated. After the incubation had ended, aliquots were taken from the solutions in 
the microwells for SDS PAGE as described above for phase 1. Further details 
regarding the SDS PAGE analyses are provided in Section 2.1.1.4, pp. 100 - 102 and 
in the supplementary data (CD)).  
The data points obtained during the second incubation period (describing EMD- EMD 
interactions and EMD-polystyrene interactions (control)), were replotted to represent 
the gain of protein by the polystyrene surface rather than the loss of protein from 
solution. The points were replotted as A0-AT (where A0 = initial absorbance at the start 
of phase 2 and AT = absorbance measured at time T between the start and the end of 
phase 2). They were then subjected to curve-fitting on OriginPro 9.1 (OriginLab 
corporation, Northampton, MA), to identify the equation that best fitted the data which 
would allow kinetics descriptors such as half-time T1/2 and the maximum ordinate value 
(i.e. the final amount of protein adsorbed to the polystyrene surface at equilibrium) to 
be calculated.  
OriginPro comprises over 150 functions for curve-fitting, grouped as “function 
selection” sets (e.g.: exponential, logarithm, polynomial). Within each set, OriginPro 
can perform curve-fitting with model ranking for a given dataset. For the “gain of 
protein by polystyrene surface” data plots, 70 functions fitted the data to some degree, 
with 21 yielding an r-square value of between 0.99 and 1. The Hill equation model 
(Hill, 1910) was one of these and fitted both plots for “EMD-EMD” and “EMD-
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Polystyrene” reactions. It was therefore chosen as the best fitting model and was used 
to predict T1/2 and the maximum ordinate value reached. 
Figur 3e 2 Summary of the methodology used to investigate EMD-EMD 
interactions using a microplate based assay. A solution of EMD proteins 
(150 µg/mL) was left to incubate for 24 hours in microwells (phase 1). 
Aliquots of the solution were taken for SDS PAGE analyses before and 
after incubation (at the time points T= 0 hours, 24 hours, indicated). Then 
the microwells were emptied and fresh EMD solution (150 µg/mL) was 
added again in the test microwells (phase 2). Aliquots of the solution were 
taken for SDS PAGE analyses before and after incubation (at the time 
points T= 24 hours, 48 hours, indicated). The absorbance was monitored at 
220nm. 
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2.2.2.3 Effect of proteins adsorbed on the bottom of the microwells on 
the absorbance value: a possible confounder 
During the course of these binding experiments, it was an inevitability that proteins 
would bind to the bottom of the microwells in addition to the microwell sides. The aim 
of this experiment was to investigate how the microplate absorbance measurements 
were affected by proteins binding to the bottom of the microwells. The methodology 
was again based on determination of the depletion of free protein from solution. 
Proteins coating the bottom of the microwells are lost from solution but they may still 
contribute to the UV absorbance measured, as they will still be in the light path. The 
question was therefore whether the layer of proteins adsorbed to the bottom of the 
microwell exhibited significant UV absorbance compared to the amount in solution, 
potentially confounding the data. To determine the significance of this potential 
confounder a solution of EMD (at concentration 150 µg/mL) was freshly prepared as 
described above (Section 2.2.2.2) and 200 µL were incubated for 24 hours at 37°C in 
the microwells (n=6) along with blank microwells containing a solution comprised of 
PBS:1 % acetic acid at a ratio 284:1. The microplate was covered with cling film to 
prevent evaporation. At the end of incubation, the solutions were discarded from the 
microwells, immediately after which the absorbance was read again. The average 
absorbance measurements were recorded1 and the blank values subtracted. Any 
absorbance remaining was assumed to be associated with proteins adsorbed to the 
microwell bottom. 
The data obtained (in Section 3.2.2.3) suggested that proteins adsorbing to the bottom 
of the microwells (either directly to the surface or via immobilised proteins already 
present on the surface) could be reliably detected using UV absorbance spectroscopy. 
This could therefore provide an ‘end point’-based microplate assay for monitoring 
protein-protein interactions (as opposed to the method described above based on 
using UV absorbance spectroscopy to monitor the depletion of protein from solution as 
it interacts with immobilised proteins already on the well surfaces). However, as 
described in the next Section an attempt was made to address the issue of protein 
adsorption to the bottom of the microwells by pre-blocking the bottom of the microwells 
with standard blocking proteins used in numerous assays such as western blotting and 
enzyme linked immunosorbent assays. 
1 Note: The absorbance measurements started 4.5 minutes after the EMD solution 
was prepared. As 4.5 minutes represent only 0.3% of the 24-hour incubation 
period, the starting time of absorbance measurement was considered to be the 
starting time of experiment. 
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2.2.2.4 Blocking the bottom of the microwells to inhibit adsorption of test 
proteins 
To prevent any EMD proteins from binding to the bottom of the microwells and 
confounding the determination of the absorbance values of the solutions remaining in 
the microwells, an attempt was made to block EMD binding to the bottom of the 
microwells. This required an effective blocker that would prevent EMD proteins from 
binding to the polystyrene surface. Microplate-based immunological assays employ 
various blocking regimes to abolish non-specific binding of detection antibodies to 
exposed microwell surfaces once the sample containing the antigenic target of interest 
has been adsorbed (Gibbs, 2001). Gold standard blockers bovine serum albumin 
(BSA) and non-fat dry milk proteins (NFDM) were tested therefore to investigate their 
ability to prevent the unwanted adsorption of EMD on to the microwell bottom. 
Solutions of BSA and NFDM were added into microwells and the proteins allowed to 
bind (block) the microwell surfaces. The microwells were then washed and the ability 
of the blocked surfaces to bind EMD were tested by adding EMD in solution and 
monitoring its depletion from solution using UV absorbance spectroscopy. As shown in 
Figure 33 below, effective blocking was expected to result in the absorbance 
remaining constant over the incubation period whereas the absence of blocking 
(control) would cause the absorbance to fall over time as the EMD was removed from 
solution by binding to the well surfaces. 
Figure 3 3 Hypothetical signal expected over incubation time in microwells 
effectively blocked (orange dashed line) compared to control (solid black 
line) with no blocking . In case of effective blocking the concentration of 
EMD in solution would remain constant, causing a constant absorbance 
signal overtime. In contrast, in the control without blocking, absorbance 
would fall with time as the concentration of EMD in solution falls as it 
adsorbs the well surfaces.  
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Blocking solutions were prepared by dissolving BSA cat no. 05479 (Sigma-Aldrich, St 
Louis, MO) and NFDM cat no. 170-6404 (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) at 1 % in a mixture of PBS and 1 % acetic acid (290:1). Two hundred 
microliters of each blocking solution were added to microwells (n=6) and the 
microplate was sealed with parafilm and incubated overnight at 4°C. The next day, the 
microwells were washed 3 times with PBS and tapped dry. EMD dissolved at 166 
μg/mL in a mixture of PBS and 1 % acetic acid (290:1) was prepared and an aliquot 
was taken immediately for SDS PAGE analyses later. Two hundred microliters of the 
EMD solution were then added to the blocked microwells. As a control, 200 µL of EMD 
were also added to non-blocked wells (n=6). The absorbance was recorded1 at 220 
nm at hourly intervals for 24 hours at room temperature. After incubation, 15 µL 
aliquots were taken from the microwells, pooled, frozen to -80°C and lyophilised. The 
lyophilisates were re-dissolved to their original volume (90 µL) in non-reducing sample 
buffer for analytical SDS PAGE (see Section 2.1.1.4 pp. 100 - 102 and Supplementary 
data (CD)). The experiment is summarised in Figure 34 below.  
1 Note: The absorbance measurements started 10 minutes after the EMD solution was 
prepared. As 10 minutes represent only 0.7% of the 24-hour incubation period, the 
starting time of absorbance measurement was considered to be the starting time 
of experiment. 
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Figur 3e 4 Summary of microwells blocking trial. (1) A solution of 1% BSA or 1% 
NFDM was left to incubate overnight in microwells at 4°C. At the end of 
incubation the microwells were washed and tapped dry. (2) Then, fresh 
EMD solution (166 µg/mL). The control condition consisted of incubating 
fresh EMD solution in microwells that were not previously incubated with 
BSA or NFDM. Aliquots of the solution were taken for SDS PAGE analyses 
before and after incubation with EMD (at the time points T= 0 hours, 24 
hours, indicated). The absorbance was monitored at 220nm. 
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2.2.2.5 Behaviour of WT and mutant pY64H r-amelogenins in the 
microplate-based assay 
The r-amelogenins used throughout the thesis carried a His-tag for purification by 
nickel column chromatography (see Figure 24, p. 108), which was the initial 
purification strategy and a standard method for purifying recombinant proteins. The 
initial aim was then to obtain cleaved and purified WT and p.Y64H mutant r-
amelogenins for use in protein binding studies. However, nickel column 
chromatography did not completely purify r-amelogenins successfully (see Section 
3.1.2.1.3), while preparative SDS PAGE provided highly purified fractions (see Section 
3.1.2.3.1). As the initial acetic acid extraction and subsequent preparative SDS PAGE 
could reach a high degree of purification, it became clear that nickel column 
chromatography and the associated His-tag were redundant. A further advantage with 
using His-tag-free r-amelogenins is that it bypasses the time-consuming and costly 
His-tag cleavage step. To this end, His-tag-free WT and p.Y64H mutant r-amelogenins 
(respectively “WT-His” and “Mut-His” r-amelogenins) were expressed by E. coli BL21 DE3 
competent cells using plasmids generated by a commercial company (Novoprotein 
Scientific, NJ, USA) during the final write up period of the thesis (earlier attempts by 
the company to produce these plasmids were unsuccessful due to ‘technical 
problems’). Details regarding the plasmids and sequences are provided in Appendix A. 
WT-His and Mut-His  r-amelogenins were initially purified using the acetic acid extraction 
procedure (kindly performed by Dr Sarah Myers and Mr. Matthew Percival). Time 
precluded further purification by preparative SDS PAGE and as described below, 
these were used directly along with WT+His and Mut+His  r-amelogenins (also extracted 
in 3% acetic acid) in the microplate assay which  simply measured the absorbance of 
protein accumulating directly on the bottom of the wells (see Section 2.2.2.3, p. 130).  
The acetic acid extracts containing r-amelogenins were lyophilised, desalted against 
125 mM formic acid (see Section 2.1.1.3, p. 99*, for details on desalting procedure) 
and lyophilised. The protein content of the extracts was analysed by mass 
spectrometry (see Appendix B for His-tag-free r-amelogenins and Figure 39 (p. 145) 
for His-tagged r-amelogenins). The lyophilisates were then dissolved in 1 % acetic 
acid to provide a 1.62 mM stock solution. The stock solutions were diluted 217.4 times 
in PBS pre-warmed to 37°C, to give a final r-amelogenin concentration of 7.46 µM. 
Considering that r-amelogenins were by far the major proteins in the acetic acid 
extracts, the concentration values disregarded any contaminants present. Immediately 
after preparing the test solutions, aliquots were taken for analytical SDS PAGE. Then, 
200 µL of each solution were added into empty polystyrene UV-transparent microwells 
(n=6) and left to incubate for 24 hours at 37°C. The microplate was covered with cling 
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film to prevent evaporation. The depletion of protein from solution was monitored by 
UV absorbance spectroscopy at A220nm. Absorbance was recorded every minute during 
the first 4 hours of incubation, then every 30 minutes until the end of the incubation 
period. The average absorbance of the 6 replicates for each of the 4 recombinant 
proteins were plotted1 after subtracting the blank values using Excel software, with the 
standard deviations calculated. The blank solution was comprised of PBS:1 % acetic 
acid at a ratio 216.4:1 (PBS: acetic acid). At the end of the incubation, 20 µL aliquots 
were taken from each of the microwell replicates, pooled, frozen to -80°C and 
lyophilised. The lyophilisates were re-dissolved to volume (120 µL) in 1X non-reducing 
sample buffer for analytical SDS PAGE. Further details regarding the SDS PAGE 
analyses are provided in Section 2.1.1.4 pp. 100 - 102 and in the supplementary data 
(CD)). Meanwhile the microplates were inverted and tapped forcefully to remove the 
solutions from the microwells, and the UV absorbance at 220 nm recorded and 
attributed to proteins present on the bottoms of the wells. 
1 Note: The absorbance measurements started 7 minutes after the EMD solution was 
prepared. As 7minutes represent less than 0.5% of the 24-hour incubation period, 
the starting time of absorbance measurement was considered to be the starting 
time of experiment. 
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Chapter 3 Results 
3.1 Production and purification of r-amelogenins 
3.1.1 Expression of recombinant WT and p.Y64H amelogenins in E. 
coli and their extraction in acetic acid. 
3.1.1.1 Expression of recombinant WT and mutant p.Y64H amelogenins 
in E. coli 
R-amelogenins WT+His and Mut+His were produced in large quantities using an E.coli
expression system. The expression of WT+His or Mut+His  r-amelogenin was induced
with IPTG when the cell density was sufficient, that is, when the culture density
OD600nm was above 0.6 AU (see Section 2.1.1.1, pp. 92 - 93).
From a starting value below 0.1 AU, which corresponds to the starting time of the large
scale growth of E. coli, the OD600nm reached the value 0.67 AU after 2.5 hours growth.
At this time, the expression of r-amelogenin was induced by adding IPTG and the
cultures were incubated overnight. Figure 35 (p. 137) shows the SDS PAGE of total
protein present in the E. coli . Cultures induced overnight with IPTG expressed a
prominent 27 kDa protein that was absent in non-induced cultures. This band was
confirmed to be amelogenin by western blotting using anti-amelogenin specific
antibodies (Figure 35B). Prominent cross-reactively was present at 27kDa with less
intensely stained bands at 54 kDa, suggesting the presence of an amelogenin dimer.
A cross-reactive band at 30 kDa was present in samples from both non-induced and
induced E. coli cultures. Clearly, some bacterial protein of unknown identity was cross-
reacting with the anti-amelogenin antibody. The r-amelogenin was seen to be running
3-5 kDa higher than the positive control due to the presence of a His-tag in the case of
the recombinant. Also, cross-reactive bands at 15 and 20 kDa were present, at
relatively low concentration in samples from induced E. coli cultures. These may be
breakdown products of the r-amelogenin.
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Figure 53  SDS PAGE and western blotting of expressed E. coli proteins. R-
amelogenin was expressed by E. coli cells in large quantities, as WT+His or 
Mut+His (carrying a His-tag). (A) SDS PAGE showing that overnight 
incubation after induction with IPTG resulted in the expression of a 
prominent protein at 27 kDa. (B) Western blot showing that the 27 kDa 
protein cross-reacted with anti-amelogenin antibodies. with less intense 
cross-reactivity at 53 kDa.  
(MW = molecular weight markers; Ctr = r-amelogenin (minus His-tag) at 24 
kDa). 
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3.1.1.2 Optimisation of 3% acetic acid amelogenin extraction procedure 
3.1.1.2.1 Optimisation of E. coli extraction in terms of ‘weight of E. coli to 
volume of acetic acid’ used in the extraction procedure 
To identify the ratio of weight of E. coli to volume of acetic acid that gave the maximum 
yield of r-amelogenin in a single extraction step but without over dilution, E. coli paste 
was resuspended in 3% acetic acid at 0.33, 0.17, 0.033 and 0.0033 g/mL (see Section 
2.1.1.2.1, p. 95). Figure 36A below shows that easily detectable amounts of r-
amelogenin were present in the 0.33, 0.17 and 0.033 g/mL extracts whereas r-
amelogenin was less easily detected in the 0.0033 g/mL extract (when equal volumes 
of sample were loaded on the gels). The obvious reason for this is that the r-
amelogenin was diluted by a factor of 100 in the 0.0033 g/mL extract compared to the 
0.33 g/mL extract. To account for the different dilution factors, the staining intensity 
associated with each band was quantified by gel densitometry (Figure 36B). From the 
table it is clear that extracting r-amelogenin from E.coli paste at 0.0033 g/mL provided 
the greatest yield of r-amelogenin. However, large volumes are more difficult to handle 
in downstream processing steps (e.g. lyophilisation) so as a compromise, extraction at 
0.033 g/mL was chosen as the optimum ‘weight of E. coli to volume of acetic acid’ ratio 
for extraction (giving a yield of r-amelogenin about 7 times greater than extracting at 
0.33 g/mL).  
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3.1.1.2.2 Optimisation of the mixing regimen and temperature on the yield of WT 
r-amelogenin extraction
The results reported above suggested that using 30 mL of acetic acid to extract WT+His 
r-amelogenin from 1 g of E. coli (equivalent to 0.033 g/mL extract, see Section
3.1.1.2.1 above) was efficient and demanded relatively little effort to extract the bulk of
the WT+His r-amelogenin. However, for E. coli expressing Mut+His , the process was not
so efficient, as it was more difficult to resuspend the cells in acetic acid, albeit not
impossible. The extraction regimen was therefore optimised in an attempt to make it
quicker and improve the yield, and to ease the procedure. The extraction process was
carried out as summarised in Figure 37A, using either manual mixing or a 0.5-1 minute
ultrasonication step to resuspend the cells.
To verify the effect of the heating treatment on the extraction procedure, the extraction,
using ultrasonication, was carried out with or without the heating step, as summarised
in Figure 37B p. 141.
SDS PAGE analysis in Figure 37A shows that Mut+His  r-amelogenin (27kDa) was 
successfully extracted in acetic acid. The similarity of the protein profiles observed and 
the amount of 27 kDa protein obtained (as indicated by similar band staining intensity) 
indicated that ultrasonication did not obviously alter the protein content, nor the yield of 
r-amelogenin extraction. These observations contrast with those of Svensson Bonde
and Bulow (2012) who suggested that sonication may not be “very feasible in large
scale” and may reduce the purity of the amelogenin extract obtained (Svensson Bonde
and Bulow, 2012). In this study, ultrasonication provided a quicker means of
resuspending the cells without affecting the quality of r-amelogenin extraction and
therefore it was adopted as the mixing regimen.
Analytical SDS PAGE, shown in Figure 37B, showed the protein profiles obtained
when fresh cells were resuspended in acetic acid, mixed and either heated to 75°C or
kept at room temperature for 20 minutes. Gel densitometry analysis indicated that with
the heat treatment, the 27 kDa band intensity was 33% stronger in the supernatant
and 66% weaker in the pellet obtained compared respectively with the 27 kDa band
intensities in the supernatant and pellets obtained by the procedure without heating.
This indicates that the heating step significantly increased the yield of r-amelogenin
extraction. However, analytical SDS PAGE also indicated that heating may increase
the extraction of other contaminants as well, although not significantly. This was
considered to be non-problematic, since the r-amelogenin extract would be subjected
to further purification using a panel of secondary purification techniques (strategy
summarised in Figure 40, p. 146) as described in the next Sections.
- 141 -
Figure 73 Panel (A) summarises the optimisation of the mixing regimen for acetic 
acid extraction of r-amelogenin. The effects of ultrasonication and manual 
mixing on the resulting acetic acid extract were compared. SDS PAGE 
showed similar protein profiles in the acid soluble fractions for both mixing 
regimens used, indicating that ultrasonication did not affect the yield nor 
the quality of extraction of r-amelogenin. Panel (B) shows the effect of heat 
treatment on the yield. SDS PAGE showed the contents of the initial cell 
resuspension in acetic acid (lane labelled 1, black frame), of the final 
pellets and acetic acid-soluble fractions obtained with the heating step 
(‘Heat’, lanes labelled 2, red frames ) or without heating (‘No Heat’, lanes 
labelled 3, blue frames). This experiment showed that heating the mixture 
to 75°C significantly increased the yield of extraction of r-amelogenin in 
acetic acid. 
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3.1.1.2.3 Large scale acetic acid extraction of r-amelogenin using the optimised 
methodology 
The extraction process using 3% acetic acid was optimised specifically for the mouse 
WT+His and Mut+His r-amelogenins. This series of optimisations provided a method for 
large scale preparation, summarised in Figure 38 below. These findings are mostly 
consistent with those of Svensson Bonde and Bulow (2012). For scaling up, longer 
sonication time (2-3 minutes) was needed in order to obtain a homogeneous mixture. 
The acetic acid extract obtained was lyophilised, desalted, lyophilised again and 
analysed by mass spectrometry (Figure 39, p. 145).
Figure 83  Flow-diagram of the optimised extraction procedure. (1) E. coli were 
washed in 150 mM NaCl and (2) resuspended in 3% acetic acid at 30 mL/g 
wet weight of cells. The suspension was (3) mixed by sonication and (4) 
heated at 75°C for 20 minutes. (5) The acid soluble proteins were separated 
from insoluble residues by centrifugation at 3220 g for 20 minutes and (6) 
the supernatant containing the acid soluble proteins was lyophilised. 
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The spectrum obtained (Figure 39, p. 145) for the lyophilisate (desalted) showed 
peaks at 24732.99, 24748.33, 24764.22, 24779.83, 24795.63, 24812.20 Da. The peak 
at 24732.99 Da possibly corresponds to the WT+His r-amelogenin which has lost a 
methionine; its MW predicted on ProtParam (Ahirwar et al., 2015) is 24864.42 Da. The 
methionine lost is likely Met1 as E. coli endogeneous methionine aminopeptidases can 
remove N-terminal methionine (Gibbs, 2001). The presence of the other peaks at 
24748.33, 24764.22, 24779.83, 24795.63, 24812.20 Da indicate additions of 16 Da, 
which can be caused by oxidations at various degrees (from 1 to 5 additions of 16 Da). 
For clarity, the hypothesis is summarised in Table 8.  
Table 8  Interpretation of mass spectrometry spectrum (peaks observed, Figure 
39) obtained from the desalted lyophilisate). In the hypothesis that
additions of 16 Da correspond to oxidations, the number of oxidations are
referred to as “+ … Ox.”
r-amelogenin state Predicted MW Total MW observed on 
spectrum  
Full length m0 = 24864.42 Da None 
Full length –Met1 m1 = 24733.23 Da 24732.99 Da 
[Full length –Met1] +1x Ox. = m1 + 16 Da 24748.33 Da 
[Full length –Met1] +2x Ox. = m1 + 32 Da 24764.22 Da 
[Full length –Met1] +3x Ox. = m1 + 48 Da 24779.83 Da 
[Full length –Met1] +3x Ox. = m1 + 64 Da 24795.63 Da 
[Full length –Met1] +5x Ox. = m1 + 80 Da 24812.20 Da 
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3.1.2 Strategies for secondary purification to obtain purified r-
amelogenin for binding studies 
Following optimisations as described above, the procedure for r-amelogenins  
extraction in 3% acetic acid was scaled up as summarised in Figure 38 (p. 143). This 
process resulted in a significant enrichment of r-amelogenin. However, acid-soluble 
bacterial proteins were still visible (with contaminants of 10 – 75k Da visible on SDS 
PAGE with Coomassie Blue staining, see Figure 37). Secondary purification was 
therefore needed to remove these and to isolate r-amelogenin at a suitable purity for 
future use in binding assays. A panel of standard protein purification techniques was 
tested and eventually optimised (Sections 3.1.2.1 – 3.1.2.3). The purification strategy 
is summarised below in Figure 40. 
Figure 04  Secondary purification of r-amelogenin from 3% acetic acid extract. 
Summary of the strategy developed to determine the optimum method 
providing with r-amelogenin at a suitable purity for future binding studies. 
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3.1.2.1 Purification of r-amelogenin using nickel column chromatography 
As shown previously (see Section 3.1.1.2.2, pp. 140 - 144), acetic acid extracts were 
enriched with r-amelogenin but still contaminated with bacterial proteins (seen on 
analytical SDS PAGE as bands ranging 10 - 75 kDa; Figure 37). Further purification 
steps were therefore trialled to reduce these bacterial contaminants. The first method 
tested was that of nickel column affinity chromatography. 
The results presented below detail the purification of r-amelogenin using standard two-
round nickel column chromatography. The two-round nickel column chromatography 
procedure is summarised in Figure 41 overleaf.  
- 148 -
Figure 14  Purification of r-amelogenin using two rounds of nickel column 
chromatography. The results obtained from steps (1), (2) and (3) are shown 
in Figures 42, 43 and 44 as indicated on the flow chart. 
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3.1.2.1.1 First round of nickel column chromatography to accomplish an 
effective “clean-up” 
The acetic acid extract (produced by the procedure summarised in Figure 38, p. 143) 
was desalted and subjected to a first round of nickel column chromatography to purify 
His-tagged r-amelogenin from any bacterial contaminants co-extracted in the acetic 
acid. To summarise, the technique employs immobilised nickel ions in a column 
through which the sample is pumped. His-tag has a high affinity for nickel 
(Jeyachandran et al., 2009) and His-tagged proteins (i.e. r-amelogenin) are retained 
on the column while other proteins are washed out in the flow-through. The His-tagged 
protein is subsequently recovered by increasing the concentration of imidazole in the 
buffer passing through the column which competitively displaces the His-tagged 
protein from the nickel allowing for elution and collection.  
The chromatogram obtained using this method is shown in Figure 42A along with 
Coomassie Blue-stained SDS PAGE analysis showing the protein content of the 
starting material (the crude acid extract) and the protein content of the two peaks 
collected during chromatography. SDS PAGE of the starting material showed the clear 
presence of a 27 kDa component that corresponded to the molecular weight of His-
tagged r-amelogenin along with a number of contaminating bacterial proteins. The first 
2 fractions collected after the sample was injected onto the column (Fr 1 and Fr 2) 
corresponded to the flow-through of proteins that failed to bind to the column in 20 mM 
imidazole. SDS PAGE of these two fractions confirmed that the flow-through 
comprised the bulk of bacterial contaminants. On increasing the imidazole 
concentration to 200 mM, a second peak was eluted and collected in Fr 3, Fr 4 and Fr 
5. Analytical SDS PAGE showed that these fractions (especially Fr 3) were highly
enriched in r-amelogenin, migrating at 27 kDa. Figure 42B reproduces the SDS PAGE
analysis described above to allow it to be compared to a corresponding anti-
amelogenin western blot. The intense immuno cross-reactivity detected at 27 kDa
confirmed that protein migrating at this molecular weight was r-amelogenin. The cross-
reactivity above 27 kDa was presumably due to the presence of His-tagged r-
amelogenin homodimers migrating at 54 kDa.
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3.1.2.1.2 Second round of nickel column chromatography to isolate cleaved r-
amelogenin 
The His-tagged r-amelogenin eluted in Fr 3 (see Figure 42, p. 150) was subjected to 
His-tag cleavage by incubation with HRV3C protease (method described in Section 
2.1.2.1.2, p. 109). The ratio of enzyme-to-substrate was previously optimised 
(Appendix C) and 3 µL of stock HRV3C protease per mg substrate was identified 
within the range of minimum amounts of enzyme resulting in a maximum yield. The 
cleavage was carried out in 50 mM Tris-HCl, pH=8, previously shown to be an 
effective cleavage buffer (Appendix D).  
 
Figure 34  SDS PAGE showing the efficacy of His-tag cleavage from r-amelogenin 
using HRV protease over 24 hours. The 27 kDa uncleaved His-tagged r-
amelogenin was cleaved with approximately 50% efficiency to a generate 
His-tag-free r-amelogenin cleavage product at around 24 kDa. The cleavage 
reaction mixture also contained an additional three bands (46, 50 and 54 
kDa) possibly representing homodimers of cleaved and uncleaved r-
amelogenins and heterodimers of cleaved and uncleaved r-amelogenin 
respectively. The Figure has been adapted from Gabe et al, 20171 
  
                                               
1 Figure 43 is adapted from Gabe et al. (2017) under the terms of the Creative Commons 
license CC BY (https://creativecommons.org/licenses/by/4.0/) 
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Analytical SDS PAGE with Coomassie Blue staining (Figure 43) showed that the His-
tag cleavage was only 50% efficient, as both 24 kDa (‘cleaved’) and 27 kDa band 
(‘uncleaved’) r-amelogenins were present in the cleavage mixture. The apparent 
homodimer migrating at 54 kDa was observed in the uncleaved sample but after 
cleavage, another two bands migrating at 50 and 46 kDa were evident. The 46 kDa 
and 50 kDa bands could correspond to homodimers of r-amelogenin and heterodimers 
of cleaved and uncleaved r-amelogenin respectively. The cleaved sample also 
contained a band migrating below 10 kDa which corresponds to the cleaved His-tag. 
Following incubation with HRV3C protease, the reaction mixture was buffer-
exchanged into 20 mM imidazole nickel column chromatography binding buffer ready 
for reloading on the nickel column for a second round of nickel column purification. 
The second round of nickel column chromatography was carried out to isolate cleaved 
r-amelogenin (now freed of its His-tag) from the remaining uncleaved His-tagged r-
amelogenin, the cleaved His-tag and the HRV3C protease (which itself is His-tagged).
The cleaved r-amelogenin was the only protein in the mixture without a His-tag and in
theory at least, should not have bound to the nickel column but instead should have
eluted in the flow-through.
- 155 - 
 
Figure 44A below shows the chromatogram and Coomassie Blue-stained SDS PAGE 
analysis of the fractions obtained. SDS PAGE of the starting material showed the 
presence of the cleaved and uncleaved r-amelogenin migrating at 24 and 27 kDa 
respectively. The initial flow-through collected in Fr 1 contained only a trace of the 
expected cleaved r-amelogenin – clearly the cleaved r-amelogenin was retained on 
the column even though the His-tag had been cleaved off (the reason for this 
phenomenon is explored in Section 4.1.2.2.3, p. 221). In an attempt to elute cleaved r-
amelogenin, the imidazole concentration was increased to 60 mM; this was an attempt 
to compete off the cleaved r-amelogenin whilst leaving the uncleaved His-tagged r-
amelogenin still bound to the column. Increasing the imidazole concentration in the 
buffer flowing through the column to 60 mM immediately resulted in the elution of 
protein which was collected in Fr 2. SDS PAGE of Fr 2 showed that 60 mM imidazole 
was able to elute the 24 kDa cleaved r-amelogenin while leaving the uncleaved r-
amelogenin still bound to the nickel column. The uncleaved r-amelogenin (and the 
cleaved His-tags) was subsequently eluted from the column as expected by increasing 
the imidazole concentration to 200 mM.  
Figure 44B shows each fraction presented in Figure 44A run on a single gel to make 
comparisons between each fractions easier to see. The analytical SDS PAGE 
graphically demonstrated that the methodology was able to separate cleaved (Fr 2) 
from uncleaved r-amelogenin (Fr 3). However, upon staining the gel with silver, a more 
sensitive stain than Coomassie Blue (Morrissey, 1981), revealed that the uncleaved r-
amelogenin (Fr 2) was still contaminated with traces of uncleaved r-amelogenin and 
possibly HRV3C protease (Figure 44C). Interestingly, Fr 3 contained the bulk of 50 
and 54 kDa- molecular complexes which required 200 mM imidazole for elution while 
Fr 2 contained the 46 kDa complex eluting with 60 mM imidazole . This agreed with 
the idea that the 50 and 54 kDa- molecular complexes are comprised of heterodimers 
of the cleaved and uncleaved r-amelogenin and homodimers of the uncleaved r-
amelogenin whilst the 46kDa complex is a dimer of the cleaved r-amelogenin (since 
the presence of a His-tag in the complex increased its affinity for the nickel column). 
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In summary, using classic two-step nickel column chromatography methodology 
produced a fraction highly enriched with r-amelogenin, though the fraction was not 
absolutely pure as judged by silver stained SDS PAGE. Separating the cleaved r-
amelogenin was problematic in that it was still bound to the nickel column even without 
a His-tag and an elevated imidazole concentration (60 mM) was required to elute the 
protein; this possibly explains the presence of contaminating uncleaved protein that 
was also eluted in small amounts in the presence of 60 mM imidazole. In addition, the 
efficacy of the proteolytic cleavage step to remove the His-tag was only about 50% 
which would have an obvious impact on the yield obtained.  
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3.1.2.2 Purification of r-amelogenin using size exclusion chromatography 
As purification of r-amelogenin based on His-tag affinity chromatography did not 
generate absolutely pure r-amelogenin, SEC was trialled as an alternative 
methodology. Using this methodology, separation is based on the molecular weight of 
the components of interest. The procedure is easily scalable and does not necessitate 
the use of and disposal issues associated with hazardous chemicals (unlike nickel 
columns, which are regenerated with highly toxic nickel II solution).  
The effect of operational variables such as the column matrix pore size and the 
column bed height were tested to see the degree of separation achieved. The 
development of a size-exclusion-based purification method is summarised in Figure 45 
overleaf.  
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Figure 54  Purification of r-amelogenin using SEC: optimisation of bed height 
and pore size. Once lyophilised, the acetic acid extract was directly 
subjected to SEC. For a bed height of 35 cm, two matrices with different 
pore sizes were tested: Bio-gel P-30 matrix (detailed in Section 3.1.2.2.1) 
and Bio-gel P-10 matrix (detailed in Section 3.1.2.2.2). The second bed 
height tested was 95 cm, using Bio-gel P-10 matrix (detailed in Section 
3.1.2.2.3). Small aliquots from the fractions collected were taken for 
analytical SDS PAGE. 
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3.1.2.2.1 Size exclusion chromatography using Bio-gel P-30 matrix, 35 cm bed 
height  
An attempt to isolate r-amelogenin (WT+His) from the acetic acid extract was made 
using a XK column (1.6 cm diameter * 35 cm bed height) packed with polyacrylamide 
matrix Bio-gel P-30. According to the manufacturer, this matrix has a fractionation 
range of 2.5 – 40 kDa, which brackets the 27 kDa r-amelogenin. Figure 46 below 
shows the separation of the acid extract components using 125 mM formic acid as the 
mobile phase. Analytical SDS PAGE with Coomassie Blue staining confirmed that the 
initial sample was comprised of the 27 kDa r-amelogenin and a number of 
contaminants (mostly migrating between 7-17 kDa). It was anticipated that the 27 kDa 
r-amelogenin would elute early and the first UV peak was collected into six fractions.
SDS PAGE of these 6 fractions showed that the r-amelogenin at 27 kDa was found
predominantly in fractions 1- 3. Fraction 1 contained the r-amelogenin at the highest
purity with fractions 2-3 containing increasing amounts of the lower molecular weight
contaminants, indicating that Bio-gel-p30 was not able to provide the degree of
purification required. The broader peaks eluting later corresponded to small molecules
(e.g. amino acids and other metabolites) present in the acetic acid extracts; they were
not resolved by analytical SDS PAGE due to their small sizes (data not shown).
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Figure 64  Separation of acetic acid extract components by SEC using Bio-gel P-
30 matrix, 35 cm bed height. The chromatogram and accompanying SDS 
PAGE analysis showed that the r-amelogenin at 27 kDa was found in the 
first UV elution peak at 25 mL after injection, predominantly in fractions 1- 
3. Fraction 1 contained the r-amelogenin at the highest purity with fractions 
2-3 containing increasing amounts of the lower molecular weight 
contaminants ranging 7 – 17 kDa. At 60-100 mL after elution, a number of 
lower UV peaks (below 50 mAU UV value) were visible. This likely 
corresponded to small UV absorbing molecules (amino acids, metabolites, 
salts or other non-protein components) that were retained through the 
column pores, due to their smaller radii. 
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3.1.2.2.2 Size exclusion chromatography using Bio-gel P-10 matrix, 35 cm bed 
height  
The Bio-gel P-10 polyacrylamide matrix, whose nominal exclusion limit range is 1.5-20 
kDa, was expected to improve the isolation of amelogenin away from the lower 
molecular weight contaminants compared with matrix P-30. In theory, the 27 kDa r-
amelogenin should be excluded from the matrix beads and elute quickly in advance of 
smaller contaminants below 20 kDa which would be retained as they diffuse into the 
matrix beads during the chromatographic run. The result is shown in Figure 47 below. 
Analytical SDS PAGE with Coomassie Blue staining showed that the 27 kDa r-
amelogenin was eluted in the first 4 fractions, corresponding to the first UV peak. 
Again, the very first fraction, representing the very first protein to elute from the 
column, contained r-amelogenin in the most pure state but even here, low molecular 
weight contaminants were visible. Most of the r-amelogenin eluted over the next 3 
fractions and contained far more low molecular weight contaminants.  
Isolation of 27 kDa r-amelogenin was, however, not improved compared with that 
observed with Bio-gel P-30 (Figure 46), as the bulk of r-amelogenin was collected with 
lower molecular weight contaminants.  
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Figure 74  Separation of acetic acid extract components by SEC using Bio-gel P-
10 matrix, 35 cm bed height. The chromatogram and accompanying SDS 
PAGE analysis showed that r-amelogenin at 27 kDa was found in the first 
UV elution peak, 20 mL after injection and predominantly in fractions 1 – 4. 
The first fraction contained r-amelogenin in the most pure state but also 
contained low molecular weight contaminants. The majority of the r-
amelogenin eluted over the next three fractions and contained far more low 
molecular weight contaminants. 
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3.1.2.2.3 Size exclusion chromatography using Bio-gel P-10 matrix, 95 cm bed 
height  
As shown above, columns of Bio-gel P10 and P30 matrices with 35-cm bed height 
failed to provide an adequate purification of r-amelogenin. In an attempt to improve the 
resolution, the bed height was increased to 95 cm. The content of each fraction 
collected was analysed by SDS PAGE with Coomassie Blue staining, shown below in 
Figure 48. Increasing the bed height to 95 cm appeared to provide a slightly better 
resolution of lower molecular weight contaminants (Figure 48) compared with the 
previous conditions working with 35 cm-bed heights (Figures 46 and 47, pp. 163 and 
165), however, the 27 kDa r-amelogenin was still not isolated in a sufficiently pure 
state. In all of the size exclusion chromatographies tested, the bulk of r-amelogenin 
was never found at single band purity (Figures 46 - 48). The reasons for such a less-
than-ideal performance are discussed later in Section 4.1.2.3, p. 225 
 
Figure 84  Separation of acetic acid extract components by SEC Bio-gel P-10, 95 
cm bed height. The chromatogram and accompanying SDS PAGE analysis 
showed that r-amelogenin at 27 kDa was found in the first UV elution peak, 
20 mL after injection and predominantly in fractions 1 – 9. The first fraction 
contained r-amelogenin in the most pure state but most of the r-
amelogenin was eluted over the next 8 fractions, which contained far more 
low molecular weight contaminants.   
- 167 - 
 
3.1.2.3 Purification of r-amelogenins using preparative SDS PAGE 
The purification techniques tested previously (nickel column chromatography, Section 
3.1.2.1 and SEC, Section 3.1.2.2) failed to isolate r-amelogenin to single band purity 
by analytical SDS PAGE (as determined by Coomassie Blue and silver staining) from 
the acetic acid extract. This may be due interactions of r-amelogenin with the column 
matrices, or the aggregative nature of r-amelogenin, possibly interacting with the 
contaminants (discussed later in Sections 4.1.2.2.2, p. 221 and 4.1.2.3, p. 225). In 
either case, this would be refractory to achieving a good separation. Since analytical 
SDS PAGE could evidently resolve the 27 kDa r-amelogenin from contaminants (as 
evidenced by the analytical SDS PAGE gels shown in the previous pages), preparative 
SDS PAGE was trialled to isolate r-amelogenin away from the bacterial protein 
contaminants comprised in the crude acetic acid extract, according to their apparent 
molecular weight. Experiments were therefore carried out (1) to isolate His-tagged r-
amelogenin from the acetic acid extract (Section 3.1.2.3.1, summarised in Figure 49), 
and (2) to isolate cleaved r-amelogenin (Section 3.1.2.3.2, summarised in Figure 53) 
using preparative SDS PAGE. Preparative SDS PAGE involves collecting protein 
fractions as the proteins separating on the gel are deliberately run off the bottom of the 
gel (an outcome to be avoided at all costs during analytical SDS PAGE).  
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3.1.2.3.1 Isolation of His-tagged r-amelogenin from acetic acid extracts by 
preparative SDS PAGE 
The crude acetic acid extract obtained as described in Section 3.1.1.2.3 (p. 143) was 
desalted, resuspended into SDS PAGE sample buffer and loaded on the preparative 
SDS PAGE gel as described in the Section 2.1.2.3, p. 115 (details on the composition 
of the gel are provided in Table 4 p. 102). The resulting fractions were collected and 
analysed using analytical SDS PAGE with Coomassie Blue staining using this 
technique. The procedure is summarised in Figure 49. Following this method, WT+His r-
amelogenin ready for cleavage was found at single band purity (Figure 50, p. 170) in 
fractions 25-52.  
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Figure 94  Purification strategy of WT+His r-amelogenin from acetic acid extracts 
using preparative SDS PAGE (Figure 26 reproduced). The desalted acetic 
acid extract was resuspended into SDS PAGE sample buffer and heated, to 
solubilise the proteins. The mixture was loaded on to the preparative SDS 
PAGE gel to separate its components according to their apparent 
molecular weights. From the fractions collected, small aliquots were taken 
and their content was analysed by analytical SDS PAGE with Coomassie 
Blue staining (Figure 50), silver staining and western blot (Figure 51) to 
identify the fractions containing r-amelogenin. These fractions were pooled 
together, desalted and lyophilised. The lyophilisate was subjected to mass 
spectrometry (Figure 52) and was ready to be subjected eventually to His-
tag cleavage and nickel column chromatography, to obtain a purified 
‘cleaved’ r-amelogenin. 
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After the fractions of interest (fractions 25 – 52) were analysed by analytical SDS 
PAGE with Coomassie Blue staining (Figure 50, p. 170), the purity and identity of r-
amelogenin in the fractions was further assessed by analytical SDS PAGE with silver 
staining and western blotting (Figure 51 p. 171). 
Analytical SDS PAGE with silver staining (Figure 51A) showed single band purity in 
fractions 25 to 49. The identity of r-amelogenin in these fractions was confirmed by an 
anti-amelogenin western blot (Figure 51B). Interestingly, strong immuno-cross-
reactivity was seen from fraction 24 onwards whereas silver staining detected proteins 
that appeared to migrate just under 27 kDa in fractions 22 - 23 and were poorly cross-
reactive with anti-amelogenin antibody (Figure 51B). Fractions 25 to 49 were then 
pooled together and desalted. The lyophilisate obtained after the round of preparative 
SDS PAGE yielded 4.90 mg of purified r-amelogenin from the 10 mg of desalted 
extract (a yield of ~50%). 
The lyophilisate obtained was then subjected to mass spectrometry. The spectrum 
obtained is shown in Figure 52 p. 173. The spectrum showed peaks at 24749.60, 
24763.15, 24780.55, 24812.4. 24827.85, 24844.45, 24860.20, 24876.25, 24892.4 Da. 
The peak at 24749.60 Da possibly correspond to WT+His r-amelogenin which has lost a 
methionine (likely Met1 )1 and has one oxidation (+16 Da)2. The presence of the other 
peaks at 24763.15, 24780.55, 24812.4. 24827.85, 24844.45, 24860.20, 24876.25, 
24892.4 Da indicate additions of 16 Da, which can be caused by oxidations at various 
degrees (from 2 to 10 additions of 16 Da). For clarity, the hypothesis is summarised in 
Table 9 (p. 174).  
1 As described in the Section 3.1.1.2.3, the loss of the N-terminal methionine is likely caused by 
E. coli endogenous methionine aminopeptidase (Ben-Bassat et al., 1987).
2 The MW predicted on ProtParam (Gasteiger et al., 2005) for r-amelogenin (minus Met1) is 
24733.23 Da. One oxidation on a residue adds 16 Da, resulting in a total mass of 
23749.23 Da. 
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Table 9  Interpretation of mass spectrometry spectrum (peaks observed, Figure 
52) obtained from the final lyophilisate). In the hypothesis that additions of
16 Da correspond to oxidations, the number of oxidations are referred to as
“+ … Ox.”
r-amelogenin state Predicted MW Total MW observed on 
spectrum  
Full length m0 = 24864.42 Da None 
Full length –Met1 m1 = 24733.23 Da None 
[Full length –Met1] +1x Ox. = m1 + 16 Da 24749.60 Da 
[Full length –Met1] +2x Ox. = m1 + 32 Da 24763.15 Da 
[Full length –Met1] +3x Ox. = m1 + 48 Da 24780.55 Da 
[Full length –Met1] +5x Ox. = m1 + 80 Da 24812.4 Da 
[Full length –Met1] +6x Ox. = m1 + 96 Da 24827.85 Da 
[Full length –Met1] +7x Ox. = m1 + 112 Da 24844.45 Da 
[Full length –Met1] +8x Ox. = m1 + 128 Da 24860.20 Da 
[Full length –Met1] +9x Ox. = m1 + 144 Da 24876.25 Da 
[Full length –Met1] +10x Ox. = m1 + 160 Da 24892.40 Da 
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3.1.2.3.2 Isolation of cleaved r-amelogenin by preparative SDS PAGE 
The previous section described the results when using preparative SDS PAGE to 
isolate pure His-tagged-r-amelogenin from the crude acetic acid extract. The strategy 
was that the purified protein would then be subjected to enzymatic cleavage to remove 
the His-tag (see Figure 49, p. 169) and then the cleaved r-amelogenin could 
theoretically be purified from uncleaved r-amelogenin using nickel column 
chromatography. This method would provide a product free of any bacterial 
contaminants since initial preparative SDS PAGE of the crude acetic extract was 
highly efficient at delivering purified uncleaved 27 kDa r-amelogenin (see previous 
Section). However, as evidenced in Figure 44B (p. 156), nickel column 
chromatography was not 100% efficient in separating cleaved and uncleaved r-
amelogenin. Given the exceptional purification power of preparative SDS PAGE (see 
previous Section), it was therefore decided to develop a modified approach that 
involved desalting and lyophilising the crude acetic acid prior to subjecting the entire 
spectrum of proteins present to His-tag cleavage. Preparative SDS PAGE would then 
be used to purify the cleaved r-amelogenin from the uncleaved r-amelogenin and 
bacterial contaminants. In effect, this approach would speed up the purification 
process as the nickel column chromatography steps would be no longer required. The 
process is summarised in Figure 53, below. 
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Figure 35  One-step purification of His-tag-free r-amelogenin from acetic acid 
extracts using preparative SDS PAGE. The methodology carried out is the 
same as that described in Section 3.1.2.3.1, except that a His-tag cleavage 
(with subsequent lyophilisation, desalting and lyophilisation) was added. 
The contents of the fractions obtained from preparative SDS PAGE 
purification are shown in Figure 54. 
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Analytical SDS PAGE with Coomassie Blue staining of every third fraction collected 
(Figure 54A) showed that preparative SDS PAGE of the crude acetic extract following 
cleavage was able to isolate cleaved r-amelogenin migrating at 24 kDa (fractions 38 - 
47). Figure 54B, showing silver stained analytical SDS PAGE for all fractions between 
38 and 47 shows that contaminating, uncleaved r-amelogenin at 27 kDa began to 
appear from fraction 45 onwards. Trace amounts of a slightly lower molecular weight 
contaminant were present in fraction 39, though in negligible amounts and typically 
fractions 39 to 44 could be pooled, desalted and lyophilised to prepare purified 24 kDa 
His-tag-free r-amelogenin. 
.  
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3.2 Development of protein-binding assays 
In the search for mechanisms underlying AI and possibilities for a therapy, AI was 
identified as a conformational disease for the first time, using a mouse model carrying 
the mutation p.Y64H, which phenocopies the human mutation p.P70T (Barron et al., 
2010, Brookes et al., 2014). These reports hypothesised that the p.Y64H mutation 
causes amelogenin to aggregate during trafficking through the ER, which in turn leads 
to ER stress and ultimately to ameloblast apoptosis (Further description of these 
studies are provided in Section 1.3.4.1.3, p. 70). Having developed methods for 
producing purified r-amelogenin, the next aim was to use WT and mutant p.Y64H r-
amelogenin to investigate the effect of the mutation on amelogenin-amelogenin 
interactions in vitro, in order to test the above hypothesis.  
Several approaches can be used to study protein-protein interactions (e.g. QCM, SPR, 
ELISA). In the present study, the aim was to develop a cost effective and high 
throughput microplate-based assay to study amelogenin–amelogenin interactions. 
Such an assay would not only be useful for studying amelogenin-amelogenin 
interactions per se but would also provide a screening tool for testing potential 
therapeutics that might modulate any abnormal amelogenin-amelogenin interactions. 
To this end, attempts were made to develop two binding assays.  
3.2.1 Method 1: Fluorescence-based binding assay 
The basic strategy for method 1 involved immobilising amelogenin (bait protein) to 
microplate well surfaces to which was added FITC labelled amelogenin (the free ligand 
in solution). After incubation, microwells were washed and any amelogenin-
amelogenin binding was determined by measuring the fluorescence remaining bound 
to the microwells (see Figure 29, p. 123). To conserve r-amelogenin during method 
development, the 20 kDa amelogenin abundant in enamel matrix derivative (EMD – 
the non-commercial form of Emdogain) was purified by preparative SDS PAGE to be 
used as a surrogate for initial method development.  
The results presented below detail: 
(i) FITC-labelling of EMD
(ii) purification of the FITC labelled 20 kDa amelogenin from EMD and
(iii) trialling of FITC-20 kDa amelogenin in the microplate based binding
assays
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3.2.1.1 FITC-labelling of whole EMD. 
Whole EMD protein was dissolved in 0.1 M Na2CO3 at pH = 9, and labelled overnight 
with FITC (Section 2.2.1.1, p. 120). The labelled proteins were subjected to analytical 
SDS PAGE and visualised by UV excitation. The gels were also stained with 
Coomassie Blue to confirm the efficiency of the labelling (Figure 55). 
Figure 55  SDS PAGE analysis showing that EMD proteins were successfully 
labelled with FITC. Coomassie Blue staining and fluorescein-specific 
fluorescence revealed similar banding patterns. 
SDS PAGE analyses as shown in Figure 55 revealed that all proteins in EMD were 
successfully labelled with FITC, since all bands visible by Coomassie Blue staining 
were also visible using UV excitation of the fluorescent label.  
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3.2.1.2 Purification of the 20 kDa amelogenin from FITC-labelled EMD 
using Preparative SDS PAGE 
Following overnight labelling, the FITC reaction mixture was lyophilised, desalted 
against formic acid, lyophilised and subjected to preparative SDS PAGE. The process 
is summarised in Figure 56 below. The fractions obtained were analysed by analytical 
SDS PAGE. UV excitation was used to visualise the bands (Figure 57A), along with 
Coomassie Blue staining (Figure 57B) and silver staining (Figure 57C). 
Figure 65  Diagram summarising the preparation and purification of FITC-labelled 
EMD proteins. 
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The SDS PAGE analyses in Figure 57 (pictures A-B) showed that on UV excitation 
and Coomassie Blue staining, the 20 kDa bands appeared well resolved, indicating 
that the purification process was successful. The fact that the FITC-labelled proteins 
were visible on fluorescence (Figure 57A) indicated that the purification process did 
not affect the fluorescence. 
The component of interest, the 20 kDa-amelogenin, appeared in fractions 41-49. The 
purity of these fractions, and that of the neighbouring fractions (37 and 39) was 
analysed by silver staining of the analytical gel (Figure 57C). In the fractions of 
interest, the 20 kDa band appeared as the strongest signal by far. Other components 
were visible at 36 kDa, possibly dimers. Other bands were visible at lower molecular 
weight in all of the fractions analysed, including the blank lane, which suggested that 
these bands originated from extraneous contamination that occurred during the 
preparation of the electrophoretogram (e.g. dirty gel comb) rather than being present 
in the fractions themselves. The fractions 41 to 49 were then pooled together and 
desalted for the binding assays.  
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3.2.1.3 Measuring amelogenin binding between free FITC-labelled 
amelogenin and immobilised amelogenin as binding partners 
For the fluorescence-based binding assay (described in Section 2.2.1.3, pp. 122 - 
123), it was necessary to ensure that the microplate wells were saturated with 
adsorbed bait protein and establish whether the adsorbed proteins could resist 
subsequent washing, blocking and handling steps. For convenience, FITC-labelled 20 
kDa amelogenin (purified from EMD as described previously) was used as a surrogate 
protein to investigate the binding kinetics of amelogenin to the microwell surfaces and 
to determine the conditions required to achieve saturation of the microwells. The FITC-
labelled 20 kDa amelogenin was dissolved in binding buffer at concentrations between 
1 and 20 µg/mL, to determine the concentration required to saturate the microwell 
surface . To optimise binding conditions, three buffers were compared for binding: 
Na2CO3 at pH = 9, PBS at pH = 7.4 or TBS at pH = 7.2. For each of these buffers, the 
incubation was carried out overnight either at room temperature or at 4°C. After 
incubation, the microwells were washed 3 times and blocked with 1% bovine serum 
albumin (BSA) solution (see Section 2.2.1.3 , pp. 122 - 123) for one hour at room 
temperature. Afterwards the microwells were washed three times and pure water was 
added before the fluorescence associated with adsorbed FITC-labelled 20 kDa 
amelogenin was measured. The process is summarised in Figure 58.  
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Figur 85e  Experimental design of a preliminary test to determine the binding 
conditions necessary for FITC-labelled 20 kDa amelogenin to adsorb to, and 
saturate, microwell surfaces. Any fluorescent amelogenin that bound to the 
microwell surface was detected using a fluorescence plate reader (Figure 
reproduced from Figure 29). 
Preliminary microwell-coating test using FITC labelled 20 kDa 
amelogenin 
 
? 
(1) FITC- 20 kDa amelogenin in binding buffer
(Incubation overnight at room temperature or 4°C) 
(2) Washing
(3) Blocking
(4) Washing
(5) Fluorescence detection
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After carrying out the incubation, blocking and washing steps (as summarised in 
Figure 58, p. 185) the fluorescence readings were recorded (Figure 59, p. 186). The 
data obtained were plotted as averages of 3 repeats. For all conditions, the 
fluorescence detected increased with increasing initial concentration of the FITC-
labelled 20 kDa amelogenin added to the microwells. With PBS (pH 7.4) and Na2CO3 
(pH 9) based binding buffers, fluorescence approached a plateau at around 5 µg/mL 
FITC-labelled 20 kDa amelogenin and the amount of protein adsorbed appeared to be 
greater at room temperature. In contrast, when TBS (pH 7.2) was used as the binding 
buffer, a clear plateau region, indicative that the microwell surface had been saturated, 
was not evident and the fluorescent signal continued to increase with increasing initial 
concentration of FITC labelled 20 kDa amelogenin added to the microwells. 
The data were subjected to OriginPro curve-fitting in order to estimate parameters 
such as the concentration at which half-‘saturation’ (C1/2) occurs and the maximum 
fluorescence signal achieved. The optimum models for incubations in PBS (pH 7.4) 
and Na2CO3 (pH 9) found were sigmoidal/growth curves (Hill and Bolzmann) while an 
asymptotic based model best fitted the data for TBS (pH 7.2). The parameters 
generated by the models are reported in Table 10. 
Table 01  Comparison of buffers and incubation temperatures used to coat 
microwells with FITC labelled 20 kDa-amelogenin. This table compares the 
parameters generated by the fitting models (Figure 59). C1/2 is the 
concentration at which, in theory, the signal would be half of the saturation 
value; and the maximum signal, ‘Signal max’ is the signal at saturation. 
Standard deviations are specified between brackets below values reported. 
Buffer PBS  
Bolzmann or Hill 
TBS 
Asymptote 
Na2CO3 
Hill 
Temperature Room T 4°C Room T 4°C RoomT 4°C 
C1/2 (µg/mL) 2.368 
(±0.281) 
2.211 
(±0.138) 
10.072 
(±5.160) 
7.470 
(±1.350) 
2.265 
(±1.099) 
1.742 
(±1.112) 
Signal max 
(units) 
0.077 
(±0.019) 
0.051 
(±0.016) 
0.119 
(±0.033) 
0.067 
(±0.005) 
0.076 
(±0.036) 
0.042 
(±0.020) 
The fluorescence signals were read at neutral pH in pure water which would 
theoretically maximise the signal obtained as fluorescein fluorescence is inhibited at 
low pH (Chen et al., 2008). Even so, the signals in this case were very weak (below 
0.1 on average), even though labelled protein was supposedly saturating the microwell 
surfaces. This raised doubts as to whether this method would be sensitive enough to 
accurately determine the binding of labelled protein free in solution to unlabelled 
protein immobilised on the microwell surfaces. This, together with the fact that the 
labelling chemistry protein modifies lysine residues (Maeda et al., 1969), which may 
- 188 -
modify protein behaviour, switched focus towards the second method of using the 
microplate format to measure amelogenin interactions. This second method was 
developed with the aim of monitoring the interaction of unlabelled protein free in 
solution to unlabelled protein pre-adsorbed to the microwell surfaces by the reduction 
in UV absorbance of the microwell contents as the free protein in solution interacted 
with the immobilised bait protein. 
- 189 -
3.2.2 Method 2: Monitoring the kinetics of amelogenin-amelogenin 
interactions as a function of a reduction in UV absorbance 
The second method involved simply incubating unlabelled amelogenin in UV 
transparent microplate wells and monitoring the decrease in UV absorbance 
(illustrated in Figure 60 below) as amelogenin initially adsorbed to microwell surfaces 
(protein-polystyrene binding) followed by binding of amelogenin remaining free in 
solution to the immobilised amelogenin covering the microwell surfaces (protein-
protein binding). Protein concentration in solution is usually monitored 
spectrophotometrically at 280 nm, which is the absorbance maximum of tryptophan 
and tyrosine. However, the EMD proteins (mostly amelogenins) used as a model 
protein are not particularly rich in these residues. Therefore absorbance was 
measured at 220 nm, which is within the range of wavelengths at which peptide bonds 
absorb maximally (Goldfarb et al., 1951)  
The results presented in this Section detail development of the microplate assay with 
regards to: 
(i) the effect of the starting EMD concentration on the EMD-polystyrene
binding equilibrium (Section 3.2.2.1),
(ii) the optimisation of the methodology to investigate the kinetics of EMD
protein-protein interactions (Section 3.2.2.2),
(iii) the effect of EMD proteins adsorbed to the bottom of the microwell and
attenuating the UV before it passes through the free proteins still in
solution potentially confounding the absorbance readings (Section 3.2.2.3)
(iv) attempts to block EMD adsorption to the bottom of the microwells to
circumvent the issue of UV attenuation by EMD adsorbing to the bottom of
the microwells (Section 3.2.2.4).
(v) an attempt to use the assay to study mutant p.Y64H and WT r-
amelogenins interactions (Section 3.2.2.5).
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3.2.2.1 Effect of initial EMD concentration on binding equilibrium: 
determination of a concentration required to saturate the 
microwell surfaces.  
As illustrated in Figure 60 above, the hypothesis behind the microplate assay was to 
monitor protein interactions between proteins free in solution and proteins already 
immobilised to the polystyrene microwell surfaces at saturating levels, by tracking the 
depletion of protein from solution.  
To optimise the starting concentration of EMD proteins required to saturate the 
polystyrene microwell surfaces, freshly prepared EMD solutions in PBS:1% acetic acid 
(290:1) ranging in concentration between 33.2 and 166 and µg/mL were added into 
empty microwells and left to incubate for 24 hours with the absorbance monitored at 1 
hour time-points. The absorbance measurements (n=6 corrected by blank subtraction) 
are plotted in Figure 61A1. The graph obtained showed that for all concentrations 
tested, the absorbance decreased over 24 hours and the decrease of absorbance was 
characterised by a fast drop (in one or two phases) within the first 10 hours of 
incubation, after which it stabilised, indicating that the binding reactions, whatever their 
nature (EMD-polystyrene and/or EMD-EMD), had reached equilibrium. SDS PAGE 
analysis with Coomassie Blue staining of the solutions left in the microwells after 24 
hours (Figure 61B) supported the spectrophotometric data in that protein concentration 
was decreased in these solutions after 24 hours incubation. 
  
                                               
1 Note: The absorbance measurements started 10 minutes after the EMD solution was 
prepared. As 10 minutes only represent 0.7% of the total 24-hour incubation, the 
starting time of absorbance measurement was considered to be the starting time 
of experiment. 
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Figure 16  (A) A range of initial EMD concentrations (33.2 – 166.0 µg/mL) was 
used to investigate EMD adsorption onto the microwell surfaces by measuring 
the depletion of EMD from solution spectrophotometrically over time. (B) To 
confirm that proteins were being removed from solution by adsorption to the 
microwell surfaces, the contents of solutions before incubation (“0h”) and at the 
end of incubation (“24h”) were analysed by SDS PAGE. All the incubations were 
carried out at room temperature, in PBS:1% acetic acid (290:1). Absorbance data 
shows mean ± SD, n=6. 
A 
B 
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For the highest starting EMD concentrations (99.6 to 166 µg/mL), the contents of the 
solutions at the end of incubation showed similar signals on SDS PAGE analysis with 
Coomassie Blue staining (Figure 61B). This implies that the maximum equilibrium 
concentration was reached. At lower initial EMD concentrations (33.2 and 66.4 µg/mL), 
in contrast, the proteins remaining in solution appeared less concentrated on analytical 
SDS PAGE (Figure 61B) suggesting that equilibriums were reached, but not to 
saturation. So, within for initial EMD concentrations of 99.6 to 166.0 µg/mL, the 
polystyrene surface was apparently entirely covered by EMD proteins; this is illustrated 
below in Figure 62. At 166.0 µg/mL the drop of EMD concentration to the saturation 
level resulted from the binding equilibrium of EMD proteins still free in solution to those 
immobilised on the polystyrene surface (EMD-EMD-polystyrene interactions).  
 
Figure 26  Diagram illustrating the hypothesis in respect of equilibrium reached 
in the microwells, at initial EMD concentrations of (A) 33.2 µg/mL, (B) 66.4 
µg/mL, (C) 99.6 µg/mL and (D) 166.0 µg/mL). (A-B) At lower initial EMD 
concentrations (33.2 and 66.4 µg/mL) the solutions at equilibrium appeared 
less concentrated as proteins bound to polystyrene. The equilibrium 
concentrations in solution were lower than at the initial concentrations of 
99.6 and 166.0 µg/mL. (C-D) At the higher initial concentrations (99.6 and 
166 µg/mL), the equilibrium concentration appeared to reach its maximum 
value, being identical in both cases (highlighted by a dashed red frame). 
The polystyrene surfaces were therefore assumed to be saturated, and 
within that range of starting concentration, the binding equilibrium 
reflected that of protein-protein binding, that is: between EMD proteins still 
free in solution and those covering the polystyrene.  
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As described in Figure 60 (p. 190), the initial hypothesis speculated that an initial 
binding phase, involving EMD-polystyrene interactions, would occur until the 
polystyrene microwell surfaces were saturated with protein and thereafter, a second 
binding phase comprising EMD-EMD interactions would become evident. However, 
there was no obvious inflection point identifying a time point when a distinct EMD-EMD 
binding phase became prominent over the initial EMD-polystyrene binding phase 
during which the microwell surfaces were brought to saturation. It may well be that 
these two phases may occur simultaneously, explaining why there was no obvious 
inflection points on the graphs (Figure 61A). It was concluded that it would not be 
possible to monitor protein loss from solution that was attributable to EMD-EMD 
interactions in isolation from the protein lost from solution due to EMD-polystyrene 
interactions occurring during saturation of the polystyrene microwell surfaces.  
In order to overcome this problem it was decided to temporally separate the saturating 
of the surface of the microwells from the subsequent phase involving EMD interactions 
with immobilised EMD saturating the microwells. Quite simply, at the end of the 
incubation to saturate the microwell surfaces, the depleted protein solution was 
discarded and replaced with fresh EMD solution. The reduction in UV absorbance of 
this fresh solution over time would then more likely reflect the kinetics of EMD binding 
to the EMD already immobilised and saturating the polystyrene microwell surfaces. 
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3.2.2.2 Optimisation of the methodology to characterise the kinetics of 
protein-protein (EMD-EMD) interactions  
As described above, it appeared to be impossible to track the initial phase of EMD 
immobilisation on to the polystyrene microwells separately from any subsequent EMD 
interactions between EMD still free in solution and the immobilised EMD. To monitor 
the EMD- immobilised EMD binding reaction in isolation, the assay was adapted by 
first  saturating the surface of the microwells during an initial incubation with EMD 
solution and then once saturation equilibrium was achieved the solution was discarded 
and replaced with fresh EMD solution for a second phase of incubation during which 
protein-protein interactions could be tracked. As illustrated in Figure 63, showing an 
hypothetical result, any decrease of absorbance /protein concentration in solution 
during the second incubation, could be assumed to reflect the rate of protein-protein 
binding rather than the combination of [(EMD-polystyrene)+ (EMD-immobilised EMD)] 
binding1.  
 
Figure 36  Hypothetical signal obtained while monitoring initial EMD-polystyrene 
interactions that saturate the microwell surfaces and subsequent EMD-EMD 
interactions occurring after the addition of fresh protein solution. The 
absorbance decrease in this second incubation period is assumed to be due to 
depletion of the solution due to the freshly added EMD interacting with the EMD 
already immobilised to the polystyrene surfaces during the initial saturation 
step.  
                                               
1 For clarification (and to relate back to the research question) the final aim of this thesis is not 
to compare protein-protein interactions with protein-polystyrene interactions but to 
compare WT r-amelogenin – WT r-amelogenin interactions with mutant p.Y64H r-
amelogenin – mutant p.Y64H r-amelogenin interactions. Here, while the protein-
polystyrene interactions were of no interest with regard to answering the research 
question; they are an incidental and necessary component of the method. 
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EMD proteins were dissolved at 150 µg/mL in PBS:1% acetic acid (284:1) (which is 
within the range known to saturate the microwell surfaces, Section 3.2.2.1 p. 192) was 
incubated at 37°C for 24 hours in the microwells (Phase 1) of polystyrene plates. At 
the end of the incubation period, aliquots were taken from the microwells for SDS 
PAGE analyses of the protein content of the solution, and the microwells were then 
emptied. Fresh solutions of EMD (at 150 µg/mL in PBS:1% acetic acid (284:1)) were 
added to the saturated microwells in order to track ensuing EMD-EMD binding 
(Condition “EMD-EMD-polystyrene”). At this point EMD was also added to fresh 
microwells as a control (“Ctr”, or Condition “EMD-Polystyrene”). The decrease in UV 
absorbance was then monitored over the next 24 hours as protein-protein interactions 
depleted the free protein free in solution (Phase 2). At the end of this second 
incubation period, aliquots were taken for SDS PAGE analysis.  
The decrease in absorbance recorded over the whole 48 hours (n=6), was corrected 
by blank subtraction and plotted as reported in Figure 64 along with the SDS PAGE 
analysis of protein remaining free in solution at the end of each of the two incubation 
periods. 
Analytical SDS PAGE confirmed that proteins were depleted from solution during the 
first 24-hour incubation period during which the microwells became saturated. After 24 
hours, this solution was removed and replaced with fresh EMD ready for the 2nd 
incubation period (24 – 48 hours) during which it was assumed that EMD-EMD 
interactions would occur that could be followed as a separate set of events from the 
initial protein-polystyrene interactions that occurred during the previous 24 hours. As 
would be expected, the SDS PAGE profile of the fresh EMD added after the initial 24 
hours was identical to the profile of the EMD added at time 01. However, after 48 hours 
the profile showed evidence of significant depletion that presumably occurred due to 
binding of free protein in solution to the previously saturated microwell surfaces. The 
protein profile associated with the control microwell, (comprising fresh EMD added to 
empty microwells at the 24 hour point) showed that the protein content was reduced at 
48 hours (this is essentially a repeat of the initial incubation designed to saturate the 
microwells – it simply facilitates comparing the reduction in absorbance arising from 
protein–protein binding in the 24-48 hour period to the protein surface binding). 
Remarkably, SDS PAGE analysis suggests that not all proteins adsorbed to the 
1 Note: The absorbance measurements started 4.5 minutes (Phase 1) and 8 minutes 
(Phase 2) after the EMD solutions were prepared. As 4.5 and 8 minutes represent 
respectively 0.55 and 0.3% of the 24-hour incubation periods, the starting times of 
absorbance measurements were considered to be the starting times of 
experiment. 
- 197 -
polystyrene surfaces, as low molecular weight (< 10 kDa) components remained at the 
same concentration after 24 hours of incubation on analytical SDS PAGE 
It is noteworthy that the plateau region of the plot representing EMD-EMD binding in 
phase 2 was at a higher absorbance level than the plateau region obtained for the 
control sample and the plateau region associated with phase 1 during which the 
microwell surfaces were being saturated with EMD. This difference, marked ΔAbs on 
Figure 64, is thought to have been due to the absorbance of EMD on to the bottom of 
the microwell during phase 1 attenuating the UV light passing through fresh EMD 
solution added for phase 2. The cause of this difference will be reviewed again later, 
below. 
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The data points shown in Figure 64 (p. 198), obtained during the second incubation 
period (and so describing EMD-immobilised EMD binding and EMD-polystyrene 
binding (control)), were replotted to represent the gain of protein by the polystyrene 
surface rather than the loss of protein from solution. The points were replotted as A0-
AT (where A0 = intial absorbance at the start of phase 2 and AT = absorbance 
measured at time T between the start and the end of phase 2). The curves were then 
subjected to curve-fitting using OriginPro software and sigmoid Hill fit was identified as 
the best fitting model (Figure 65 below). The parameters extracted from this model are 
compared in Table 11. The Hill equation suggested that the times required to reach 
half equilibrium (T1/2, identified in Hill equation as ‘K’) were similar both when EMD was 
interacting with immobilised EMD (EMD-EMD-Polystyrene) or when EMD was 
interacting directly with polystyrene (EMD-EMD-Polystyrene). This similarity could be 
because there is still a possibility that “Phase 1” might be a combination of EMD-
polystyrene and EMD-EMD binding. However, the depletion of free EMD from solution 
was greater when it was interacting with immobilised EMD compared to when it was 
interacting with polystyrene (with a ‘Maximum gain’ value predicted 14% higher).  
Figure 56  Depletion of EMD from solution (calculated as AT subtracted from A0 
and plotted against time) using Hill curve-fitting. The conditions compared 
show measurements of absorbance depletion after adding 150 µg/mL EMD 
solution to empty microwells (control - white marker), or to microwells 
previously saturated with EMD (solid black markers). The Hill model shows 
that both conditions had similar half-time rates, but apparent maximum 
gain was greater (14% higher) in the case of microwells previously 
saturated with EMD during phase 1. This difference could be due to 
adsorption by EMD already immobilised to the bottom of the microwell 
elevating the absorbance readings obtained during phase 2 when freshly 
added EMD was interacting with the immobilised EMD. 
- 201 - 
 
 
Table 11  Kinetics parameters predicted by OriginPro curve-fitting with Hill 
Sigmoid equation (displayed above in Figure 65), describing the gain of 
EMD proteins by polystyrene for EMD-EMD-Polystyrene and EMD-
Polystyrene (ctrl). 
Hill sigmoid Parameters Maximum gain T1/2 
EMD-Polystyrene (Ctr) 0.5199 0.5148 
EMD-EMD-Polystyrene 0.5939 0.5583 
 
The Hill equation describes the effect of ligand concentration on the proportion of 
macromolecules saturated by that ligand and was originally derived to describe the 
sigmoidal curve associated with haemoglobin binding (Hill, 1910). The Hill equation 
best fitted the plots and can be used to predict T1/2 and the maximum ordinate value 
reached (maximum gain). Any conclusions drawn need to be considered carefully as 
the Hill equation usually relevant to describe other types of reaction than those 
reported throughout the Section 3.2.2.  
To summarise, the data suggest that EMD-EMD interactions can be monitored 
quantitatively by spectrophotometric measurement of the depletion of free EMD 
remaining in solution. Obviously, the ultimate aim would be to compare WT and 
mutant p.Y64H r-amelogenins in the system by tracking the depletion of solubilised 
WT r-amelogenin as it interacts with immobilised WT r-amelogenin saturating the 
microwell surfaces. The kinetics of this process would then be compared to the 
kinetics associated with solubilised mutant p.Y64H r-amelogenin as it interacts with 
immobilised mutant p.Y64H r-amelogenin saturating the microwell surfaces. 
However, as described above, these experiments also raised the issue that EMD 
adsorbed to the bottom of the microwell during the saturation phase attenuates the UV 
light passing through the EMD solution placed in the microwell during phase 2 when 
the interaction of freshly added EMD with the immobilised EMD was being monitored 
(manifesting as ΔAbs shown in Figure 64, p. 198). Attempts to eliminate the effect of 
this confounding factor are the subject of the next Section. 
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3.2.2.3 Effect of proteins adsorbed on the bottom of the microwells on 
the binding assay performance 
As described in the previous Section, EMD immobilised to the bottom of the microwells 
of the polystyrene plates may potentially confound absorbance readings taken during 
phase 2 of the binding assay, when freshly added EMD was added to the microwells 
already saturated with immobilised EMD. This was investigated by measuring how the 
absorbance was affected by EMD binding to the bottom of the microwells. A solution of 
150 µg/mL EMD proteins in PBS:1% acetic acid (284:1) was left to incubate in the 
microwells at 37°C for 24 hours1. At the end of incubation, the solution was discarded 
from the microwells, immediately after which the absorbance was read again. The 
absorbance measurements (n=6 corrected by blank subtraction) are plotted in Figure 
66.  
 
Figure 66  The effect of EMD proteins bound to the bottom of the microwells on 
absorbance values. (1) Over an incubation period of 24 hours, the absorbance 
decreased by 0.49 units after addition of fresh EMD solution (150 µg/mL), 
presumably due to EMD proteins binding to the surfaces of the microwells. The 
incubation was carried out at 37°C, in PBS:1% acetic acid (284:1). (2) The 
absorbance read after discarding the solution (after incubation) was 0.24 units, 
which is due to the layers of EMD that adsorbed on the bottom of the 
microwells. Data shows mean ± SD, n=6. 
                                               
1 Note: The absorbance measurements started 4.5 minutes after the EMD solution 
was prepared. As 4.5 minutes represent only 0.3% of the 24-hour incubation 
period, the starting time of absorbance measurement was considered to be the 
starting time of experiment. 
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In the first 24 hours of incubation the absorbance dropped in a similar fashion to that 
observed previously (Figure 64), stabilising at a value of around 0.92. After discarding 
the EMD solution, the absorbance dropped to 0.24. This residual absorbance likely 
reflects EMD proteins that bound and accumulated onto the bottom surface of the 
microwells during the first 24 hours of incubation. This experiment confirms therefore 
that proteins bound to the bottom surface of the microwells had a significant effect on 
absorbance reading during the binding assays reported previously.  
An absorbance value of 0.24 is not negligible and in fact is close to the value 0.3, 
which is considered the ideal value to use for spectrophotometric measurements, as it 
is the point where 50% of the photons emitted by the light source are absorbed, which 
allows for readings of the highest precision. This actually opens up the possibility to 
compare the extent of binding or aggregation of WT and p.Y64H r-amelogenins by 
measuring the direct accumulation of the proteins on the bottom of the microwells 
rather than by measuring their depletion from solution. However, these would be end-
point measurements.  
For continuous kinetics analyses based on depletion of protein from solution, it would 
be preferable to eliminate the signal bias caused by EMD proteins bound to the bottom 
surfaces of the microwells. One method to achieve this would be to block the bottom 
surface of the microwells with a blocking protein; in a similar way to that employed 
when using microwell plates in classic ELISA where a blocking protein is applied after 
the target antigen has adsorbed to the microwells to prevent non-specific adsorption of 
detection antibodies to exposed microwell surfaces. As detailed in the next Section 
(3.2.2.4), a preliminary assay was therefore designed to test the efficacy of gold 
standard blocking proteins used in ELISAs for this purpose. 
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3.2.2.4 Attempts to block the microwells 
To prevent any EMD proteins from binding to the bottom of the microwells and 
affecting the absorbance values, the use of a blocker (covering the bottom surface of 
the microwells only) was trialled. This required the availability of an effective blocker 
that would prevent EMD proteins from binding to the surface of the microwells. Gold 
standard blockers BSA and NFDM were tested for this purpose.  
Blocking was carried out by adding 200 µL of 1% BSA or NFDM solutions into the 
microwells, incubating and washing before the addition of 200 µL EMD solution (made 
of EMD dissolved in PBS:1% acetic acid (290:1)). The volume of the blocking solution 
was the same as that of EMD solution in this preliminary test (to ensure that the 
surface covered by EMD solution could be entirely blocked, which would show 
whether blocking was effective). If that was indeed the case, then one should expect 
that EMD would not bind to the blocked microwell surfaces and instead remain in 
solution, providing a constant absorbance signal overtime (unlike the control with no 
blocker where absorbance would steadily decrease as the EMD adsorbed to the 
microwell surfaces). The theory for this is illustrated in Figure 67. 
Figure 76  Hypothetical signal expected over incubation time (orange dashed 
line) in microwells effectively blocked compared to control with no blocking. 
The absorbance measurements (averages, n=6, corrected by blank subtraction) over 
time1 are plotted in Figure 68A. Analytical SDS PAGE (Figure 68B) shows the content 
of the aliquots taken before incubation and at the end of incubation. 
1 Note: The absorbance measurements started 10 minutes after the EMD solution was 
prepared. As 10 minutes represent only 0.7% of the 24-hour incubation period, the 
starting time of absorbance measurement was considered to be the starting time 
of experiment. 
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Figure 86  Evaluation of the ability of the gold standard blocking proteins bovine 
serum albumin (BSA) and non-fat dry milk proteins (NFDM) to block EMD 
binding to microwell surfaces. (A) After adding fresh EMD solution, absorbance 
measurements in empty microwells (control) or in microwells previously 
blocked followed the same pattern, indicating that the blocking was not 
effective. (B) The solutions in the microwells at the end of the incubation were 
analysed using analytical SDS PAGE which confirmed  that the amount of EMD 
remaining in solution after 24h incubation, and showed that blocking the 
microwells with either blocking protein had little effect on the depletion of EMD 
from solution (i.e. did not block EMD adsorbing to the microwell surfaces). All 
the incubations were carried out at room temperature, in PBS:1% acetic acid 
(290:1). Absorbance data shows mean ± SD, n=6. 
 
The absorbance measurements (Figure 68A) show that blocking with neither BSA nor 
NFDM significantly altered depletion kinetics. Consistently, the results obtained on 
SDS PAGE analysis (Figure 68B) showed that under all conditions tested, the 
concentration of EMD decreased by similar levels leaving equal amounts of EMD left 
in solution at the end of incubation. These data together indicated that blocking the 
microwells was not successful. The possible causes for this are hypothesised and 
discussed in Section 4.2.2.3. (pp. 247 – 252). 
As described above, previous experiments (Section 3.2.2.3) showed that it was 
feasible to spectrophotometrically determine the amount of EMD adsorbed on to the 
bottom of the microwell after incubation with end point absorbance values (reflecting 
the amount of proteins that bound to the bottom of the microwell after 24-hour 
incubation of EMD solution), of 0.24. This value is close to the value 0.3, which as 
described above is the most accurate absorbance value for quantitative 
spectrophotometric measurements. At the beginning of the project, it was not 
A B 
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envisaged that enough protein could be adsorbed onto the microwell surface to be 
directly measured spectrophotometrically in this way. However, the fact that the 
accumulation of EMD on the microwell bottom could be measured directly, raised the 
possibility of comparing interactions between WT and mutant p.Y64H r-amelogenins 
simply by direct spectrophotometric measurement of the proteins accumulating on the 
microwell bottoms at the end of the incubation period.  
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3.2.2.5 Characterisation of the behaviour of WT and mutant p.Y64H r-
amelogenins in the microplate-based assay 
Throughout this thesis, the focus has been on the production, purification and use of 
His-tagged r-amelogenins (as the initial strategy was to use nickel affinity 
chromatography, the standard purification method for recombinant proteins, to obtain 
purified WT+His and Mut+His r-amelogenins) in protein-protein binding studies. However, 
during the course of the work it became clear that nickel chromatography was not 
completely suitable for use with these proteins and preparative SDS PAGE was able 
to produce purer fractions. This led to the realisation that nickel chromatography and 
the associated His-tag were not actually required as the initial acetic acid extraction 
and subsequent preparative SDS PAGE were sufficient to achieve a high degree of 
purification. A further advantage of using His-tag-free r-amelogenins is that the time-
consuming and costly His-tag cleavage step can be eliminated. To this end, a 
commercial company (Novoprotein Scientific, NJ, USA) was tasked with generating 
plasmids encoding WT and mutant p.Y64H r-amelogenins without His-tag, respectively 
“WT-His” and “Mut-His” r-amelogenins. However, this proved problematic and two 
separate batches of plasmids delivered during the final phase of the experimental work 
failed to result in the expression of protein for reasons unknown. A third batch of 
plasmids delivered during the write up phase of the thesis did express both WT-His and 
Mut-His r-amelogenins. Details regarding their sequences and the plasmid used are 
provided in Appendix A. Their identities were confirmed by mass spectrometry (see 
Appendix B) the spectra obtained showed high degree of purification with a clear 
peaks corresponding to r-amelogenins at 20160.10 Da for WT-His and 20134.2 to Mut-
His after acetic acid extraction (kindly performed by Dr Sarah Myers and Mr. Matthew 
Percival). WT-His and Mut-His r-amelogenins were tested along with WT+His and Mut+His r-
amelogenins in the microplate assays based on simply measuring the absorbance of 
protein accumulating on the bottom of the microwells directly (see Section 3.2.2.3 pp. 
202 - 203).  
WT+His and Mut+His r-amelogenins were used in the uncleaved state due to time 
constraints at this late stage in the research. The use of His-tagged proteins in 
functional studies is widely practiced with the assumption that the tag has no effect on 
protein conformation or function (Chant et al., 2005) and there are several examples 
where His-tagged enamel proteins have been used in functionality studies (e.g. His-
tagged amelogenin, ameloblastin and enamelin were used to investigate interaction of 
these enamel proteins with fibronectin (Beyeler et al., 2010) and His-tagged 
ameloblastin was used to investigate growth factor-like activity of ameloblastin and its 
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effect on the effect on cell attachment and proliferation of periodontal ligament cells 
(Zeichner‐David et al., 2006).  
Freshly prepared r-amelogenin solutions (comprising 7.45 µM solutions of WT-His, Mut-
His, WT+His, Mut+His r-amelogenins in PBS: 1% acetic acid at 216.4:1 ratio) were added 
to empty polystyrene microwells and left to incubate for 24 hours at 37°C. The 
absorbance of the microwells (n=6 corrected by blank subtraction) was tracked over 
24 hours and the absorbance measurements are plotted in Figure 69 (p. 209). The 
microwell contents were then discarded and the absorbance attributable to protein 
bound to the bottom surface of the microwells (see Section 3.2.2.3 p. 202 for further 
explanation) was measured as reported in Figure 70 (p. 210); The contents of the 
solutions before (“0h”) and after (“24h”) incubation were analysed using Analytical 
SDS PAGE with Coomassie Blue staining (Figure 69B) with the staining intensity of 
the protein bands compared by gel densitometry.  
For WT-His, both absorbance measurements and analytical SDS PAGE showed a 
minor decrease (~8-10%) of r-amelogenin concentration in solution after 24 hours 
incubation and in keeping with this, the absorbance due to bound protein on the 
bottom of the microwells was close to zero (Figure 70). This data indicated that WT-His 
r-amelogenin did not associate with the polystyrene surface of the microwells but
instead remained in solution. In contrast, Mut-His, WT+His and Mut+His r-amelogenin all
disappeared from solution over 24 hours incubation, presumably as they associated
with the polystyrene microwell surfaces. For Mut-His, the absorbance appeared to
decrease by ~37% over the 24 hours incubation period and SDS PAGE showed that
the staining intensity of the 24 kDa band decreased by ~45% over that time (Figure
69). As for WT+His and Mut+His r-amelogenins, the absorbance decrease over 24 hours
was even greater, in that the absorbance appeared to decrease by ~62% and the
staining intensity of the 27 kDa (His-tagged) bands was reduced by ~80% after 24h
incubation on analytical SDS PAGE (Figure 69). The absorbance measurements of
what was left on the bottom of the microwells demonstrated average readings ranging
between 0.16 and 0.29 units (Figure 70), which confirmed that the Mut-His, WT+His and
Mut+His r-amelogenins associated with the polystyrene surface of the microwells in
contrast to WT-His, which did not. The result is summarised in Table 12.
Table 21  Comparison of binding behaviours of WT-His, Mut-His, WT+His, Mut+His r-
amelogenins in the microplate based assay. Summary of the data obtained 
in the Section 3.2.2.5. 
r-Amelogenin Associates with microwell surface? 
WT-His No 
Mut-His Yes 
WT+His Yes 
Mut+His Yes 
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Figure 07  Comparison of absorbance readings in the microwells after discarding 
the r-amelogenin solution (after 24-hour incubation, see Figure 69A) for WT 
and mutant p.Y64H r-amelogenins ± His-tag. Solid-line arrows reflect the 
difference of absorbance with the absorbance at the end (24 hours) of 
incubation (Figure 69A). Dashed-line arrows reflect the difference of 
absorbance with the absorbance at the beginning of incubation (Figure 
69A). The initial and final absorbance values of incubation (Figure 69A) are 
indicated, as A0 and A24h. Absorbance data shows mean ± SD, n=6. 
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Figure 69A suggested that both WT+His and Mut+His disappeared from the solution more 
rapidly than WT-His and Mut-His r-amelogenins. The data in Section 3.2.2.3 (p. 202) 
previously opened up the possibility of comparing the extent of binding or aggregation 
of WT and mutant p.Y64H r-amelogenins by measuring the direct accumulation of the 
proteins on the bottom of the microwells rather than by measuring their depletion from 
solution. It is important to bear in mind that this does not account for an exact 
comparison of protein binding kinetics but rather a preliminary descriptive estimation 
as the proteins binding to the bottom of the microwells mask the actual kinetics of 
protein depletion from solution. 
As it was done previously in Section 3.2.2.2 (Figure 65 p. 200) the data obtained in 
this Section (Figure 69A) were replotted1 to represent the gain of protein by the 
polystyrene surface (A0-AT (where A0 = initial absorbance, time 0 and AT = absorbance 
measured at any time T between the start and the end of incubation), which allowed all 
curves to start from the same point, at abscissa and ordinate = 0. The graphs obtained 
are shown in Figure 71 below. The curves representing Mut-His, WT+His and Mut+His, 
subjected to curve-fitting using OriginPro software, successfully fitted the Hill sigmoid 
model (previously used in Figure 65 to analyse EMD depletion from solution). The data 
points representing WT-His were not subjected to curve-fitting because, as explained 
previously, WT-His did not significantly disappeared from solution.  
The models generated for Mut-His, Mut+His and WT+His recombinants (Figure 71) 
predicted that the maximum gain of r-amelogenin to polystyrene surface was ~40-60% 
higher with the His-tagged r-amelogenins Mut+His, WT+His, and also, the depletion pace 
was faster, with the time taken to reach half saturation predicted to be 15 minutes with 
the His-tagged r-compared with 41 minutes for the non-tagged Mut-His recombinant.  
This model highlights, despite the ‘masking’ effect of proteins binding to the bottom of 
the microwells, that:  
 In His-tag-free r-amelogenins, the single amino acid change of a tyrosine into a
Histidine caused a significant gain of protein by the polystyrene surface, which
can fit to a Hill sigmoid curve with R2=0.996.
 However, the addition of a His-tag in the primary sequence in both WT and
mutant r-amelogenins increased the amplitude and pace of gain of proteins on
polystyrene surfaces to such an extent that both curves representing WT+His
and Mut+His had similar shapes. Moreover, WT+His r-amelogenin appeared to
adhere to the polystyrene surface more than Mut+His r-amelogenin.
1 Note: The absorbance measurements started 7 minutes after the EMD solution was 
prepared. As 7 minutes represent less than 0.5% of the 24-hour incubation period, 
the starting time of absorbance measurement was considered to be the starting 
time of experiment. 
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Chapter 4   Discussion 
4.1 Purification strategy used to obtain purified r-amelogenin: 
preparative SDS PAGE identified as the most effective 
technique 
4.1.1 Purification of r-amelogenin 
As described in the literature review (Section 1.3.5 p. 84), efforts have been made 
previously to purify r-amelogenin. One of the most frequently published purification 
methods for producing recombinant mouse M180 amelogenin expressed by E. coli 
starts with cell lysis under denaturing conditions (6 M guanidine hydrochloride) 
followed by centrifugation, precipitation with ammonium sulphate and preparative C4 
reverse phase column chromatography in 0.1% trifluoric acid/acetonitrile (Simmer et 
al., 1994). This method has been widely used to provide r-amelogenin for use in in 
vitro studies e.g. characterising amelogenin assembly into nanospheres (Moradian-
Oldak et al., 1994). The method had the advantage of not being dependent on a His-
tag but did not provide r-amelogenin at single band purity on SDS PAGE. Moradian-
Oldak et al (1994) noted that the methodology generated mouse recombinant 
amelogenins that co-eluted with contaminating E. coli proteins. This purification 
method originally yielded 4–11 mg purified proteins (in acetonitrile) per litre cell culture 
(Simmer et al., 1994). The method was subsequently modified by adding a His-tag 
(MRGSHHHHHHGS) to the N-terminal with the introduction of a nickel column affinity 
chromatography step. With this method the yield was increased to 70 mg/L cell culture 
(Buchko et al., 2013). 
Nickel column affinity chromatography was used by others to purify r-amelogenins for 
use in functional or structural studies (Moradian-Oldak et al., 2000, Taylor et al., 2006). 
The purity of the r-amelogenin obtained directly by nickel column chromatography was 
not commented on by Moradian-Oldak et al (2000) while the fractions obtained by 
Buchko et al. (2013), comprising His-tagged r-amelogenin were subjected to further 
purification using reverse phase C18 columns to increase purity (Buchko et al., 2013). 
Later reports provided more detailed analyses and assessments of the ability of nickel 
column affinity chromatography to purify r-amelogenin: these include a publication 
(Taylor et al., 2006) and this thesis. The relevance of nickel column to purify r-
amelogenin is discussed in greater detail in Section 4.1.2.2 (pp. 218 – 224). 
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Other purification methods include salting out (e.g. using ammonium sulphate) 
followed by cation exchange chromatography and direct use of reverse phase 
chromatography. These were used to obtain rP172 and rM179 to characterise their in 
vitro cleavage by MMP-20 (Ryu et al., 1999).  
A recent method based on the preferential solubility of amelogenin in acetic acid 
allowed the extraction and significant enrichment of r-amelogenins from bacterial 
pellets (Svensson Bonde and Bulow, 2012). This method is discussed in greater detail 
in Section 4.1.2.1 (pp. 216 - 217). The solubility of amelogenin in acetic acid was also 
used to extract native amelogenins from porcine teeth (Wang et al., 2018) but the 
method would also have extracted the other enamel matrix proteins such as 
ameloblastin and enamelin which are equally soluble in acetic acid. The use of acetic 
acid as a selective solubilising agent for r-amelogenin, published by Svensson Bonde 
and Bulow (2012) negated the need for His-tag based purification and provided a 
simple route to His-tag-free r-amelogenin preparations for use in functional studies and 
the methodology has since been used by others. For example, Buchko and Shaw, 
(2015) used it to prepare isotopically-labelled amelogenin for NMR analyses (Buchko 
and Shaw, 2015). They extracted r-amelogenin from E. coli in acetic acid and dialysed 
the extracts against acetic acid to remove salts and reduce the ionic strength to limit 
amelogenin aggregation. The r-amelogenin was then further purified using reverse-
phase HPLC. Dialysis and HPLC improved the purity of the fractions but contaminants 
were still visible on analytical SDS PAGE after Coomassie Blue staining. Buchko et al. 
(2015) adjusted their protocol by using 6M guanidine hydrochloride for E. coli cell lysis, 
instead of 2% acetic acid and reported that the amelogenin yield was improved but 
more contaminants were co-extracted. 
To date then, the extraction and purification of r-amelogenin is complex with most 
reported methodologies using denaturants such as guanidine hydrochloride (Simmer 
et al., 1994, Taylor et al., 2006, Buchko and Shaw, 2015) or urea (Taylor et al., 2006) 
to achieve an initial extraction of r-amelogenin followed by further downstream 
purification steps.  
This thesis tested a panel of purification methods to extract and purify r-amelogenin 
from E. coli. The first priority was to define a method that could provide r-amelogenin 
at single-band purity on analytical SDS PAGE after silver staining in sufficient amounts 
for use in downstream functionality studies. Single-band purity on analytical SDS 
PAGE with silver staining generally reflects a satisfactory purity due to the high 
sensitivity of silver staining: it has a detection limit “100 times lower than that of 
Coomassie Blue staining” as reviewed by Shevchenko et al (1996) (Shevchenko et al., 
1996) and currently the silver staining kit (cat no. 24612, ThermoFisher Scientific, 
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Leicestershire, UK) employed in this thesis allows for detection down to 0.25 ng 
proteins per band.  
 
4.1.2 Purification methods tested to determine the optimum 
purification of r-amelogenin 
This section critically discusses: (i) the optimisation of acetic acid extraction of His-
tagged mouse r-amelogenin (Section 4.1.2.1), (ii) His-tag-affinity nickel column 
purification of His-tagged mouse r-amelogenin (Section 4.1.2.2), (iii) SEC purification 
of His-tagged mouse r-amelogenin (Section 4.1.2.3) and (iv) the use of preparative 
SDS PAGE to purify His-tagged mouse r-amelogenin (Section 4.1.2.4). The 
purification strategies tested are summarised below in Figure 72. 
 
 
Figure 27  Strategies tested to extract and purify mouse r-amelogenin from E. coli. 
(i) The extraction of r-amelogenin in acetic acid, based on its preferential 
solubility in acidic, was optimised. Strategies for optimisation are 
discussed in Section 4.1.2.1. After optimisation of step (i) was achieved, 
the acetic acid extract (lyophilised, desalted and lyophilised) was subjected 
to secondary purification, to isolate r-amelogenin. The purification 
methods tested were (ii) the gold-standard nickel column chromatography 
method, discussed in Section 4.1.2.2, (iii) SEC, discussed in Section 4.1.2.3 
and (iv) preparative SDS PAGE, discussed in Section 4.1.2.4. 
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4.1.2.1 Acetic acid extraction effectively reduced bacterial contamination 
The acetic acid extraction technique reportedly producing r-amelogenin from E. 
coli at > 95% purity in a single purification step was previously published (Svensson 
Bonde and Bulow, 2012). This technique is based on the simple premise 
that amelogenin is soluble in 3% acetic acid at 80°C whereas E. coli proteins are 
insoluble under these conditions. First, the volume of acetic acid for extraction was 
optimised (Section 3.1.1.2.1, p. 138). This optimisation is also referred to as 
“optimisation of ‘weight of E. coli to volume of acetic acid”) as Svensson Bonde and 
Bulow (2012) reported that the total yield increased with increasing volumes of acetic 
acid (using 0.035 - 0.35 g/mL acetic acid) without, however, providing any specific 
details. The extractions using 0.33 and 0.17 g/mL acetic acid provided a good yield 
(Section 3.1.1.2.1, pp. 138 - 139). and conveniently small working volumes. Increasing 
the ratio of solvent to solute allows more solute to enter the solution until equilibrium is 
re-established. Therefore extractions using 0.033 and 0.0033 g/mL acetic acid were 
predicted to yield more dilute extracts of larger volume that contained a greater 
absolute amount of amelogenin. Indeed, taking the larger dilution factor into account 
(Figure 36B p. 139), the highest yield of amelogenin was obtained with 0.0033 g/mL 
acetic acid. This is in agreement with the observation by Svensson Bonde and Bulow, 
that the total extraction yield increased with increasing volume of acetic acid 
(Svensson Bonde and Bulow, 2012). However, although extraction at 0.0033 g/mL 
provided an optimum yield, the excessive dilution led to handling problems and made 
downstream tasks such as lyophilisation more difficult. Therefore, extraction at 0.033 
g/mL acetic acid was chosen as the preferred option since the yield was acceptable 
and extraction volume was manageable. 
While Svensson Bonde and Bulow (2012) reported that the final fraction purity was 
higher when only heat treatment was used for cell lysis/purification, compared to when 
sonication was used, the results obtained (Section 3.1.1.2.2, pp. 140 - 141) showed 
that ultrasonic mixing did not make any significant difference to sample purity. In 
contrast to Svensson, Bonde and Bulow (2012)’s statement that “sonication is not very 
feasible in large scale”, it was found that ultrasonication facilitated mixing and 
extraction of r-amelogenin Mut+His r-amelogenin in particular (Section 3.1.1.2.2, p. 
140). However, Svensson Bonde and Bulow (2012) did not specify how sonication was 
carried out and the equipment used in this thesis (see Section 2.1.1.2.2, p. 95) may 
have been more powerful given that it was a sonic probe specifically designed to 
disrupt tissue. The results obtained in Section 3.1.1.2.2 supported Svensson Bonde 
and Bulow (2012)’s finding that heating the sample improved the extraction of r-
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amelogenin (Figure 37B, p. 141). Heat treatment is a convenient cell lysis method to 
extract recombinant proteins from E. coli cells (Middelberg, 1995). By disrupting the 
membranes it facilitates the release of proteins. It may, however, denature some 
proteins (Kim et al., 2000) but to extract r-amelogenin, it was assumed to be safe to 
use as enamel matrix derivatives were reported to resist heat treatments “without 
precipitating (Gestrelius et al., 2000) or losing their bioactivities” (Nagano et al., 2004), 
as reviewed by Svensson, Bonde and Bulow (2012).  
Following the optimisation of volume, mixing regimen and temperature, the protocol 
established was carried out as shown in Section 3.1.1.2.3 (p. 143). While the volume 
of acetic acid was optimised for the extraction of r-amelogenin WT+His (Section 
2.1.1.2.1, p. 95), the mixing regimen and temperature were optimised for r-amelogenin 
Mut+His (Section 2.1.1.2.2, p. 95). For consistency, the optimisations should have been 
ideally carried out for both r-amelogenin WT+His and Mut+His, but at this stage this was 
not important since the final extraction method adopted (Section 3.1.1.2.3, p. 143) was 
highly reproducible for both r-amelogenins, WT+His and Mut+His. 
The mass spectrometry analysis of the extracted WT+His (lyophilised, desalted and 
lyophilised) showed 5 major peaks ranging from 24732.99 Da to 24812.20 Da (Figure 
39, p. 145). According to the data generated using the Protparam tool (Gasteiger et 
al., 2005) the first peak at 24732.99 Da corresponded to the predicted molecular 
weight of r-amelogenin WT+His but minus 131 Da, indicating that the N-terminal 
methionine had been removed by E. coli methionine aminopeptidase (Ben-Bassat et 
al., 1987), an issue that was previously reported in respect of the expression of r-
amelogenins (Simmer et al., 1994, Svensson Bonde and Bulow, 2012). The other 
peaks, which are found 16 Da apart, correspond most likely to oxidised species (see 
Table 8, p. 144). The origin of this oxidation is unclear but as described in the Material 
and Methods (Section 2.1.1.2.3, p. 97) the acetic acid extract was lyophilised, desalted 
and lyophilised again before being subjected to mass spectrometry. These additional 
steps may cause oxidation of some amino acids (Challener, 2017). 
The spectra obtained (Appendix B) for WT-His and Mut-His extracted in acetic acid 
(extraction kindly performed by Dr Sarah Myers) and subjected directly to mass 
spectroscopy without prior lyophilisation showed a high degree of purification with a 
clear peak corresponding to r-amelogenin at 20160.10 Da for WT-His and 20134.2 to 
Mut-His, which also appeared to have lost the N-terminal methionine (Appendix B). Less 
pronounced peaks at 20175.30 and 20149.60 Da were visible on the spectra for WT -His 
and Mut-His respectively again suggesting possible oxidation, though at much lower 
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levels than those observed for r-amelogenin WT+His (Section 3.1.1.2.3, pp. 144 – 145). 
The His-tagged r-amelogenins may be more sensitive to oxidation simply because 
they were subjected to desalting and lyophilisation and of course the His-tag contains 
3 methionines and 7 histidines, which are amino acids sensitive to oxidation (Uchida, 
2003, Ji et al., 2009): 
“MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSLEVLFQ”  
Figures 36 (p. 139) and 37 (p.141) indicated that the r-amelogenin made up > 90% of 
the initial acetic acid extract. This initial extraction was effort- and cost-effective, and 
provided an extremely efficient clean-up, generating hundreds of milligrams of extract 
out of 10 g of E. coli (wet weight cells harvested). However, as contaminants were 
clearly detectable by analytical SDS PAGE with Coomassie Blue and silver staining 
techniques, secondary purification steps were needed to reach optimal purity for use in 
binding studies: (i) nickel column chromatography (Section 4.1.2.2), SEC (Section 
4.1.2.3) and (ii) preparative SDS PAGE (Section 4.1.2.4). 
4.1.2.2 His-tag purification was not an optimum method to purify r-
amelogenin 
Following expression in E. coli and extraction in acetic acid, which removed major 
contaminants, the r-amelogenin extract was subjected to standard nickel column 
purification. The procedures tested are summarised in Figure 73 (p. 220) (omitting all 
lyophilisation and desalting steps for clarity). 
4.1.2.2.1 Principles and general considerations of recombinant proteins His-tag 
purification  
Nickel affinity chromatography is a popular methodology to purify recombinant proteins 
by including a fusion tag at the N- or C-terminal. The His-tag is widely used (Hochuli et 
al., 1988) as the imidazole rings of histidine are electron donors that allow for the 
formation of co-ordination bonds with the immobilised nickel (Terpe, 2003) which 
preferentially retains the recombinant His-tagged protein on the column. The method is 
simple and in its basic form consists of expressing His-tagged proteins in a given 
organism (e.g. bacteria) followed by a first round of nickel column chromatography to 
remove bacterial contaminants. The His-tagged recombinant protein is isolated and 
then the His-tag can be removed enzymatically if a suitable cleavage site is included in 
the His-tag sequence. A second round of nickel column chromatography removes any 
remaining uncleaved recombinant protein. It may also remove the protease if this also 
carries a His-tag, yielding a purified product. The inclusion of His-tag in r-amelogenins 
for purification purposes has been previously reported (Moradian-Oldak et al., 2000, 
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Tarasevich et al., 2007, Tao et al., 2015). Researchers reported that the addition of a 
His-tag into the sequence of mouse full-length r-amelogenin rM179 increased its 
expression levels in E. coli, which they proposed to be due to the fact that the His-tag 
increased the hydrophilicity of the r-amelogenin (Svensson et al., 2006). 
The choice of buffers for nickel column chromatography used is critical since the 
protein of interest needs to be solubilised in order for it to be applied to, and bind to, 
the nickel column and then to be successfully eluted and isolated from bacterial 
contaminants. His-tag cleavage buffers were also optimised to obtain a maximum 
enzyme activity. The enzyme-to-protein ratio was optimised (see Appendix C) so as to 
provide a maximum yield with minimum amounts of protease.  
However, r-amelogenin was never successfully purified by the His-tag-based 
purification protocol, as illustrated in Figure 73 and discussed, below. 
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Figure 37  Summary of His-tag-based purification procedures tested and 
optimisations carried out. Standard nickel column chromatography 
included an initial round of nickel column chromatography before His-tag 
removal. His-tag removal was not 100% efficient and remaining uncleaved 
amelogenins and enzyme had to be removed by a second round of nickel 
column chromatography. However, a second round of nickel column 
chromatography after His-tag removal did not completely isolate cleaved  r-
amelogenin from uncleaved  r-amelogenin.  
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4.1.2.2.2 Partial efficiency of His-tag removal from r-amelogenin 
From Figure 43 (p. 153) it is clear that the efficiency of the His-tag cleavage from r-
amelogenins was considerably less than 100%. Analytical SDS PAGE of the cleavage 
reaction mixture showed the very clear presence of cleaved r-amelogenin at 24 kDa 
and uncleaved r-amelogenin at 27 kDa. Increasing the concentration of cleavage 
enzyme or increasing the incubation time had little effect on improving the efficiency of 
the cleavage reaction, as described in Appendix C.  
Previous reports also indicated that cleavage of the His-tag from r-amelogenin is 
inefficient. For example, Taylor et al (2006) used rTEV protease to cleave His-tags 
from r-amelogenin (Taylor et al., 2006) and noted the poor yield obtained. In general, 
cleavage efficiency of other recombinant proteins was as low as 50% and this was 
suggested to be caused by steric hindrance blocking the cleavage site and preventing 
enzyme access (Waugh, 2011). Amelogenin aggregation at physiological pH and 
temperatures has been well studied (Moradian-Oldak et al., 1994, Moradian-Oldak et 
al., 1995, Moradian-Oldak et al., 1998, Simmer et al., 1994, Tan et al., 1998, 
Wiedemann-Bidlack et al., 2007, Aichmayer et al., 2010) and amelogenin-amelogenin 
interactions or intra-amelogenin interactions may cause the His-tag cleavage site to be 
inaccessible to the HRV3C cleavage enzyme under certain conditions. An attempt was 
made in this thesis to increase the solubility of the r-amelogenin by carrying out the 
cleavage reaction at pH 8 and 9; conditions known to reduce the tendency of 
amelogenin aggregation (Tan et al., 1998). However, as described in Appendix D 
increasing the pH to 8 or 9 did not help matters.  
4.1.2.2.3 Nickel column purification did not successfully isolate r-amelogenin. 
Ideally, cleaved r- amelogenin, lacking a His-tag, should not be retained on the nickel 
column and is expected to elute in the flow-through fraction. In contrast, the uncleaved 
r-amelogenin, cleaved His-tag and His-tagged HRV3C protease should bind to the 
column. However, Figure 44 (pp. 156 - 157) showed that the second round of nickel 
chromatography was unable to completely separate cleaved from uncleaved r-
amelogenin because the cleaved r-amelogenin appeared to show significant affinity for 
the column. It could be eluted by increasing the imidazole concentration to 60 mM but 
this resulted in the co-elution of uncleaved r-amelogenin and other contaminants 
(reproduced in Figure 74A below). Another secondary nickel column purification was 
performed independently by Dr Sarah Myers using a more refined stepped imidazole 
gradient (at 50, 60, 70, 90, and 200 mM imidazole) in the second round of nickel 
column chromatography. SDS PAGE analysis of these fractions, shown in Figure 74B, 
showed that cleaved and uncleaved r-amelogenins were visible in all eluted fractions 
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with the higher concentrations of imidazole eluting increased amounts of uncleaved r-
amelogenin . 
 
 
Figure 47  Comparison of isolation efficiency of cleaved r-amelogenin by (A) two-
round nickel affinity chromatography or (B) second round of Nickel column 
chromatography with ‘refined’ stepped elution at 50, 60, 70, 90, 200 mM 
imidazole. The cleaved r-amelogenin, which does not carry a His-tag, was 
not collected in the flow-through as expected but was eluted by increasing 
the concentration of imidazole to 50 mM and higher concentrations. At 50 
mM imidazole, the bulk of cleaved r-amelogenin was collected with a minor 
trace of uncleaved r-amelogenin. At 60 and 70 mM imidazole, significant 
amounts of cleaved r-amelogenin were clearly co-eluted with the uncleaved 
r-amelogenin, with a higher proportion of uncleaved r-amelogenin at higher 
concentrations of imidazole. The bulk of uncleaved r-amelogenin was 
eluted at 200 mM imidazole . A trace amount of HRV3C protease (His-
tagged) is visible in elution fractions at 50 - 200 mM imidazole. Figure 74 is 
taken from Gabe et al, 20171; the data for Figure 74B was acquired by Dr 
Sarah Myers. 
  
                                               
1 Figure 74 is reproduced from Gabe et al. (2017) under the terms of the Creative 
Commons license CC BY (https://creativecommons.org/licenses/by/4.0/). 
- 223 - 
 
 
 Retention of His tag free cleaved r-amelogenin to the nickel column 
The reason why the cleaved r-amelogenin still has affinity for the nickel column may 
be due to the high histidine content of amelogenin (14 residues in M180). Moreover, 
as illustrated below, amelogenin includes di- and tri-histidine repeats which may act as 
a pseudo His-tag and cause non-specific binding to the nickel column: 
MPLPPHPGSPGYINLSYEVLTPLKWYQSMIRQPYPSYGYEPMGGWLHHQIIPVLSQQ
HPPSHTLQPHHHLPVVPAQQPVAPQQPMMPVPGHHSMTPTQHHQPNIPPSAQQPF
QQPFQPQAIPPQSHQPMQPQSPLHPMQPLAPQPPLPPLFSMQPLSPILPELPLEAWP
ATDKTKREEVD 
If amelogenin is an unstructured protein as described in Section 1.2.1.3.2 (p.19) the di- 
and tri-histidine repeats could be in close proximity in space and form co-ordinate 
complexes with the nickel in a similar fashion to the hexahistidine motif making up the 
His–tag even though they may be distant from each other in terms of their linear 
position in the amelogenin primary sequence.  
As described in the Section 1.2.2.1 (pp. 20 - 21) amelogenin has a strong tendency to 
aggregate and one other explanation for the retention of cleaved His-tag free r-
amelogenin on the nickel column is that the cleaved r-amelogenin is simply interacting 
with the uncleaved r-amelogenin that is strongly bound to the column by virtue of its 
His-tag. However, this is unlikely since the imidazole elution buffers were 4 M with 
respect to urea; a chaotropic agent well known for its ability to solubilise amelogenin 
(Eggert et al., 1973, Brookes et al., 2002). In addition, from Figure 73B it is clear that 
cleaved r-amelogenin is eluted with 50 mM imidazole whereas the uncleaved r-
amelogenin remains bound to the column. Imidazole is not a chaotropic agent and this 
data indicates that the cleaved r-amelogenin was being displaced from the nickel 
column by competing imidazole molecules as opposed to being solubilised from an 
aggregated state involving column-bound uncleaved r-amelogenin. 
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To recap, His-tag-based purification methodology was not suitable to obtain r-
amelogenins for future uses because: 
1) His-tag cleavage with HRV3C protease was not efficient. 
2) Cleaved r-amelogenin could not be isolated from uncleaved r-amelogenin using 
nickel column chromatography due to the apparent interaction of cleaved r-amelogenin 
with the nickel column.  
Although nickel chromatography is the standard methodology for purifying His-tagged 
proteins, it is reported elsewhere that the methodology can provide satisfactory yields 
of recombinant proteins but the purity of the proteins obtained is not always ideal 
(Lichty et al., 2005).  
Practically, the necessary inclusion of urea in the buffers to solubilise the amelogenin 
is not compatible with the enzymatic removal of the His-tag. The urea denatures the 
HRV3C enzyme, and according to the manufacturer, will completely inhibit its activity. 
This incompatibly required the use of an additional time-consuming desalting step prior 
His-tag removal (see Figure 41 p. 148 in Section 3.1.2.1). Since His-tag-based 
purification was not an optimum method to obtain r-amelogenin for functional studies, 
other purification techniques were tested and optimised. Their respective efficiencies 
are addressed and compared in the Sections 4.1.2.3 and 4.1.2.4. 
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4.1.2.3 Size exclusion chromatography on Bio-gel P columns did not 
isolate r-amelogenin from lower molecular weight contaminants  
SEC separates proteins within a mixture according to their apparent molecular weights 
or more accurately according to their hydrodynamic radii (Grubisic et al., 1967). Larger 
molecules are excluded from the column matrix and quickly pass through the column 
carried along in the mobile phase and are eluted first while lower molecular weight 
components with a smaller hydrodynamic radius can diffuse from the mobile phase 
into the beads. Their progress through the column is retarded and depends on their 
rate of diffusion in and out of the beads.  
Figures 46 - 48 (Section 3.1.2.2, pp.163, 165, 166) showed that none of the SEC 
methods employed to isolate r-amelogenin from bacterial contaminants present in the 
crude acetic acid extracts was successful; this is despite adjusting the column pore 
size and the column length. The very first fraction to elute from the columns was 
reasonably pure r-amelogenin but the bulk of the r-amelogenin was eluted over 
several fractions and these fractions were contaminated with bacterial low molecular 
weight contaminants (previously extracted, with r-amelogenin, in acetic acid).  
SEC was carried out using 125 mM formic acid which solubilised the r-amelogenin. 
Formic acid in conjunction with Bio-gel P-30 (as used here) was successfully used to 
isolate the full-length amelogenin from the lower molecular weight enamel matrix 
proteins present in extracts of developing enamel matrix (Fincham et al., 1981). 
However, the fact that most of the r-amelogenin co-eluted anomalously along with the 
low molecular weight contaminants suggested that formic acid was not effective in 
eliminating  interactions between  the r-amelogenin and the low molecular weight 
contaminants or perhaps more likely, did not prevent interactions between the  r-
amelogenin and the column matrix (which would retard the migration of r-amelogenin 
down the column such that it eluted with the low molecular weight contaminants.  
Another possibility is that amelogenin, described as an IDP (Delak et al., 2009) may 
adopt a continuum of different conformations, each with different hydrodynamic 
volumes or shapes. These different conformers of r-amelogenin may diffuse at 
different rates and co-elute with contaminants of their respective hydrodynamic radii.  
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4.1.2.4 Preparative SDS PAGE successfully purified r-amelogenin from 
acetic acid extracts 
While r-amelogenin was co-eluted with lower molecular weight contaminants on SEC, 
an alternative ‘molecular sieving’ method, preparative SDS PAGE, avoided this issue. 
Analytical SDS PAGE was used in this thesis to check the effectiveness of nickel 
column chromatography and SEC at resolving r-amelogenin from contaminants. It was 
apparent that the technique itself can successfully resolve r-amelogenin from 
contaminants. It is possible to cut bands out of the gels and extract the protein but the 
yield is in the microgram range at best. However, large scale preparative SDS PAGE 
promised the resolving power of analytical SDS PAGE with yields associated with 
chromatographic methods and was successfully trialled as an alternative to the 
chromatographic methods tested.   
sodium dodecyl sulphate (SDS) is an amphoteric detergent that binds to proteins via 
its dodecyl aliphatic tail through hydrophobic interactions (Laemmli, 1970, Reynolds 
and Tanford, 1970a). The sulphate group the effectively covers the protein with 
negative charges which repel each other and force linearization of the protein so that it 
is denatured and takes on a rod like conformation (Reynolds and Tanford, 1970b) as 
indicated in Figure 75 below. The proteins thus attain a more or less constant charge 
to mass ratio and when driven through a sieving medium (cross linked acrylamide) by 
an electric field they migrate as a function of their molecular size (Reynolds and 
Tanford, 1970b).  
 
Figure 57  Principle of protein linearisation by SDS. SDS is a detergent that binds 
to proteins by hydrophobic interactions (Reynolds and Tanford, 1970a). It 
covers the proteins with negative charges and linearises them, which allow 
to separate them according to their molecular weight (which will be directly 
proportional to their molecular sizes in this case). 
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When SDS linearises amelogenin, every molecule will attain the same rod-like 
conformation reducing the continuum of hydrodynamic radii which means that all 
molecules will migrate through the molecular sieve at the same rate as a tight, well 
resolved band.  
The results obtained (Section 3.1.2.3, pp. 167 - 178) showed that preparative SDS 
PAGE permitted the isolation of r-amelogenin to single-band purity. Furthermore, the 
resolving power was such that it not only separated His-tagged r-amelogenins from 
bacterial contaminants in the acetic acid extracts (Figures 50-51, pp. 170 - 171) but it 
also separated cleaved from uncleaved His-tagged r-amelogenins (Figure 54 p. 177).  
The purification procedures involving preparative SDS PAGE are summarised below in 
Figure 76. The results obtained indicated that the His-tag was redundant as it 
appeared likely that r-amelogenin, engineered without a His-tag, could be purified to 
single band purity from the crude acetic acid extracts simply be a single round of 
preparative SDS PAGE. 
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Figure 67  Secondary purification of r-amelogenin using preparative SDS PAGE. 
(A) Initially the strategy was to use preparative SDS PAGE to purify 
uncleaved r-amelogenin from the crude acetic acid extract (Section 
3.1.2.3.1), cleave off the His-tag and then separate the cleaved from the 
uncleaved r-amelogenin by nickel column chromatography. However 
cleaved and uncleaved proteins were never completely separated by nickel 
column chromatography (discussed in Section 4.1.2.2, p. 222). (B) An 
alternative method (which omitted the nickel chromatography) was simply 
to subject the proteins in the crude acetic acid extract to His-tag cleavage 
and then use preparative SDS PAGE to isolate the cleaved r-amelogenin 
from uncleaved r-amelogenin and contaminating bacterial proteins. This 
method gave ‘cleaved’ r-amelogenin at single band purity on analytical 
SDS PAGE with silver staining (Section 3.1.2.3.2) thus rendering the His tag 
redundant. (Discussed in Section 4.1.2.4, pp. 230 - 231). 
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4.1.2.4.1 Preparative SDS PAGE provided a high resolution purification of His- 
tagged r-amelogenin from crude acetic acid extracts 
Coupled with acetic acid extraction, which initially enriched the amelogenin fraction 
(discussed in Section 4.1.2.1, p. 216), preparative SDS PAGE allowed for the isolation 
of cleaved and uncleaved r-amelogenins and 20 kDa amelogenin from EMD to single 
band purity as determined using analytical silver stained SDS PAGE (Figures 51, 54 
and 57 in pp. 171 - 182). This Section focuses on the isolation of WT+His r-amelogenin 
using preparative SDS PAGE.  
Figures 50, 51 (pp. 170 - 171), showed that fractions 25 to 49 contained WT+His r-
amelogenin migrating at an apparent MW of 27 KDa. The earlier fractions, 22- 23, 
running at a slightly lower molecular weight of 24.5 kDa also stained well with silver 
staining. However, western blotting of this gel, using a polyclonal anti-amelogenin to 
the 12 amino acid C-terminal telopeptide, showed that the immunoreactivity was 
reduced for the bands in these earlier slightly smaller fractions. This suggests that the 
antibody had a weaker affinity for the epitope (i.e. the telopeptide). This together with 
the slightly lowered molecular weight suggests that the telopeptide may have been 
attacked by exopeptidases which shortened the telopeptide sequence. In effect, this 
would have shortened the size of the epitope and reduced the proportion of polyclonal 
antibodies still able to recognise the truncated sequence leading to a reduced 
immunological staining on the blot. It appears therefore, that the r-amelogenin may be 
susceptible to C-terminal degradation by exopeptidases, possibly of bacterial origin. 
Fortunately, the amount of r-amelogenin affected (i.e. fractions 22-23) is relatively 
small compared to the bulk of protein present in fractions 25-49 that corresponds to 
the full length r-amelogenin. It should be noted that this apparent C-terminal 
degradation was only discovered thanks to the very high resolving power of 
preparative SDS PAGE. The degradation of the C-terminal telopeptide would have no 
effect on the  His-tag and therefore r-amelogenin purified by nickel column 
chromatography would have generated a mixed fraction containing full length r-
amelogenin and r-amelogenin suffering from C-terminal truncation.    
4.1.2.4.2 Quantitative yield of r-amelogenin generated by acetic acid extraction 
coupled with preparative SDS PAGE 
As shown in Figure 77 below (p.232), 10 g of E. coli from 1.6 L of culture generated 
418 mg of crude lyophilised acetic acid extract.  Following desalting and lyophilisation 
of this extract, 171.5 mg of WT+His r-amelogenin protein were obtained. Ten milligrams 
of this were subjected to preparative SDS PAGE which yielded a total of 4.9 mg of 
protein following desalting and lyophilisation. Working backwards, this equates to a 
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yield of 52.5 mg/L bacterial culture, which compares well with the typical yield of 
recombinant protein technology which ranges from 4 to 200 mg/L (Lehmann et al., 
2003, Qing et al., 2004, Sivashanmugam et al., 2009). It is all the more satisfactory 
since the r-amelogenin is obtained at single band purity on silver stained analytical 
SDS PAGE. A first round of His-tag nickel column chromatography (Section 3.1.2.1 
pp. 149 - 151) yielded 14.5 mg r-amelogenin out of 37.4 mg of desalted extract; the 
yield, calculated as 41.5 mg per litre cell culture (Figure 78 below, p. 233), was 
therefore slightly lower, and crucially, was not at single band purity compared to 
preparative SDS PAGE. The yield and purity of the final r-amelogenin fractions 
obtained after preparative SDS PAGE and nickel column chromatography are 
compared below in Table 13.  
Table 31 Strategies employed to purify r-amelogenin: Comparison of the yield 
and purity obtained in the final fractions after preparative SDS PAGE or 
nickel column chromatography. This table highlights the observations 
reported in Figures 77 and 78 (overleaf). 
Method Yield Purity 
Preparative SDS 
PAGE-based 
purification  
(Figure 77) 
52.5 mg proteins per litre 
cell culture 
Single band on analytical 
SDS PAGE with 
Coomassie Blue staining 
and with silver staining 
Nickel column 
chromatography-
based purification 
(Figure 78) 
41.5 mg proteins per litre 
cell culture 
Major band on analytical 
SDS PAGE with 
Coomassie Blue staining 
with visible contamination 
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4.1.3 Impact of preparative SDS PAGE on r-amelogenin production 
4.1.3.1 Preparative SDS PAGE by-passes the need for a His-tag  
As shown above in Figures 77 and 78 (Section 4.1.2.4.2), preparative SDS PAGE 
appeared to be superior to nickel column chromatography for purification of His-tagged 
r-amelogenin away from the milieu of bacterial contaminants present in the crude 
acetic acid extracts, giving a yield of ~50 mg His-tagged r-amelogenin per litre of 
bacterial culture. The initial plan was that the purified His-tagged r-amelogenin would 
then be subjected to His-tag cleavage and the cleaved r-amelogenin purified by nickel 
chromatography (Figure 76A, p. 229). However, the degree of resolution provided by 
preparative SDS PAGE was such that a simplified method was developed that 
involved subjecting all of the proteins present in the acetic acid extract to His-tag 
cleavage and then purifying the cleaved r-amelogenin from the uncleaved r-
amelogenin and bacterial contaminants using preparative SDS PAGE (Figure 76A, p. 
229). When this second approach was used by subjecting 10 mg of the cleaved 
lyophilised acetic acid extract to preparative SDS PAGE the final yield of purified 
cleaved r-amelogenin was in the order of 1 mg, which equates to around 10 mg of 
cleaved r-amelogenin per litre of bacterial culture. This apparent reduction in yield is a 
reflection of the fact that in this case, the 10 mg of starting material contains a mixture 
of cleaved and uncleaved r-amelogenin so there is less target protein in the 10 mg of 
starting material to begin with. In addition, the preparative SDS PAGE fractions 
containing the cleaved and uncleaved r-amelogenins overlapped slightly (see fractions 
45 -47 in Figure 54, p. 177), so not all fractions containing the cleaved r-amelogenin 
were pooled to obtain the final yield. 
In summary then, the results obtained not only support that a His-tag is now redundant 
to purify r-amelogenin but also show that the presence of a His-tag is in itself 
problematic as its removal is not 100% efficient; this complicates the purification 
process, particularly affecting the yield. The excellent resolving power of preparative 
SDS PAGE, coupled with the acetic acid extraction technique provides for a far better 
approach to obtaining purified r-amelogenins and that is to engineer a His-tag-free r-
amelogenin that can be extracted in acetic acid and purified to single band purity from 
the contaminating bacterial proteins by preparative SDS PAGE. Abandoning the His-
tag would dramatically reduce costs as the HRV3C protease is expensive and it would 
provide a rapid means of delivering mg quantities of His-tag-free r-amelogenin using 
one round of purification only. Crucially, the yield would be expected to return to ~50 
mg of recombinant per litre of bacterial culture since the purification process would be 
exactly the same as that shown in Figure 77 above (p. 232). The only difference would 
be that the E. coli would be expressing His-tag-free r-amelogenin as opposed to His-
- 235 -
tagged r-amelogenin. For that, the choice of expression system is important, 
considering Svensson et al (2006)’s observation that the addition of a fusion His-tag 
increased bacterial growth and r-amelogenin expression (Svensson et al., 2006) as 
discussed earlier in Section 4.1.2.2 (p. 219). Svensson et al. (2006) used BL21(DE3) 
E. coli cells transfected with pET11a vector, which may be sensitive to the properties
of the r-amelogenin they express.
An attempt was made to engineer an expression vector to express His-tag free r-
amelogenin but the commercial partner undertaking the work experienced undisclosed
technical difficulties in producing the vectors. Functional vectors resulting in the
expression of both WT and mutant Y64H r-amelogenins at comparable levels to the
vectors expressing the His-tagged r-amelogenins were finally delivered during the
write-up period of this thesis but as discussed elsewhere, time limited their use
experimentally.
4.1.3.2 Preparative SDS PAGE may provide a route to  r-amelogenin 
produced by eukaryotic expression systems 
One drawback of expressing amelogenin using bacterial expression systems is that 
Ser16 will not be phosphorylated as it is in the native protein. However, eukaryotic 
systems will produce correctly phosphorylated amelogenin. 
Taylor et al. (2006) expressed human r-amelogenin in an eukaryotic baculovirus 
system which yielded 10 mg r-amelogenin per litre culture using nickel 
chromatography. However, the r-amelogenin was sensitive to degradation within the 
Sfx insect cells. These degradation products, presumably many of them carrying the 
His-tag, were clearly present in the nickel column elution fractions on analytical SDS 
PAGE following Coomassie Blue staining (Taylor et al., 2006) and full-length r-
amelogenin could not be isolated to single band purity. The potential of preparative 
SDS PAGE to provide a ready source of purified phosphorylated r-amelogenin is an 
exciting prospect for the field. 
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4.1.3.3 Preparative SDS PAGE purification may increase protein 
oxidation. 
The previous sections highlight the benefits of preparative SDS PAGE for purifying r-
amelogenin. However, in the interests of providing a balanced and critical discussion it 
is important to mention one possible drawback; increased protein oxidation linked to 
SDS PAGE.  
The mass spectra obtained from Figure 39 (p. 145) and Figure 52 (p. 173) are 
compared in this Section (Figure 79, below). Figure 79 shows numerous species 
corresponding to r-amelogenin carrying multiples of 16 Da (i.e. oxygen) in both the 
crude acetic acid extract and the r-amelogenin purified by preparative SDS PAGE. The 
number of species exhibiting evidence of oxidation was greater in the sample 
subjected to preparative SDS PAGE. 
 Preparative SDS PAGE caused oxidation
The polymerisation of the acrylamide/bis acrylamide monomers to form the 
polyacrylamide gel used in SDS PAGE gels involves the oxidising agent ammonium 
persulphate (see Section 2.1.1.4, pp. 100 - 101). Excess persulphate in SDS gels is 
known to oxidise proteins as they migrate through the gel and histidine, cysteine and 
methionine side chains are particularly sensitive to oxidation. However, this problem 
has been addressed by Sun and Anderson, 2004 who advocated thorough degassing 
of the gel solutions to remove molecular oxygen and replacing the persulphate 
triggered polymerisation system with a photopolymerisation system using flavin as an 
alternative initiator. This, together with adding the antioxidant thioglycolate to the 
running buffer, reportedly eliminated protein oxidation during SDS PAGE (Sun and 
Anderson, 2004). The potential effect of protein oxidation on protein structure and 
function clearly needs to be considered and it would be preferable in future studies to 
take the preventative steps described above to protect the r-amelogenin from any 
oxidation incurred during preparative SDS PAGE.     
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4.2 Development of microplate binding studies to dissect the 
molecular mechanisms in AI. 
As described in Section 1.3.4.1.3 (p. 70), the first evidence of a mechanism underlying 
AI was published in 2014 using mice carrying a p.Y64H mutation. This mechanism 
was proposed to be driven by ER stress that subsequently triggered a  pro-apoptotic 
UPR. ER stress generally arises following pathological interactions (aggregation) of 
affected proteins transiting the ER and p.Y64H amelogenin in affected mice was 
abnormally retained in within the ameloblasts (Brookes et al., 2014). A compound, 4-
phenyl butyrate, reported to relieve ER stress (Iannitti and Palmieri, 2011), rescued the 
phenotype in heterozygous female mice (Brookes et al., 2014) providing the first 
possibility that  AI could be relieved therapeutically. However, further work is needed 
to further dissect the underlying mechanism; especially in terms of how the p.Y64H 
mutation affects amelogenin-amelogenin interactions and in turn how potential 
therapeutic agents might modulate such interactions or modulate the UPR. Key 
questions are: How did the single-point mutation trigger ER stress and a subsequent 
pro-apoptotic UPR? How did 4-PB rescue the phenotype? Further studies can help 
answer these questions.  
This section (4.2) describes initial trials of microplate based binding tests for use in 
studying amelogenin-amelogenin interactions.  
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4.2.1 A fluorescence labelling-based microplate binding assay was 
not successful. 
The fluorescence labelling-based microplate binding assay consisted of immobilising 
amelogenin (bait protein) to microwell surfaces and adding FITC-labelled amelogenin 
(the free ligand in solution) to allow it to bind to the unlabelled bait on incubation. After 
incubation, microwells would be washed and any amelogenin-amelogenin binding 
would be determined by measuring the remaining fluorescence. This would provide a 
simple method to analyse the effect of the p.Y64H mutation on amelogenin binding 
behaviour. First, to try and establish the conditions required to saturate the microwells 
with the bait amelogenin, a preliminary experiment was conducted using FITC-labelled 
amelogenin as a bait (see Section 2.2.1.3, pp. 122 – 123). Different concentrations 
and incubation conditions were tested and the protocol carried out (Figure 29 p. 124) 
was the same as that planned for the actual binding assay except that no FITC-
labelled amelogenin was added as “free ligand” and the fluorescence measured at the 
end was to reflect the amount of bait adsorbed.  
In order to determine the amount of bait r-amelogenin required to saturate all binding 
sites within the wells, FITC-labelled EMD was incubated in the microwells overnight in 
PBS, TBS or bicarbonate (Section 3.2.1.3, p. 184). The fluorescence signals obtained 
following coating of the microwells reached clear plateau values of 0.05141 (PBS, 4°C) 
and 0.04167 (bicarbonate, 4°C) fluorescence units (Figure 59, p. 186). These were 
reached at low starting concentrations of EMD (less than 10 µg/mL). This suggests 
that the protein may have only formed a monolayer and that no protein-protein 
interaction occurred. With TBS, the signal kept going up, suggesting it coated the 
microwell and then interactions between free and immobilised 20kDa amelogenins 
made the signal keep going up. The signals obtained by incubating the amelogenin 
solutions at room temperature (20°C) were higher than at 4°C, suggesting that higher 
temperatures of incubations for coating favoured amelogenin binding to microplates 
surfaces. This is understandable since amelogenin propensity to aggregate increases 
with the temperature (Moradian-Oldak et al., 1998).  
Remarkably, the signals in all cases were very weak (below 0.1 on average), even 
though labelled protein may have saturated the microwell surfaces. This raised doubts 
as to whether this method would be sensitive enough to accurately determine the 
binding of labelled protein free in solution to unlabelled protein immobilised on the 
microwells surfaces. At the very least, it was clear that FITC as a label was not 
sensitive enough for the purpose. 
FITC covalently modifies positive lysine R-groups and the N-terminal portion of 
proteins, and so, could modify their binding behaviour. This is what may have 
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happened with the surrogate 20 kDa amelogenin from EMD, interfering with its 
immobilisation on the polystyrene surface of the microwell. A similar issue was 
reported in other works using BSA, as FITC-labelling altered its blocking abilities: 
FITC-labelled BSA did not withstand PBS or PBS-0.1% Tween washing (Ahirwar et al., 
2015) unlike unlabelled BSA, which is a gold standard blocker in ELISA protocols 
(Gibbs, 2001). 
In the case of the actual proposed binding assay, unlabelled amelogenin would have 
been bound to the microwells as bait. In this case, lysine modification might be an 
advantage as FITC-labelled amelogenin ligand would not bind the microwells. This 
would avoid nonspecific binding to the polystyrene. However at this stage, the 
robustness of fluorescence-based microplate binding assays could not be 
demonstrated as the preliminary study was not successful.  
A second method to study amelogenin-amelogenin binding was developed based on 
UV-absorption spectrometry to monitor the depletion of solubilised amelogenin from 
solution in real time as it bound to amelogenin immobilised on the microwell surfaces. 
As discussed in the next Section, this avoided the need for labelling or covalent 
modifications and no washing steps were involved. The method, utilising UV-
transparent microplates could, in theory, be used to determine the kinetics of protein-
protein interactions as proteins were depleted from solution over time. 
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4.2.2 Protein depletion from solution in UV-transparent microplates 
provided with an end-point measurement and limited kinetic 
information 
Unlabelled amelogenin was incubated in UV transparent microwells and the decrease 
in UV absorbance was monitored over time, reflecting the depletion of amelogenin 
from solution, as amelogenin initially adsorbed to the microwell surfaces (protein-
polystyrene binding) and then amelogenin remaining free in solution binding to the 
previously immobilised amelogenin (protein-protein binding). The hope was that this 
would then permit determination of the kinetics of amelogenin-amelogenin binding 
(illustrated in Figure 80).  
 
Figure 08  Principle of protein (amelogenin) depletion assay using UV-transparent 
microwells. Panel (A) illustrates the initial hypothesis that (1) amelogenin 
would bind to the polystyrene and then (2) free amelogenin would bind to 
immobilised amelogenin. Panel (B) displays the decrease of absorbance 
expected, reflecting the interactions occurring in (A). After phase (1) of 
amelogenin-polystyrene binding, there is an inflexion point and the second 
slope (2) would reflect previously free amelogenin binding to the 
immobilised amelogenin. The assumption is that amelogenin-polystyrene 
binding occurs more readily than amelogenin-amelogenin binding so that 
the microwells are saturated before amelogenin-amelogenin binding 
begins. The aim is to characterise phase (2), that is, amelogenin-
amelogenin binding.  
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4.2.2.1 The absorbance decrease reflected the major EMD proteins 
binding to the polystyrene surfaces 
4.2.2.1.1 Amelogenin bound to polystyrene surfaces 
In all tests carried out, absorbance decreased throughout the incubation period 
(Section 3.2.2, Figures 61 p. 192, 64 p. 198, 66 p. 202, 68 p. 205), which indicated that 
EMD, used as a surrogate for r-amelogenin, bound to the polystyrene surface. 
Consistently, analytical SDS PAGE with Coomassie Blue staining showed that the 
concentration of amelogenins left in solution (looking at the 20 kDa band) was, as 
expected, reduced after incubation (Figures 61 p. 192, 64 p. 194, 68 p. 205).  
The binding of hydrophobic amelogenin to polystyrene was expected as polystyrene 
(Figure 81 below) is hydrophobic. Amelogenin has a high content of hydrophobic 
amino acids such as proline and leucine. The binding of leucine to polystyrene was 
demonstrated by studies on LK14 peptide (Mermut et al., 2006). The adsorption of 
proteins to polystyrene is mediated by their hydrophobic regions (Norde et al., 1995). 
This is likely mediated by hydrophobic interactions between the benzene rings of 
polystyrene and hydrophobic amino acid residues (Qiang et al., 2017), as illustrated in 
Figure 81 below.  
Figure 18  Principle of adsorption of EMD proteins on polystyrene surface. The 
adsorption of protein on polystyrene is mediated by hydrophobic 
interactions and the residues involved are most likely those of 
hydrophobic amino acids (red box, on the right).  
 
However, analytical SDS PAGE of proteins remaining unadsorbed from solution 
indicated that low molecular weight (< 10 kDa) components were not adsorbed to any 
degree during the incubation period (shown in Figures 61, p. 192 and 64, p. 198). 
These could be soluble components of EMD such as amelogenin degradation 
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products (Brookes et al., 1995) which may not be able to engage in hydrophobically 
driven interactions and therefore did not bind to hydrophobic polystyrene. 
The first step in developing the method was to establish the starting concentration of 
EMD sufficient to saturate the microwell surfaces. The results in Section 3.2.2.1 (pp. 
191 – 192) showed that the equilibrium was reached after 10 hours of incubation as 
the absorbances plateaued from that point onwards (Figure 61A p. 192). The 
polystyrene microwell surfaces could be saturated using EMD at an initial 
concentration ranging 99.6 to 166 µg /mL. For both 99.6 and 166 µg/mL as starting 
concentrations, the contents of solution at equilibrium displayed equal signals on 
analytical SDS PAGE after Coomassie Blue staining in Figure 61B (p. 192). This was 
illustrated in Figure 62 (p. 193), reproduced below in Figure 82. 
Figure 28  Saturation of the polystyrene surface was obtained using EMD at 
initial concentrations of 99.6 - 166 µg EMD / mL. As the EMD concentrations 
at equilibrium appeared to be the same on analytical SDS PAGE (illustrated 
by the dashed red boxes), the polystyrene surfaces were assumed to be 
saturated, with the equilibrium existing between free EMD and the 
immobilised EMD. 
4.2.2.1.2 Characterising the kinetics of EMD binding:  Mathematical modelling 
of the UV absorption curves 
It is worth noting that in contrast to what was hypothesised initially (Figure 80, p. 241) 
the pattern of UV absorbance decrease (Figure 61A p. 192) was not a linear graph 
with inflexion point. This could be because: 
 With time the concentration of free EMD in solution would fall, so binding did
not occur under constant conditions and slowed down towards the equilibrium;
 Free EMD- immobilised EMD interactions may be occurring at the same time
as free EMD- polystyrene interactions, confounding the protein-protein and
protein-polystyrene binding kinetics, as illustrated in Figure 83 below. This
precludes seeing a distinct inflexion point.
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Figure 38  Amelogenin-amelogenin and amelogenin-polystyrene binding may 
occur simultaneously: hypothesis. 
 
It was important to ensure that the initial phase of EMD-polystyrene binding was not 
confused with EMD binding to immobilised EMD for kinetic analysis. Passive 
adsorption by hydrophobic binding to polystyrene may cause denaturation of the 
proteins adsorbing, which is a well-known issue (Butler et al., 1993). and could alter 
subsequent amelogenin self-assembly.  
To overcome this issue and avoid confounding the kinetics of EMD-EMD binding with 
those of EMD-polystyrene binding, the binding assay was carried out to include an 
initial incubation phase that saturated the polystyrene surface with EMD, followed by a 
second incubation with fresh EMD solution, allowing free EMD to bind to immobilised 
EMD (See Section 2.2.2.2, pp. 126 – 129 for detailed methodology), presumably 
representing EMD-EMD binding. The results obtained in Section 3.2.2.2 (Figure 64 p. 
198) indicated that free EMD bound to immobilised EMD, with a greater propensity (in 
terms of rates of depletion from free solution) than that observed for EMD-polystyrene 
binding (Section 3.2.2.2, pp. 200 - 201).  
The depletion kinetics at the 1st and 2nd phases of EMD binding (respectively EMD  -
polystyrene and EMD – EMD binding) were subjected to curve-fitting and the Hill 
sigmoid equation generated the best fit, encompassing all time-points (see Figure 65 
p. 200) with R2 > 0.99. The Hill equation originally described the saturation of 
haemoglobin with oxygen as a function of oxygen tension (Hill, 1910). It can be 
expressed as the following equation (as written in OriginPro 9.1 software (OriginLab, 
Northampton, MA)):  
y = Vmax. (xn/(Kn + xn)) 
The variable y is the velocity of binding reaction and x is the concentration of ligand. 
The equation generates 3 parameters: Vmax (= maximum velocity), K (= 
concentration of ligand required to reach half of maximum velocity) and n (= 
cooperation or “Hill” coefficient, whose value indicates whether ligands positively or 
negatively cooperate while binding to the macromolecule.  
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The Hill equation is however not actually applicable to the data presented in the thesis, 
as it expresses the velocity of the reaction as a function of reactant concentration. 
Besides, the Hill equation is related to various equations in biology describing 
equilibria: Langmuir isotherms, used in adsorption studies, Michaelis-Menten equation 
in enzymology or EC50  calculations in pharmacology (Goutelle et al., 2008). 
In the current work, the exponential functions would have been more relevant 
biologically to the second phase of depletion if this represented EMD-EMD binding 
only. As indicated in Figure 20 p. 87 (Section 1.3.6.1), the rate of protein-protein 
binding is a differential equation. Exponential equations were among the equations 
tested for curve-fitting (Section 2.2.2.2, p. 128) but did not generate a fit to R2 > 0.99, 
comprising all time-points. The Hill equation was therefore chosen, because for all 
graphs obtained it proved to be the most convenient tool for interpretation and 
comparison. It generated the following parameters: 
 Vmax = ‘Maximum gain’ of EMD to polystyrene surface predicted 
 K=T1/2 = time to reach half of maximum depletion. This allows to 
compare .paces of depletion. 
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4.2.2.2 EMD binding to EMD immobilised on the bottom of the microwells 
caused the decrease in UV absorbance as EMD was depleted as it 
bound to immobilised EMD  
The absorbance measurements reported in Section 3.2.2.2 (Figure 64, p. 198), 
including the plateau region, were higher for EMD-EMD binding than EMD-polystyrene 
binding. At equal equilibrium concentrations (shown by analytical SDS PAGE in Figure 
64, p. 198) the difference of absorbance observed (ΔAbs, in Figure 64, p. 198) 
probably reflected EMD binding to the EMD already immobilised to the bottom of the 
microwells so that the absorbance recorded was actually an aggregated value of this 
material and any free EMD left unbound in solution (as illustrated below in Figure 84A 
below). This was an unavoidable consequence of the UV light path passing through 
the bottom of the microwell. This was also observed in the initial test to determining 
sufficient starting EMD concentration to saturate the microwells, where the absorbance 
at equilibrium was higher at starting EMD concentration of 166 µg/mL (Section 3.2.2.1, 
p. 192) as illustrated in Figure 84B below.
Figure 48  EMD bound to the bottom of the microwells affected the true 
absorbance reading associated with unbound EMD remining free in 
solution. Absorbances values were higher at equilibrium when more EMD 
had bound to the bottom surface of the microwells (highlighted by dashed 
red boxes and red double-headed arrows). This was observed (A) in the 
two-phase incubation assay (Section 3.2.2.2, p. 198) and (B) in the 
saturation test (Section 3.2.2.1, p. 192) where the EMD concentration in 
solution was the same at equilibrium but the absorbance values differed. 
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To confirm and further characterise the effect of proteins bound to the bottom of the 
microwells on the absorbance reading, a third test was carried out (Section 2.2.2.3, p. 
130), to measure the absorbance of what remained bound to the bottom of the 
microwell after discarding the contents of the microwell once the 2nd incubation had 
reached equilibrium. The final absorbance read, post-incubation, was 0.24 which is not 
negligible (Section 3.2.2.3 p. 202). So, it is clear that the higher absorbance values at 
equilibrium (as discussed above, in Figure 84) were due to EMD proteins bound to the 
bottom of the microwells.  
This implies that the interpretation of protein binding kinetics is complicated by proteins 
binding to the bottom of the microwells (which makes 22% of surface covered by 200 
µL EMD solution) causing the depletion of free EMD in solution to be underestimated 
during the second incubation phase.  
However, the results obtained (Section 3.2.2.3, pp. 202 - 203) opened up the 
possibility that the binding behaviour of WT and mutant p.Y64H r-amelogenins can be 
compared by measuring the direct accumulation of proteins on the bottom of the 
microwells, as the value 0.24 obtained with EMD is close to 0.3, which is where 
absorbance measurements can be read with the highest precision1. This method 
would provide end-point measurements but not direct real-time kinetics. To monitor the 
kinetics of EMD-EMD binding (shown as EMD depletion from solution) adjustments 
were needed to eliminate the bias caused by EMD binding to the bottom of the 
microwells. An option was to block the bottom of the microwell from binding to EMD as 
discussed in below in Section 4.2.2.3. 
4.2.2.3 Blocking did not prevent EMD from binding to polystyrene 
Microplate-based immunological assays use different blocking regimes to prevent non-
specific adsorption of detection antibodies to the microwell surface. Ideally, antibodies 
will only be retained in the microwell if they recognise and bind specifically  to the 
target antigen that has been immobilised to the microwell surface. BSA and NFDM are 
gold standard blockers in ELISA tests (Gibbs, 2001). BSA forms a monolayer when 
binding to polystyrene surfaces (Fair and Jamieson, 1980) and is predicted to interact 
with polystyrene via CH3 groups, resisting washes in PBS (Jeyachandran et al., 2009). 
NFDM has proved a more effective blocker than BSA in western blotting and in ELISA, 
as well as being cheaper (Johnson et al., 1984) and like casein (which is its major 
1 To reiterate the interpretation of the results obtained in Section 3.2.2.3 (p. 202), an 
absorbance value of 0.3 corresponds to the point where 50% of the photons emitted 
by the light source are absorbed, which allows for reading at the highest precision. 
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component) was found to be the most effective blocker against peroxidase-conjugated 
immunoglobulin non-specific binding to polystyrene microwells (Vogt Jr et al., 1987). 
In this thesis, the ability of BSA and NFDM to block EMD from binding to polystyrene 
was tested first, before any attempt to block the bottom of the microwells (See Section 
2.2.2.4 pp. 131 – 133 for the method). If the blockers prevented EMD from binding to 
the polystyrene, the concentration of EMD added to a blocked microwell was expected 
to remain constant over the incubation period (illustrated in Figure 85A below), causing 
a constant absorbance reading over time to be obtained (illustrated by the orange 
dashed line in Figure 85B below). The absorbance pattern would be clearly different 
from when EMD was added to the “Control” microwells which were not blocked (black 
line in Figure 85B) . 
Figure 58  Absorbance pattern expected in case of successful blocking. Panel A 
illustrates the effect of blocking. (A) Without blocker (black box), EMD 
proteins bind to the microwell surface, so their concentration in solution 
decreases. In the presence of blocker (orange box), EMD is expected not to 
bind to the microwells surface and remain at constant concentration in 
solution. the absorbance of protein is expected to remain constant over 
time with blocker (dashed orange line in panel B). 
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The absorbance patterns obtained (Figure 86A below) however, did not show 
significant difference in the binding of EMD whether or not the microwells were 
blocked with BSA or NFDM before adding EMD solution. Three hypotheses to explain 
this can be drawn, as illustrated in Figure 86 B-D (below): 
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 The gold standard blockers were washed off before adding EMD solution
(Figure 86B).
The washes were carried out three times simply with PBS (see Figure 34, p.133), but it 
is unlikely that BSA or NFDM were removed in these conditions, as both are common 
blockers in ELISA tests and can withstand high stringency washes with PBS even in 
the presence of 0.05% Tween 20 – a non-ionic detergent commonly added to ELISA 
wash buffers to minimise loose nonspecific binding . Both BSA and NFDM are 
“permanent blockers” that “only need to be added once” and can withstand multiple 
washes (Gibbs, 2001). For example, BSA withstands washes and phosphate-BSA 
complexes forming reportedly tend to favour BSA-polystyrene binding (Jeyachandran 
et al., 2009).  The next hypothesis is that the blockers were not washed off during 
washes with PBS, but were removed by EMD acting as a binding competitor. 
 EMD had a stronger affinity than the blockers for the polystyrene
(Figure 86C)
Assuming that amelogenin may have a greater affinity for polystyrene surfaces than 
BSA or NFDM, then, its addition could quickly displace the adsorbed blocker by the 
“Vroman” effect. The Vroman effect originally described the displacement of fibrinogen 
initially adsorbed to a surface caused by plasma proteins having a greater affinity for 
that surface (Vroman et al., 1980) but is the general definition of the competitive 
desorption of one protein by another (Hirsh et al., 2013). It has been reported using 
QCM that BSA previously adsorbed to a surface was displaced by competitive binding 
of other proteins such as fibronectin (Felgueiras et al., 2016) Similarly, SPR studies 
suggested that albumin was displaced by competitive binding of fibrinogen and IgG 
(Green et al., 1999). As for NFDM, the Vroman effect has not been documented. This 
does not mean that NFDM  cannot be displaced by competitive adsorption of EMD or 
other proteins. This hypothesis could be verified using AFM, QCM-D, Time-of-Flight 
Secondary Ion Mass Spectrometry, Time-of-flight mass spectrometry or SPR, which 
were employed to characterise competitive protein displacement on surfaces (Green 
et al., 1999, Hirsh et al., 2013). QCM is suitable technique in particular to characterise 
protein surface adsorption and blocking abilities (Reimhult et al., 2008). Alternatively, it 
would be a simple matter to run the contents of a blocked microwell following the 
addition of amelogenin on SDS PAGE to see if the blocking protein had been 
desorbed into solution. 
Should the Vroman effect occur, one could expect that the kinetics of absorbance 
depletion would differ between conditions as the EMD would have to displace the 
blocker first before it could bind the surface itself (unless this process occurred very 
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quickly). How, then, can the fact that the absorbance patterns are similar be explained 
(Figure 86A, above)? 
It maybe that EMD can displace the blocking protein very quickly; The time-point 
measurements were every 30 minutes, which may not provide a sufficient temporal 
resolution if EMD displaced the blocker very quickly. 
 EMD bound to BSA or NFDM with the same affinity as it bound to
polystyrene (Figure 86D).
BSA and NFDM are the most common blockers used in the laboratory as they prevent 
non-specific protein binding in ELISA studies (Gibbs, 2001) or western blotting. 
Naturally, they are only suitable providing the detection antibodies do not bind to them 
instead of the microwell surface. For BSA and NFDM, there is a risk of cross-reactivity 
with anti-phosphotyrosine antibodies while using BSA prepared from fraction V (which 
is the BSA used in this thesis, see Section 2.2.2.4, p. 131) as it may contain 
phosphotyrosine (Gibbs, 2001). In addition, in the case of BSA, some cross-reactivity 
was reported to human antibodies (Chart et al., 1998) or to vaccina virus complement 
control protein (Xiao and Isaacs, 2012). In contrast, the literature abounds with 
thousands of examples where BSA and NFDM have been used successfully as 
blockers suggesting that in general proteins do not interact with them. However, this is 
not to say EMD proteins follow this trend.  
As blocking did not prove effective it could not be used to solve the issue around the 
undesirable binding of EMD to the bottom of the microwells and further development is 
required. At this stage then, the microplate binding assay can be used to provide an 
end-point measurement of EMD binding to the bottom of the microwells by using UV 
spectroscopy to directly measure the amount of proteins adsorbed to the bottom of the 
microwells after 24-hour incubation. 
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4.2.2.4 Achievements, future developments and prospectives  
4.2.2.4.1 UV-transparent microplate-based depletion measurements provide a 
cost-effective and simple method to analyse amelogenin binding 
behaviour 
To recap, the microplate binding assays developed and discussed previously in 
Section 4.2.2 provided reliable end-point measurements as a means to compare 
binding behaviours of WT and p.Y64H mutant r-amelogenins. This approach consisted 
of incubating proteins in polystyrene in microwells until saturation and protein-protein 
binding equilibriums are reached, and measuring the absorbance (after discarding the 
solutions) of what is left on the bottom of the microwell. Comparing the solution 
contents before and after incubation also confirmed protein depletion.  
This assay provides an exciting prospective, as it allows high-throughput studies, the 
protocol is easy to carry out and is adaptable in that the solution conditions are easily 
modified. The use of 384 microwell microplates would further reduce the amounts of 
precious r-amelogenin even further as the microwell volume is only 131 µL compared 
to the 392 µL in a microwell from a 96 microwell plate. 
4.2.2.4.2 Impact of the proposed method and future use 
As it stands, the method developed here could also be used as a preliminary 
screening tool to determine conditions (buffer, pH, range of concentrations, 
temperature etc.) for subsequent binding studies using SPR, QCM and AFM.  
As mentioned in Section 1.3.4 (p. 64) in vitro studies are useful adjuncts to in cellulo or 
in vivo studies, as they allow detailed understanding of biological mechanisms. On 
their own, in vitro studies rarely reflect in vivo events. Notably, common in vitro protein 
binding experiments may involve protein labelling and may be limited by protein 
solubility. Due to amelogenin’s propensity to aggregate in physiological-like buffers 
(Tan et al., 1998), it has proved problematic to study amelogenin binding behaviour or 
assembly (see Sections 1.2.2.2.4 pp. 25 - 26 on amelogenin supramolecular 
assembly, and 1.3.3.2.1 p. 59 regarding the studies of p.P70T mutation). 
Therefore, in techniques such as SPR (further details are provided in appendix E), 
which require that amelogenin should be solubilised (according to Biacore handbook 
(Biacore Assay Handbook 29-0194-00 Edition AA)), cost-effective pilot studies could 
be helpful to determine conditions that mimic as closely as possible those existing in 
vivo or in cellulo (eg. amelogenin concentrations, buffer, pH) while still being 
compatible with SPR. The microplate binding assay developed in this thesis 
(discussed throughout Section 4.2.2, pp. 241 - 247) can then be integrated into the 
pipeline below (Figure 87):  following in vivo observations, it could provide a step that 
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would guide the choice for conditions to use in more elaborate binding studies using 
SPR or QCM. This would help dissecting in vivo events such as mechanisms 
underlying AI with greater accuracy, which itself would help characterising therapeutic 
targets. 
Figure 78  Experimental pipeline for dissecting protein binding behaviours in 
vivo (“in vivo events. Following initial in vivo observations (step 1) the 
microplate binding assay developed (Section 4.2.2) can provide pilot data 
(step 2) to guide the design of protein-protein interaction studies (step 3). 
Accurate characterisation of in vivo events is a first step for drug 
discovery. The interest of this pipeline is discussed in text, p. 253-254 
regarding amelogenin-amelogenin binding studies (short term prospective) 
and pp. 263-264 regarding amelogenin binding to other proteins (middle-
long term prospective). 
However, the microplate binding test described here is open to further improvements 
that would allow it to be used to generate more exhaustive and accurate binding 
kinetics data such that it could replace the more expensive and lower throughput 
techniques such as SPR and QCM. The improvements to consider are discussed in 
the next Section (4.2.2.4.3). 
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4.2.2.4.3 Immediate possibilities for improvement of the microplate-based 
binding assay 
The following improvements should be considered, to generate more accurate and 
reliable binding kinetics data using the microplate assay. 
 Measure accurately the initial rate of binding reaction 
The absorbance measurement recordings reported in Section 3.2.2 (Figures 61A, 64, 
66, 68A, 69A) started within 4.5 to 10 minutes after preparing EMD solutions, which 
should be the actual starting point of the experiments. In this thesis, this was 
considered as negligible as it only represent 0.3 – 0.7% of the total duration of the 
absorbance measurements. Nonetheless further development would be needed to 
measure the initial reaction rates. In the short term, using QCM or SPR in complement 
could help to measure the initial binding reaction rates. 
 Prevent any amelogenin from binding to the bottom surface of the 
microwells and masking the solution depletion kinetics.  
To reiterate Section 4.2.2.2 (p. 247), all surfaces binding and immobilising EMD and r-
amelogenin solutions were polystyrene, the bottom surface comprises 22% of the total 
surface exposed to the protein solutions which is not negligible. The rate at which 
proteins adsorb to the bottom surface of the microwell masked the rate at which they 
disappeared from solution due to binding to the rest of the microwell surface which is 
problematic. Initially, the approach taken was to block  the bottom of the microwells 
with gold standard blockers BSA and NFDM, but these were not effective (Discussed 
in Section 4.2.2.3, pp. 247 - 252). Alternative ‘anti-fouling’ methods remain to be tested 
and investigated. Polystyrene surfaces can be transformed to prevent protein binding. 
For example,  PLL-g-PEG adsorbed on to polystyrene prevented BSA adsorption to 
the surface (Hecker et al., 2018) and there are many other potential blockers that 
could be tested. Another approach to consider is chemically transforming the surfaces 
of the microwell. For example, treating the surface to make it hydrophilic by plasma 
irradiation or by corona discharge (Onyiriuka et al., 1991). This may inhibit amelogenin 
binding if the binding is hydrophobic in nature. 
 Test different concentrations of amelogenins to generate data relevant  to 
the Hill equation. 
The Hill equation was chosen in EMD adsorption curve-fitting (see Figure 65, p. 200) 
as a function of time (as Discussed in Section 4.2.2.1, p. 244). However the Hill 
equation is (in simplified terms) the expression of a reaction velocity as a function of 
the initial reagent concentration. To be able to use the Hill equation model (with 
biological relevance), the next step would then consist of testing different starting 
concentrations of amelogenin/EMD and plot them against initial depletion rates.   
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4.2.2.4.4 General risks to consider with microplate-based studies: amelogenin 
is an aggregative protein 
Amelogenin is prone to self-assembly and aggregation. It is also an intrinsically 
disordered protein . Although its best-known assembly mode is to form nanospheres, 
an ellipsometry and AFM study showed that when adsorbing to surfaces, it formed 
smaller structures, either monomers or reduced oligomers, and it may adopt various 
quaternary structures depending on the adsorption surface used (Tarasevich et al., 
2009a, Tarasevich et al., 2009b). This effect may be an issue for any technique where 
amelogenin is adsorbed . 
4.2.2.4.5 Relevance of EMD as a surrogate 
The convenience of using EMD as a surrogate for mouse r-amelogenin is that it 
comprises mostly amelogenins and is available in abundant quantities for method 
development purposes (Sections 3.2.2.1 – 3.2.2.4 in Results chapter, and 4.2.2.1 – 
4.2.2.4 in Discussion chapter) (Maycock et al., 2002). EMD contains a mixture of 
porcine amelogenins (Maycock et al., 2002) which share a high degree of homology 
with mouse amelogenins (Brookes et al., 1995). However, EMD is a heterogeneous 
mixture of amelogenins, comprising  all of the amelogenin processing products, 
together with non-amelogenin components such as ameloblastin (Kuramitsu-Fujimoto 
et al., 2015) found in trace amounts in the pig secretory stage enamel  used to 
produce EMD. Clearly, EMD is not comprised of 100% full length amelogenin, the 
amelogenin isotype comprising the r-amelogenins  used here and therefore  the 
following caveats need to be taken into account: 
· Caveat 1: EMD It is a heterogeneous mixture. It comprises proteins that may exhibit
a wide range of different binding affinities, giving absorbance data that reflect an 
average of all proteins rather than one specific species, unlike the r-amelogenins used 
in this thesis. This complicates the interpretation of protein binding kinetics.   
· Caveat 2: Its major component is the 20 kDa “P148” amelogenin processing product,
which raises 2 concerns: 
(1) P148 does not contain the hydrophilic telopeptide. Studies comparing rP147
and the full length telopeptide-bearing rP172 showed that the telopeptide played a role 
in amelogenin assembly and amelogenin-mineral interactions (Wiedemann-Bidlack et 
al., 2007, Kwak et al., 2009). The ideal surrogate would have been full length porcine 
amelogenin P173 but this is not the most abundant isoform in EMD. 
(2) P148 is found in the enamel matrix only since it is a proteolytic processing
product of P173. As explained in the Sections 1.2.1.2.1 (p. 17) and 1.2.3.1.1 (pp. 30 – 
31), P173 is the major isoform of parent amelogenin, which transits through the 
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ameloblast secretory pathway and towards secretion; given the conservation of 
amelogenin between species (Brookes et al., 1995) P173 would be the most 
appropriate surrogate for M180 and therefore, for the r-amelogenins used in this 
thesis. 
 
In spite of the caveats mentioned above  using EMD as a surrogate proved useful in 
these preliminary studies. It demonstrated that the method could be used to track the 
depletion of a relevant protein from solution as it bound to proteins adsorbed to the 
microplate microwell walls (discussed above in Section 4.2.2) and using microplate-
based assay to compare the binding behaviours of WT and p.Y64H mutant r-
amelogenins where feasible (discussed in the Section 4.2.3). Specifically, using EMD 
as surrogate informed on: 
 Experimental design. 
 Suitable starting concentrations (100 -160 μg/mL) which saturated the 
polystyrene surfaces and subsequently provided a sufficient negative change 
of absorbance that could be accurately tracked as the proteins were depleted 
from solution by interaction with the immobilised protein phase.  
  The incubation time required to reach binding equilibrium (for saturating the 
microwell surfaces in order to establish the immobilised phase and for the 
subsequent binding of freshly added protein this immobilised phase; around 10 
-15 hours). 
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4.2.3 Effect of the p.Y64H mutation on mouse amelogenin binding 
properties and the possibilities of dissecting molecular 
mechanisms underlying AI. 
Using the experimental design developed with EMD as a surrogate (discussed above 
in Section 4.2.2), the binding behaviours of WT and mutant p.Y64H r-amelogenins  
were compared. This Section discusses the results obtained.  
4.2.3.1 The hypothesis that the p.Y64H mutation causes amelogenin to 
become aggregative is supported by these data 
The possibility that the p.Y64H amelogenin increases amelogenin-amelogenin binding 
propensity is supported by the results obtained in Section 3.2.2.5 (pp. 207 - 212): 
- The absorbance measurements and analytical SDS PAGE gel densitometry analyses
(Figure 69 p. 209) showed that WT-His remained more or less in solution at constant 
concentration (excepting for a 8-10% minor decrease of signal). Mut-His was depleted 
from solution by 45% over 24 hours incubation. 
- Reading the absorbance of the proteins adsorbed onto the bottom of the microwells
left after discarding the solutions (Figure 70 p. 210), the recombinant Mut-His yielded an 
absorbance value of 0.29. In contrast, the absorbance values read after discarding 
WT-His microwells were 5-7-fold lower (0.04) with a much smaller standard deviation 
which confirms that in contrast to Mut-His, WT-His was hardly bound to polystyrene.  
Mut-His r-amelogenin appeared better at binding to the microwells than WT-His, which 
did not show any obvious aggregation behaviour as it stayed in solution over the 
incubation period. This suggests that the p.Y64H mutation increased r-amelogenin 
apparent hydrophobicity and propensity to aggregate. This pilot experiment therefore 
provided with a further step in understanding the effect of the p.Y64H mutation, as 
discussed below in Section 4.2.3.2. However, the difference of binding behaviour was 
not observed with the His-tagged r-amelogenins, where WT+His showed higher 
aggregation propensity than Mut+His. It is clear that the presence of the His-tag 
appeared to make a huge difference on the behaviour of r-amelogenin in this 
experimental system. This point is addressed in greater detail later in Section 4.3.2 (p. 
268). 
It is worth noting that the r-amelogenins employed were expressed in E. coli, [which 
differs from the eukaryotic system of expression] and therefore lacked phosphorylation 
on Ser16 (See Section 4.1.3.2, p. 235). Although both WT and mutant p.Y64H r-
amelogenins lacked this phosphorylation, this may have compromised the comparison 
between WT and mutant p.Y64H r-amelogenin. The effect of phosphorylation has 
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been itself a subject of great interest (see Section 1.2.1.3.1, p. 18 for detailed 
explanations).  
 
4.2.3.2 Hypothesis regarding the effect of the mutation p.Y64H 
As suggested in the Section 1.3.4 (pp. 64 - 65) understanding the effect of the 
mutation p.Y64H on amelogenin function, in the disruption of amelogenesis, requires a 
combination of in vitro, in cellulo and in vivo studies; to reiterate, in brief: 
- In vitro and (if applicable) in silico data would dissect the mechanism 
underlying AI in fine details. 
- In cellulo studies are also needed to dissect the underlying mechanisms of AI, 
while providing a broader picture. 
- In vivo studies are needed as initial observations and also, at some point, to 
validate the data obtained in vitro and/or in cellulo.  
Built on the literature review and on the pilot data discussed above in Section 4.2.3.1, 
there are various possible consequences of the p.Y64H mutation to consider, at 
different levels. The hypotheses are illustrated in the diagram below, adapted from 
Figure 13 (p. 65). The relevant sections of the literature review and thesis data are 
displayed on the Figure below. 
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Figure 88  Hypothetical or identified effect(s) of the amelogenin p.Y64H mutation. 
This figure represents the scales which may be impacted by the mutation 
p.Y64H, i.e.: locally, in the amino acid sequence (box “functional domain
impacted”) at the amelogenin structure and function scale (boxes “folding”
and “assembly”) or at the cellular or extracellular scales
(boxes”intracellular” and “extracellular trafficking”). Futher description can
be found in the text below.
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As shown in Figure 88 above, the p.Y64H mutation in amelogenin may have effects at 
different scales: 
 Locally, as a single point mutation. 
Tyrosine and Histidine have different propensities for exposure to aqueous surface 
and as well, can participate to different types of interactions (as reviewed in Section 
1.3.4.3.1, pp. 79 - 82). At higher scales this single point mutation per se can 
hypothetically affect the conformation and binding properties of amelogenin. 
 Locally, affecting the ATMP domain 
As ATMP domain is reportedly involved in amelogenin interaction with itself and with 
other proteins (reviewed in Sections 1.2.2.2.1, p. 22 and 1.2.5.2.2, pp. 47 - 49), the 
mutation may affect amelogenin recognitions properties and interaction with itself 
and/or other proteins, an avenue to consider. 
The two “local” effects, cited above, can be described in silico as they only concern a 
few amino acids, as such. However, in silico studies are limited at this level since 
amelogenin 3-dimensional structure has not been solved, to date (see Section 
1.2.1.3.3, p. 20). Awaiting structural data, the effect of the p.Y64H mutation was 
studied in vitro, focusing on amelogenin binding properties. 
 Affecting amelogenin binding properties in vitro 
The pilot data obtained with the microplate-based binding assay developed in this 
thesis (Sections 3.2.2.5, 4.2.3) suggested that the p.Y64H mutation increased 
amelogenin’s propensity to aggregate. This appears supported previously reported 
data, which found abnormal retention of mutant p.Y64H amelogenin in the ER, as 
detailed in the next paragraph. 
 Affecting amelogenin intracellular trafficking in cellulo and in vivo.  
As detailed in Section 1.3.4.1.3 (p. 70), ameloblasts expressing p.Y64H amelogenin 
displayed abnormally engorged ER vesicles, with mutant amelogenin, which strongly 
suggested ER stress (Brookes et al., 2014). Consistently, an increase of UPR markers 
was observed, including pro-apoptotic markers, which would explain the premature 
ameloblast apoptosis noticed in vivo by Brookes et al (2014). Abnormal retention of 
p.Y64H amelogenin was also observed in cellulo in COS-7 cells while co-transfected 
with ameloblastin (see Section 1.3.4.3.2, p. 82). These latter data are capital to 
validate any in vitro or in silico data, past, present or future. 
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To compare the binding behaviours of WT-His and Mut-His r-amelogenins with more in 
vivo relevance, the next step would be to obtain recombinants that carry 
phosphorylation on Ser16. This can now be achieved since, as developed in this thesis, 
amelogenin can be purified using acetic acid extraction and preparative SDS PAGE 
(see Section 4.1.3.2, p. 235). Instead of E. coli, the expression system would need to 
be eukaryotic, which would include the relevant protein folding machinery operating in 
the ER during the secretory pathway (and overcome the problem of bacterial cleavage 
of the N-terminal methionine). Following purification however, a challenge would still 
potentially in whether the r-amelogenins can recover their native conformation. 
A caveat in many in vitro experiments is that they rely on correct protein folding and 
conformation is achieved via the amino acid sequence alone- however, this is not 
always enough to fold a protein – as chaperones are often necessary to catalyse 
protein folding to their native functional conformations (Hartl et al., 2011). 
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4.2.3.3  Future tests to develop a therapeutic for AI as a conformational 
disease 
Clearly, data obtained using the WT-His and Mut-His r-amelogenins suggested that their 
binding behaviour was affected by the p.Y64H mutation. The current results (Section 
3.2.2.5, pp. 207 - 212, discussed in Section 4.2.3.1, p. 258) supported that r-
amelogenin was more aggregative while carrying the mutation p.Y64H, which is 
consistent with its abnormal retention observed in the ameloblasts and the subsequent 
ER-stress and pro-apoptotic UPR (Brookes et al., 2014). However, the results 
obtained in this thesis (Section 3.2.2.5) were generated by one pilot experiment due to 
time constraints, so further work including the use of other techniques would be 
advisable to corroborate the data obtained and confirm their reproducibility.  
Characterising the way in which the p.Y64H mutation affects protein-protein 
interactions will be invaluable in helping to dissect ER-stress and UPR mechanisms 
driving AI in the presence of this mutation and help develop therapeutic strategies and 
targets. 
This section proposes middle- and long-term strategies to study the pathogenesis of AI 
and other enamel diseases: 
-  In the middle-term, studying the effect of p.Y64H mutation on how amelogenin 
interacts with other proteins (e.g. chaperones and UPR activation trans-ER-membrane 
sensors) involved in the ameloblast secretory pathway (Discussed in Section 4.2.3.3.1 
overleaf). 
-  In the long-term, the UPR has been associated with enamel fluorosis (Brookes 
et al., 2017a), so the scope of ER-stress and UPR- studies can be widened to 
understand and possibly treat other enamel diseases (Discussed in Section 4.2.3.3.2 
overleaf). 
 
4.2.3.3.1 Analysing impaired protein-protein interactions in the presence of the 
p.Y64H mutation  
Section 3.2.2.5 showed that the effect of the p. Y64H mutation significantly affected 
amelogenin aggregation. Various binding partners for amelogenin, other than 
amelogenin itself, were previously identified in vitro (as reviewed in Section 1.2.5.2.1, 
pp. 45 - 47); for example ERAF components such as BiP/Grp78, calreticulin, protein 
disulphide isomerase precursor, apasin-ERP57 (Fukuda et al., 2013), cytoskeleton 
components such as actin, vimentin, tubulin (Fukuda et al., 2013), cytokeratins 5 and 
14 (Ravindranath et al., 2001, Ravindranath et al., 2003), or other EMPs such as 
ameloblastin (Ravindranath et al., 2004), with which it colocalises in the intracellular 
secretory pathway (Mazumder et al., 2014). As suggested in Section 1.3.4.3.2 (pp. 82 
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- 83), the p.Y64H mutation could affect the binding equilibria related to amelogenin 
self-assembly, amelogenin-ameloblastin interactions, or amelogenin interactions with 
ER folding machinery. These interactions may be interdependent and necessary to the 
proper trafficking of amelogenin in the ameloblast and to its extracellular function 
(Figure 19, p. 83). 
Therefore, in the middle-term, the effect of the p.Y64H mutation on the binding of 
amelogenin with other relevant proteins is worth investigating. This could be done 
using the microplate-based method developed in this thesis (discussed in Section 
4.2.2), possibly in combination with other techniques. The pipeline proposed in Figure 
87 (p. 254) and possible improvements to the microplate binding assay (discussed in 
the Section 4.2.2.4.3 pp. 255) would provide an efficient strategy to characterise the 
kinetics of protein-protein interactions involved. 
The choice of amelogenin-binding partners to study can be guided by data from the 
literature, and ideally, the availability of an “interactome” database would be of great 
help (Shoemaker and Panchenko, 2007). The online “Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING)” (https://string-db.org) is a possible starting 
point. However, little information is currently available regarding the amelogenin 
interactome.  
This research prospective mentioned, the studies on protein-protein interactions 
involved (and impaired) in the context of ER-stress and UPR (see Section 1.3.4.1.3 p. 
70 on the mouse model carrying the mutation p.Y64H) could serve a wider 
investigation in the long-term, as UPR has been reported in other enamel pathologies 
(addressed below in Section 4.2.3.3.2);  
 
4.2.3.3.2 Conformational diseases and therapy in amelogenesis 
 ER stress and UPR found in cases of AI 
The mouse model expressing the amelogenin p.Y64H mutation is the first model 
showing ER stress as mechanism driving AI (Barron et al., 2010, Brookes et al., 2014). 
A recent paper by Brookes et al, 2017, addressed the role of the UPR in enamel 
pathologies (Brookes et al., 2017a): AI and fluorosis. Following the publication on 
amelogenin p.Y64H , ameloblast ER stress was observed as well with enamelin 
mutations p.55I in mouse and p.L31R in human (Brookes et al., 2017b). The secretory 
stage ameloblasts secretion pathways were impaired as enamel matrix proteins were 
abnormally retained. Notably, UPR markers (e.g., Grp78, Xbp1, Grp94, and Atf4) were 
upregulated in ameloblasts expressing  amelogenin p.Y64H and Enamelin p.S55I.  
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 ER stress and UPR found in fluorosis
The mechanisms underlying fluorosis have been studied for decades. Histological
studies reported that fluoride disturbed intracellular protein trafficking (Matsuo et al.,
1996). This supported the idea that the ameloblasts were suffering ER stress.
Supporting this finding, a study using the ameloblast-derived cell line LS8 and porcine
enamel organ epithelial cells showed that UPR components were up-regulated in
response to fluoride. The researchers observed that fluoride promoted IRE1 activation,
with up-regulation of BiP (Grp78), Xbp-1, and Chop expression (Kubota et al., 2005).
 Therapeutic prospective
Identifying the UPR as an aetiological factor in AI or fluorosis offered prospective for 
developing therapeutic interventions that could potentially abolish AI in affected 
familes or fluorosis. In the mouse model (X-linked AI) carrying the mutation 
amelogenin p.Y64H, treatment with 4-phenylbutyrate restored the phenotype in 
heterozygous mice for the mutation (Brookes et al., 2014). 4-Phenylbutyrate also 
protected the ameloblast-like cell line ALC from cytotoxicity caused by fluoride, again 
by impacting on elements of the UPR (Suzuki et al., 2017). The precise mechanism of 
action of 4-phenylburtyrate is not entirely known to date, although both reports 
showed that it mitigates UPR-pro-apoptotic outcome. 
Conformational diseases in general are currently subject to intense research. The 
possibility of modulating intracellular protein-protein interactions with a view to 
reversing aggregation-linked ER stress is one major approach in attempts to identify a 
therapeutic intervention. As well as acting as an anti-apoptotic agent, 4- 
phenylbutyrate is also reported to act as a chemical chaperone and has been shown 
to restore a stalled secretory pathway in cells expressing the mutated sodium 
transporter responsible for cystic fibrosis (Rubenstein et al., 1997) or reduced the 
aggregation of mutant myocilin in a case of glaucoma (Yam et al., 2007). It had, 
though, no such effect on ameloblasts expressing p.Y64H amelogenin. Otherwise, 
BiP/Grp78 expression enhancer (BIX) has also been shown to restore correct protein 
folding and so potentially alleviate ER stress (Hetz et al., 2013). In the search to 
restore correct protein folding, a comprehensive characterisation of the effect of 
candidate drugs on protein-protein interactions is required. This will facilitate the 
design of therapeutics that can control pathological aggregation. 
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4.3 The presence of His-tag altered the binding/aggregation 
behaviour of amelogenin 
In Section 3.2.2.5 (pp. 207 - 212), WT+His and Mut+His r-amelogenins clearly exhibited 
different binding behaviours when compared to their His-tag-free homologues. This 
section addresses (i) the predicted chemical properties of the His-tag (Section 4.3.1), 
then (ii) highlights the issues associated with using His-tagged amelogenin in binding 
assay reported in this thesis (Section 4.3.2) finally (iii), this section reviews the role of 
His-tag in purification methodologies and in protein binding studies (section 4.3.3). 
4.3.1 Predicted and measured properties of fusion-His-tag 
Histidine has well-known unique binding properties (Section 1.3.4.3.1, pp. 79 – 82) as 
its imidazole ring mediates various types of interactions including cation metal 
coordination via its electron-donating secondary amine. In immobilised metal affinity 
chromatography (in this thesis, a nickel column was used) the number of His residues  
comprising the His-tag affects the purification efficiency; as longer His-tags improve 
the protein purity (Hochuli et al., 1988). However, increasing the length of the His-tag 
increases the risk of altering the protein structure and function. Balancing both these 
factors (final protein purity and maintaining protein function), hexahistidine-tags are the 
preferred option (Bornhorst and Falke, 2000) and are very commonly used. Using 
hexahistidine tags, the binding affinity of the tag for immobilized Ni2+-nitrilotriacetic acid 
ranges from KD = 1-10 μM for fusion-tag proteins (Nieba et al., 1997, Lata et al., 2005) 
to KD = 14 nM for oligopeptides (Knecht et al., 2009). Hexahistidine-tagged proteins 
can be eluted by competition with imidazole at 100 mM or higher concentrations 
(Bornhorst and Falke, 2000).  
 
The His-tag employed in this thesis is 40 amino acids long (see sequence below) and 
includes a cleavage site for rhinovirus 3C protease (underlined) : 
“MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSLEVLFQ# ” 
Using the on line tool ProtParam (https://web.expasy.org/protparam/), this His-tag has 
calculated a pI of 9.46 and a grand average of hydropathicity (GRAVY) index of -
0.603, which suggests that it is hydrophilic (Kyte and Doolittle, 1982, Gasteiger et al., 
2005). As summarised in Table 14 below, the inclusion of this His-tag in the r-
amelogenin may not have significantly affected the Kyte and Doolittle GRAVY index, 
but would have increased the pI from 6.51 to 6.87; which is significantly closer to 
physiological pH. So, as the binding assays used PBS: 1% acetic acid at ratios 
216.4:1 to 290:1, whose pH is within physiological values, which is closer to the His-
tagged r-amelogenins’ pI;  His-tagged r-amelogenins would be expected to be less 
- 267 - 
 
soluble and more aggregative than His-tag-free amelogenins.  This may explain why 
both WT+His and Mut+His r-amelogenins used in this thesis were more aggregative, or 
were better able to bind polystyrene microwell surfaces, than WT-His r-amelogenin . 
Crucially however, in contrast to WT-His r-amelogenin, Mut-His r-amelogenin appeared to 
exhibit significant aggregative or polystyrene binding properties. Whatever the case, 
the mutation was having a significant impact on r-amelogenin behaviour.  
 
Table 41  Differences of pI and hydropathicity predicted by Protparam between 
WT-His 1 and WT+His 2 mouse amelogenins (Gasteiger et al., 2005): effect of 
the addition of His-tag. 
 
  
                                               
1 The pI and GRAVY indexes were calculated from the sequence of His-tag-free 
mouse M180 amelogenin WT (WT-His). The ‘input’ sequence is provided in 
Appendix A. 
 
2 The pI and GRAVY indexes were calculated from the sequence of recombinant  His-
tagged mouse M180 amelogenin WT (WT+His) used in this thesis. The ‘input’ 
sequence is provided in Table 3 p. 92 (Section 2.1.1.1). 
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4.3.2 His-tag altered r-amelogenin function, masking the effect of 
mutation p.Y64H. 
As mentioned earlier in Section 4.2.3.1 (p. 258), the presence of the His-tag 
significantly enhanced apparent binding of r-WT r-amelogenin to the plastic. The gain 
of proteins by the polystyrene surface was greatly enhanced and accelerated when 
His-tagged r-amelogenins were used. The models generated by curve-fitting with the 
Hill equation (Figure 71, p. 212) predicted that the depletion from solution of both 
WT+His and Mut+His r-amelogenins was 50% higher and faster that the depletion of WT-
His r-amelogenin , with a ‘half-time’ of 15 minutes (-vs- 40 minute predicted for Mut-His). 
(To reiterate, these kinetics parameters were only a rough estimate and do not permit 
accurate comparison (Discussed in Section 4.2.2.1.2, pp. 244 - 245)).  
If EMD binding to polystyrene is hydrophobic then the inclusion of the His-tag may 
have enhanced hydrophobic interaction; as shown in Table 14 (Section 4.3.1, p.267), 
the GRAVY index predicted on Protparam tool is less negative, which suggests an 
increase in hydrophobicity (Kyte and Doolittle, 1982). As mentioned previously in the 
Section 4.3.1, the change of pI (see Table 14), which is closer to the reaction pH, may 
play an important role.  
Beyond these parameters (GRAVY, pI, etc.), which are predicted simply from amino 
acid sequences, the enhanced aggregative behaviour seen in the presence of the His-
tag may be caused by the His-tag rendering the hydrophobic parts of the r-amelogenin 
more accessible to the surface. In some way this would alter the conformation of r-
amelogenin, making it more aggregative. This is important in studies that use 
recombinants with the His tag still attached, which may possibly mislead the data 
reported previously in binding studies; this is addressed in the next Section. 
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4.3.3 r-amelogenin is often used in functionality studies with the 
His-tag still in place 
The use of His-tagged proteins in functionality studies is widely practiced under the 
assumption that the tag has no effect on protein conformation or function (Chant et al., 
2005). As His-tag affinity purification is a relatively simple and well-established method 
(Hochuli et al., 1988) the addition of a His-tag has been extensively used to purify 
proteins for crystallographic studies, for which the tag was not removed (Derewenda, 
2004). There are several examples where His-tagged enamel proteins have been 
used in functionality studies, e.g. His-tagged amelogenin, ameloblastin and enamelin 
were used to investigate interaction of these enamel proteins with fibronectin (Beyeler 
et al., 2010) and His-tagged ameloblastin was used to investigate the growth factor-
like activity of ameloblastin and its effect on cell attachment and proliferation of 
periodontal ligament cells (Zeichner‐David et al., 2006). A panel of in vitro studies of 
amelogenin self-assembly and mineral binding, used r-amelogenins carrying an N-
terminal His-tag: “RGSHHHHHHGS”. The addition of this His-tag sequence, which is 
not cleavable, was initially for purification purposes (Moradian-Oldak et al., 2000, 
Tarasevich et al., 2007, Lakshminarayanan et al., 2010, Tao et al., 2015). Some 
reports estimated that the presence of His-tag in in vitro studies did not alter 
amelogenin nanosphere formation nor its calcium phosphate nucleation behaviour 
(Moradian-Oldak et al., 2000, Tarasevich et al., 2007), while other studies reported 
that the presence of the same His-tag (RGSHHHHHHGS) affected amelogenin 
assembly and adsorption behaviour to hydroxyapatite (Tao et al., 2015). Tao et al 
(2015) proposed that at pH 8, the His-tag promoted oligomer–oligomer interactions by 
lowering the net protein charge and promoting imidazole ring-stacking interactions. In 
this thesis, the His-tag clearly affected the binding of r-amelogenin to polystyrene 
surfaces at physiological pH and temperature. The mechanisms involved are unclear, 
though one may propose that the His-tag imparted some specific conformation on the 
r-amelogenin, which altered the availability of specific residues or domains to interact 
with the polystyrene. 
Clearly, based on the pilot data presented in this thesis and the literature, it would be 
preferable to conduct functionality studies with r-amelogenins free of any tags in order 
to maximise confidence in the data obtained. The use of His-tags for functionality and 
structural studies does not guarantee that the results obtained will necessarily reflect 
in vivo situations. For example, a His-tag proved to be problematic when studying 
Gcn5-related N-acetyltransferase as the His-tag bound to the substrate-binding site 
and affected the enzyme’s active site conformation and activity (Majorek et al., 2014). 
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That the His-tag affected the behaviour of amelogenin-amelogenin interactions should 
be considered in the design of future functionality studies. For example, when carrying 
out SPR studies, sensor chips are available whose surfaces are functionalised with 
Ni2+ so that His-tagged protein can be captured prior to running a binding experiment 
(Biacore Series S NTA Sensor Chips). The resulting data would need to be interpreted 
in the knowledge that the His-tag could influence the results obtained.  
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Chapter 5 Conclusions and future work 
To recap, the work achieved in this thesis responds to the initial aims as follows: 
5.1 Aim 1: Production and purification of r-amelogenins 
1) The previously reported method, using acetic acid for extracting His-tag-free r-
amelogenins from E. coli at a high level of purity (Svensson Bonde and Bulow, 2012) 
was optimised for His-tagged recombinants prior to further purification using nickel 
column chromatography, the ”gold standard” purification methodology. 
2) Nickel column chromatography proved less than ideal for purifying r-amelogenin 
since His-tag cleavage was not 100% efficient. This means that cleaved and 
uncleaved recombinants needed to be subjected to a second round of nickel column 
chromatography to separate them but this was confounded by the fact that amelogenin 
contains tri- and di histidine repeats which seem to act as pseudo His tags that made it 
impossible to produce a final product that exhibited single band purity using silver 
stained analytical SDS PAGE. 
3) As an alternative, preparative SDS PAGE proved to be an effective means for 
purifying r-amelogenin and was able to produce a final product that exhibited single 
band purity using silver stained analytical SDS PAGE. Preparative SDS PAGE 
negated the need for nickel chromatography, therefore rendered the His-tag 
redundant, and provided the potential to purify His-tag-free r-amelogenins. 
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5.2 Aim 2: Investigation of the effect of p.Y64H mutation 
associated with AI in mouse, on amelogenin-amelogenin 
binding  
1) A simple binding assay using UV-transparent microplate was developed with EMD
as a surrogate with the aim to be used to compare WT and p.Y64H r-amelogenins in
terms of their ability to adsorb to the polystyrene surface of the microwells (EMD-
polystyrene binding) and, on top, to bind to the adsorbed EMD (EMD-EMD binding).
2) Given that the use of a His-tag is now redundant to purify r-amelogenin, plasmids
coding His-tag-free WT-His and Mut-His r-amelogenins were produced to provide
recombinants for use in the microplate-based binding assay. Time limitations only
allowed for a pilot study to be carried out, comparing the behaviours of WT+His, Mut+His,
WT-His and Mut-His r-amelogenins. The data obtained among His-tag-free r-amelogenins
(WT-His and Mut-His) suggested that Mut-His adsorbed strongly, whereas WT His-tag-free
r-amelogenin showed weak adsorption. This suggests that the mutation had a
significant impact on amelogenin behaviour in terms of its binding properties. In
contrast, the His-tagged r-amelogenins (WT+His and Mut+His) both adsorbed strongly in
the microplate assay.
3) Therefore, the comparative data between WT+His and WT-His r-amelogenins suggests
that His-tags can have a significant impact on amelogenin behaviour and this should
be considered when planning functional studies using r-amelogenins purified using
His-tag-based methodologies.
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5.3 Future work 
Following these conclusions, the following prospective can be considered: 
1) Given the purifying power of preparative SDS PAGE, r-amelogenins can be
obtained, as close as possible to the native M180 amelogenin, for binding 
studies. 
Time limitations allowed the use in the binding assay of r-amelogenins extracted in 3% 
acetic acid only, illustrated in Figure 89A (because the plasmids expressing His-tag-
free r-amelogenins were delivered during the write-up phase of this thesis). So, next: 
 the r-amelogenins will all be subjected to a round of preparative SDS PAGE to
yield single band purity on silver staining analytical SDS PAGE (Figure 89B).
 Furthermore, r-amelogenins can be expressed in an eukaryotic system, which
will allow, for example, phosphorylation on Ser16 (Figure 89B).
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Figure 98  Production and purification of His-tag free r-amelogenins for 
microplate-based binding assays: current achievements and future 
prospectives. At this stage (box A), the WT and mutant p.Y64H r-
amelogenins were expressed in E. coli, extracted in acetic acid, where they 
account for >90% of all proteins (see Section 4.1.2.1, p. 216) for further 
details). Due to time constraints, the acetic acid extracts (desalted) were 
tested directly in the microplate binding assays without further purification 
by preparative SDS PAGE.  Future improvements would employ an 
eukaryotic system, so that the proteins produced are as close as possible 
to the native M180 amelogenin. They could be purified by preparative SDS 
PAGE and after desalting, used in microplate-based binding assay 
developed (Discussed in Section 4.2.2). 
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2) To investigate further the effect of the amelogenin mutation p.Y64H in vitro,
the following prospective is to consider:
2.1) Data reproducibility. 
Repeat the pilot binding assay carried out in this thesis, to corroborate the results 
obtained and confirm their repeatability. 
2.2) UV-transparent microplate binding assay: method development 
Pursue the development of the microplate-based binding assay, so that absorbance 
measurements reflect directly and accurately amelogenin adsorption to the sides of 
the microwells, i.e: Prevent any amelogenin from binding to the bottom surface of the 
microwells. 
2.3) Studying the effects of p.Y64H mutation 
 Choice of techniques for studying protein-protein interactions.
Considering the experimental pipeline proposed (Figure 87, reproduced below), other 
protein binding techniques can be employed to confirm or complete those obtained 
with the UV-transparent microplate-based assay.  
Figure 09  (Figure 88 reproduced) Experimental pipeline for dissecting protein 
binding behaviours in vivo. 
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 Choice of proteins for protein binding assays.
The results obtained in this thesis suggest that the p.Y64H mutation affected 
amelogenin-amelogenin binding and aggregation behaviour. The p.Y64H mutation 
may also affect amelogenin binding to other proteins (if these interactions indeed 
occur in WT), for instance chaperones, or EMP (such as ameloblastin) co-secreted 
with amelogenin in the secretory-stage ameloblasts. This point is worth considering 
further, in order to dissect the pathological mechanisms underlying ER stress- related 
AI:   
.  
Figure 19  The amelogenin p.Y64H mutation may perturb the balance of protein-
protein interactions involving amelogenin. Future routes to investigate for 
protein-protein interactions are indicated. 
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Appendix A Preparation of His-tag-free r-
amelogenins WT and mutant p.Y64H for 
microplate-based binding studies 
Recombinant His-tag-free amelogenins either WT (WT-His) or carrying the p.Y64H 
mutation (Mut-His), were expressed by E. coli BL21(DE3) competent cells previously 
transfected with vector pET30a /Amelx-WT-His or Amelx-Mut-His. The plasmid 
production and transfection were performed by a commercial company (Novoprotein 
Scientific, NJ, USA). Vector pET30a carried the T7 promoter, LacI operator, WT or 
p.Y64H mutant His-tag-free amelogenin gene (Amelx-WT-His or Amelx-Mut-His) and 
kanamycin resistance gene to allow for the selective growth of transfected cells. The 
predicted amino acid sequences of the r-amelogenins are shown below in Table 1.
Table 1 Primary sequences or r-amelogenins WT-His and Mut-His. The 
position of p.Y64H point mutation is indicated in red. 
r-amelogenin Primary sequence 
WT-His 
MPLPPHPGSPGYINLSYEVLTPLKWYQSMIRQPYPSYGYEPM
GGWLHHQIIPVLSQQHPPSHTLQPHHHLPVVPAQQPVAPQQ
PMMPVPGHHSMTPTQHHQPNIPPSAQQPFQQPFQPQAIPPQ
SHQPMQPQSPLHPMQPLAPQPPLPPLFSMQPLSPILPELPLE
AWPATDKTKREEVD 
Mut-His 
MPLPPHPGSPGYINLSYEVLTPLKWYQSMIRQPHPSYGYEPM
GGWLHHQIIPVLSQQHPPSHTLQPHHHLPVVPAQQPVAPQQ
PMMPVPGHHSMTPTQHHQPNIPPSAQQPFQQPFQPQAIPPQ
SHQPMQPQSPLHPMQPLAPQPPLPPLFSMQPLSPILPELPLE
AWPATDKTKREEVD 
E. coli cells storage and growth, induction of r-amelogenin expression, and 
extraction in acetic acid were kindly performed by Dr. Sarah Myers. The cell growth 
and r-amelogenin induction conditions were the same as those described in Section 
2.1.1.1 (induction with IPTG) pp. 92 - 93. The extraction in acetic acid is the same 
as described in 2.1.1.2 p. 94. The acetic acid extracts were desalted against 125 
mM formic acid (See section 2.1.1.3, p. 99)
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Appendix B    Preparation of His-tag-free WT and 
p.Y64H mutant r-amelogenins for microplate-based
binding studies 
Recombinant His-tag-free amelogenins either wild-type (WT-His) or carrying the 
p.Y64H mutation (Mut-His), were expressed by E. coli BL21 (DE3) and extracted in 
acetic acid were (See Appendix A for details). The supernatants of acetic acid 
extracts were subjected to mass spectrometry.
The results of mass spectrometry analysis are displayed below in Figure 1 (spectra 
for r-amelogenin WT-His) and Figure 2 (spectra for r-amelogenin Mut-His). This 
appendix supports the text in Section 4.1.2.1 (p. 217)
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Appendix C Determination of a minimum 
working enzyme/protein ratio 
The N-terminal His-tag initially included in the sequence of r-amelogenin for 
purification purposes had to be removed using HRV3C (71493, Merck), a recombinant 
restriction-grade protease from human rhinovirus protease. HRV3C catalyses the 
hydrolysis between glutamine and glycine within the sequence LEVLFQ/GP. It is 
however an expensive reagent (currently priced at £226.10 / mL stock solution). To 
limit the need for costly amounts of HRV3C, the cleavage reaction was optimised to 
determine the most cost-effective enzyme-to-substrate ratio. 
The ratios tested ranged from 2 µL enzyme solution per mg desalted acetic acid 
extract to 20 µL enzyme solution per mg desalted acetic acid extract. The acetic acid 
extract containing r-amelogenin WT+His was resuspended at 2mg/mL into a solution of 
1.5M NaCl, 0.5M Tris-HCl, pH = 7.5, which is the standard cleavage buffer 
recommended by the manufacturer for the restriction grade HRV3C protease 
(Millipore-71493, Herfordshire, UK). The protease (in its stock solution at 2U/µL) was 
added into the r-amelogenin solution, to 2, 2.4, 4, 10, or 20 µL per mg substrate 
protein. The mixture was left at 4°C over 72 hours and for each condition 50µL aliquots 
were taken to -80°C every 24 hours. The aliquots taken were lyophilised and 
resuspended to original concentration in 1X sample buffer for analytical SDS PAGE. 
The yields of cleaved r-amelogenin were measured by gel densitometry. The 
optimisation procedure is summarised in Figure 3 below and the results obtained are 
shown in Figure 4. 
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Figure 3 Summary of the procedure optimising the (enzyme-to-target) protein 
ratio, expressed as µL stock solutions HRV3C per mg desalted acetic acid 
extract. Acetic acid extracts of r-amelogenin were desalted and 
resuspended in His-tag removal buffer (recommended by the manufacturer 
for HRV3C) and stock solutions of HRV3C proteases were added as 0 
(Control), 2, 2.4, 4, 10, 20 µL per mg proteins. The mixture was incubated 72 
hours, with small aliquots taken each 24 hours for analytical SDS PAGE. 
The results obtained are shown in Figure 4. 
Small aliquot of each fraction 
(taken each 24 hours) 
E. coli culture
and expression of r-amelogenin 
Crude extraction in 3% acetic acid 
Desalting and lyophilisation 
Resuspension (2mg/mL) in standard His-tag removal buffer:
 150 mM NaCl, 50mM Tris-HCl pH 7.5.
+ 0, 2, 2.4, 4, 10, 20 µL enzyme per mg protein
(72 hours incubation)
Analytical SDS PAGE 
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Figure 4 shows the effect of increasing incubation times and enzyme-to-substrate 
ratios on the efficiency of His-tag cleavage. In the control, containing no enzyme 
(“Control” in Figure 4 above), the uncleaved r-amelogenin at 27kDa is present 
through the incubation period indicating that there was no significant degradation over 
the 72-hour incubation time.  
In the samples subjected to His-tag removal (i.e., where HRV3C was added to the 
mixture at 2 to 20 µL per mg protein extract), two additional bands were visible: one 
minor 22kDa band corresponding to the HRV3C enzyme (orange arrows in Figure 4), 
and one prominent 24kDa band, corresponding to the cleaved (His-tag-free) r-
amelogenin. The 22kDa band corresponding to the HRV3C enzyme was more intense 
in the samples containing more enzyme. The fact that the band intensity of the 
‘cleaved’ (His-tag-free) and ‘uncleaved (His-tagged) r-amelogenin are similar on all 
‘test’ lanes indicated that neither the time of incubation, nor the enzyme: substrate 
ratio significantly affected the yield of His-tag removal. Given this, an enzyme-to-
substrate ratio of 3µL of stock enzyme per mg of substrate was used for the cleavage 
reactions.   
In all conditions tested, it was clear that the His-tag removal reaction never 
approached 100% efficiency.  
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Appendix D  Effect of buffer composition and pH on 
efficiency of His-tag removal 
As described in Appendix C it was decided to use the HRV3C enzyme at an enzyme-
to-substrate ratio of 3µL per mg substrate protein mixture. This optimisation was 
carried out at pH 7.5 in the buffer suggested by the manufacturer -150 mM NaCl, 
50mM Tris-HCl . However, in the course of the work, some cleavages were carried 
out at pH 8 in 50mM Tris-HCl and even at pH 9 in 0.1M Na2CO3 
The rationale of carrying out the cleavage at pH 8 in 50mM Tris-HCl using was 
twofold. First the slight increase in pH and the reduction in ionic strength due to 
omission of the 150mM NaCl would be expected to aid r-amelogenin solubility and 
possibly allow it to be more accessible to the enzyme.  
The rationale of carrying out the cleavage at pH 8 and 9 in 0.1M Na2CO3 is that this 
more extreme pH would be expected to favour further the solubility and reduce the 
aggregation of r-amelogenin (Tan et al., 1998), therefore increasing its accessibility to 
the protease HRV3C. The buffer 0.1M Na2CO3 at pH = 9 also allowed the cleavage 
products to be directly labelled with fluorescein at this point if required (as fluorescein 
labelling is carried out in this buffer system). 
The freeze dried acetic acid extract was dissolved at 2mg/mL in the cleavage buffers 
and stock HRV3C solution was added to 3 µL per mg protein and incubated for 72 
hours. The cleavage buffers were: Tris-HCl (pH=8), 0.1M Na2CO3 (pH=8), or 0.1M 
Na2CO3 (pH=9). As controls, small aliquots were taken before adding the HRV3C; then 
small aliquots were taken after adding HRV3C every 24 hours for analytical SDS 
PAGE. The aliquots taken for analytical SDS PAGE were lyophilised and resuspended 
to original concentration in 1X sample buffer.  
The procedure is summarised in Figure 5 below and the results obtained are shown in 
Figure 6. 
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Figure 5 Summary of the procedure designed to test the effect of buffer 
composition and pH on r-amelogenin His-tag removal efficiency. The His-
tag cleavage was carried out by incubating the acetic acid extract 
comprising r-amelogenin with HRV3C protease at 3 µL stock HRV3C 
solution per mg proteins for 72 hours. Incubation was done in either of 
these buffers: Tris-HCl (pH=8), 0.1M Na2CO3 (pH=8), or 0.1M Na2CO3 (pH=9). 
Small aliquots were taken before adding the HRV3C as controls and small 
aliquots were taken after adding HRV3C every 24 hours for SDS PAGE 
analyses. The results obtained are shown in Figure 6.
E. coli culture
and expression of r-amelogenin 
Crude extraction in 3% acetic acid 
Desalting and 
lyophilisation 
0.1M Na2CO3 
pH9 
 50mM Tris-
HCl pH8
Analytical 
SDS PAGE 
0.1M Na2CO3 
pH8
His-tag cleavage 
Small aliquot taken 
at 0, 23, 48, 72h  
His-tag cleavage His-tag cleavage 
Analytical 
SDS PAGE 
Analytical 
SDS PAGE 
Small aliquot taken 
at 0, 23, 48, 72h  
Small aliquot taken 
at 0, 23, 48, 72h  
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Analytical SDS PAGE in Figure 6 above showed that for all buffers, His-tag cleavage 
was effective, as a 24 kDa band is visible in all lanes except the controls, which have 
not been subjected to His-tag removal. However the cleavage yield never approached 
100%.  
Neither the composition of buffers nor the duration of incubation appeared to significantly 
affect the cleavage efficiency, since the intensities of the  ‘cleaved’ and ‘uncleaved’ 
bands appeared similar between different lanes (except the controls,  which did not 
contain HRV3C enzyme ). Figure 6B shows that the cleavage in 0.1M Na2CO3 was as 
effective as that carried out in 50mM Tris-HCl (Figure 6A. Figure 6C shows that 
increasing the pH to 9 did not affect the rate of cleavage either.  
It did not make significant difference either whether the r-amelogenin was WT or mutant 
p.Y64H.
Reference 
TAN, J., LEUNG, W., MORADIAN-OLDAK, J., ZEICHNER-DAVID, M. & FINCHAM, A. 
G. (1998) The pH dependent amelogenin solubility and its biological
significance. Connective tissue research, 38, 215-221.
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Appendix E   Protein-protein interactions and existing 
analytical techniques 
As mentioned in Section 1.3.6, “Understanding protein interactions is key to 
understanding normal amelogenesis as well as the aetiology of amelogenesis 
imperfectas driven by perturbed protein interactions”. To this end, the choice of protein 
binding studies to carry out is crucial. This appendix will complement  Sections 1.3.6.2 
-1.3.6.3 by providing further details on the principles, advantages and limitations of 
some existing in vivo and in vitro techniques. 
E.1 Protein-protein interaction assays in vivo 
This section reviews major in vivo protein-protein interactions studies. It details Y2H 
assay (Fields and Song, 1989) PCA (Johnsson and Varshavsky, 1994), FRET (Stryer, 
1978) and cross-linking (Wong, 1991). Their principles, pros and cons are summarised 
in Table 2 in this appendix. Other techniques including immunofluorescence microscopy, 
which previously identified amelogenin binding partners (See Section 1.2.5.2, p. 45 - 49) 
are not detailed here. 
Overall, in vivo protein-protein interactions studies are invaluable as they can generate 
the most relevant information on actual in vivo events. However, for detailed 
characterisation of protein-proteins interactions, in vitro studies are carried out as they 
can provide binding kinetics data, they are versatile and easier to handle. 
E.2 Protein-protein interaction assays in vitro 
There exists a plethora of in vitro methods to study protein-protein interactions. This 
Section addresses in vitro studies which do not require labelling or addition of a fusion 
protein or fusion tag. Popular methods include SPR (Karlsson et al., 1991), QCM 
(Sauerbrey, 1959), ITC (Freire et al., 1990),DLS (Pecora, 2013) or AFM (Binnig et al., 
1986). Their principles, pros and cons are summarised in Table 3 in this appendix. 
Other techniques related to microplate-based binding assays, including ELISA, are 
addressed in the Section 1.3.6.3-4 of the thesis and are not detailed in this appendix. 
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Supplementary data 
Details of analytical SDS PAGE and western blotting  
 
As indicated in section 2.1.1.4 p. 001  301-  (“SDS PAGE and western blotting”), the 
sample loading for each SDS PAGE analysis was optimised. This was to obtain strong 
enough band staining to display the proteins present in the extracts, and at the same 
time, avoid overloading so that the bands could be distinguished clearly. 
The volumes and concentrations differed depending on: 
- The visualisation technique employed; e.g.: silver staining is much more sensitive 
than Coomassie Blue (Morrissey, 1981)  
- The sample itself, e.g. The starting material was usually more concentrated than the 
purification fractions collected; it was sometimes so concentrated that dilution was 
necessary to be able to distinguish its contents on analytical SDS PAGE. 
This appendix details the sample preparation and loading for the analytical SDS PAGE 
and western blotting Figures comprised in the results (Chapter 3). It details: 
- The composition of samples before electrophoresis   
- The molecular weight markers used (and their dilution, if there is). 
- The volumes of samples and markers loaded 
It specifies also the staining techniques employed.  
- For Coomassie Blue staining, the duration of staining with Coomassie Blue is 
provided. As for the reagent employed, details are in the ‘Materials and 
Methods’ chapter (Section 2.1.1.4) pp. 001  201-  
- For silver staining, the duration of staining and development steps are provided 
here. As for details about the kit and whole procedure employed, see Materials 
and Methods’ chapter (Section 2.1.1.4) pp. 001  201-  
- For western blotting, this section provides with the duration of incubation with 
the primary and secondary antibodies, the dilution factor and the buffers in 
which the antibodies are diluted. The primary and secondary antibodies do not 
change between all western blots. The blotting procedure and reagents are all 
detailed in the Materials and Methods’ chapter (Section 2.1.1.4) pp. 101 , 301  
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1.1 Expression of recombinant WT and mutant p.Y64H 
amelogenins in E. coli (Section 3.1.1.1) 
 
 
 
 
Figure 53   
(Section 3.1.1.1 p. 1 73 ) 
SDS PAGE and western blotting 
of expressed E. coli proteins. 
The sample preparation, 
loading and staining/blotting 
methods are detailed below. 
Figure 63 A (Section 3.1.1.2.1 p. 1 93 ) 
Optimisation of the weight of E. coli paste to volume 
of acetic acid in the extraction process. 
The sample preparation, loading and staining/blotting 
methods are detailed below. 
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Figure 73  (Section 3.1.1.2.2 p. 141 ) 
Optimisation of the mixing regimen and temperature on the yield of r-amelogenin 
extraction. 
The sample preparation, loading and staining/blotting methods are detailed below. 
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1.2 Optimisation of 3% acetic acid extraction method (Section 
3.1.2.1) 
 
 
 
 
Figure 24 B  
(Section 3.1.2.1.1 p. 051 ) 
Nickel column chromatography 
round 1. 
The sample preparation, loading 
and staining/blotting methods are 
detailed below. 
Figure 34  (Section 3.1.2.1.2 p. 351 ) 
Optimisation of the mixing regimen and temperature 
on the yield of r-amelogenin extraction. 
The sample preparation, loading and staining 
/blotting methods are detailed below.  
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Figure 44   
(Section 3.1.2.1.2 p. 1 65 ) 
Nickel column chromatography round 2. 
The sample preparation, loading and 
staining /blotting methods are detailed 
below. 
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1.3 Purification of r-amelogenin using nickel column 
chromatography (Section 3.1.2.2) 
 
 
 
Figure 64  (Section 3.1.2.2.1 p. 361 ) 
Separation of acetic acid extract components by 
size exclusion chromatography using Bio-gel-
p30 matrix, 35 cm column length 
The sample preparation, loading and staining 
/blotting methods are detailed below. 
Figure 74  (Section 3.1.2.2.2 p. 1 56 ) 
Separation of acetic acid extract components by 
size exclusion chromatography using Bio-gel-
p10 matrix, 35 cm column length 
The sample preparation, loading and staining 
/blotting methods are detailed below. 
Figure 84  (Section 3.1.2.2.3 p. 1 66 ) 
Separation of acetic acid extract 
components by size exclusion 
chromatography using Bio-gel-p10 
matrix, 95 cm column length. 
The sample preparation, loading and 
staining /blotting methods are detailed 
below.  
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1.4 Purification of r-amelogenin using preparative SDS PAGE 
(Section 3.1.2.3) 
 
Figure 05  (Section 3.1.2.3.1 p. 071 ) 
Analytical SDS PAGE with Coomassie Blue staining to identify the fractions of 
interest (those containing r-amelogenin). 
The sample preparation, loading and staining /blotting methods are detailed below. 
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Figure 15  (Section 3.1.2.3.2 p. 171 ) 
Analytical SDS PAGE of the fractions of interest (obtained by preparative SDS PAGE) 
with silver staining and western blotting. 
The sample preparation, loading and staining /blotting methods are detailed below.  
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Figure 45 A (Section 3.1.2.3.2 p. 1 77 ) 
Analytical SDS PAGE showing the isolation of ‘cleaved’ r-amelogenin from 
‘uncleaved r-amelogenin using preparative SDS PAGE. (A) Coomassie Blue staining. 
The sample preparation, loading and staining /blotting methods are detailed below.  
Figure 45 B (Section 3.1.2.3.2 p. 1 77 ) 
Analytical SDS PAGE showing the isolation of ‘cleaved’ r-amelogenin from 
‘uncleaved r-amelogenin using preparative SDS PAGE. (B) Silver staining. 
The sample preparation, loading and staining /blotting methods are detailed below.  
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1.5 Fluorescence-based binding assay (Section 3.2.1) 
 
 
 
Figure 55  (Section 3.2.1.1 p. 081 ) 
EMD proteins sucessfully labelled with FITC 
The sample preparation, loading and staining /blotting 
methods are detailed below. 
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Figure 75  (Section 3.2.1.2 p. 281 ) 
Fractions obained when FITC-labeled EMD proteins were subjected to preparative 
SDS PAGE. 
The sample preparation, loading and staining /blotting methods are detailed below.  
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1.6 Monitoring the kinetics of amelogenin-amelogenin interactions 
as a function of UV absorbance (Section 3.2.2) 
 
 
 
 
Figure 16 B (Section 3.2.2.1 p. 291 ) 
A range of initial EMD concentrations (33.2 – 166 µg/mL) was used to investigate 
EMD adsorption onto the microwells surfaces. 
The sample preparation, loading and staining /blotting methods are detailed below.  
Figure 46   
(Section 3.2.2.2 p. 1 89 ) 
Analysis of EMD-EMD binding 
kinetics. 
The sample preparation, loading 
and staining /blotting methods 
are detailed below. 
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Figure 86  (Section 3.2.2.2 p. 2 50 ) 
Ability of goldstandard blockers BSA and NFDM to 
block EMD from binding to microwell surfaces. 
The sample preparation, loading and staining /blotting 
methods are detailed below. 
Figure 96 B  
(Section 3.2.2.5 p. 2 90 ) 
Comparison of r-amelogenin depletion 
from solution after 24h incubation in 
microwells for WT-His, Mut-His, WT+His, 
Mut+His. 
The sample preparation, loading and 
staining /blotting methods are detailed 
below. 
